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Abbreviations 
ALS amyotrophic lateral sclerosis 
ATP adenosine triphosphate 
BAC bacterial artificial chromosome 
BACHD bacterial artificial chromosome containing full-length huntingtin 
Ca2+ calcium ions 
CNS central nervous system 
DIV day(s) in vitro 
Drp 1 dynamin-related protein 1 
E embryonic day 
Fis 1 fission protein 1 
GABA Ȗ-aminobutyric acid 
HD Huntington disease 
Hdh mouse huntingtin gene 
HTT human huntingtin gene, also IT15 
HTT human huntingtin protein 
Htt rat or mouse huntingtin protein 
H+ proton(s) 
IGF-1 insulin-like growth factor 1 
IT15 interesting transcript 15, Huntington disease gene, also HTT 
Mfn mitofusin 
Miro 1 mitochondrial Rho-GTPase 1 
MSNs medium-sized spiny neurons 
mPT mitochondrial permeability transition 
NAA N-acetylaspartic acid 
NMDA N-methyl-D-aspartate 
OD optical density 
Opa 1 optic atrophy 1 
PGC-1α  peroxisome proliferator-activated receptor Ȗ coactivator 1α 
PR progressive ratio 
polyQ polyglutamine 
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RQ respiratory quotient 
SEM standard error of the mean 
SMA spinal muscular atrophy 
STHdh immortalized striatal mouse neurons with human exon 1 
TCA tricarboxylic acid, in TCA cycle 
TSPO translocator protein/tryptophan-rich sensory protein 
VCO2 volume of oxygen consumed 
VDAC voltage-dependent anion channel 
VO2 volume of carbon dioxide released 
WT wild type 
8OHdG 8-hydroxy-2’-deoxy guanosine 
1H NMRS 1H nuclear magnetic resonance spectroscopy 
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Summary 
Summary (English) 
The current work addresses the characterization of metabolic abnormalities in the BACHD rat 
and the therapeutic effects of olesoxime treatment. 
The BACHD rat is a recently established transgenic model of Huntington disease (HD), which 
expresses full-length human mutant huntingtin (mHTT) with 97 CAG repeats. It is shown here 
that metabolic dysfunction is a prominent, early feature of the HD-related pathological 
phenotype in these rats. BACHD rats suffer from growth impairment and obesity due to deficits 
in energy metabolism. These deficits are traceable during growth and senescence based on 
altered physiological parameters. It can be concluded that metabolic abnormalities underlie 
temporal changes, which when considered a general feature of HD, could explain 
discrepancies in the outcomes of earlier studies on metabolic dysfunction in HD patients and 
animal models. 
In order to therapeutically address metabolic dysfunction in the BACHD rat, a long-term 
treatment study with the mitochondria-targeting, neuroprotective compound olesoxime was 
conducted. Although olesoxime did not influence the growth deficit and development of 
obesity in the BACHD rat, it revealed a positive influence on mitochondrial function and 
specific behavioral and neuropathological phenotypes. It is suggested that these benefits 
resulted from improved mitochondrial function and a stabilizing effect on intracellular calcium 
homeostasis, leading to decreased calcium-dependent activation of the protease calpain-1 
and reduced calpain-mediated proteolysis of mutant huntingtin. Further studies with earlier 
start of olesoxime treatment could help to understand why the compound only exerted 
selective beneficial effects in the BACHD rat, and to provide further insight into the mechanism 
of action. 
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Zusammenfassung (Deutsch) 
Die vorliegende Arbeit befasst sich mit der Charakterisierung stoffwechselphysiologischer 
Auffälligkeiten in der BACHD-Ratte, sowie den therapeutischen Auswirkungen einer 
Behandlung mit Olesoxime. 
Die BACHD-Ratte ist ein aktuelles Tiermodell der Huntington Erkrankung (HD), welches das 
vollständige mutierte Huntingtin-Gen mit 97 CAG-Wiederholungen exprimiert. Wie hier 
gezeigt wird, stellen Stoffwechselauffälligkeiten prominente Krankheitsmerkmale der BACHD-
Ratte dar. BACHD-Ratten zeigen beeinträchtigtes Wachstum und ausgeprägte Fettleibigkeit 
infolge von Defiziten im Energiestoffwechsel, welche während des Wachstums und der 
Seneszenz anhand veränderter physiologischer Parameter nachweisbar sind. Die Befunde 
lassen darauf schließen, dass Defizite im Energiestoffwechsel zeitlichen Änderungen 
unterliegen, was unter der Annahme der Allgemeingültigkeit für HD, widersprüchliche 
Ergebnisse früherer Studien zur Stoffwechseldysfunktion in HD-Patienten und Tiermodellen 
erklären könnte. 
Zur Therapie der Stoffwechselstörungen wurde eine Behandlung mit der auf Mitochondrien 
wirkenden Substanz Olesoxime durchgeführt. Obwohl kein Einfluss auf die zuvor 
beschriebene Wachstumsstörung und Fettleibigkeit festgestellt werden konnte, zeigte sich ein 
positiver Effekt auf die Funktion der Mitochondrien sowie auf bestimmte Verhaltens- und 
neuropathologische Merkmale der BACHD-Ratte. Es wird angenommen, dass Olesoxime 
durch Verbesserung der mitochondrialen Funktion den Kalziumhaushalt stabilisiert, und 
dadurch der Kalzium-abhängigen Prozessierung von mutiertem Huntingtin durch die Protease 
Calpain-1 entgegenwirkt hat. Zukünftige Studien mit frühem Behandlungsbeginn könnten 
Aufschluss darüber geben, warum der Wirkstoff nur selektive Verbesserungen in der BACHD-
Ratte gezeigt hat, und darüber hinaus helfen den genauen Wirkmechanismus zu 
entschlüsseln. 
 
Publications 
 
5 
 
Publications 
List of publications 
Journal articles are listed in chronological order according to publication date. Equal 
contribution of two authors is indicated by an ‘&’ sign linking the authors’ names. 
I. Verwaest KA, Vu TN, Laukens K, Clemens LE, Nguyen HP, Van Gasse B, Martins JC, 
Van Der Linden A, Dommisse R. (1)H NMR based metabolomics of CSF and blood 
serum: a metabolic profile for a transgenic rat model of Huntington disease. Biochimica 
et Biophysica Acta 2011; 1812:1371-1379. 
II. Yu-Taeger L, Petrasch-Parwez E, Osmand AP, Redensek A, Metzger S, Clemens LE, 
Park L, Howland D, Calaminus C, Gu X, Pichler B, Yang XW, Riess O, Nguyen HP. A 
novel BACHD transgenic rat exhibits characteristic neuropathological features of 
Huntington disease. Journal of Neuroscience 2012; 32(44):15426–15438. 
III. Gouarné C, Tardif G, Tracz J, Latyszenok V, Michaud M, Clemens LE, Yu-Taeger L, 
Nguyen HP, Bordet T, Pruss RM. Early deficits in glycolysis are specific to striatal 
neurons from a rat model of huntington disease. PLoS One 2013; 8(11):e81528. 
IV. Clemens LE, Jansson EK, Portal E, Riess O, Nguyen HP. A behavioral comparison of 
the common laboratory rat strains Lister Hooded, Lewis, Fischer 344 and Wistar in an 
automated homecage system. Genes, Brain & Behavior 2013; 13(3):305-21. 
V. Eckmann J & Clemens LE, Eckert SH, Hagl S, Yu-Taeger L, Bordet T, Pruss RM, 
Muller WE, Leuner K, Nguyen HP & Eckert GP. Mitochondrial Membrane Fluidity is 
Consistently Increased in Different Models of Huntington Disease: Restorative Effects 
of Olesoxime. Molecular Neurobiology 2014; 50(1):107-18. 
VI. Jansson EKH & Clemens LE, Riess O, Nguyen HP. Reduced motivation in the BACHD 
rat model of Huntington disease is dependent on the choice of food deprivation 
strategy. PLoS One 2014; 9(8):e105662. 
Publications 
 
6 
 
 
VII. Clemens LE & Weber JJ, Wlodkowski TT, Yu-Taeger L, Michaud M, Calaminus C, 
Eckert SH, Gaca J, Magg JCD, Weiss A, Jansson EKH, Eckert GP, Pichler BJ, Bordet 
T, Pruss RM, Riess O and Nguyen HP. Olesoxime suppresses calpain activation and 
mHTT fragmentation in the BACHD rat. Brain 2015; 138(12):3632-53. 
  
Publications 
 
7 
 
 
Statement of personal contribution 
Statements are given according to the order, in which the publications were listed above. 
I. Involved in breeding and maintenance of animals, dissection, blood sampling and 
serum preparation. 
II. Involved in maintenance of animals, automated homecage assessment of metabolic 
parameters, dissection of animals and preparation of the manuscript. 
III. Assessment of mHTT accumulation in primary neurons. Involved in data interpretation 
and manuscript preparation. 
IV. Main investigator. Performed the experiments. Main role in data analysis and 
interpretation as well as preparation of the manuscript. 
V. Main investigator (together with J. Eckmann). Breeding and maintenance of animals, 
dissection and sample collection. Involved in data analysis. Main role in data 
interpretation and manuscript preparation. 
VI. Main investigator (together with E. Jansson). Shared main role in study design, 
breeding, maintenance of animals, metabolic measurements and dissection, data 
analysis, interpretation, manuscript preparation. 
VII. Main investigator (together with J. Weber). Breeding and maintenance of animals. 
Main role in performance of behavioral experiments and animal dissection. Assisting 
role in immunohistochemical staining, main role in microscopy. Assisting role in 
isolation of mitochondria and western blotting. Main role in data analysis and 
interpretation as well as in manuscript preparation. 
 
 8 
 
Introduction 
Huntington Disease 
9 
 
Introduction 
Huntington disease (HD) 
Natural history of the disease 
Huntington disease (HD) is an autosomal-dominantly inherited, fatal, neurodegenerative 
disorder. Its prevalence is estimated highest in Europe and populations of European descent1. 
The average frequency of affected persons in Europe, North America and Australia amounts 
to a minimum of 6 per 100,0002,3. 
The behavioral symptoms of HD are historically classified as a triad of motor dysfunction, 
psychiatric disturbances and cognitive impairments. Symptoms are multifaceted and vary 
considerably among patients4. Motor symptoms present as involuntary movements (chorea) 
and hindered voluntary motor function through bradykinesia, rigidity and dystonia5. Psychiatric 
abnormalities include apathy, depression, irritability and obsessive compulsive behavior5. 
Finally, cognitive impairment comprises difficulties in information processing, memorization as 
well as executive function6. 
Behavioral changes are directly associated with central nervous system (CNS) dysfunction7 
and degeneration8. Brain atrophy is characterized by a loss of both gray and white matter, as 
well as gliosis8–10. The earliest and most severe decay occurs in the striatum, although cortical 
thinning and loss of white matter can also be observed before manifestation of the clinical 
disease8,11. Degeneration of extra-striatal, subcortical areas follows during early disease 
stages and includes hippocampus, amygdala, thalamus as well as hypothalamus8–10,12,13. The 
magnitude of brain atrophy differs among patients and is likely connected to the large 
variability in behavioral symptoms14. 
Clinical onset of HD typically refers to the appearance of gross motor abnormalities. However, 
more subtle behavioral changes as well as neurodegenerative processes are already 
detectable in mutation carriers many years before motor symptom onset15,16. 
The sole cause of developing HD is the expansion of an unstable repeat of CAG base triplets 
in the coding region of the IT15 gene (consequently later termed Huntingtin gene, HTT) on 
chromosome 4p16.317. CAG repeat lengths up to 34 are considered to lie in the normal range,  
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while more than 35 CAG repeats likely lead to the development of HD18,19. Full penetrance is 
assumed for repeat lengths of 42 CAGs and more18. 
Transmission of the disease typically results from inheritance of one mutated allele from an 
affected parent. The incidence of de novo mutation was estimated to lie around 0.1 % for 
transmission from a father with a high, but normal CAG repeat20, but to account for up to 10 % 
of diagnosed cases21. An anticipatory effect has been described, based on the finding that 
intergenerational changes in CAG repeat lengths more often concern expansions than 
contractions, particularly when transmitted paternally22,23. 
The age of disease onset correlates inversely with CAG repeat length24–26. An average patient 
with a repeat length of 40 CAGs has a 50 % probability to develop the disease around the age 
of 60 years, while this decreases to around 40 years in case of 45 CAGs, and 30 years in 
case of 50 CAGs18. Patients with more than 60 CAG repeats, which typically arise from large 
intergenerational expansions transmitted by the father27, can develop juvenile HD, defined by 
disease onset before the age of 20 years28. 
CAG repeat length has further been reported to correlate with progression and duration of 
disease, with higher CAG repeats (and early disease onset) leading to faster progression and 
thus shorter disease duration29. However, despite these correlations, CAG repeat length 
explains only about 50 % of the variation in onset and course of disease24,26. Other genetic as 
well as environmental factors constitute significant modifiers of HD30,31. 
Wild type huntingtin protein 
HTT mRNA is expressed throughout the body with highest expression levels in neurons32–34. 
It is translated into the ~350 kDa (3144 amino acid) HTT protein with similar expression 
pattern35–37. Within cells, HTT is localized predominantly in the cytoplasm, where it seems to 
be concentrated along microtubules and attached to many membranous structures within cell 
somata, neurites and synapses38–41. 
Based in particular on its co-localization with microtubules, HTT has been considered to 
function as a scaffold protein involved in intracellular trafficking. This idea received support  
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from subsequent studies performed on cell and animal models of HD. HTT was found to 
interact directly with proteins involved in transport processes42–45 and to promote vesicular 
transport46 as well as endo-45,47 and exocytosis48. Further studies identified a multitude of other 
interaction partners of HTT, linking it to cellular pathways such as autophagy49–51, Ca2+ 
homeostasis52,53, cell metabolism54,55, cell signaling56,57, synaptic transmission58,59 and 
apoptosis60. Moreover, HTT has been found to bind to a variety of transcription factors61–64 
and proteins involved in translation60,65, which strongly implicates a role in gene expression. 
Interestingly, HTT is able to translocate from the cytoplasm to the nucleus in response to 
cellular stress signaling66. 
Due to its various functions within the cell, HTT is crucial for embryonic and postembryonic 
development, as demonstrated in mouse models of HD67–76. Its absence leads to early 
embryonic lethality67–69, while severely reduced expression results in a significant growth 
impairment75 and downregulation in adolescence causes neurodegeneration74. HTT’s vital 
function during adulthood is ascribed to anti-apoptotic properties77–80. 
Mutant huntingtin protein  
In HD patients, the mHTT allele is translated into a mutated protein (mutant huntingtin, mHTT), 
which carries an abnormally long glutamine (polyQ) stretch after amino acid 17 close to the 
N-terminus81. Similar to HTT, mHTT is abundant throughout the body82–84, even though 
degenerative processes are restricted to selective, neuronal tissues. In contrast to HTT, mHTT 
shows an abnormally high concentration in cell nuclei82,85. In addition, mHTT-expressing cells 
develop mHTT-containing protein aggregates in both nucleus and neurites85,86. 
The presence of the elongated polyQ stretch leads to a disruption of normal HTT function87 
as well as a toxic gain of function88. The pathogenic events in HD concern a multitude of 
different cellular pathways related to normal HTT function and beyond. These are affecting 
intracellular transport, gene as well as protein expression, protein degradation pathways, 
cellular energy metabolism, ion homeostasis, cell signaling and apoptosis88. 
It was initially believed that the mHTT aggregates found in HD patients85,86 and disease 
models89,90 were the primary source of disease pathogenesis. Characteristics of the  
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aggregation process seemed to explain the late age of onset of HD91 as well as the 
dependency of disease onset and progression on the polyQ repeat length90,92,93. However, a 
series of follow-up studies dissected the process of aggregate formation in relation to 
cytotoxicity94–98, leading to the overall conclusion that cell death is primarily induced by toxic 
aggregation precursors and that earlier results had been misinterpreted due to the causal 
relationship of precursors to aggregate formation99. 
N-terminal fragments of mHTT have been proposed to constitute such toxic aggregation 
precursors. This assumption is in part based on the findings that N-terminal mHTT fragments 
are more prone to form aggregates than full-length mHTT93,100,101. Fragments of mHTT are 
further found in the brains of HD patients post mortem89,92, and their abundance increases 
with longer CAG repeats and positively correlates with cell death in vitro77,95,100,102. Most 
importantly, it has been demonstrated that N-terminal mHTT fragments are more cytotoxic 
than full-length mHTT77,100,103. N-terminal fragments of mHTT derive from the cleavage by 
proteolytic enzymes. The two most prominent protease families implicated in proteolytic 
cleavage are calpains104,105 and caspases106. Inhibition of either protease has been shown to 
reduce aggregate formation and mHTT toxicity both in vitro105,107 and in vivo108,109. The 
particular toxicity of mHTT fragments is thought to be conveyed via a conformational 
change110–112, which affects protein interactions60,98,113 and disrupts signaling pathways. In 
addition, truncation of mHTT impairs its ability to shuttle between cytoplasm and nucleus in 
response to cellular stress signaling66. As a result, mHTT fragments accumulate in the 
nucleus85,89,105,114, which has been shown to enhance their detrimental effects94,100,115,116. 
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Models of human HD 
As molecular pathways underlying the mHTT-mediated pathogenesis cannot easily be 
investigated in HD patients, a multitude of disease models have been established to imitate 
the human pathological condition. 
Cell and animal models of HD 
Molecular aspects of HD have been studied intensely in mammalian cells including 
lymphoblasts35, fibroblasts117, embryonic stem cells118,119 and inducible pluripotent stem 
cells120 from HD patients and control subjects. In addition, cell lines93,106,121–123 and primary 
cell cultures94 expressing mHTT with various lengths of the protein and polyQ tract have been 
used. In order to further understand the disease on organismic level, animal models of HD 
have been established. Small invertebrates such as worms124 and flies125 can be used to study 
the order and progression of molecular HD-related phenotypes, while larger, mammalian 
species such as mouse126–140, rat141,142, sheep143, pig144 and monkey145 enable the analysis of 
systemic abnormalities and the interplay between cell populations in the body. Of these, 
rodent models certainly had the most impact on the evaluation of disease mechanisms as well 
as preclinical testing. 
As HD does not naturally occur in animals, it needed to be induced. In the first rodent models 
of HD, this was achieved by lesioning the striatum with injections of toxins such as 
kainate146,147, ibotenate148, quinolinate 149 or 3-nitroproprionate150. After the identification of 
the disease-causing gene, a range of genetic animal models were generated88. The models 
are typically classified according to the specific nature of their transgenic constructs. Some 
carry classic transgenic constructs that are inserted at random positions in the genome, and 
express either full-length or truncated mHTT under endogenous or exogenous promotors 
(transgenic models). In contrast, there are models where the CAG repeat of the endogenous 
HTT locus has been extended (knock-in models). Although knock-in and full-length transgenic 
models offer a better opportunity to study the mechanism behind mHTT pathogenicity, they 
are limited by having more discrete and slowly developing phenotypes compared to the 
transgenic fragment models, which express the more toxic species of mHTT88. The exact 
phenotypes associated with mHTT expression in these various models differ151–153. 
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Figure 1. Cell and animal models of HD 
The most widely used model organisms of HD are mammalian cell lines, such as the immortalized striatal 
precursor cell line STHdh (left), and genetic mouse models of HD, like the HdhQ111 knock-in mouse, the 
donor organism for the STHdh cell line. A common background strain for transgenic mouse models is the 
C57BL/6 mouse (middle). Sprague Dawley rats (right) were used as a background strain to create the 
two existing transgenic rat models. The latest of them, the BACHD rat, was characterized in this work. 
Photographs were taken in our laboratory and animal facilities. Scale bar: 10 µM. 
The BACHD rat model of HD 
The BACHD rat is the latest rat model of HD and has been generated in our laboratory142. 
BACHD rats overexpress full-length human mHTT with 97 alternating CAA/CAG repeats on a 
bacterial artificial chromosome (BAC). This construct has also been used to generate the 
BACHD mouse130. 
Two lines of mHTT-overexpressing BACHD rats have been established142. Line TG9 
expresses mHTT at 2.5 fold of the expression level of the endogenous rat huntingtin (Htt), 
which is comparable to the expression level of mHTT in the BACHD mouse. Line TG5 
expresses mHTT at 4.5 fold of the expression level of Htt, the highest expression level among 
the available founders. In both lines, the transgene is inserted at a single site. The position 
within the genome as well as the copy number of inserts likely define the differential 
expression between the two lines. In this work, primarily TG5 rats (Crl:CD(SD)-
Tg(HTT*97Q)21.2Hpn/Hpn) hemizygous for mHTT have been used, and will in the following 
simply be referred to as BACHD rat. 
In the original publication of the BACHD rat model, behavioral and neuropathological 
abnormalities reminiscent of HD in humans have been reported142. Similar phenotypes have  
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been detected in both lines, although they were stronger in line TG5 compared to line TG9. 
The behavioral abnormalities consist of motor dysfunction and psychiatric disturbances. With 
regard to neuropathology, BACHD rats display mHTT aggregates and nuclear accumulation 
of mHTT throughout the brain, detectable from early on and increasing with age. At advanced 
ages, the presence of dark neurons and reduced dopamine uptake in the striatum point to 
neurodegenerative processes. Later studies confirmed these initial findings and added to our 
current knowledge on the behavioral phenotype of the BACHD rat by providing indications for 
cognitive impairments154,155. 
A prominent pathological feature of the BACHD rat, which became apparent shortly after the 
generation of the rats, is the development of obesity. Metabolic abnormalities are part of the 
human HD pathology, and other mouse and rat models display various forms of metabolic 
disturbances, as detailed below. Thus, it was of interest to further investigate their 
characteristics, and to address them in a therapeutic approach, which was realized in this 
work. 
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Metabolic dysfunction in HD 
Systemic metabolic abnormalities in HD patients 
Besides the classical triad of symptoms, a variety of other abnormalities contribute to the 
burden of HD, which can be broadly classified as metabolic disturbances. Similar to the 
classical HD symptoms, metabolic disturbances vary largely in frequency and severity of 
manifestation among HD patients, suggesting a modulatory role of other genetic or 
environmental factors and making it difficult to assess their general role in HD. 
Symptomatic patients can present with endocrine abnormalities of the major hypothalamus-
pituitary axes, such as hypercorticotropism, hypersomatotropism and hypogonadotropism156. 
They often suffer from signs of autonomous nervous system dysfunction, like gastrointestinal, 
urinary, cardiovascular and, in men, sexual problems157. HD patients become progressively 
cachectic at late stages158–160, which has been attributed to the exhausting choreatic 
movements161–163 as well as dysphagia164, and the most common cause of death is aspiration 
pneumonia165. 
Preceding these severe manifestations during the end stage of HD, earlier signs of abnormal 
energy metabolism have been recognized, which are detectable before clinical symptom 
onset. There are indications for growth deficits, as significantly lower measures of head 
circumference, weight and BMI have been detected in children carrying the mHTT allele 
compared to healthy children166. Furthermore, intracranial volume has been found to be 
already reduced at the prodromal stage in HD mutation carriers167. In some studies, reduced 
body mass168–173 and increased metabolic rate161,162,174 have been detected before motor 
symptom onset. In addition, increased brain glucose consumption has been found in some 
areas of presymptomatic HD patients175,176, preceding overall reduced consumption rates at 
late stages of disease177–183. Remarkably, some mutation carriers have been shown to fail 
countervailing increased energy expenditure, despite increased caloric intake168,170,184. Some 
patients further show impaired glucose tolerance185–187 and insulin response174,188,189 as well 
as a higher risk to develop diabetes190, despite the waste of both lean170,172,184 and fat 
mass168,170. This suggests that the regulation of energy metabolism is highly disturbed. 
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It is still unclear, how this condition develops. As for the classical symptoms, the progressive 
degeneration of cell populations in the CNS, particularly the loss of hypothalamic neurons13, 
is held responsible. 
Systemic metabolic abnormalities in HD animal models 
Metabolic abnormalities, as well as causes and consequences, have been studied more 
intensely in rodent models of HD191. HD mice and rats develop metabolic abnormalities, 
although with variable characteristics (Table 1). 
Transgenic mouse models expressing N-terminal fragments of mHTT, are reported to have 
similar body weights as WT mice at young ages, but eventually show indications of impaired 
growth followed by progressive weight loss. These mice die prematurely during early 
adulthood. Knock-in mouse models in general show similar phenotypes, although they appear 
much later in life compared to the fragment mice, and are not always detected. On the 
contrary, the full-length mHTT-expressing mouse models are found to have increased body 
weights compared to their WT littermates. Reports on the tgHD fragment rat model of HD are 
inconsistent, with the initial characterization showing reduced growth and body weights, while 
later studies reported increased body weights compared to WT rats, particularly in females. 
Differences in body weight among animal models of HD are the result of changes in body size 
and body composition. Several models show an initial accumulation of fat mass and wasting 
of both fat and lean mass at older ages. Onset and severity of this catabolic condition seem 
to depend on the HD-related genetic context74–76 as well as on other genetic and 
environmental factors such as background strain192, gender152,193,194 and housing 
conditions195. Impaired growth and enhanced fat accumulation have been attributed to the 
decreased availability of insulin-like growth factor 1 (IGF-1)196,197, as well as dysfunctional 
adipocyte metabolism with impaired lipolysis and increased secretion of the hormone 
leptin198,199. Similar to HD patients, it could be demonstrated that cerebral hypometabolism is 
preceded by a hypermetabolic state with increased glucose consumption in the forebrain of 
HD mice153, supporting the idea of early hypermetabolism as a general feature of HD200. 
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Table 1: Abnormalities with regard to energy balance in rodent models of HD 
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Studies on insulin metabolism have demonstrated that insulin insensitivity is unlikely to be the 
cause for impaired glucose utilization in HD. Although it seems to be clear that insulin 
secretion is hampered due to impaired gene expression189 and exocytosis233,234, the deficits 
likely occur only in the presence of mHTT with very long CAG stretches, which are rarely found 
in adult onset HD patients235. 
Several studies suggest that not only central dysregulation, but also individual tissue defects 
seem to add to the metabolic phenotype in HD, as abnormalities in intrinsic pathways in 
muscle219,236, adipose199,211 and bone237 tissues (among many others238) have been 
demonstrated in HD animal models. However, by switching off mHTT expression only in the 
hypothalamus of the BACHD mouse, the metabolic phenotype has been completely 
abolished194, arguing against an important role of these individual pathways in shaping 
systemic metabolic abnormalities. 
Cellular energy metabolism in HD 
Similar to the classical signs of HD, metabolic abnormalities appear like a part of the HD 
symptomology that stems from neuronal dysfunction and degeneration. However, disturbed 
energy metabolism at the cellular level might play a much more important etiological role by 
triggering neuronal dysfunction in the first place153. 
Compromises in cellular energy metabolism in HD 
A large body of evidence has been collected to support the idea of disturbed cellular energy 
metabolism in HD based on findings in patients and animal models. Early glycolytic deficits 
are indicated by impaired glucose consumption despite unchanged oxidative phosphorylation 
in presymptomatic HD mutation carriers239. Reduced activity of several tricarboxylic acid 
(TCA) cycle enzymes further points to decreased TCA cycle turnover240–243, which can be a 
result of defective substrate supply via upstream oxidation processes (i.e. glycolysis, 
proteolysis and lipolysis), or reduced downstream flux (i.e. respiratory chain activity). Impaired 
respiratory chain activity mainly due to the decreased activity of complexes II, III and IV has 
also been found. However, the deficit has specifically been detected at symptomatic243–246 but  
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not presymptomatic247 stages, suggesting that these defects are secondary to other energetic 
restraints200. 
Metabolic disturbances can also be traced in tissues and body fluids from HD patients as well 
as HD animal models, with the most consistent findings being a decline in amino acid levels248–
250
 and creatine251–253, as well as an accumulation of lactate253–256. 
Mitochondrial dysfunction in HD 
Irrespective of their probable secondary role in dysfunctional cellular energy metabolism200, 
mitochondria are considered to be key players in translating energetic deficits into 
cytotoxicity257–262. Mitochondria host major metabolic pathways and orchestrate energy 
supply, Ca2+ homeostasis as well as cell death in response to cellular demands263. The 
presence of mHTT seems to interfere with all of these processes. Toxic effects have been 
suggested to result from direct binding of the N-terminal region of mHTT to the outer 
mitochondrial membrane264–268 or by disturbing the transcription of nuclear-encoded 
mitochondrial genes269,270. In HD patients and disease models, mitochondria have a reduced 
production rate of adenosine triphosphate (ATP)271–273, show impaired Ca2+ handling264–
266,274–277
 and release more reactive oxygen species resulting in oxidative damage242,243,278–
280
. More recent reports further highlight the importance of altered properties for morphological 
adaptations of mitochondria that are required for mitochondrial function and maintenance of 
mitochondrial integrity upon cellular stress281. In this regard, mHTT alters the activity of 
proteins of the fission and fusion machinery resulting in the fragmentation of the mitochondrial 
network267,282–287 and disrupts HTT-mediated transport processes leading to impaired 
mitochondrial trafficking285,287–289. 
Cellular energetic deficits and neurodegeneration in HD 
A causal relationship between energetic deficits and the neurodegenerative processes 
underlying the HD pathogenesis has been assumed after noting that inherited 
mitochondriopathies as well as disruption of mitochondrial function with the respiratory chain 
complex II inhibitors 3-nitropropionate150 and malonate290 were accompanied by selective  
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neurodegeneration and associated symptoms highly reminiscent of HD291. It was concluded 
that striatal neurons would probably demise through an excitotoxic mechanism, as excitotoxin 
application revealed similar selective lesions291. 
Excitotoxicity292 refers to the excessive activation of glutamate receptors, prominently the 
ionotropic N-methyl-D-aspartate (NMDA) receptor, leading to intracellular Ca2+ overload and 
ultimately the death of the postsynaptic neuron293. Mitochondria are crucially involved in this 
cascade. When mitochondrial Ca2+ buffering is insufficient, elevated cytosolic Ca2+ levels lead 
to the activation of numerous signaling pathways that act back on the organelles and trigger 
the initiation of cell death294. This is mediated by mitochondrial permeability transition (mPT), 
a process characterized by the formation of a pore complex in the inner mitochondrial 
membrane. Pore formation results in the dissipation of the proton gradient, disruption of ion 
homeostasis as well as ATP production, and subsequent organelle swelling and outer 
membrane rupture, although the details of this process are still under debate295,296. 
Energetic deficits enhance the vulnerability for excitotoxicity297,298, particularly in striatal 
medium-sized spiny neurons (MSNs)299. MSNs show a generally reduced Ca2+ buffering 
capacity277,300,301 and preferentially express the NR2B subtype of the NMDA receptor302, which 
has been linked to excitotoxicity303. The selective vulnerability to excitotoxicity is further 
enhanced in the presence of mHTT. Studies have identified several pathological effects of 
mHTT expression that can trigger excitotoxicity in HD striatum, including impaired glutamate 
reuptake, increased postsynaptic glutamate receptor activity as well as intracellular 
sensitization of Ca2+ release by the endoplasmic reticulum (ER)304. It remains elusive though, 
where the cascade of events that ultimately terminates in the selective death of vulnerable 
neurons starts. The detrimental processes might not be triggered by one event alone, but 
rather be the result of a multitude of concurrent insults overcharging the cell. 
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Therapeutic strategies for HD 
To date, there is no medication available that can slow down or prevent the onset or 
progression of HD in humans. Current therapies are restricted to alleviating disease symptoms 
and thereby improving the patients’ quality of life. However, several promising treatment 
strategies are under investigation, which raise hope for the future. 
Present and future treatment of HD 
A variety of symptomatic treatments are indicated for HD. Exercise and a balanced nutrition 
are recommended to support health in general. Physiotherapy can be useful to strengthen 
muscles or loosen rigidities, and speech language therapy can ameliorate speech and 
swallowing problems. In addition, psycho-social support can help patients and their family 
members to cope with the burden of HD. Symptomatic medical treatment further targets motor 
as well as cognitive and psychiatric pathologies, but as the drugs often evoke side effects and 
interfere with each other, their usefulness has to be outweighed according to the symptoms 
of the individual patient. Commonly prescribed drugs to reduce involuntary movements are 
dopamine antagonists (e.g. haloperidol) or presynaptic dopamine depleters (e.g. 
tetrabenazine). Psychiatric symptoms are treated with antidepressants (e.g. carbamazepine), 
antipsychotics (e.g. clozapine), anxiolytics (e.g. benzodiazepine) or tranquilizers (e.g. 
chlorpromazine).305 
Therapeutic strategies for HD have been developed for basically every aspect discovered to 
be involved in the disease pathogenesis, and at least minor benefits have been demonstrated 
for a multitude of compounds and approaches in preclinical studies88. Unfortunately, promising 
candidates have so far failed to exert disease-modifying effects in clinical trials in HD 
patients306. Due to the increasing understanding of the disease though, the research 
community awaits a breakthrough in the coming years307. Among strategies such as 
enhancing mHTT degradation, improving neurotrophic support and reducing inflammation, the 
most promising therapeutic approach is the reduction of mHTT expression308. The single 
mutation and sole genetic cause responsible for HD enables the direct targeting of the inflicted 
protein on the transcriptional or translational level. RNA interference309,310, translational 
repression with antisense oligonucleotides311 and transcriptional repression using zinc finger  
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proteins312 have proven to be successful and beneficial in animal models. Delivery and 
distribution issues as well as allele-selectivity and -specificity constitute the major areas of 
research in this area308. 
The therapeutic compound olesoxime 
Olesoxime is a cholesterol derivative, which was discovered in a small-molecule screen for 
neuroprotective compounds at Trophos SA, Marseille (www.trophos.com). In the initial 
screening, primary motor neurons were deprived of serum, incubated in the presence or 
absence of olesoxime, and survival was monitored313. The screen revealed highly beneficial 
effects of the compound. Further assays on neurons subjected to other pathological stimuli, 
including striatal neurons transfected with mHTT, all showed increased survival314. 
Binding and localization analysis revealed that the compound concentrates at the site of 
mitochondria314 and interacts with the voltage-dependent anion channel (VDAC)315 as well as 
the translocator protein (TSPO)316 on the outer mitochondrial membrane313. As these proteins 
are considered to play a role in mPT317, it was proposed that olesoxime’s mechanism of 
neuroprotection was the inhibition of mPT and subsequent cell death313. In accordance with 
this idea, olesoxime was found to prevent cell death induced by various toxins313,314,318 to a 
similar magnitude as cyclosporine A, a potent mPT inhibitor. Further studies discovered a 
variety of interesting aspects around olesoxime’s molecular effects, but the exact mechanism 
of cytoprotection remained elusive. Olesoxime was reported to prevent cytochrome c release 
from mitochondria and the subsequent activation of caspases in the cytosol319. These effects 
did not seem to derive from improved mitochondrial Ca2+ handling or inhibition of Ca2+ 
release314. Olesoxime further did not directly inhibit caspases, activate prosurvival kinases or 
modulate the transcription of proapoptotic genes via the transcriptional regulator p53319. 
Besides the direct effect on the initiation of mitochondria-mediated apoptosis, olesoxime was 
found to promote microtubule-based neurite outgrowth and microtubule-dependent 
mitochondrial transport, specifically in differentiated neuronal cells320, and to improve 
oligodendrocyte-mediated remyelination321. 
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In vivo studies demonstrated consistently beneficial outcomes regarding neuroprotection and 
regeneration in animal models of motor neuron diseases313,314,322 as well as 
neurodegenerative disorders314,321,323, and neuroprotective and antinociceptive effects in 
models of peripheral neuropathies320,324–326. 
The therapeutic potential of olesoxime was further investigated in clinical trials on motor 
neuron diseases. Olesoxime showed excellent safety and tolerability in the patients314. 
Moreover, the treatment was easy to apply, as olesoxime reaches the brain in sufficient 
amount upon oral administration of one daily dose327, and therefore medication does not 
involve invasive or time-consuming procedures. Two trials, one on survival in end-stage 
amyotrophic lateral sclerosis (ALS) patients327 and one on motor symptom onset in early stage 
spinal muscular atrophy (SMA) patients328 were conducted. The ALS trial revealed a negative 
outcome, while the trial on SMA patients showed striking beneficial effects on the clinical end 
point, suggesting better efficacy of olesoxime in early phases of disease. 
As no further studies were performed to investigate the effects of olesoxime treatment in an 
animal model of HD despite the positive in vitro results329 and the implication of mitochondrial 
dysfunction in HD200, it would be of significant interest to investigate a potential therapeutic 
effect of olesoxime on the HD pathology in vivo, as performed in this work. 
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Objectives of the current work 
The primary aims of this work were to identify and characterize abnormalities in energy 
metabolism in the BACHD rat model of HD, as well as to therapeutically target metabolic 
defects with the compound olesoxime. These aims were pursued in several independent 
studies: 
I. Validation of a system for automated metabolic phenotyping of rats 
The reliability of automated behavioral phenotyping in general and the assessment of 
metabolic parameters in particular were investigated in four commonly used wild type rat 
strains. 
II. Characterization of metabolic abnormalities in the BACHD rat 
Three studies were designed to assess the body constitution, systemic energy homeostasis 
and blood metabolite profile of the BACHD rat. Moreover, mitochondrial function was analyzed 
in primary neuronal cultures and in brain tissue from adult BACHD rats. 
III. Evaluation of olesoxime treatment effects 
A treatment study was carried out in order to evaluate a potential therapeutic effect of 
olesoxime in the BACHD rat. This study included phenotypes evaluated before, but also 
extended the characterization of the BACHD rat. Thus, it should be noted that the 2nd and 3rd 
part are not completely separate, and some findings on metabolic abnormalities, represent 
data obtained during the treatment study. 
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Ethical statement 
All experiments described herein involving animals were carried out by persons with 
appropriate training and expertise. Operating procedures were approved by the local ethics 
committees and carried out in accordance with the guidelines of the Federation of European 
Laboratory Animal Science Associations and the German Animal Welfare Act, based on 
European Union legislation (Directive 2010/63/EU). 
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Results and discussion 
I. Automated metabolic phenotyping in rats 
Detailed behavioral characterization is an important part of establishing novel animal models 
in a variety of research fields, and automated behavioral observation has been promoted to 
provide in several ways better behavioral measurements than classical tests330,331. First, these 
systems offer a standardized testing environment to reduce variability, while also allowing for 
customization of the setup to run specific protocols. Second, as measurements are highly 
computerized, behavioral data are gathered objectively. Third, the systems are able to 
measure a broad spectrum of parameters simultaneously, providing amounts of data which 
an experimenter could not obtain manually. Last, the systems offer the opportunity to assess 
behavioral parameters over longer periods of time, so that – theoretically - novelty-induced 
and baseline behavior can be separated. Due to these extended possibilities, we aimed at 
utilizing an automated test system for the behavioral and metabolic characterization of the 
BACHD rat. 
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Validity of automated phenotyping in rats 
(Publication IV and Appendix A) 
For the characterization of the BACHD rat, the PhenoMaster automated behavioral 
phenotyping system for rats, produced by TSE Systems Germany, was purchased. As the 
system had not been validated before, the reliability of its test results was addressed by 
analysis of behavioral data from four commonly used wild type (WT) rat strains known to differ 
in their behavioral characteristics (Publication IV332). WT rats of the strains Lister Hooded, 
Lewis, Fischer 344 and Wistar (Figure 3) were observed at three different ages over 70 hours 
in individual home cage-like testing cages, measuring locomotor activity, fine movements, 
food and water intake, the volume of oxygen (VO2) consumed and the volume of carbon 
dioxide (VCO2) released. 
 
Figure 2. The rat strains used for the validation of automated phenotyping 
In order to validate the automated behavioral phenotyping system, PhenoMaster, the behavior of rats 
from the four rat strains Lister Hooded, Lewis, Fischer 344 and Wistar (from left to right), was assessed. 
The rats differ in morphological appearance, physiological parameters and behavioral characteristics. 
Photographs display 6 weeks old rats in our animal facility. 
The measurements were found to be sensitive enough to reveal phenotypic differences 
between the strains, and reliable enough to recapitulate general behavioral characteristics 
that were in accordance with previous results from classical tests333,334. In addition, the 
automated phenotyping generated new data on the rat strains such as the dissection of 
novelty-induced and baseline behavior as well as differences in the circadian activity pattern. 
However, when rats from the same four strains were reinvestigated in another automated 
phenotyping system (PhenoTyper, Noldus Information Technology, The Netherlands), 
specifically the differences in circadian activity were not reproduced, questioning their actual 
validity (Appendix A and Reference335). Moreover, detailed analysis of the metabolic data 
revealed the presence of some form of stressor, as two of the four rat strains showed a drop  
Results and Discussion 
Automated metabolic phenotyping in rats 
31 
 
 
in body weight gain during the experiments compared to the week before and after the 
measurement (Publication IV332 and Reference336). This stress effect was also found in 
Sprague Dawley rats, which form the background of the BACHD rat model336. 
It can be assumed that the stress response had been induced by the social and environmental 
changes during the test, specifically the individual housing in cages differing from the home 
cage in acoustic and olfactory environment as well as micro-climate. In this regard, it is known 
that the transfer of animals to a novel environment and the separation from their social group 
can induce stress in rats337–341. Also, the stress response was less pronounced for rat strains 
known to be less anxious342,343. 
Importantly, as the negative effect differed in magnitude for all rats, it can be considered to be 
a confounding factor. This is illustrated by the finding that values for food intake and VO2 from 
strongly affected rats were lower than expected from their respective body sizes. Thus, the 
automated phenotyping did not seem to give a fair picture of the differences between the rat 
strains, and metabolic data in particular was likely biased by inter-strain differences in stress 
resistance. 
Summary and outlook 
The data suggest that automated behavioral phenotyping offers the possibility of gathering 
large data sets, which would likely be impossible to obtain in similar amount and detail in a 
manually manner. However, the studies also point out that the outcomes from such tests need 
to be analyzed carefully, as their validity is unclear and results might be confounded by 
potential stress-inducing factors. Systems with the opportunity of measuring groups of animals 
might provide more reliable outcomes, but this needs further evaluation. 
To resolve the role of isolation and novelty in inducing stress during automated behavioral 
phenotyping, three groups of rats will be studied, either socially housed throughout the study, 
individually housed directly upon transfer to the test cages or individually housed after 
acclimatization to the test cages in a social environment. With this setup it should be possible 
to determine, if stress is induced by changes in the social environmental conditions, by 
changes in the environment alone, or by an interaction of social and non-social factors. 
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II. Metabolic abnormalities in the BACHD rat 
Soon after the generation of the BACHD rat, it became clear that the animals display some 
form of metabolic dysfunction, as they appeared obese. Knowing of metabolic abnormalities 
in other HD disease models including the BACHD mouse (Table 1), and the occurrence of 
metabolic problems in HD patients, this observation led to evaluate abnormalities in metabolic 
function as HD-related pathology in the BACHD rat. 
The chapter is divided into the three major parts: 
 Systemic metabolic disturbances 
 Mitochondrial dysfunction 
 Conclusion 
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Systemic metabolic disturbances 
Longitudinal analysis of body constitution 
(Publication VI344 and Appendix B) 
In order to confirm the impression of altered body constitution, the body weight, size and 
composition of BACHD and WT rats were assessed. 
Body weight 
The body weight development of numerous cohorts of BACHD rats from line TG5 has been 
followed by now (Publication II142, VI344, Reference154 as well as Jansson and Clemens et al., 
unpublished) up to an age of 18 months (Publication II142). In most cases, BACHD rats have 
been found to show identical body weights to WT rats. Occasionally though, significantly 
reduced body weights have been found in some cohorts, particularly when the thorough 
analysis of litter pairs was conducted (Clemens and Jansson et al., unpublished). These 
results stand in contrast to what was expected given the rats’ obese appearance. The 
assumed increase in fat mass despite similar or even reduced body weight further suggests 
that BACHD rats have a lower lean mass compared to WT rats. 
Body size and composition 
In order to test the hypothesis of reduced lean mass, the rats’ body composition was 
investigated by detailed dissection (Publication VI344 and Appendix B). As proposed, BACHD 
rats were found to carry excess amounts of adipose tissue and to have lower lean masses. 
The difference in lean mass was the result of reduced bone and muscle as well as organ mass 
and came along with an overall reduced body size. Differences were already detectable at 1 
month of age, and did not show any progression from 3 months onwards. Thus, BACHD rats 
show growth impairment and obesity. 
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Figure 3. The BACHD rat 
BACHD rats (upper row) have a distinct morphological phenotype. Most prominent are an adolescent 
face, small head and obese appearance compared to WT littermates (lower row). The pictures show adult 
rats at the age of 6 months. 
Interestingly, male rats of line TG9 show consistently lower body weights compared to their 
WT littermates (Publication II142 and Yu-Taeger et al., unpublished). Thus, it is possible that 
the lean mass phenotype is similar for rats of line TG9 and TG5, while the obesity phenotype 
is more pronounced in TG5 rats. Preliminary results from the dissection of female BACHD rats 
further indicate that females do not show similar differences in body size and body 
composition, with the brain being the only detectable dystrophic organ (Yu-Taeger and 
Clemens et al., unpublished). Similar gender differences were found in HD patients168, 
suggesting that gender is an important modifier of the metabolic phenotype in HD. 
It has been assumed in the past that developmental deficits do not play a role in HD, as mHTT 
expression was found to rescue embryonic lethality caused by loss of HTT69,130,131, and 
homozygous HD mutation carriers appeared to develop normally before the onset of HD 
symptoms345. However, subtle differences might have been overlooked, as morphometric 
measurements had not specifically been undertaken in those study groups, while there are 
indications for reduced body size in children at risk for HD166. It is likely that the magnitude of  
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this phenotype might be enhanced in rats not only due to the long CAG repeat and the 
overexpression of mHTT, but also due to species-specific effects of large litter sizes and 
nursing effects, which are not present in humans. Thus, further investigations on HD patients 
are required to better understand the disease and to evaluate the role of body size and body 
composition phenotypes in HD. 
Effects of altered body constitution on other phenotypes 
(Publication VI344) 
Differences in body size and body composition in an animal model might obscure results 
obtained from behavioral analyses. For instance, it has been shown that Rotarod 
performance, a commonly used indicator for striatum-based motor dysfunction346, depends 
on body weight with lighter animals performing better than heavier ones347. It was further found 
that motivational aspects play an important role in modulating motor test outcomes348. This 
again relates to differences in body constitution, as it has been shown that leptin, which is 
positively associated with the amount of white adipose tissue stored in the body198, is a 
negative regulator of neuronal circuits of motivation349. 
In the light of these findings, and considering the abnormal body constitution observed in the 
BACHD rat, it was reasoned that the altered body constitution of BACHD rats likely modulates 
the outcome of tests based on the motivation to work for food rewards, a common strategy 
used for the positive reinforcement in conditioning experiments (Publication VI344). A variety 
of operant conditioning tests working with food reward are currently used in our laboratory for 
the cognitive characterization of the BACHD rat (Publication VI344 and Jansson et al., 
unpublished). Thus, it was of interest to investigate, if BACHD rats displayed altered 
motivation to work for food rewards. For this reason, the rats’ performance was assessed in 
the progressive ratio (PR) test, a common motivational test, as well as in a free-feeding 
experiment measuring the rats’ general hunger levels. When WT and BACHD rats were food-
restricted to reach the same percentage of their free-feeding body weight, BACHD rats were 
less motivated in the PR test. However, the free-feeding test revealed that BACHD rats were 
per se less hungry under this food restriction regimen. Adjusting the level of food restriction  
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by feeding WT rats more than BACHD rats eliminated the difference in free food intake as well 
as in PR performance. This suggests that BACHD rats do not have a general lack of 
motivation, but need to be food-restricted differently from WT rats to be equally hungry due to 
their obscured body constitution. The idea is supported by the finding that food restriction to 
equal free-feeding and PR results, concomitantly led to a discrete difference in body weight 
between BACHD and WT rats, which reflected the difference in lean mass. 
Measurement of energy homeostasis 
(Publication I350, II142, VI344, Appendix B, C and D) 
Impaired growth and the development of obesity can be indicators of disrupted energy 
balance, which is characterized by a dysequilibrium in the relation of energy intake to energy 
expenditure. In order to investigate why BACHD rats display a distorted body constitution, 
aspects of the rats’ energy balance were therefore assessed in several longitudinal studies. 
Activity 
Locomotor activity, a considerable contributor to energy expenditure, was measured in 
individually-housed rats kept for 70 hours in the PhenoMaster system (Publication II142). 
BACHD rats displayed reduced horizontal (ambulation) and vertical (rearing) activity 
compared to WT rats at 3 and 6 months of age, when a metal grid cage top (similar to the rats’ 
home cage lid) was used. The difference in both parameters disappeared after changing to 
flat, solid, plastic lids in order to implement respirometric measurements at the age of 
9 months, as described below. Although it is possible that the vanishing of this phenotype was 
due to age-related changes, this is rather unlikely as a second cohort of rats subsequently 
tested in the metabolic cage setup from 2 months onwards, did not show hypoactivity at any 
age (Appendix C). Thus, it is probable that the metabolic cage setup itself had influenced the 
behavior of the rats, possibly by leading to reduced activity of WT rats under these conditions. 
In a separate study performed by collaboration partners155, the activity of BACHD rats was 
reinvestigated during a 1 hour exposure to an empty arena. Interestingly, the rats exhibited 
initial hyperactivity at 1 month of age and a gradual decline in locomotor activity with age, 
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becoming significantly reduced compared to WT rats at 4 months. It is likely that the 
measurement of locomotor activity in such short trials reflects differences in exploratory 
behavior, anxiety or habituation rather than baseline activity. In this regard, BACHD rats have 
been found to be more explorative155 as well as less anxious (Publication II142 and VII) than 
WT rats using different tests. However, such differences might still be important, as they might 
translate into altered activity levels and affect daily energy expenditure under normal housing 
conditions. 
Altogether, it remains uncertain, if the rats differ in their baseline locomotor activity. A separate 
analysis of locomotor activity starting before the age of 1 month and conducted in the rats’ 
home cages might reveal a final conclusion. This should also preferably be performed with 
social groups rather than isolated animals, as the studies on the establishment of the 
PhenoMaster system have indicated potential stressful effects of the temporary isolation 
(Publication IV332 and Appendix A). 
Food intake 
Data on food intake as a measure of energy intake were gathered in the PhenoMaster system 
in the course of study II142 and VII (Appendix C). The overall amount of food consumed was 
significantly lower in the BACHD rat. However, considering that BACHD rats were found to be 
smaller than WT rats, this reduced food intake in absolute measures might simply reflect the 
rats’ smaller body size. Relating food intake to body weight is unlikely to reveal a better 
measurement, as the rats also differ in body composition. Thus, the rats’ food intake was 
normalized to their approximate lean mass to account for their smaller body size (Appendix C). 
After lean mass adjustment, BACHD rats showed significantly higher food intake at 2 months, 
and similar food intake compared to WT rats at older ages (Appendix C). 
As the studies on establishing the PhenoMaster system had indicated that animals might not 
feed properly during the observation period (Publication IV332 and Appendix A), the results 
were validated in a manual, longitudinal assessment of ad libitum food intake in a cohort of 
pair-housed BACHD and WT rats in their home cages (Publication VI344). Despite the initial 
doubts, the results from the second study replicated the earlier findings. The study confirmed  
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the increased food intake at early ages (here detected between the age of 6 and 9 weeks), 
and revealed stable, but moderately lower, food intake from approximately 19 weeks onward. 
Interestingly, an additional difference in food spillage was detected between BACHD and WT 
rats, with BACHD rats leaving significantly less food spillage behind than WT rats 
(Publication VI344). It is unknown, if this reflects a lower amount of food spilled by the rats, or 
if BACHD rats eat more of the food dust they produced, since the food dust might be easier 
to access compared to the food in the food grid. This behavioral difference represents an 
interesting aspect for further evaluation and has to be taken into account in future studies 
involving food intake measurements in BACHD rats. 
Water intake 
During studies II142, VI344 (Appendix B) and VII (Appendix C), the rats’ water intake was 
measured. BACHD rats showed dramatically reduced water intake in all studies. When the 
water intake measured in the PhenoMaster was normalized to lean mass, the phenotype 
vanished (Appendix C). However, the difference in absolute water intake was much more 
pronounced when measured in the rats’ home cages, still suggesting a true difference. 
Considering the results from the dissection study (Publication VI344), reduced water intake 
might be linked to the particularly low weights of organs involved in water balance, such as 
pancreas, salivary glands and kidneys (Appendix B). The results further imply that even 
though BACHD rats were obese, they did not develop diabetes at least until the age of 
12 months, as this would typically be accompanied by increased water intake351. 
In an earlier study on water balance, which is commonly referred to, the assumption has been 
made that increased thirst and drinking reflect general features of HD352. However, the data 
presented in this study does not support the authors’ conclusion. First, they had observed that 
R6/2 mice have a higher absolute water intake, but this was only found at older ages, when 
these mice tend to be diabetic353. Considering that R6/2 mice (like BACHD rats) have been 
described to have increased food intake at young ages195, this suggests a reduced water to 
food ratio and thus reduced water consumption of R6/2 mice at young ages, similar to our 
findings. Second, HD patients had been asked to fill a questionnaire on dry mouth 
experiences, where they reported the frequent incidence of such situations. That the patients 
did frequently experience a feeling of dry mouth, however, rather points to inadequate fluid 
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intake or disturbed water balance, which would again indicate decreased and not increased 
water intake in relation to their demands. 
Oxygen consumption rate and respiratory quotient 
The PhenoMaster system was equipped to measure the rates of VO2 and VCO2 (Appendix C), 
which provide information on energy expenditure and substrate oxidation354. BACHD rats 
were found to have decreased absolute values of VO2, but again the difference disappeared 
when related to lean mass. 
Interestingly, a progressive increase in VO2 was detected with age during the light phase, 
reaching statistical significance at 12 months. This finding was accompanied by a trend 
towards increased fine movements during the light phase at 12 months of age, and is 
reminiscent of higher sedentary energy expenditure found in early symptomatic patients due 
to chorea162. Thus, this might indicate that BACHD rats develop involuntary movements at 
older ages. 
The presence of increased food intake despite similar levels of activity and VO2 suggests that 
the rats were in a positive energy balance and might thus give an explanation for the 
development of obesity in the BACHD rat. On the other hand, increased food intake does not 
necessarily correlate with increased calorie intake. Gastrointestinal malabsorption has been 
described for HD mice355 and might also be present in BACHD rats. 
In line with the difference in relative food intake, an increase in the respiratory quotient (RQ, 
the ratio of VCO2 to VO2) was detected in the BACHD rat at 2 months of age, and a trend 
towards reduced RQ was found from 6 months onwards (Appendix C). Viewed together with 
the results on food intake and VO2, this indicates a high energy demand at young ages, which 
is covered specifically by carbohydrate metabolism. A low RQ is typically found under 
starvation, when carbohydrate sources are unavailable. This latter result might be related to 
suppressed feeding in older animals in response to PhenoMaster exposure as shown earlier 
(Appendix A and Reference336). Since it is unclear, if BACHD and WT rats were similarly 
affected by the stress-inducing effect, the results should be interpreted with caution. 
Defects in the regulation of metabolic functions have been implicated in HD174. Although, 
explicit studies on this issue were not performed, several observations suggest that regulatory 
function per se is not impaired in the BACHD rat. As BACHD rats have been found to grow 
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improperly, the increased food intake observed at young ages might be considered as a 
regulatory response to provide better nutritional supply and enhance growth. As BACHD rats 
further become obese, the subsequent reduction in food intake might be regarded as a 
regulatory response to counteract further fat accumulation. Another important regulatory 
function that concerns energy metabolism is the regulation of body temperature. N171-82 Q 
mice have been reported to have difficulties maintaining their body temperature, particularly 
upon cold exposure216. Cold stress response was not evaluated here, however body 
temperature was measured at baseline (Yu-Taeger et al., unpublished) and during stress-
induced hyperthermia experiments (Clemens et al., unpublished). No difference between 
BACHD and WT rats were detected up to 12 months of age, further suggesting functional 
regulatory circuits at these ages. 
Blood parameters as surrogate markers of HD 
(Appendix D) 
As blood parameters can be useful surrogate markers of disease, specific parameters related 
to the growth defect and obesity found in BACHD rats were investigated, and a serum 
metabolite profile was generated. 
IGF-1 and leptin levels 
In line with the body size and body composition phenotype of BACHD rats (Publication V344 
and Appendix B), plasma levels of IGF-1 were found to be decreased and leptin levels to be 
increased in BACHD compared to WT rats (Appendix D). Reduced IGF-1 levels were also 
detected in primary striatal neurons from BACHD rat embryos (Appendix E), underlining the 
contribution of this pathology to the BACHD rat phenotype, and pointing to an early deficit. 
Seemingly controversial results have been obtained for IGF-1 and leptin levels in patients and 
mouse models of HD. However, when taking a closer look, the results indicate that alterations 
in these two factors are quite certainly linked to mHTT expression, and that temporal changes 
in IGF-1 and leptin levels in the course of disease are responsible for the differential outcomes. 
Moreover, a masking effect of background strain differences, as well as a modulating effect 
of the specific characteristics of the mHTT protein introduced, likely contribute, as discussed 
in Appendix D. 
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Blood metabolite profile 
Based on CSF and serum metabolites, a dysregulation of energy metabolism was found in 
the tgHD fragment rat model of HD222, as analyzed by 1H nuclear magnetic resonance 
spectroscopy (1H NMRS) performed by a collaboration partner (Publication I350). An additional 
longitudinal analysis of serum samples from BACHD rats produced valuable data on the time 
course of metabolic alterations (Reference356 and Appendix D). In this study, significant 
abnormalities in serum metabolites related to energy metabolism were detected in the BACHD 
rat. Reduced serum levels of glucose, lactate, and amino acids, as well as increased lipid 
levels were found at young ages, while an accumulation of glucose and lactate as well as the 
depletion of lipids was detected at old ages. These results are interpreted as a triphasic course 
of metabolic dysfunction, with an early phase of energetic restraint during the major growth 
phase due to impaired utilization of lipids for energy supply, a phase of normal metabolic 
function during adulthood, and a phase of energetic restraint due to impaired glucose 
utilization based on mitochondrial dysfunction during senescence. 
The early deficit in lipid utilization cannot only explain the accumulation of fat mass, but also 
the growth deficit in the BACHD rats, as it suggests that the rats had to use amino acids to 
cover their energy demands, leading to a lack of building units for protein synthesis, and to 
reduced secretion of IGF-1357. 
Moreover, the results support the idea of temporal changes in the appearance of metabolic 
abnormalities. Early alterations seem to be triggered by the high energy demand of growth 
processes, while alterations at the late age of 18 months are likely associated with ageing, 
and mirror changes found in symptomatic HD patients. It is possible that similar, early changes 
are present in HD mutation carriers during development, but this has not been investigated so 
far. Furthermore, the temporal variability of metabolic alterations might possibly explain why 
metabolic abnormalities are not always detected in HD mutation carriers. 
Summary and outlook 
The studies demonstrate that BACHD rats show systemic metabolic abnormalities, which lead 
to growth impairment and obesity. The alterations underlie a specific temporal pattern related 
to growth and ageing, and are likely triggered by sustained compromise in mitochondrial 
function. Moreover, metabolic phenotypes can confound other test results. 
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The confounding effect of differences in body constitution on motivational aspects might 
underlie differences in leptin levels. Measurement of the rats’ leptin levels at different food 
restriction regimes could reveal conclusions on this. A thorough reanalysis of behavioral 
parameters assessed in the rats so far on possible bias due to the obscured body constitution, 
should further be considered. 
Concerning the temporal pattern of metabolic alterations, it would be particularly interesting 
to evaluate, if HD patients show similar early changes. In order to address this question, the 
analysis of metabolic dysfunction in HD patients would need to be extended to very early, 
presymptomatic ages, preferably to the growth phase. However, involving children at risk is 
difficult because of ethical concerns. Thus, another approach to evaluate the generality of 
these early alterations in HD would be to assess early metabolic dysfunction in other HD 
animal models. 
For future studies on the BACHD rat, it would be important to implement younger as well as 
older ages into the screening. Concerning the young ages, malnourishment of pups during 
their early postnatal development might be a possible enhancing factor in the development of 
growth deficits, and could be causal for the variability observed in body weight among different 
cohorts. A study of the phenotypes of BACHD rats from large and small litters might shed light 
on this issue. Older ages would be interesting to assess, as it is possible that BACHD rats 
reach an age, where they ultimately start losing weight and show neurodegeneration similar 
to the late appearance of such phenotypes in the tgHD rat141. 
Finally, it would be of utmost interest to know what the initial events leading to fat accumulation 
and impaired glucose metabolism are. Still, only little is known about the exact cellular 
pathologies leading to these deficits199,211. Also, it is unclear to which proportion CNS and 
peripheral tissue dysfunction contribute to the initiation of systemic metabolic dysfunction. In 
this regard, the BACHD rat constitutes an excellent model to study the contribution of different 
organs to disease pathogenesis, as the transgene contains LoxP sites, which enable the 
directed inactivation of the gene through Cre-mediated excision. Studies on this have been 
made in the BACHD mouse, and the results suggest that the development of obesity depends 
largely on the expression of mHTT in the hypothalamus194. However, the cellular mechanisms 
behind this finding could not be identified so far212,213. 
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Mitochondrial dysfunction 
As mitochondrial dysfunction is a prominent feature of HD257–262, and the investigations on 
systemic metabolic abnormalities of BACHD rats revealed indications for mitochondrial 
deficits, markers of mitochondrial function were analyzed ex vivo. Mitochondrial oxidative 
phosphorylation via the enzymes of the respiratory chain represents the major pathway of 
cellular energy production and hence an important target. Furthermore, compromised 
respiratory function might cause, or result from, other deficits such as reduced glycolytic flux 
or impaired mitochondrial network dynamics, which were also addressed in the following 
studies. 
Mitochondrial respiration 
(Publication III358 and VII) 
A collaboration partner investigated mitochondrial respiration in the presence of different 
substrates in primary cortical and striatal neurons from BACHD rat embryos 
(Publication III358). Interestingly, mitochondrial respiratory capacity rather than the activity of 
individual complexes was found to be compromised. This deficit was only observed in striatal 
neurons when relying on physiological levels of glucose for energy production. In the presence 
of supraphysiological glucose levels, or when supplemented with pyruvate or lactate, striatal 
neurons showed no deficits, suggesting hampered glycolytic flux as underlying cause. 
Anaerobic glycolysis was also found to be impaired in these cells. The findings suggest a 
defect in glycolysis rather than mitochondrial respiratory chain deficiency at early ages in the 
BACHD rat. Mitochondrial respiratory chain deficits are also not found in HD patients before 
reaching late stages200, while decreased glycolytic capacity is detectable at prodromal 
stages239. 
However, it is important to note that the reactions of the glycolytic pathway are not 
disconnected from mitochondria. In particular, the initial step of glycolysis and crucial 
pacemaker for glucose import into cells, the phosphorylation of glucose by the enzyme 
hexokinase, depends on hexokinase binding to mitochondria359. 
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In contrast to the results from primary embryonal cultures, a mild respiratory deficit was 
detected in live brain mitochondria from 13 months old BACHD compared to WT rats, with 
significantly lower complex II and IV activities (Publication VII). This deficit was accompanied 
by a distinct decrease in the protein levels of ATP synthase (Publication VII), suggesting 
reduced mitochondrial energy production in these rats. Reduced complexes II–IV activities 
have been found particularly in striata from HD patients246,360. The findings add support to the 
conclusion made from serum metabolite analysis, which is that dysfunctional mitochondrial 
respiration plays a role in the BACHD rat, but at older ages. 
Ca2+ homeostasis 
(Publication VII) 
Changes in respiratory activity might in several ways be linked to altered Ca2+ homeostasis. 
Reduced mitochondrial respiratory activity might evoke increases in intracellular Ca2+, as this 
would lead to impaired energy availability for maintenance of ion homeostasis and to reduced 
mitochondrial Ca2+ buffering capacity due to reduced mitochondrial membrane potential. On 
the other hand, increased intracellular Ca2+ levels might be causative for mitochondrial 
respiratory defects due to mitochondrial Ca2+ overload. Although there was no opportunity to 
directly measure Ca2+ levels, indications for disrupted Ca2+ homeostasis were found 
specifically in the cerebral cortex of 13 months old BACHD rats, as discussed below. 
IP3R 1 
BACHD rats showed increased cortical levels of the ER Ca2+-exporter inositol-1,4,5-
trisphosphate receptor 1 (IP3R 1), which is upregulated in response to elevated cytosolic Ca2+ 
levels361 (Publication VII). Interaction with mHTT has been shown to facilitate IP3R 1 activity 
upon stimulation, and render neurons more vulnerable to excitotoxic stimuli53,362. Excessive 
IP3R 1-mediated Ca2+-release into the cytosol can further prime apoptosis363. Thus, the 
finding suggests a selective dysregulation of Ca2+ balance in cortex of 13 months old BACHD 
rats, which might give rise to apoptotic cell death. 
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The calpain proteolytic system 
Furthermore, an overactivation of the Ca2+-dependent protease calpain-1 was detected in 
cortical but not striatal samples from BACHD rats (Publication VII). The enhanced calpain-1 
activity was accompanied by reduced levels of the endogenous calpain inhibitor calpastatin, 
which is known to be degraded in the presence of high Ca2+ levels364, further supporting the 
idea of cortical Ca2+ derangements in the BACHD rat at 13 months of age. Ca2+-mediated 
calpain activation has been recognized as a major executer of degradation processes in 
neurodegenerative diseases365–368 and plays a particular role in HD due to proteolytic 
cleavage of mHTT into the more toxic fragments104,105. Accordingly, enhanced cortical 
calpain-1 activation in the BACHD rat resulted in increased proteolytic cleavage of mHTT in 
this tissue (Publication VII). Furthermore, cortex hosted a higher amount of mHTT aggregates 
and showed stronger mHTT nuclear accumulation compared to striatum (Publication VII), in 
line with the idea that mHTT fragments are particularly prone to aggregate formation93,100,101 
and nuclear accumulation85,89. 
Interaction of mHTT with mitochondria 
(Publication VII) 
Accumulation of mHTT fragments on mitochondria is thought to be directly connected to 
mitochondrial dysfunction in HD369. In order to assess the possibility of a direct influence of 
mHTT on mitochondria, levels of mitochondria-associated mHTT were measured in isolated 
mitochondria from 13 months old rats. Both, HTT and mHTT, as well as full-length and 
fragmented forms of the proteins, were detected in these samples. Prominently, fragments 
were present in higher amounts in the mitochondrial fractions from BACHD rats, than in those 
from WT rats. It has previously been argued that binding of mHTT to mitochondria might 
disrupt the communication of the organelles with their surroundings, leading to a loss of 
mitochondrial sensory function and regulatory capacity266,370. Thus, the interaction of mHTT 
with mitochondria might ultimately be responsible for mitochondrial pathologies observed in 
the BACHD rat, and in HD in general. 
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Oxidative stress 
(Appendix E) 
Signs of oxidative stress have been detected in symptomatic HD patients242,243,278–280, and can 
be cause for or consequence of mitochondrial deficits371. 
 
8OHdG 
As a marker for oxidative stress that might arise from dysfunctional mitochondria372, the 
amount of 8-hydroxy-2’-deoxy-guanosine (8OHdG) was measured in culture media from 
primary BACHD rat neurons (Appendix E). No differences between BACHD and WT rat 
primary neuronal cultures were found in the amount of 8OHdG produced. These results are 
in accordance with the general idea of oxidative damage being a rather late event in HD200. 
PGC-1α 
The presence of mHTT fragments in cell nuclei is considered to cause transcriptional 
dysregulation. One important protein that has been shown to be affected is the peroxisome 
proliferator-activated receptor Ȗ coactivator 1-α (PGC-1α), which mediates the transcriptional 
response to oxidative stress373 and is believed to play a major role in the mitochondria-related 
pathology of HD374,375. To assess a possible role of PGC-1α for metabolic abnormalities in the 
BACHD rat, mRNA and protein levels were assessed. No differences in PGC-1α expression 
were detected between BACHD and WT rats at 13 months of age (Clemens et al., 
unpublished), suggesting that oxidative stress might not be prominent at that age either. It is 
possible though that the expression levels of different splice variants of PGC-1α376 or levels 
of downstream targets211 are altered in BACHD rats instead, as such alterations have 
previously been described for HD. However, based on the results discussed so far, which 
point to a late onset of mitochondrial respiratory deficits in the BACHD rat, a prominent role of 
oxidative damage up to the age of 13 months is rather not expected. 
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Mitochondrial membrane fluidity 
(Publication V377) 
The viscosity or fluidity of cellular membranes determines the properties of membrane-
associated enzymes, receptors and ion channels378–381 and might thus be connected to 
altered mitochondrial function in HD. 
Mitochondrial membrane fluidity 
Significantly increased mitochondrial but not plasma membrane fluidity was detected in 
13 months old BACHD rats as well as two other HD models (the HdhQ111 knock-in mouse as 
well as STHdhQ111 cells), suggesting that mitochondrial membrane fluidity changes represent 
a general pathological feature of HD (Publication V377). The role of mitochondrial membrane 
fluidity changes remains unclear though. Increased membrane fluidity in general is thought of 
as a coping strategy under conditions of reduced nutrient supply or increased energy 
demand382–385, for which several indications were found in the BACHD rat. The changes might 
therefore reflect a mechanism to overcome energy shortage. However, it might at the same 
time leave the cells more vulnerable towards stressors, as increased mitochondrial membrane 
fluidity has been specifically linked to mPT386–388. 
Mitochondrial membrane cholesterol 
Cholesterol is the major determinant of membrane fluidity389. As disturbances in cholesterol 
metabolism and associated cholesterol deficits have been described in HD329,390,391, levels of 
mitochondrial membrane cholesterol were determined. However, out of the three HD models 
investigated, a reduction of membrane cholesterol, concomitant with increased membrane 
fluidity, was only detected in the BACHD rat (Publication V377). This implies that either the 
increased membrane fluidity was not caused by a cholesterol deficit, or that the detection of 
cholesterol deficits in the other models had failed. The latter has to be considered, since 
methodological shortcomings of measuring cholesterol levels have been pointed out recently 
and held responsible for contradictive findings on cholesterol levels in HD392. As changes in 
membrane fluidity were found to be restricted to mitochondrial membranes, it is possible that 
specifically the import of cholesterol into mitochondria might be responsible for this phenotype.  
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In this regard, mHTT has been reported to bind to the outer mitochondrial membrane 
transporter VDAC393, which regulates cholesterol import into mitochondria394. Thus, VDAC 
constitutes a potential target for further studies on the connection between membrane fluidity 
changes, mitochondrial cholesterol import and mitochondrial mHTT accumulation. 
Mitochondrial dynamics 
(Publication VII and Appendix E) 
In order to investigate, if other mitochondrial deficits are present, which might account for the 
respiration deficit observed in the BACHD rat, or otherwise contribute to impaired intracellular 
energy supply, mitochondrial network dynamics were analyzed. Dynamic functions are crucial 
for mitochondrial network integrity281 and disturbances are highly implicated in HD260. 
Fusion and fission 
The levels of the mitochondrial fusion-promoting factors mitofusin (Mfn) 1 and 2, as well as 
optic atrophy (Opa) 1, and the fission-promoting factors fission (Fis) 1 and dynamin-related 
protein (Drp) 1, which are crucial for mitochondrial morphological adaptations395, were 
measured in cortical and striatal brain lysates from 13 months old rats (Publication VII). A 
tendency to reduced levels of fusion factors and increased levels of fission factors was 
detected on mRNA (Clemens et al., unpublished) and protein level (Publication VII). 
As changes in the levels of fusion and fission factors have only been reported for late stage 
HD patients284, this finding is again in line with the idea that 13 months old BACHD rats do not 
suffer from profound mitochondrial impairments and are not in a condition reminiscent of end-
stage HD. However, mitochondrial deficits might start to develop in BACHD rats around the 
age of 13 months, as indicated by the respiratory deficit and the cortex-restricted Ca2+ 
derangements. Specifically, increased cytosolic Ca2+ levels have been linked to disrupted 
mitochondrial dynamics. Ca2+ activates the phosphatase calcineurin, leading to the 
dephosphorylation of Drp 1 and its translocation to mitochondria282. Moreover, Ca2+ activates 
calpains (which was detected in the cortex of 13 months old BACHD rats in Publication VII), 
resulting in the degradation of Mfns396. In addition, calpain-derived mHTT fragments 
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accumulate on mitochondria, where mHTT has been shown to bind to Mfn 2267 and Drp 1285,287 
and to enhance Drp 1’s fission-promoting activity285,287. That these processes are important 
for the pathogenesis of HD has been demonstrated by the finding that both overexpression of 
Mfn 2 and Opa 1, as well as functional silencing of Drp 1, can rescue mHTT-expressing cells 
from mitochondrial dysfunction and improve cell survival267,282. 
Axonal mitochondrial transport 
A second important aspect of mitochondrial dynamics is the organelles’ intracellular transport 
in response to local demands397. To assess possible transport defects, the transport of 
mitochondria along axonal processes was recorded in primary cortical and striatal neurons 
from BACHD rat embryos (Appendix E). Significantly reduced relative motility of mitochondria 
was observed in both cortical and striatal cultures from BACHD rats. As such transport defects 
have been found in embryonal cultures from other HD disease models287, this phenotype 
seems to constitute a general and very early HD-related pathology. 
It is debated398, whether axonal transport defects occur due to physical hindering by mHTT 
aggregates399 or the loss of a promoting effect of HTT on axonal trafficking288. The latter might 
to some degree also be influenced by the presence of aggregates, as HTT is sequestered into 
these structures. The  results from the present study suggests a rather minor role of aggregate 
load in promoting axonal transport defects, as impaired mitochondrial motility was found to be 
of similar magnitude in striatal and cortical neuronal cultures, although aggregates are found 
in much higher concentration in cortex (demonstrated for BACHD rats in Publication II142, for 
BACHD rat primary neurons in Publication III358 and Appendix E, and for HD patients in 
Reference86). 
Several other mechanisms have been described, which might be responsible for axonal 
transport defects in the BACHD rat. It has been shown that decreased phosphorylation of HTT 
due to disrupted IGF-1/Akt signaling halts axonal transport processes400. As decreased levels 
of IGF-1 were also observed in the BACHD rat primary neuronal cultures (see Appendix E), 
this might provide a reasonable explanation for the reduced motility. Two further mechanisms 
have recently been highlighted: The first one concerns reduced translocation of GAPDH to 
vesicles, a process mediated by HTT, and disrupted in the presence of mHTT401. The other 
one regards the blockage of the mitochondrial Rho-GTPase Miro 1, which links the transport  
 
Results and Discussion 
Metabolic abnormalities in the BACHD rat 
51 
 
machinery to mitochondria via connection with Mfn 2402,403. A direct link to HD has not been 
established yet, but Ca2+-mediated disruption of Miro 1 binding to mitochondria404 has been 
described for a model of ALS. This mechanism might contribute to HD-related transport 
defects, given that Ca2+ derangements are early features of HD264 and the enhanced binding 
of mHTT to Mfn 2 might disturb the interaction of Mfn 2 with Miro 1. 
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Summary and outlook 
Our data suggest that mitochondrial disturbances can be detected at earliest ages, although 
mitochondrial respiratory chain dysfunction is likely a late event. Moreover, mitochondrial 
dysfunction might results from abnormal binding of mHTT to the organelles. 
In order to add evidence to the hypothesis of profound mitochondrial damage as a late event 
in the pathogenesis of HD, further studies should investigate both glycolytic and mitochondrial 
respiratory chain function longitudinally from birth to senescence. This would enable to 
evaluate when the deficits appear, how they progress with age and how they might be 
interrelated. 
Many of the findings are potentially linked to a direct pathological effect of mHTT binding to 
mitochondria. Further studies should address the physiological role of HTT binding to 
mitochondria and the pathological consequences of mitochondria-associated mHTT in order 
to reveal better insight into the molecular mechanisms of mitochondrial dysfunction in HD. 
Such studies should further evaluate possible links between the mitochondrial pathologies, as 
some proteins such as VDAC and Mfn 2 seem to be ubiquitously involved. The identification 
of common pathways might offer better targets for future therapeutic approaches. 
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Conclusion 
Metabolic dysfunction has emerged as a prominent feature of HD. However, many questions 
around the development, characteristics and importance of metabolic abnormalities are still 
awaiting an answer. Major reasons for this are the lack of detailed longitudinal data from HD 
patients, particularly including early prodromal stages, as well as seemingly contradicting 
results from rodent models of HD. The present work implies that discrepancies in study 
outcomes might be due to temporal changes in surrogate markers in the course of disease. 
In case of the BACHD rat, this manifests in a triphasic pattern of metabolic abnormalities with 
early changes during growth, normal values during adulthood, and late alterations during 
senescence. Mitochondria-associated deficits are present at early ages, but the burden of 
mitochondrial dysfunction with respiratory chain impairment most likely forms a later event 
(Figure 4). 
The individual phenotypes detected in the BACHD rat might be regarded as a network of 
interconnected pathologies, evoking and enhancing each other (Figure 5). The presence of 
mHTT leads to deficits in mitochondria-associated cellular pathways of energy metabolism. 
Prominently, a deficit in lipid oxidation likely triggers fat accumulation and the development of 
obesity, and further contributes to energetic deficits. Energetic deficits in turn are probably 
responsible for the improper growth and the smaller body size of the BACHD rats. Finally, it 
is reasonable to assume that mitochondrial function becomes increasingly impaired as the 
rats age, eventually triggering the degeneration of tissues vulnerable to energetic deficits. 
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Figure 4. Summary of metabolic abnormalities in the BACHD rat 
The scheme shows the metabolic abnormalities detected in BACHD rats at different ages, with white 
squares meaning reduced compared to WT rats, light gray squares meaning similar to WT rats and dark 
gray squares meaning increased compared to WT rats. The age at observation is indicated in the top line 
in monthly steps from prenatal (E) to 18 months of age. The gross morphological appearance of young, 
middle-aged and old rats is illustrated on top of the scheme. 
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Figure 5. Possible interconnectivity of metabolic phenotypes in the BACHD rat 
The presence of mHTT leads to discrete deficits in mitochondria-associated cellular pathways of energy 
metabolism, which are likely to be the cause for growth impairment and obesity. Furthermore, 
mitochondrial function becomes increasingly compromised with age, and might finally culminate in 
neuronal demise. The arrows represent the hypothetical connections between the phenotypes 
investigated. 
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III. Olesoxime treatment study 
In a longitudinal therapeutic study, BACHD rats were treated with olesoxime supplied via the 
food from the age of 5 weeks until the age of 13 months, their behavior and metabolic function 
was assessed, and neuropathological phenotypes were investigated. 
The chapter is divided into four major parts: 
 Main effects of olesoxime 
 Mechanism of action of olesoxime 
 Outlook 
 Conclusion 
Results and Discussion 
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Main effects of olesoxime 
Olesoxime-treated BACHD rats showed specific improvements in behavior and 
neuropathology compared to placebo-treated BACHD rats (Publication VII, Appendix B 
and C). These concerned the selective amelioration of cognitive and psychiatric abnormalities, 
increased cortical thickness and a significant reduction in mHTT aggregation and nuclear 
accumulation throughout the brain. The drug effect appeared to be the result of reduced 
calpain-mediated proteolysis, which seemed to be the main source of mHTT fragments in the 
BACHD rat (Publication VII). Furthermore, olesoxime seemed to have influenced 
mitochondria in several ways (Publication V377 and VII): Olesoxime treatment led to a 
restoration of mitochondrial membrane fluidity and respiratory function, and reduced the 
association of mHTT fragments with mitochondria. It further modulated the levels of several 
mitochondrial proteins involved in mitochondrial cholesterol import, metabolite exchange, 
respiratory chain function, Ca2+ homeostasis, calpain activation and mitochondrial dynamics, 
all of which could have contributed to improved mitochondrial function, enhanced Ca2+ 
handling capacity and reduced calpain activity. 
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Mechanism of action of olesoxime 
The calpain proteolytic system 
(Publication VII) 
The most prominent effect of olesoxime was the reduction of calpain-1 overactivation and 
concomitant inhibition of mHTT fragmentation in BACHD rat cortex (Publication VII). A parallel 
decrease in calpain-1 activity and increase in calpastatin expression was detected 
(Publication VII), which represents a reversion of the initial pathological condition found in the 
BACHD rat (as discussed above). It is theoretically possible that the primary effect of 
olesoxime was a transcriptional upregulation of calpastatin, as calpastatin overexpression has 
been shown to abolish calpain activation and to have cytoprotective effects405. However, a 
more simple explanation is that calpastatin levels were restored as a downstream event of 
reduced calpain-1 activation, as calpastatin itself is a calpain target364. In addition, it is rather 
unlikely that olesoxime directly influenced transcription, as it has been found to be exclusively 
localized at mitochondria314. For the same reason, it is unlikely that olesoxime had acted as a 
direct inhibitor of calpains, but rather indirectly influenced their activation status via effecting 
mitochondria. 
Ca2+ homeostasis 
(Publication VII) 
Given the mitochondrial localization of olesoxime314, it was hypothesized that the compound 
had exerted its beneficial effects by improving mitochondrial function, thereby stabilizing Ca2+ 
homeostasis, decreasing Ca2+-related calpain-1 activation and aborting the generation of toxic 
mHtt fragments, as well as their exaggerated negative influence on mitochondria. The finding 
of overactive calpain-1 and increased protein levels of IP3R 1 in untreated BACHD rats 
(Publication VII) support the idea of disturbed Ca2+ homeostasis, as discussed above. 
However, since there was no opportunity to measure Ca2+ levels, Ca2+ handling or the effects 
of olesoxime on Ca2+ balance in the BACHD rats directly in this study, the proposed 
mechanism remains hypothetical. 
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Mitochondrial permeability transition 
(Publication VII) 
Olesoxime has previously been suggested to inhibit mPT313, but thus far a detailed 
mechanism could not be provided. On the contrary, there are indications that olesoxime 
(unlike the mPT inhibitor cyclosporine A) does not directly affect mitochondrial Ca2+ release 
and mitochondrial swelling in isolated organelles314. Instead, olesoxime inhibited the release 
of apoptosis-inducing factor (AIF)319, which triggers cell death in an mPT-independent way382. 
Interestingly, calpains (which were found to be inhibited by olesoxime treatment in 
Publication VII) have been shown to mediate AIF release406,407, which is executed in the 
presence of sufficiently high Ca2+ levels408. Thus, it is possible that olesoxime does not 
modulate mPT, but rather prevents AIF release through improved cellular Ca2+ handling and 
alleviation of calpain activation. 
Interaction with VDAC and TSPO 
(Publication VII) 
Olesoxime has previously been shown to bind to VDAC and TSPO on the outer mitochondrial 
membrane313. VDAC seems to be particularly interesting, as also mHTT has been shown to 
interact with this protein393, and VDAC is standing at the junction of glycolytic and 
mitochondrial respiratory function in the cell359 (as explicated above). It has earlier been 
suggested that the interaction of mHTT with VDAC might impair the protein’s transport 
function, and be responsible for deficits in mitochondrial energy metabolism409. Thus, 
reduction of mHTT fragment accumulation at mitochondria might improve the communication 
of the organelles with their surroundings, leading to a compensatory upregulation of VDAC 
protein expression (as observed in Publication VII), improved mitochondrial-cytoplasmic 
metabolite exchange and amelioration of cellular and mitochondrial deficits. 
The study did not include the evaluation of olesoxime’s influence on TSPO, which might also 
be involved in mediating its beneficial effects. Interestingly, TSPO ligands enhance Ȗ-
aminobutyric acid (GABA) signaling with similar effects on psychiatric disturbances as 
revealed by carbamazepine treatment410. Carbamazepine acts anticonvulsant, mood-
stabilizing and reduces neuropathic pain. It is known to potentiate GABA signaling, and was 
found to reduce intracellular Ca2+ levels, calpain activation, mPT and cell death in  
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ischemia/reperfusion injury411. As this is highly reminiscent of the effects observed in this study 
(Publication VII), it seems likely that olesoxime’s actions are, at least in part, mediated via 
enhanced TSPO function. 
Both VDAC and TSPO are implicated in mitochondrial cholesterol import412, and olesoxime 
restored mitochondrial cholesterol levels as well as membrane fluidity changes in the BACHD 
rat (Publication V377), further strengthening the idea of a crucial involvement of these two 
proteins in mediating olesoxime’s beneficial effects. 
Selective olesoxime effects in the BACHD rat 
(Publication V377, VII, Appendix C and D) 
Olesoxime ameliorated deficits, which were selectively found in cortex but not striatum of 
BACHD rats (Publication VII). The absence of increased IP3R 1 levels, calpain-1 
overactivation and extensive mHTT fragmentation in striatum suggests that Ca2+ 
derangements were not present in this tissue at 13 months of age. This could be due to an 
adaptive response of striatal neurons to Ca2+ insults, as a compensatory change in Ca2+ 
sensitivity has been reported for striatal but not cortical neurons from HD mouse models301. 
The results are further in accordance with our earlier findings, which show that signs of 
neurodegeneration can be found in cortex but not striatum of 13 months old BACHD rats 
(Publication II142). 
Olesoxime also showed selective beneficial effects on systemic phenotypes. Although 
olesoxime restored the mitochondrial respiration deficit (Publication VII) and membrane 
fluidity changes (Publication V377), the drug failed to ameliorate systemic metabolic 
abnormalities in the BACHD rat, specifically the rats’ obesity and growth defect as well as the 
associated changes in food intake, RQ, plasma IGF-1 and leptin levels (Appendix C and D). 
This implies that mitochondrial respiratory chain defects and altered membrane fluidity were 
not the primary cause for the systemic metabolic abnormalities in HD. In case of the respiration 
defect, this assumption would be in line with the idea that this pathology is a later event in HD. 
Importantly, it is possible that olesoxime is not per se incapable of restoring systemic 
metabolic alterations. Considering the early appearance of metabolic abnormalities in the  
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BACHD rat, treatment might have simply started too late, and have only been ineffective in 
restoring phenotypes, which were already manifest. This is supported by the finding that 
olesoxime treatment in late stage ALS patients did not yield significant improvements327, while 
the compound was highly effective in preclinical studies in ALS models where treatment had 
started early322. Moreover, treatment of children and young patients with SMA led to strong, 
beneficial outcomes328. 
Olesoxime in other HD animal models 
(Publication V377) 
As mitochondrial dysfunction and Ca2+ dysregulation are consistent features of HD across 
different animal models, benefits from olesoxime treatment can be expect to be found beyond 
the BACHD rat. In this regard, olesoxime reversed alterations in mitochondrial membrane 
fluidity not only in the BACHD rat, but also in the HdhQ111 knock-in mouse and STHdhQ111 cell 
model of HD (Publication V377). It is unclear though, how effective olesoxime treatment would 
be in a fragment model of HD, as the reduction in mHTT fragment generation might only be 
marginal due to constitutive expression of mHTT fragments through the transgene. In spite of 
this fact, investigation of olesoxime’s effects in such a model would be of great interest for the 
dissection of direct effects of olesoxime on mitochondrial function, and indirect treatment 
effects via reduced fragment generation. 
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Outlook 
Earlier start of treatment 
In order to evaluate, if some selective effects of olesoxime were caused by its application after 
symptom onset, earlier start of treatment should be considered. In a first follow-up study, this 
was approached by starting olesoxime treatment in the HdhQ111 knock-in mouse model of HD, 
already in the pregnant mother animal in order to exploit the full potential of the drug (Clemens 
et al., unpublished). Thus far, only the molecular phenotypes of these mice were investigated 
to evaluate if the phenotypes found in the BACHD rat are recapitulated and to estimate sample 
sizes for main cohorts (Clemens and Weber et al., unpublished). Future studies should 
investigate the effects of olesoxime on behavior and neuropathology upon earliest possible 
treatment. If olesoxime proves to be more efficient under these conditions, it might further be 
evaluated if drug application can be shifted towards postnatal ages. This might at the same 
time shed light on the time course of early HD-related phenotypes. 
Mechanistic approach 
To rule out the unlikely but still possible influence of olesoxime on gene expression, mRNA 
levels of proteins found to be altered upon olesoxime treatment should be assessed 
quantitatively. 
To gain further insight into the mechanism behind olesoxime’s actions, its exact role in Ca2+ 
homeostasis needs to be evaluated. In this regard, a study on Ca2+ handling in STHdhQ111 
and other cells has been started. Preliminary results from fluorescence calcium imaging point 
to an increase in internal Ca2+ storage, suggesting improved Ca2+ handling capacity after 
olesoxime treatment (Klumpp, Weber and Clemens et al., unpublished). Further studies 
should dissect the contribution of ER and mitochondria to the enhanced Ca2+ storage and 
favorably include in vivo calcium imaging413. 
In addition to Ca2+ homeostasis, it would be of importance to know if olesoxime affects 
glycolysis, as defects in glycolysis are implicated in early HD239 and seem to be among the 
earliest signs of energetic defects in the BACHD rat (Publication III358). As explained above, 
hexokinase binding to VDAC provides a potential target, which should be further investigated. 
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Study validation 
Validation of olesoxime’s effects should be carried out in other full-length mHTT or fragment 
models of HD. This would further enable to investigate the contribution of reduced mHTT 
fragmentation to the beneficial effects of olesoxime, as discussed above. A pilot study to 
reproduce olesoxime’s effects in HdhQ111 knock-in mice has already been undertaken. 
Preliminary results revealed that similar pathological calpain activation and mHTT cleavage 
takes place in these mice, and that olesoxime counteracts this pathology (Clemens and Weber 
et al., unpublished). 
  
Results and Discussion 
Olesoxime treatment study 
 
65 
 
Summary and conclusion 
Olesoxime constitutes an outstanding drug candidate for HD. The beneficial effects observed 
here, together with the positive outcomes of preclinical studies in several neurodegenerative 
disorders as well as the clinical trial on SMA suggest a high chance to achieve beneficial 
effects also in HD patients. Moreover, its high safety and tolerability as well as easy application 
pave the way to faster clinical use compared to a novel drug. 
For further studies, it needs to be considered that olesoxime treatment might prove to be most 
effective when started early on. Due to the sole genetic mutation underlying the development 
of HD, HD patients have the opportunity to know about their disease before the onset of clinical 
symptoms. This enables to start treatment early and receive highest potential benefits from it. 
Olesoxime’s presumed mechanism of action is to improve mitochondrial function and through 
this regulate energy metabolism and Ca2+ balance as well as downstream pathologies. It was 
discovered that calpain activation is one of these downstream targets, and the calpain-
calpastatin system has emerged as a key player in neurodegenerative diseases. Thus, not 
only the primary target of olesoxime, the mitochondrial network, but also its secondary one, 
the calpain system, might be responsible for its ubiquitous beneficial effects in 
neurodegeneration. 
Although the details on how olesoxime stabilizes mitochondria are still elusive, the present 
studies suggest an important role for olesoxime in modulating the mitochondrial membrane 
environment. Deciphering olesoxime’s mechanism of action might be of great value for the 
understanding of neurodegenerative processes and the development of effective treatments. 
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Appendix 
The Appendix contains all data that has not been implemented in a manuscript for publication 
so far, but which is crucial for the understanding of the assumptions made in this work. 
For each section, a brief summary, the contribution of each author, the description of the 
methods applied (if not available in one of the publications), the results and a discussion of 
the results is given. 
The Appendix contains data sets of the following subjects: 
A.  Automated phenotyping in rats 
B.  BACHD rat body size and body composition 
C.  BACHD rat energy balance 
D.  BACHD rat blood parameters 
E.  BACHD rat primary neuronal cultures 
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A. Automated phenotyping in rats 
Laura E. Clemens1,2, Damaris J. Franke1,2, Erik K. H. Jansson1,2, Huu P. Nguyen1,2 
1
 Institute for Medical Genetics and Applied Genomics, University of Tuebingen, Tuebingen, Germany. 
2
 Centre for Rare Diseases, University of Tuebingen, Tuebingen, Germany. 
Summary 
Background: Automated behavioral phenotyping systems are promoted to produce robust 
outcomes, which relate better to natural animal behavior than results from classical tests that 
are run manually. In order to use automated phenotyping for the characterization of transgenic 
animal models of neurodegenerative diseases, we evaluated the validity of the commercially 
available automated phenotyping systems PhenoMaster and PhenoTyper. 
Methods: We recorded and analyzed the behavior of five, commonly used, rat strains during 
70-hour sessions in the automated phenotyping systems. 
Results: Using the PhenoMaster system, we detected strain differences in novelty-induced 
behavior, activity-related behavior, metabolism, as well as the development of these 
parameters with age. Some but not all characteristics were replicated by the PhenoTyper. 
Importantly, we detected a significant drop in weight gain in two of the four investigated rat 
strains during the measurements in both automated systems. 
Discussion: Automated phenotyping enabled the recording of large amounts of data and the 
detection of significant differences between the rat strains. However, the results differed 
between the two systems and the rats seemed to have experienced stress during the 
measurements. Thus, the validity of the outcomes is questionable and should be evaluated in 
further studies. 
Author contributions 
Conceived and designed the experiments: HPN, LEC 
Performed the experiments: LEC (PhenoMaster), DJF (PhenoTyper) 
Analyzed the data: LEC, DJF, EKHJ  
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Materials and Methods 
Animals 
Data presented here derive from rats of five different WT rat strains as part of three separate 
studies. WT rats from the strains Lister Hooded, Lewis, Fischer and Wistar were purchased 
from Charles River, Germany at the age of 3 weeks, as part of the studies described in 
Publication IV332 (PhenoMaster), and Reference335 (PhenoTyper). In addition, PhenoMaster 
data on Sprague Dawley rats derive from the study discussed in Publication VII and 
Appendix C. Housing conditions were similar for all rats and are described in Publication IV332. 
Body weight measurements 
Body weight was measured on a weekly basis, as well as immediately before and after each 
test, enabling the comparison of body weight gain before, during and after behavioral testing. 
The measurements were made using a kitchen balance (accuracy was ± 1 g). 
Automated phenotyping 
Automated behavioral phenotyping was performed with two automated homecage systems 
for rats, the PhenoMaster (TSE Systems, Germany) and the PhenoTyper 4500 (Noldus 
Information Technology, The Netherlands), as displayed in Figure 1 and listed in Table 1. 
The customized setup of the systems’ test cages differed considerably from each other as 
well as from standard home cages. Both setups had smaller floor space compared to the 
standard housing cages, with the PhenoMaster cages being the smallest (Table 1). The 
PhenoMaster cages also used an air-tight lid, which resulted in a considerably lower cage 
height compared to the home cages. In contrast, the PhenoTyper cages were higher than the 
normal home cages (Table 1). The home cages used standard cage tops, where food and 
water was placed (Figure 1). The PhenoTyper cages had a large food hopper placed vertically 
on one of its walls, and a water bottle placed on either side of it. The PhenoMaster system 
used small, free-hanging water bottles and food baskets, which were connected to scales and 
placed on top of the setup. Additional differences were the availability of a small shelter as 
well as the use on non-standard bedding in the PhenoTyper cages. The PhenoMaster used  
Appendix 
A. Automated phenotyping in rats 
90 
 
 
the regular bedding material, although in a much lower amount compared to the normal 
housing cages to avoid interference with activity measurements. Both systems were kept in 
the same experimental room, which was separate from the housing room the rats stayed in 
between experiments. 
For the experiments, the animals were transferred to the experimental room and placed 
individually in the testing cages. The rats’ behavior was investigated over a period of 2 days, 
during which they had ad libitum access to food and water and were left undisturbed except 
for a short daily visit. During visits, the animals were inspected for proper food and water 
intake. In between runs, the systems were cleaned thoroughly and new bedding as well as 
fresh water and food pellets were supplied. The exact procedures for each test system are 
given below. 
 
Table 1. Dimensions of the phenotyping cages compared to the rats’ home cages. 
Cage length, width and height are given for the PhenoMaster for rats with metabolic cage setup, the 
PhenoTyper 4500 for rats with standard setup, and standard type IV rat home cages with high lids. 
System Provider Species Cage dimensions 
length - width - height 
PhenoMaster TSE Rat 48 - 37.5 - 20 cm 
PhenoTyper Noldus Rat 45 - 45 - 65 cm 
Home cage  Rat 55 - 38 - 24.5 cm 
 
PhenoMaster 
A detailed description of setup and procedures are available in Publication IV332. Briefly, the 
PhenoMaster system (Figure 1) consisted of 12 home cage-like testing cages with metabolic 
setup, which were composed of a cage with 48 x 37.5 cm floor area and 20 cm high walls, a 
solid plastic lid with tubes connected for respirometric measurements, a free-hanging water 
bottle and small food basket equipped with sensors for the detection of food and water intake,  
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as well as a frame with infrared motion detectors for activity assessment surrounding the cage. 
The cage floor was covered with 200 g of wooden bedding. A total of 48 rats (12 rats per 
strain) were analyzed. The behavior of each animal was assessed during a 70-hour 
observation period. Thus, four runs were needed in order to measure all rats, resulting in a 
total duration of 12 days for the entire experiment. During a given run, the animals were 
assigned to one of the 12 test cages in a pseudo-randomized manner, so that each run 
included 3 animals from each of the 4 rat strains. Each measurement started 40 ± 5 minutes 
before the onset of the dark phase. Data were collected in 20-minute sample intervals. 
Measurements were carried out at the ages of 2, 4 and 6 months. 
 
Figure 1. Setup of the phenotyping cages compared to the rats’ home cages. 
The PhenoMaster system for rats with metabolic cage setup (left), the PhenoTyper 4500 for rats with 
standard setup (upper right), and a standard type IV rat homecage with high lid (lower right) are shown. 
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PhenoTyper 
A detailed description of setup and procedures are available in Reference335. Briefly, the 
PhenoTyper 4500 system (Figure 1) consisted of 4 test cages with a 45 x 45 cm large arena 
and 65 cm high transparent walls, as well as an infrared camera on top of the cage for 
continuous light and dark phase observation. Our setup included a black shelter located in 
one corner, and a large feeding area and two water bottles placed along one of the walls. The 
floor was covered with gray cellulose bedding (Cellu-Dri Soft®, Shepherd Speciality Papers, 
USA) for better detection of rats with white fur color. A total of 48 rats (12 rats per strain) were 
analyzed. The behavior of each animal was assessed during a 70-hour observation period. 
Thus, eight runs were needed in order to assess all rats, resulting in a total duration of 24 days 
for the entire experiment. A given cage was specifically assigned to measure the behavior of 
one of the rat strains. Pseudo-randomization could not be made, as camera settings needed 
to be individually adjusted to optimize the detection of the different fur colors and body sizes 
of the rats from the 4 strains. Each run included one animal from each of the 4 strains. Two 
types of measurements were taken at each age. The first measurement started 30 minutes 
before the onset of the dark phase and lasted for 1 hour. During the 1-hour observation time, 
a continuous video was recorded. After this, the rats were removed, the program settings 
changed, and the rats were put back into the cages for another 69 hours. During this second 
run, the rats’ behavior was live-tracked, as the system was not capable of storing video files 
of such large size. 
Data analysis 
Raw data from the PhenoMaster were exported, pre-processed into hourly bins and sorted by 
genotype, treatment and age using a script for R statistics developed in our institute332. Video 
data from the PhenoMaster were tracked for activity-related parameters with the software 
EthoVision XT 7.1 (Noldus Information Technology) and additionally manually tracked for 
rearing behavior. All pre-processed data were then graphed and statistically analyzed with the 
software GraphPad Prism (GraphPad Prism version 6.00 for Windows, GraphPad Software, 
San Diego California USA, www.graphpad.com), and are presented in the following as mean 
and standard error of the mean (SEM).  
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Results 
PhenoMaster compared to PhenoTyper 
We detected significant differences between the strains in the PhenoMaster, which 
mainly derived from higher light phase and lower dark phase activity of Lister Hooded 
rats compared to the other three rat strains (as presented in detail in 
Publication IV332). During PhenoTyper observation, however, such a difference could 
not be detected (Figure 2). Moreover, all rat strains showed a more pronounced 
circadian rhythm in the PhenoTyper, with higher dark phase and lower light phase 
activity than during PhenoMaster observation (Figure 2).  
Stress response during automated phenotyping 
When analyzing data from the PhenoMaster experiment, we noticed that the body weight gain 
of the rats dropped during the test sessions (Publication IV332) and returned to normal when 
the rats were once again housed in their home cages. Therefore, we also investigated body 
weight gain before and after PhenoTyper tests (Figure 2), and found similar results. In both 
systems, the phenotype was most apparent in Wistar and Fischer rats. 
The effect of automated homecage observation on body weight gain was more pronounced 
in older rats (Figure 2). It has to be noted that a body weight effect is more difficult to evaluate 
at younger ages due to a considerable decline in growth over the first 3 months. Due to this, 
the 2 months old rats, except for Lewis rats, did not return to their weekly weight gain baseline 
after the test sessions. 
When comparing body weight development at two ages in old Sprague Dawley rats, which 
did not substantially grow anymore, the effect was significantly stronger at the oldest age 
(Figure 3). Furthermore, while younger rats showed a reduced body weight gain during 
automated homecage observation, older rats experienced explicit weight loss (Figure 2 
and 3). 
 
Appendix 
A. Automated phenotyping in rats 
94 
 
 
 
 
Figure 2. The circadian pattern of activity obtained during PhenoMaster and PhenoTyper 
observation. 
Locomotor activity of Lister Hooded, Wistar, Lewis and Fischer 344 rats was measured during 
PhenoMaster and PhenoTyper observation at 2 months of age. The PhenoMaster activity measurement 
was based on motion detection with infrared light beams and is expressed as number of light beam 
activations (counts). The PhenoTyper activity measurements derive from video tracking and represents 
the distance moved (in cm). Group mean without SEM for better overview, two-way repeated 
measurements ANOVA, n = 12 per group, * P < 0.05, ** P < 0.01, *** P < 0.001. 
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Figure 2. Effect of automated homecage observation on body weight gain in the different rat 
strains. 
The behavior of Lister Hooded, Lewis, Wistar and Fischer 344 rats was recorded in the PhenoMaster at 
2, 4 and 8 months of age, as well as in the PhenoTyper at 2 and 4 months of age. Body weight gain during 
the 3 days of observation was compared to the average body weight gain over 3 days during the week 
prior and post testing. Mean and SEM, two-way repeated measurements ANOVA, Fisher LSD post-test, 
n = 12 per group, */# P < 0.05, **/## P < 0.01, ***/### P < 0.001. 
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Figure 3. Body weight loss in aged rats during automated homecage observation. 
Sprague Dawley rats were subjected to automated homecage observation in the rat PhenoMaster at 
11 and 13 months of age. Body weight was measured before and after 3 days of observation. Statistical 
analysis of body weight before and after testing was performed using repeated measurements two-way 
ANOVA, and statistical analysis of body weight loss was evaluated using paired one-tailed t-tests, n = 12 
per group, * P < 0.05, ** P < 0.01, *** P < 0.001. 
  
before after
700
750
800
850
Sprague Dawley rats
Bo
dy
 
w
e
ig
ht
 
(g)
11 m
13 m
Age:
Behavioral testing:
Interaction: ns
***
***
-20
0
20
40
Bo
dy
 
w
e
ig
ht
 
lo
ss
 
(g)
before vs after:
***
-20
-10
0
10
20
30
40
before vs after:
***
a
11 months 13 months
Appendix 
A. Automated phenotyping in rats 
97 
 
Discussion 
PhenoMaster compared to other tests 
We initially reported significant inter-strain differences based on a particularly deviating 
behavior of Lister Hooded rats in the PhenoMaster system (Publication IV332). Lister rats 
showed significantly increased day-time activity, which might be ascribed to their pigmentation 
and thus better vision compared to the other rat strains investigated in our study. However, 
the difference in circadian activity could not be replicated in the PhenoTyper, implying that the 
first, peculiar results might not reflect the natural behavior of Lister Hooded rats. The deviant 
outcomes might derive from Lister Hooded rats behaving abnormally during PhenoMaster 
exposure based on the specific cage environment, or from differences in the detection method 
between the two systems. While the activity measurement in the PhenoMaster relies on 
motion detection via infrared light beams, the PhenoTyper system uses software-based 
tracking of the distance moved as obtained from video recordings. However, it remains 
unresolved why the systems gave different outcomes, and what the true behavioral 
characteristics of the rats are. Follow-up studies are needed to clarify this issue. 
Stress response during automated phenotyping 
Our data reveal a strain-dependent impairment in body weight gain during automated 
homecage observations. This drop in body weight gain was likely the effect of improper food 
intake, as susceptible rats had lower food intake than it would be expected from their 
respective body sizes. Furthermore, the rats showed a decline in RQ, which is reduced during 
starvation354 (Publication IV332). Thus, as the effect had influenced the readouts of the 
measurements, outcomes of such studies need to be interpreted carefully. 
Improper food intake and reduced body weight gain indicate that the animals experienced 
some form of stress, while being housed in the test cages. This idea is supported by the fact 
that Lister and Lewis rats, which showed little effect of automated homecage testing on body 
weight gain, are known as less anxious342,343. 
Interestingly, we further found that the drop in body weight gain during automated phenotyping 
was similar as when running classical behavioral tests336, suggesting that the home cage-like  
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test setup does not improve animal welfare aspects compared to classical testing, although 
the systems are promoted to do so. 
The stress effect of automated phenotyping seems to be of general importance, as it was 
observed in three out of the five rat strains investigated. In addition, we detected similar effects 
in mice336. 
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B. BACHD rat body size and body composition 
Laura E. Clemens1,2, Erik K. H. Jansson1,2, Huu P. Nguyen1,2 
1
 Institute for Medical Genetics and Applied Genomics, University of Tuebingen, Tuebingen, Germany. 
2
 Centre for Rare Diseases, University of Tuebingen, Tuebingen, Germany. 
Summary 
Background: Metabolic disturbances play a prominent role in HD. HD patients as well as 
disease models of HD display metabolic abnormalities including alterations in body weight, 
body size and body composition. The BACHD rat appears to be smaller and obese compared 
to WT littermates. 
Methods: We investigated the body size and body composition of BACHD rats by detailed 
dissections at the ages of 1, 3, 6, 9 and 12 months. Body size measurements included head, 
trunk and tail length. Body composition was assessed by measuring body weight, fat mass, 
individual organ mass as well as bone/muscle mass. 
Results: BACHD rats were found to have an overall shorter body length, increased fat mass, 
and reduced lean mass compared to WT rats. Consistent with their smaller size, organ weights 
were systematically reduced. Differences were present at 1 month, aggravated by 3 months, 
but did not progress from 3 to 12 months of age. 
Discussion: In line with our qualitative observation, BACHD rats are smaller and obese. The 
data suggest a preadolescent growth impairment, and no signs of progressive degenerative 
processes were detected within the first 12 months of age. 
Author contributions 
Conceived and designed the experiments: LEC, EKHJ, HPN 
Performed the experiments: LEC, EKHJ 
Analyzed the data: LEC, EKHJ 
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Animals, materials and methods 
All procedures are described in detail in Publication VI344. 
Briefly, twelve BACHD rats and twelve WT littermates were dissected at 1, 3, 6, 9 and 
12 months of age and the weights of the major adipose tissue deposits, skin and fur, visceral 
organs (heart, lungs, liver, kidneys, spleen, gastro-intestinal tract), testes, brain as well as 
remaining muscle and bone carcass, was measured. 
The lean mass was calculated by taking total body weight minus gut and skin weight, as these 
two contained large amounts of adipose tissue. 
At 12 months of age, the major glands (pancreas, thymus and salivary glands) were weighed, 
the length of the thigh bone was determined and the gastro-intestinal tract was dissected into 
its components (great omentum, gut content and gut wall) in addition to the other 
measurements. 
Data were graphed and statistically analyzed with the software GraphPad Prism (GraphPad 
Prism version 6.00 for Windows, GraphPad Software, San Diego California USA, 
www.graphpad.com), and are presented as mean and standard error of the mean (SEM). 
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Results 
Body size 
BACHD rats are moderately but significantly smaller than WT rats (Figure 1). This is reflected 
by an overall shorter body length. The difference in head and tail length was larger than the 
difference in trunk length between BACHD and WT rats. Also the length of the thigh bone 
(femur) (Figure 4) showed a larger mean reduction at 12 months of age, suggesting a 
disproportionally large effect of mHTT on the growth of head and extremities. The body length 
difference was already apparent at 1 month of age and did not progress. 
 
 
Figure 1. Body size is reduced in BACHD rats. 
Total body length, as well as the separate lengths of head, trunk and tail, were measured in different 
cohorts of rats at 1, 3, 6, 9 and 12 months of age upon dissection. White bars = WT, black bars = BACHD 
rats. Numbers over the bars represent the mean percental difference between BACHD and WT rats. Mean 
and SEM, two-way ANOVA, Sidak’s post-test, n = 12 per group, * P < 0.05, ** P < 0.01, *** P < 0.001. 
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Body composition 
BACHD rats have an abnormal body composition (Figure 2). BACHD rats showed similar body 
(and skin/fur) weights as WT rats, but had increased fat and reduced lean mass, indicating a 
growth deficit and obesity. The difference in body composition was already present at 1 month 
of age, stronger at 3 months of age, but did not further progress at older ages. 
The strongest difference between BACHD and WT rats was seen in bone and muscle mass. 
The difference in lean mass was less pronounced, as this included skin and fur mass, which 
was unchanged in BACHD rats. Also organ mass was not as strongly reduced as bone/muscle 
mass, as it varied considerably between individual organs (Figure 3). 
All organs weighed less in BACHD compared to WT rats, except for the gastro-intestinal tract, 
which was increased in weight (Figure 3). A detailed dissection of the latter was performed at 
12 months of age (Figure 4), revealing that the increase in total weight was the result of a 
significantly heavier great omentum, while gut content (chymus) and the actual gut tissue (gut 
wall) did not significantly differ from the respective parts in the WT rats. From the individual 
organs, heart, lungs, kidneys (Figure 3) as well as pancreas and salivary glands (Figure 4) 
differed strongest between BACHD and WT rats. The liver showed the least difference. 
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Figure 2. BACHD rats have a distorted body composition. 
Body weight, as well as skin/fur, fat (weight of all large adipose tissue deposits), lean (body weight minus 
fat mass, gut and skin), organ, and bone/muscle mass are shown. White bars = WT, black bars = BACHD 
rats. Numbers over the bars represent the mean percental difference between BACHD and WT rats. Mean 
and SEM, two-way ANOVA, Sidak’s post-test, n = 12 per group, * P < 0.05, ** P < 0.01, *** P < 0.001. 
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Figure 3. Organ weights are reduced in the BACHD rat. 
The weight of all large visceral organs as well as brain and testicles are shown. White bars = WT, black 
bars = BACHD rats. Numbers over the bars represent the mean percental difference between BACHD 
and WT rats. Men and SEM, two-way ANOVA, Sidak’s post-test, n = 12 per group, * P < 0.05, ** P < 0.01, 
*** P < 0.001. 
 
Figure 4. Extra measurements at 12 months of age. 
Some smaller internal organs (thymus, pancreas and submaxillary salivary glands in g, as well as the 
thigh bone (femur) in cm), were dissected in addition to the other organs at 12 months of age (left figure). 
Furthermore, the gastro-intestinal tract was dissected into its components (right figure). White bars = WT, 
black bars = BACHD rats. Mean and SEM, unpaired t-test, or Mann-Whitney test, depending on data 
distribution, n = 12 per group, * P < 0.05, ** P < 0.01, *** P < 0.001. 
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Discussion 
We performed a longitudinal dissection study in order to analyze the body size and body 
composition of the BACHD rat. We found BACHD rats to be smaller, but obese.  
The reduced body size was reflected in all organs, although some organs seemed to be more 
affected than others. The strongest difference was observed in bone and muscle mass, which 
might relate to energetic demands of muscle tissue, or depend on muscle- and bone-specific 
intracellular signaling pathways disrupted in the presence of mHTT. Pancreas and salivary 
glands were further found to be particularly small. This might be attributed to compromised 
secretory functions, as exocytosis is impaired in HD48,233,234. The liver was among the few 
organs found to be increased at 1 month of age, and showed the least difference between 
BACHD and WT rats at later ages. As obesity typically accompanies hepatic steatosis, the 
reason for the relatively larger livers compared to the other organs might lie in an accumulation 
of fat in this organ, which is in line with an abnormal histological appearance of BACHD rat 
livers (Clemens et al., unpublished). Another interesting finding was that testicle weight was 
most severely reduced compared to that of WT rats at 1 month of age, which might suggest 
delayed sexual maturation, an indicator for delayed development. 
The reduced body size was already present at 1 month of age and did not markedly progress, 
pointing to a preadolescent growth impairment. Little research has been done on 
anthropometric changes in HD. Several studies report normal body height of prodromal and 
early HD patients compared to control subjects161,162,167,168,170. The systematic investigation of 
33 different measures of body size in middle-stage HD patients, persons at risk for HD, and 
normal subjects revealed similar results, and the study mainly concluded progressive 
emaciation through loss of muscle and fat mass172. However, body height in humans is highly 
variable and small differences are possibly hard to detect. Interestingly, a study investigating 
body size in children with expanded CAG and non-expanded CAG repeats from HD families 
found reduced height, lower BMI and smaller head sizes in the mutation carriers166. Smaller 
intracranial volumes were further found in prodromal HD167, also indicating discrete growth 
impairment prior to any neurodegeneration. Given the important role of HTT for embryonic 
and postembryonic development67–74, growth retardation seems to be a reasonable 
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consequence of disturbed HTT function, particularly in HD animal models with high CAG 
repeat numbers and mHTT protein expression levels. 
We have previously reported that 13 months old BACHD rats show signs of HD-related 
neurodegenerative processes in the form of sporadic dark neurons in cortex and the limbic 
system142. The absence of a progressive reduction in brain weight up to the age of 12 months 
adds further support to the idea that BACHD rats do not experience a marked loss of neurons 
until that age. 
The accumulation of fat mass on the other hand is a phenotype not observed in HD patients, 
although it is often found in rodent models of HD. It has been linked to abnormal adipocyte 
metabolism199,211. It is conceivable that the lack of fat accumulation in HD patients might derive 
from increased muscle activity due to chorea, as the severity of chorea correlates negatively 
with BMI and fat mass. Animal models of HD instead do not typically show chorea-like motor 
abnormalities, except for the fragment models of HD. The R6/2 mouse, which has increased 
fat mass at young ages219, shows fat and muscle wasting along with chorea-like movements 
and tremor at symptomatic ages126. However, also species-specific differences as well the 
restricted housing conditions with little possibility for exercise that laboratory rodents are 
exposed to, probably contribute to the difference in fat accumulation in HD patients and animal 
models. 
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Summary 
Background: BACHD rats show altered growth and body composition, which might relate to 
differences in energy balance similar to HD patients. 
Methods: In order to investigate the rats’ energy balance, we conducted a longitudinal study 
of activity, food and water intake as well as VO2 and VCO2, using the PhenoMaster Systems. 
In addition, we measured the effects of the mitochondria-targeting compound olesoxime on 
these parameters. 
Results: BACHD rats were found to weigh similar as WT rats, but to be smaller and obese. 
Activity levels did not seem to be decreased. In absolute measures, BACHD rats ate and 
drank less, and had a lower VO2. When normalized to the rats’ lean mass, BACHD rats turned 
out to have increased relative food intake at 2 months, while water intake and VO2 ceased to 
be different at any age. The RQ was increased at 2 months of age. Olesoxime did not 
significantly influence any of the parameters analyzed. 
Discussion: In line with the observation of a smaller body size and reduced lean mass, 
BACHD rats consumed less food and had a lower metabolic rate than WT rats in absolute 
terms. Due to the rats’ abnormal body composition, lean mass and not body weight is 
considered a good parameter for normalization. Changes in food intake observed after 
normalization, as well as changes in RQ suggest that BACHD have an increased energy 
demand and high carbohydrate metabolism at young ages, during their major growth phase. 
As metabolic alterations occur very early in the BACHD rat, the lack of effect of olesoxime 
might be interpreted as its inability to reverse an already manifest phenotype. 
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Animals, materials and methods 
Animals 
All relevant information on the animals, such as study groups, housing conditions and 
olesoxime treatment are specified in Publication VII. Briefly, four groups of rats were 
investigated. BACHD rats and WT littermates received either placebo or olesoxime-loaded 
food pellets from the age of 5 weeks onwards (n = 15 per group), and metabolic analyses 
started thereafter. 
Morphological measurement 
Body weight was measured weekly, from the age of 5 weeks on, using a kitchen balance 
(accuracy was ± 1 g) in order to record body weight development and monitor the rats’ general 
health status. 
Obesity and body length scoring were conducted at 8 months of age by two individual 
observers blind to the animals’ genotype. The rats were assigned to one out of three 
categories, i.e. normal, moderately fat and obese in order to estimate the degree of obesity, 
as well as small, medium and large in order to estimate the body length. 
In addition, body length was measured at 13 months of age using a ruler (accuracy was ± 0.1 
cm). The measurements were performed after the animals had been sacrificed. 
Automated homecage observation 
Activity-related and metabolic parameters were assessed using the PhenoMaster (TSE 
Systems, Germany). A detailed description of setup and procedures are available in 
Publication IV332 and Appendix A. Briefly, the setup enabled the simultaneous assessment of 
12 animals in individual homecage-like observation cages. All cages were equipped for the 
measurement of horizontal and vertical activity, food and water intake as well as VO2 and 
VCO2 (respirometry). Measurements were carried out in one cohort of rats longitudinally at 
the ages of 2, 4, 6 and 12 months. Each measurement started 40 ± 5 min before the onset of 
the dark phase. Data were collected in 20-minute sample intervals during a total of 70 hours 
of recording. 
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Lean mass correction 
Food intake, water intake and VO2 were normalized to lean mass in order to account for 
differences in body constitution. The lean mass of WT and BACHD rats was assessed in a 
dissection study, by subtracting the weight of adipose tissue and gastro-intestinal tract from 
total body weight (Publication VI344 and Appendix B). For normalization of food intake, water 
intake and VO2 at 2 months of age, the mean of the average lean mass of 1 and 3 months old 
rats was used, as the lean mass of 2 months old rats had not been assessed. For 
normalization at 4 and 6 months of age, the mean of the average lean mass of 3, 6 and 
9 months old rats was used, as the lean mass did not significantly differ in rats of this age. 
Data analysis and statistics 
Raw data exported from the PhenoMaster software were pre-processed into hourly bins and 
sorted by genotype, treatment and age using a script for R statistics developed in our 
institute332. Graphs and statistics were created using GraphPad Prism 6.00 for Windows 
(GraphPad Software, San Diego California USA, http://www.graphpad.com). 
Longitudinal data from two groups were analyzed using two-way repeated measurements 
ANOVA and Sidak’s post-test. Longitudinal data from more than two groups were analyzed 
with two-way repeated measurements ANOVA and Tukey’s post-test. Single measurements 
for more than two groups were analyzed with one-way ANOVA and Tukey’s post- test, or a 
non-parametrical test. All data are presented as group mean and standard error of the mean. 
The α-level was set to 0.05. 
Some data from the automated homecage observation had to be excluded from the analysis 
because of technical problems. In these cases, the complete data set for the respective animal 
was removed in order to enable the repeated measurements analysis. In total, we excluded 3 
out of 48 animals for activity measurements, as these rats displayed extraordinarily high 
counts, likely because the rats had shifted around bedding inside of the test cage. We only 
excluded values that were more than three times higher than the group mean and did not 
occur repeated times for the same animal. From food and water intake data, we had to exclude 
a total of 6 out of 48 rats, as sometimes drinking bottles were leaking (leading to unreasonably  
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high values for water intake) and as sometimes food got stuck in the food basket, so that the 
animal was not able to reach it (leading to unreasonably low values for food intake). For these 
rats, we also excluded the calorimetric data, as this is likely to be confounded in this case. 
The values that had to be excluded were spread among groups and testing cages, suggesting 
that they were not the result of a systematic error or had any biological meaning. 
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Results 
Body weight, body size and body composition 
There was significant difference in body weight between BACHD and WT rats (Figure 1A). 
However, BACHD rats had an altered body constitution, characterized by reduced body size 
(Figure 1B and C) and obese appearance (Figure 1D). 
 
Figure 1. Similar body weight but abnormal body composition of BACHD rats. 
BACHD rats weigh similar as WT rats (A), but are smaller (B, C) and appear obese (D). Olesoxime does 
not influence any of these parameters. Mean and SEM, two-way repeated measurements ANOVA and 
Tukey’s post-test for body weight, two-way ANOVA and Sidak’s post-test for body length measurement, 
and Kruskal-Wallis test and Dunn’s post-test for scoring of body size and body width, n = 15 per group, 
* P < 0.05, ** P < 0.01, *** P < 0.001. 
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Energy balance 
In order to assess if the increased fat mass found in BACHD rats had been the result of a 
positive energy balance, we assessed energy balance by measuring the rats’ activity, food 
and water intake as well as VO2 and VCO2. 
Activity 
As expected for nocturnal animals, all rats were significantly more active during the dark phase 
compared to the light phase. No obvious genotype differences in circadian or ultradian 
rhythms were observed when looking at the pattern of activity over the 70-hour measurement 
(data not shown). No differences between WT and BACHD rats were further found in 
ambulatory activity or rearing behavior (Figure 2). However, BACHD rats showed a significant 
increase in fine movements during the dark phase at 6 months, and a trend during the light 
phase at 12 months of age (Figure 2). 
Water and food intake 
Absolute values for water and food intake differed significantly between BACHD and WT rats 
(Figure 3). Water intake was significantly reduced at 2, 4 and 6 months, but ceased to be 
different at 12 months of age due to a stronger decline in water intake with age in WT rats. 
Food intake was significantly reduced at 4, 6 and 12 months, while BACHD rats tended to 
have increased food intake compared to WT rats at 2 months of age. 
Respirometry 
Absolute values for VO2 as well as VCO2 were found to be reduced in BACHD compared to 
WT rats, indicating a lower basal metabolism (Figure 4). The RQ was also reduced, 
suggesting differences in nutrient metabolization (Figure 4). 
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Figure 2. BACHD rats differ in absolute measures of energy balance. 
BACHD and WT rats were subjected to automated behavioral observations for 70 hours at 2, 4, 6 and 
12 months of age. The sum for light phase, dark phase and total observation period is given for activity-
related parameters. Mean and SEM, two-way ANOVA, Tukey’s post-test, * P < 0.05, ** P < 0.01, 
*** P < 0.001. 
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Figure 3. BACHD rats differ in absolute measures of energy balance. 
BACHD and WT rats were subjected to automated behavioral observations for 70 hours at 2, 4, 6 and 
12 months of age. The sum for light phase, dark phase and total observation period is given for water and 
food intake. Mean and SEM, two-way ANOVA, Tukey’s post-test, * P < 0.05, ** P < 0.01, *** P < 0.001. 
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Figure 4. BACHD rats differ in absolute measures of energy balance. 
BACHD and WT rats were subjected to automated behavioral observations for 70 hours at 2, 4, 6 and 
12 months of age. The mean for light phase, dark phase and total observation period is given for 
respirometric data (C). Mean and SEM, two-way ANOVA, Tukey’s post-test, * P < 0.05, ** P < 0.01, 
*** P < 0.001. 
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Lean mass-corrected values 
Since BACHD rats were found to have a distorted body composition with higher fat and lower 
lean mass (Publication VI344), we normalized the total values for water intake, food intake and 
VO2 from untreated WT and BACHD rats to the average lean mass calculated elsewhere 
(Appendix C). The results show that most of the differences that were found before, 
disappeared (Figure 5). Instead, BACHD rats presented with a significantly elevated food 
intake at 2 months of age (Figure 5).. Furthermore, a progressive increase in VO2 from 4 to 
12 months became apparent due to increased VO2 during the light phase (Figure 5). 
Olesoxime effect 
We did not detect an influence of olesoxime on any of the metabolic parameters (Figure 2, 3 
and 4). However, a lean mass-normalization could not be performed with olesoxime-treated 
rats, as their lean mass had not been assessed. 
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Figure 5. Relative values of energy metabolism show a different pattern. 
Food intake and VO2 measured at different ages, were normalized to lean mass to account for differences 
in body composition. The sum (food and water intake) or mean (VO2) for light phase, dark phase and total 
observation period are shown. Mean and SEM. Two-way ANOVA, Sidak’s post-test, n = 15 per group, 
* P < 0.05, ** P < 0.01, *** P < 0.001.  
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Discussion 
We analyzed several metabolic parameters in the BACHD rat in order to evaluate possible 
alterations in energy balance, as the animals have a distorted body constitution 
(Publication VI344 and Appendix B). Moreover, the therapeutic potential of olesoxime to 
interfere with metabolic abnormalities was investigated. 
We manually rated the rats’ body size and obesity phenotype at 8 months of age, receiving a 
gross similar outcome as obtained from detailed dissection (Publication V344 and Appendix A). 
This suggests that the body size and composition phenotypes are strong enough to score 
them by eye at that age, which might be useful for future treatment studies. However, small 
differences due to treatment are unlikely to be detected by this method. 
Due to the BACHD rats’ apparent obesity, we expected to find either reduced exercise, 
increased caloric intake, or a combination of these two, which would point to a positive energy 
balance. In contrast, we detected reduced absolute caloric intake and a lower absolute 
metabolism. However, due to the difference in body constitution between BACHD and WT 
rats, their energy requirements are likely to be different. It is conceivable, that the lower values 
detected were simply attributed to the rats’ smaller body size. Relating the absolute values to 
body weight to account for size differences, however, would have been confounding, as body 
weight is not a good denominator for energy expenditure when comparing animals with 
different body composition414. Different tissues are known to have different metabolic 
activities415, and specifically fat mass contributes relatively little to the overall energy 
expenditure414. A more suitable determinant for metabolic rate is lean mass414. By normalizing 
to the average lean mass obtained from dissection (Publication VI344 and Appendix B), we 
found that food and water intake, as well the rats energy expenditure (as indicated by VO2), 
relate well to their smaller body size and thus lower lean mass, as most differences had 
vanished. Interestingly, what appeared after normalization was a significantly increased food 
consumption at 2 months of age. As VO2 was not increased at that age, this could possibly 
explain the development of obesity in the rats. 
Another interesting finding concerns the increasing VO2 during the light phase with age. There 
were no indications for a parallel increase in ambulatory activity, but a trend towards increased 
fine movements was discernable specifically in the light phase at 12 months of age. Similar  
Appendix 
C. BACHD rat energy balance 
121 
 
 
results have been obtained from early symptomatic HD patients, who had a significantly higher 
sedentary energy expenditure due to spontaneous physical activity. Total free-living energy 
expenditure was unchanged in these patients, because they appeared to engage in less 
voluntary physical activity162. Thus, it would be informative to conduct a detailed ethological 
examination in addition to the quantitative assessment of activity levels in the BACHD rat. 
We also calculated the RQ, which reflects the source of macronutrients utilized to fuel energy 
metabolism and maintain body functions. A value of 1.0 stands for the sole use of 
carbohydrates, a value of 0.7 would mean the use of only lipids, and a value of about 0.8 
would be expected when only proteins were the substrate351. Thus, a high RQ points to high 
carbohydrate metabolism, while a low RQ indicates a large contribution of lipid oxidation, 
which occurs when carbohydrates cannot be utilized or are unavailable specifically under 
starvation. The finding of increased RQ in 2 months old BACHD rats is in line with their higher 
relative food intake and suggests high carbohydrate oxidation and increased energy 
demands. The decreasing RQ at older ages (after the major growth phase of the rats) on the 
other hand could point to a defect in glucose utilization or a higher glucose demand than the 
rats can cover by food intake. The trend towards higher VO2 at older ages and rather reduced 
food intake further suggests a failure to respond to the energetic deficit, and implies that these 
moderate phenotypes do have biological significance. However, the results need to be 
interpreted with caution, as food intake seems to be impaired during PhenoMaster exposure 
in Sprague Dawley rats (Appendix A). Moreover, this stress effect seems to differ among rat 
strains depending on their emotionality, and might thus also differ between BACHD rats and 
their WT littermates. Indeed, when comparing the body weight gain of BACHD and WT rats 
before and during PhenoMaster exposure, BACHD rats seem to have a stronger decline in 
body weight gain (data not shown). Thus, the validity of the measurements (particularly those 
at old ages, when the rats lose weight during the exposure) is questionable. 
We did not observe any significant influence of olesoxime treatment on body constitution or 
energy balance in the BACHD rat, although olesoxime targets mitochondria313,314, and 
mitochondrial dysfunction is highly implicated in metabolic dysfunction in HD257–262. Thus, this 
negative result might imply that olesoxime’s effects on mitochondria are not related to their 
role in energy metabolism. On the other hand, there is the possibility that olesoxime treatment  
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had started too late to restore metabolic abnormalities, as the difference in body constitution 
between BACHD and WT rats is already detectable at 1 months of age, which is prior to the 
start of olesoxime treatment. In this regard, it has been shown that switching off mHTT 
expression in the hypothalamus of the BACHD mouse abolished metabolic phenotypes when 
the procedure was performed at early ages194. Switching mHTT expression off when the 
phenotypes were fully developed, did not improve metabolic abnormalities anymore. 
Furthermore, a recent report points to a similar failure of olesoxime to rescue manifested 
phenotypes in a mouse model of Parkinson disease, despite other improvements323. Thus, it 
would be of interest to evaluate, if with earlier start of treatment, olesoxime also capable of 
ameliorating systemic metabolic abnormalities. 
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Summary 
Background: Blood parameters can be useful surrogate markers for disease due to low 
invasive sample collection, time and cost effectiveness. Metabolic dysfunction can be traced 
in blood from HD patients. Thus, we aimed at characterizing metabolic markers in plasma and 
serum from BACHD rats. 
Methods: We measured plasma IGF-1 and leptin levels by ELISA assays, as these factors 
are related to growth and obesity. We further prepared a longitudinal serum metabolite profile 
from 1H NMR analysis to search for potential markers of metabolic dysfunction in the BACHD 
rat and to track disease progression. 
Results: We found plasma levels of IGF-1 to be decreased, and plasma levels of leptin to be 
increased in BACHD rats at 3 months of age. IGF-1 levels remained stable from 3 to 
12 months, while leptin levels further increased from 3 to 6 months of age. The serum 
metabolite profile further differed significantly in BACHD compared to WT rats. At 2–3 months, 
BACHD rats show reduced levels of glucose, lactate, amino acids and ketone bodies, but 
increased lipid levels. At 12 months of age, only lipid levels were found to be reduced. At 
18 months, glucose, lactate and pyruvate levels were increased, while lipid levels were found 
to be reduced in BACHD compared to WT rats. In addition, BACHD rats showed reduced 
levels of N-acetylaspartic acid (NAA) at 18 months of age. 
Discussion: Our results demonstrate that BACHD rats display profound changes in energy 
homeostasis, which can be traced in blood. Changes in IGF-1 and leptin levels are consistent 
with the earlier finding that BACHD rats suffer from growth impairment and obesity. The serum 
metabolite profile points to dysfunctional metabolic pathways, which are likely due to impaired  
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lipolysis in the first place, and deficits in mitochondrial respiration later on. Thus, the study 
strengthens the finding of metabolic dysfunction in the BACHD rat and confirms that blood 
analysis can be a useful tool for further treatment studies. 
Author Contributions 
Conceived and designed the study: HPN, RD, MAP 
Performed the experiments: LY-T (serum sample collection) LEC (serum and plasma sample 
collection), KV (serum metabolite analysis), MAP (IGF-1 and leptin measurements) 
Analyzed the data: LEC, KV, MAP 
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Animals, materials and methods 
Animals 
Detailed information on the animals are given in Publication VII. Briefly, for serum IGF-1 and 
leptin measurements, four groups of rats were investigated. WT as well as BACHD rats 
received either placebo or olesoxime-loaded food pellets from the age of 5 weeks onwards, 
and metabolic analyses started thereafter. For 1H NMR spectroscopy on blood metabolite 
levels, different cohorts of untreated WT and BACHD rats were used. 
Blood sampling 
Blood was collected from the tail vein 2–3 hours before the onset of the light phase. Blood 
collected for plasma was kept on ice until centrifugation at 13,200 rpm for 15 minutes at 4 °C. 
Blood collected for serum samples was incubated for 30 minutes at 37 °C to allow for 
coagulation prior to centrifugation at 3,000 rpm for 30 minutes at 4 °C. After centrifugation, 
plasma and serum were transferred into cryotubes and stored at -80 °C until shipment to the 
University of Antwerp. 
Blood metabolite analysis 
IGF1 and leptin levels were measured at the University of Vancouver, using a commercial 
ELISA kit (Mouse Quantikine ELISA kit, R&D Systems), as applied previously197. Since the 
standards in this kit are mouse IGF-1, the concentration refers to the equivalent of mouse IGF-
1. 
Serum metabolites were assessed via 1H NMR spectroscopy by our collaboration partner, as 
described in detail in Publication I350 and Reference356.  
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Results 
IGF-1 and leptin 
BACHD rats showed reduced IGF-1 and increased leptin levels at 3 and 6 months of age. 
IGF-1 levels decreased, while leptin levels increased with age in both genotypes. Leptin levels 
were also measured at 9 and 12 months of age, revealing a trend towards decreasing leptin 
levels with age in both genotypes (data not shown). Olesoxime treatment did not affect IGF-1 
levels, but moderately increased leptin levels in WT and BACHD rats. 
 
Figure 1. Reduced IGF-1 and increased leptin levels in BACHD rats. 
IGF-1 and leptin were measured at 3 and 6 months of age in WT and BACHD rats receiving placebo or 
olesoxime treatment. Mean and SEM, two-way repeated measurements ANOVA, Sidak’s post-test, n = 12 
per group, * P < 0.05, ** P < 0.01, *** P < 0.001. 
Serum metabolite profile 
BACHD rats could be distinguished from their WT littermates based on their serum metabolite 
profile356. The difference was due to changes in several serum metabolites involved in energy 
metabolism, as summarized in Figure 2. At 2–3 months of age, BACHD rats showed reduced 
levels of glucose, lactate, amino acids and ketone bodies, but increased lipid levels compared 
to their WT littermates. At 12 months of age, no differences were detectable except for lipid 
levels, which were found to be reduced in BACHD compared to WT rats. At 18 months, serum 
glucose, lactate and pyruvate levels were higher, while lipid levels were still lower than those 
of WT rats. 
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Thus, serum energy metabolite concentrations showed age-dependent changes 
characterized by a triphasic course of metabolic dysregulation, with changes at young and old 
ages, and a normal phase at intermediate ages. A simplified, extrapolated model of BACHD 
rat metabolite changes over the course of 18 months is given in Figure 3. 
Differences between WT and BACHD rats were most dramatic at 3 months of age. At that 
age, a variety of other metabolites appeared to be reduced in concentration in the BACHD rat. 
These concerned additional amino acids (i.e. valine, leucine and isoleucine, lysine, 
phenylalanine, tyrosine, glutamine, glycine and methionine) as well as molecules involved in 
the tricarboxylic acid (TCA) cycle (i.e. citrate, succinate and malonate), in neurotransmission 
(glutamate, glycine, phenylalanine, tyrosine, choline and myo-inositol), membrane constitution 
(choline and myo-inositol) and the phospagen system (creatine). At 18 months, we further 
detected a significant decrease in N-acetyl-aspartate (NAA), a marker for neuronal health. 
 
Figure 2. Changes in serum metabolites in the BACHD rat. 
(A) The heat map shows the changes found in the main energy metabolism-related metabolites assessed 
via 1H NMR spectroscopy in different cohorts of WT and BACHD rats at 2, 3, 12 and 18 months of age. 
The results from 2 and 3 months old rats were combined for better overview. Blue = reduced in BACHD 
rats, gray = similar between BACHD and WT rats, red = increased in BACHD rats. Number of samples 
from individual animals at the different ages were as follows: 2 months: WT = 12, BACHD = 6; 3 months: 
WT = 17, BACHD = 17; 12 months: WT = 17, BACHD = 13; 18 months: WT = 5, BACHD = 4. (B) 
Theoretical model of serum metabolite changes. BACHD rat serum metabolite levels reveal a triphasic 
pattern with early and late age dysregulation, and a normal intermediate phase.  
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Discussion 
We investigated blood samples from BACHD rats in order to characterize metabolic 
dysfunction and identify potential disease markers. BACHD rats differed from WT rats in their 
overall metabolite profile, suggesting that blood markers are useful surrogate markers for 
further treatment studies in the BACHD rat. 
IGF-1 and leptin 
The targeted analysis of IGF-1 and leptin levels revealed that IGF-1 is reduced and leptin 
increased in the BACHD rat in accordance with the rats’ smaller body size and obesity 
phenotype. 
IGF-1 signaling is thought to be critical in HD, as it is associated with cellular and particularly 
brain energy deficits416,417. Moreover, increasing IGF-1 levels has been shown to restore the 
energetic deficits found in HD animal models418. IGF-1 levels have been reported to be 
moderately171 or significantly168,197 lower in HD patients, as well as in a variety of other HD 
disease models197, in accordance with our findings. In contrast, the full-length mHTT 
expressing YAC128 and BACHD mice have increased levels of IGF-1197. However, while 
other models (including the BACHD rat) present with growth deficits, these mice do not show 
reduced body sizes76,194. Thus, although it is unclear why the levels of IGF-1 vary, they are 
obviously dysregulated in HD and seem to be responsible for the body size differences found 
in HD197. 
Leptin levels have been reported to be either unchanged161,162,419,420 or reduced168,171 in HD 
patients, while they were found to vary substantially between different HD mouse models. 
However, the thorough analysis of these data and the comparison with results from HD 
patients as well as the results from BACHD rats suggests that the variation derives from 
sampling at different stages of the disease, as the parameter underlies temporal changes. 
This can be illustrated with results from the following study: Leptin levels were measured in 
two mouse models of HD at different stages of disease211. The CAG140 knock-in mouse 
showed increased leptin levels at a presymptomatic stage, while the R6/2 mouse displayed 
similar leptin concentrations at an early symptomatic stage, compared to their respective WT 
counterparts. Leptin levels at a late symptomatic stage were reduced in both models. Thus,  
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leptin levels are likely to be increased early on (reflecting ages that have not been studied in 
HD patients), to reverse around symptom onset (leaving no changes detectable), and to 
decrease towards end stages (making it likely to detect reduced leptin levels in symptomatic 
HD patients). 
Differences in the characteristics of mHTT expression across HD disease models likely further 
influence leptin levels, as it has been reported that leptin levels correlate positively with CAG 
repeat length in HD mutation carriers419. And also genetic differences between background 
strains probably have an additional influence, considering the obvious variation in the 
development of obesity among different WT strains. Sprague Dawley rats, which form the 
background for the BACHD rat, are known to be prone to develop obesity421, a fact that likely 
adds to the strong obesity phenotype in this model. 
The fact that BACHD rats developed obesity despite the dramatically increased leptin levels 
implies leptin resistance and might thus further indicate a deficit in leptin signaling in the 
brain422. Hypothalamic changes are well described as a part of HD156. Furthermore, it has 
been demonstrated that switching off the expression of mHTT in the hypothalamus restored 
the obesity phenotype in BACHD mice (interestingly without affecting IGF-1 levels)194. 
However, silencing mHTT specifically in leptin receptor-expressing cells, did not lead to 
marked improvements212. 
Serum metabolites 
Serum metabolite analysis by 1H NMR spectroscopy detected changes in the major 
metabolites involved in energy metabolism, as discussed previously356. The results indicate a 
triphasic pattern of metabolic changes with age. 
BACHD rats display reduced levels of glucose, lactate, amino acids and ketone bodies, while 
the levels of lipids were found to be increased at 2-3 months of age, which is around the end 
of the rats’ major growth phase (as can be obtained from the body weight curve in 
Appendix C). That glucose, lactate and amino acids were depleted from the rats’ blood at that 
age suggests a temporary, high energy demand with higher carbohydrate-based energy 
metabolism in BACHD compared to WT rats. The reason for the high dependency on  
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carbohydrate metabolism is indicated by the increased lipid levels, which suggests impaired 
utilization of lipids for energy supply. Under such conditions, the tricarboxylic acid (TCA) cycle 
is likely to be unable to support amino acid synthesis, or amino acids participate in energy 
production, which is consistent the finding of reduced peripheral amino acid levels. The 
decrease in ketone bodies further supports this hypothesis, as under such circumstances, 
ketone bodies are utilized to provide additional energy, but cannot be replenished as this 
would require lipid oxidation. In fact, it has been shown that adipocytes isolated from mouse 
models of HD present a defect in lipolysis199. Furthermore, it is reasonable to assume that this 
deficit is responsible for the accumulation of fat mass as well as for the growth defect seen in 
BACHD rats. The latter is likely connected to the reduced IGF-1 levels observed, as IGF-1 
levels depend on the availability of amino acids357 and are lower during starvation423. 
After the major growth phase with its high energetic demands, BACHD rats do not seem to 
have metabolic deficits during a large part of adulthood, as we detected little differences in 
serum metabolites between the genotypes at 12 months of age. This is similar to HD patients, 
who live a relatively normal life before clinical symptom onset at midlife or older ages. 
Accordingly, at the old age of 18 months, energy metabolite levels are again found to be 
altered in the BACHD rat, showing a reversed pattern compared to the young ages. The 
accumulation of glucose, lactate and pyruvate suggests an impairment of carbohydrate 
metabolism at this age. Specifically, this points to impaired mitochondrial energy production, 
as respiratory chain activity is setting the pace for upstream oxidative pathways, meaning that 
a defect would lead to the accumulation of metabolites from glycolysis and TCA cycle. This at 
the same time explains why amino acid levels are restored, as with the increased availability 
of glucose, the demand for additional energy substrates would cease. 
The late metabolic changes detected in the BACHD rat are consistent with abnormalities 
found in animal models and HD patients. Increased levels of lactate253–256 and reduced 
glucose consumption177–183 are found in presymptomatic and symptomatic HD patients. 
Furthermore, mitochondrial dysfunction is a prominent feature at symptomatic stages of 
HD257–262. Thus, alterations in the metabolite profile detected in 18 months old BACHD rats 
point to an advanced stage of the HD-related pathology at that age. In this regard, we further 
detected a reduction in the levels of NAA, a marker for neuronal health and degeneration424  
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in 18 months old BACHD rats. Reduced levels of NAA are commonly found in HD251–255 with 
the most severe drop occurring around the age of disease onset425, and changes hardly being 
detectable before426. Thus, it is likely that at 18 months of age, neurodegenerative processes 
become significant in the BACHD rat. We have previously reported the presence of dark 
neurons in BACHD rats at 13 months of age. For further studies, it would be interesting to 
analyze neurodegeneration and NAA levels in the BACHD rat in more detail at short intervals 
between the age of 12 months (where no changes were found) and at ages older than 
18 months (after signs of neurodegeneration have occurred) to determine the start and 
progression of this phenotype. Unfortunately though, attempts to investigate the late phase of 
HD-related phenotypes in the BACHD rat are complicated by the fact that Sprague Dawley 
rats, the rat strains forming the background for the BACHD rat model, are generally known to 
develop obesity and a metabolic syndrome accompanied by high tumor incidence and 
mortality past the age of 12 months421. For this reason, end stage phenotypes or mortality 
have not been studied in the BACHD so far. 
One of our results seems to be contradictory to findings in HD patients, which is that amino 
acid levels were only reduced at the very early ages and restored later on, while they are 
commonly found to be reduced in patients at symptomatic stages248–250. That we did not 
observe reduced levels of amino acids beyond the age of 3 months might be attributed to the 
increased fat mass in the BACHD rat, which is not found in HD patients. It is reasonable to 
assume that BACHD rats are not completely incapable of utilizing lipids to fuel their energy 
demands, which might be supported by the finding of reduced lipid levels and reduced RQ 
found at older ages (Appendix C). For this reason, the rats might not get into a severe energy 
deficit at older ages due to the availability of storage fat, while patients instead would 
experience progressive muscle wasting. For the same reason, it might be speculated that 
BACHD rats only show little signs of neurodegeneration up to an age of 18 months. 
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Summary 
Background: Primary neuronal cultures represent useful complementary tools for studying 
molecular aspects of neurological diseases, as they provide the original cell context with all 
neuron-specific features. However, these cultures are more complex to establish, longer to 
prepare and difficult to maintain compared to clonal cell lines. Here, we aimed at establishing 
a time-efficient, and reproducible protocol for the preparation of primary neurons from BACHD 
rats, to investigate molecular aspects in cells most vulnerable to HD. Our first analyses in 
these cells were addressed to investigate early mitochondrial pathologies, as mitochondrial 
dysfunction is a prominent feature of HD. 
Methods: We prepared cultures of BACHD rat primary striatal and cortical neurons and 
determined their viability via MTT and LDH tests. HD disease phenotypes were then 
investigated, including the quantification of mHTT aggregates via a filter trap assay and 
immunoblotting, measurement of mitochondrial motility by time-lapse fluorescence 
microscopy, as well as assessment of IGF-1 and 8OHdG levels by ELISA. 
Results: We established a time-efficient protocol for the extraction of primary striatal and 
cortical neurons from the same embryo in parallel. The neurons were maintained in culture 
for up to 12 days and recapitulated several specific, HD-related phenotypes. BACHD rat 
neurons contained aggregated forms of mHTT. Although neither cortical nor striatal cells from 
BACHD rats differed in viability or showed signs of oxidative stress compared to cells from 
WT rats, a distinct difference in mitochondrial motility along with reduced IGF-1 levels were 
detected. 
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Discussion: We describe a fast and reproducible protocol for the extraction of primary 
neuronal cultures from rats. This protocol could in principle be extended for the parallel culture 
of other brain regions and could be useful not only for studying molecular mechanisms of HD, 
but also of other neurological disorders. BACHD rat primary neurons display discrete HD-
related phenotypes, which might aggravate with longer cultivation times. The results 
encourage the use of BACHD rat primary neurons for further studies on the molecular 
pathogenesis of HD, to identify therapeutic targets and to evaluate drug candidates for HD. 
Author Contributions 
Conceived and designed the study: HPN, RMP, MRH, LEC 
Developed the new, combined protocol: LEC 
Performed the experiments: LEC and JR (primary cultures, MTT assay, axonal transport), 
MAP (IGF-1 measurements) 
Analyzed the data: LEC, MAP 
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Materials and methods 
Buffers and reagents are listed in Table 1. Buffers, reagents and procedures used represent 
a combination of two previously established protocols for the isolation and cultivation of 
primary striatal (provided by Dr. Rebecca Pruss, Trophos SA, Marseille) and cortical (provided 
by Dr. Andrew Grierson, University of Sheffield) neurons from mice. These were combined to 
one conform protocol, yielding higher time-efficiency and practicability. 
Table 1. Reagents. 
Application Reagent Provider 
Catalogue Number 
Volume 
Concentration 
Buffers 
HBSS (-) no Ca2+, Mg2+ Lifetechnologies, Gibco® 14175-095 500 ml 
HBSS (+) with Ca2+, Mg2+ Lifetechnologies, Gibco® 14025-050 500 ml 
Digestion Trypsin Lifetechnologies, Gibco® 59427C 
100 ml 
2.5 % 
 Cortex 
Culture media 
Neurobasal Lifetechnologies, Gibco® 21103 500 ml 
B-27 Supplement Lifetechnologies, Gibco® 17504-044 10 ml 
L-Glutamine Lifetechnologies, Gibco® 25030-032 
5 ml 
200 µM 
Penicillin/streptomycin Lifetechnologies, Gibco® 15140-122 
5 ml 
10,000 U/ml 
Striatum 
Neurobasal Lifetechnologies, Gibco® 21103 500 ml 
B-27 Supplement Lifetechnologies, Gibco® 17504-044 10 ml 
Sodium pyruvate Lifetechnologies, Gibco® 11360-039 
5 ml 
100 mM 
BSA Sigma Aldrich 9048-46-8 A4919-G 
12.5 ml 
4 % 
Trituration 
HBSS (+) Lifetechnologies, Gibco® 14025-050 20 ml 
BSA Sigma Aldrich A4919-G 
2.5 ml 
4 % 
Glucose Sigma Aldrich G8270 2 g 
DNase I Sigma Aldrich D5025 
500 µl 
5 mg/ml in H2O 
Coating Poly-ornithine Sigma Aldrich P4638 5 µg/ml in H2O 
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Rat breedings for primary neuronal cultures 
In order to obtain rat embryos from a specific developmental stage, terminated breedings were 
set up. Twelve weeks old female, WT Sprague Dawley rats (Crl:CD (SD)) were ordered from 
Charles River Germany and acclimatized to the new facility for 2 weeks prior to breeding. 
Housing conditions in our facility are detailed in Publication V377 and VII. A total of 36 female 
rats were used in this study. For the breeding, two females were introduced into the home 
cage of one male rat. Breeding cages were prepared approximately 1 hour before the onset 
of the dark phase (this day refers to embryonic day (E) 0, prior to conception), and vaginal 
smears were made to detect mating activity, on the following morning (E 0.5, if the rat had 
conceived). The males were removed from the cages either after the first night, if clear 
indicators for mating activity had been seen, or after a total of two consecutive nights. 
 
 
Figure 1. Vaginal smears to detect mating activity. 
Vaginal smears were investigated light microscopically (magnification 100x). A: Negative smear; only few 
epithelial cells are visible. B–D: Positive smears; a high number of epithelial cells (B), hair (C) or sperm 
nests (as indicated by the arrow) (D) indicate mating activity. 
For the vaginal smears, a swab with a sterile sodium chloride-soaked dabber, was gently 
obtained from the vagina of the female rat, smeared on a glass cover slide and covered with  
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a cover slip. The smears were investigated under the light microscope as displayed in 
Figure 1. In order to further check for mating success, the body weight of the females was 
measured after breeding. 
Dissection of rat embryos 
The dissection was conducted on embryonic day E 17.5 or E 18.5 post conception. Fifteen 
pregnant females were sacrificed by inhalation of CO2. Caesarean sectioning was performed 
to extract the embryos, which were decapitated immediately. A piece of each body was 
collected for genotyping. The soft skull was incised using small eye scissors. Three cuts were 
made to open it, two placed along the sides, and one on top of the head from occipital to 
rostral until reaching the eyes. Afterwards, muscle and cartilage were folded away to reveal 
the brain, which was gently extracted with small, curved forceps, and collected in ice-cold 
HBSS (-) buffer. 
Extraction and cultivation of primary neurons 
Cortices and striata were extracted using a binocular microscope with a magnification of 5–
10x. The stepwise extraction is illustrated in Figure 2. 
Tissue from individual embryos (two samples per embryo and brain region) was collected in 
1 ml ice-cold HBSS (-) buffer. Further procedures were carried out under sterile conditions. 
The tissue was washed once with HBSS (-) and incubated for 15 minutes at 37 °C and 5 % 
CO2 with 0.5 ml HBSS (-) and 40 µl trypsin (2.5 %) for digestion. During digestion, tubes were 
inverted every 5 minutes. After digestion, the tissue was gently aspirated with a 1 ml pipette 
and transferred into a fresh tube containing 250 µl triturating solution (TS), which included 
Ca2+ to inactivate traces of trypsin left in the sample and DNase to avoid clumping through 
free DNA. The tissue was then disrupted by pipetting up and down 10 times using a 1 ml 
pipette. After the remaining tissue pieces had settled, supernatant was transferred into a fresh 
tube. Additional 250 µl of TS were added to the remaining tissue pieces and the tissue was 
triturated another 10 times. After this, either supernatant or whole samples (if no solid pieces  
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had remained) was transferred into the fresh tube. In case that parts of the tissue were still 
left, these were discarded. However, another trituration step can be added, if cell yield is 
crucial. Tubes containing the dissociated neuronal cells were then centrifuged for 5 minutes 
at 400xg, supernatant was discarded and pellets were resuspended in 1 ml of Neurobasal 
Medium with tissue-specific additives by pipetting up and down a few times with a 1 ml pipette. 
Striatal samples were filled up to a total volume of 2.5 ml (cortical samples to 5 ml) in order to 
achieve a concentration of approximately 1,000,000 cells per ml. Cells were seeded in 37 °C 
pre-warmed media on different precoated plates, depending on the assay performed 
afterwards. Media were changed after 24 hours in order to remove debris and dead cells. Half 
of the media per well were further removed on every 3rd day in vitro (DIV), and replaced by an 
equal amount of fresh media. 
 
Figure 2. Tissue dissection steps for the extraction of striatum and cortex from intact embryonic 
brains. 
Cortex and striatum were dissected from E17.5/18.5 embryos in a stepwise procedure. The brain was 
placed with its dorsal side facing upwards (A), the hindbrain was removed and discarded (B) and the 
forebrain hemispheres were separated (C). Hemispheres were then turned, placed with their medial side 
facing upwards (D), and protruding diencephalic tissue was removed and discarded (E). The cortex was 
spread open (F), the meninges were removed and discarded (G) and the dorsal part of the cortex (not 
attached to other tissues) was excised and collected (H). The striatum (loosely attached to the ventral 
part of the cortex) was gently separated and collected (I). 
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Genotyping 
Embryonic tissue samples for genotyping were collected during the dissection procedure as 
mentioned above. A detailed description of primers and PCR protocol are given in 
Publication II142. 
Cell viability assays 
We measured cell viability and cell death in primary striatal and cortical cultures. The assays 
were performed with commercially available kits (Cell Proliferation Kit I (MTT) and Cytotoxicity 
Detection Kit (LDH), Roche) following the provider’s instructions. Both are based on the 
reduction of a tetrazolium salt to form formazan crystals. The MTT test depends on the 
presence of NADH + H+ within the cells and is therefore considered to be a function of the 
activity of intracellular dehydrogenases and a measure of cell viability. The LDH test depends 
on the presence of dehydrogenases in the supernatant, which are released by dead cells and 
thus represent a measure of mortality. 
Primary neurons were seeded at a density of 50,000 per well on 96 well plates (DIV 0). For 
the MTT test, tetrazolium salt was added at DIV6, and cells were incubated for 24 hours. After 
this, cells were lyzed by addition of lysis buffer, and the optical density (OD) was measured at 
550 nm in a plate reader (BIO-TEK Synergy HT Microtiter Platereader) to measure the 
formazan concentration. For the LDH assay, cell culture media was collected at DIV 7, 
transferred to a fresh 96 well plate and incubated with tetrazolium salt. The OD was measured 
at 492 nm to measure the formazan concentration. For the analysis, OD measurements at an 
unspecific wavelength were subtracted to reduce background noise. 
Mutant huntingtin in primary neuronal cultures 
Procedures are as published in the supplemental information of Publication III358. 
The formation of insoluble (aggregated) forms of mHTT is a hallmark of HD85,86. Thus, we 
aimed at investigating, if aggregated forms of mHTT are present in the primary cultures. For 
this, striatal and cortical neurons prepared from individual BACHD and WT embryos were  
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cultured in 6-well plates at a density of 1,000,000 cells per well for cortex and 2,000,000 cells 
per well for striatum. On DIV 7, cells were harvested by trypsinization (1 ml of 0.25 % trypsin  
with EDTA (Gibco) per well) and centrifugation (10 min at 400xg). Proteins were extracted 
from cell pellets by incubation in 100 µl RIPA buffer (50 mM Tris-HCl, pH 8.0, 150 mM NaCl, 
1 % IGPAL, 0.5 % sodiumdesoxychelate, 0.1 % SDS) containing 4 % cOmplete ULTRA 
Protease Inhibitor-Cocktail with EDTA (Roche) for 30 minutes at 4 °C and subsequent 
centrifugation for 15 minutes at 4 °C at 16.400xg. Supernatant was collected and protein 
content for each sample was measured using a Bradford assay. The samples were stored at 
-80 °C until further use. 
To detect the presence of insoluble mHTT in these samples, we performed a filter trap 
assay427 optimized for the detection of mHTT. The method is based on the SDS-insolubility of 
mHTT aggregates, which are retained when filtered through a nitrocellulose membrane. For 
this purpose, 20 µg of protein lysate was mixed with SDS (final concentration 2 %) and filtered 
using a dot blotter (Dot blotter SRC 96 D, S&S Minifold I, Schleicher & Schuell, Germany). 
The membrane (Protran Nitrocellulose Membrane, Whatman) was afterwards probed with 
1C2 anti-polyQ-antibody (MAB1574, Millipore, 1:2000) over night at 4 °C and on the next day 
incubated for 1 hour at room temperature with the secondary, horse-radish-peroxidase-linked 
anti-mouse IgG, antibody (NA931, Amersham Biosciences, 1:2500). Chemiluminescence was 
created using ECL Western Blotting Detection Reagent (Amersham Biosciences) and 
detected with the Odyssey FC (LI-COR Biosciences), showing SDS-insoluble forms of polyQ-
containing protein (mHTT). 
Axonal mitochondrial transport 
We quantitatively assessed the motility of mitochondria along axonal processes of BACHD 
and WT rat neurons. For this, primary neurons were seeded at a density of 250,000 cells 
(striatum) or 200,000 cells (cortex) into coverglass chambers (4-chamber Lab-Tek™ II 
chambered coverglass, Nunc) and transfected with DsRed2Mito (encoding a fusion of 
Discosoma sp. red fluorescent protein (DsRed2) and a mitochondria-targeting sequence of 
human cytochrome c oxidase subunit VIII (Mito)) and GFP empty vector (Clontech).  
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We used two different transfection methods to account for the differential characteristics of 
striatal and cortical neurons. Cortical projection neurons grow long axonal processes, making 
it difficult to tell which axons belong to which neurons. In order to properly follow mitochondrial 
transport in these cultures, a low transfection efficiency was favorable. Thereby, axons of 
single neurons could be identified with certainty. The low transfection efficiency was achieved 
by calcium phosphate transfection (ProFection® Mammalian Transfection System, Promega) 
as previously described428. Transfection was carried out on DIV 6 according to the 
manufacturer’s instructions using 1 µg/µl DNA in a ratio of 6:4 for DsRed and GFP, 
respectively. Striatal neurons, which grow much shorter axons that can be distinguished at 
higher cell densities, were transfected with a lipofection-based method (Lipofectamine®, 
Lifetechnologies), which yielded higher transfection efficiency (0.2 µg/µl DNA were used in 
the same ratio). Media were changed in both cases 4 hours after transfection to reduce 
cytotoxic effects of the transfection process. 
On DIV 7, cells were imaged using an inverted Zeiss Axiovert microscope (Zeiss Plan-
Apochromat 63x/1.4) with a CO2- and temperature-controlled incubation chamber at 5 % CO2 
and 37 °C. Time-lapse videos of axonal mitochondrial transport were recorded with a Zeiss 
AxioCamMRm camera at a time-lapse interval of 3 seconds over 5 minutes. The image 
sequence was exported and mitochondrial motility in axonal processes was analyzed with 
ImageJ429 as previously described430. 
IGF-1 measurements 
In order to determine IGF-1 concentrations, primary striatal neurons were cultivated at a 
density of 250,000 cells per well in 24 well plates. Culture media samples collected at different 
times were stored at -80 °C until shipment. IGF-1 levels were measured at the University of 
Vancouver using a commercial ELISA kit (Mouse Quantikine ELISA kit, R&D Systems) as 
previously applied 197. Since the standards in this kit are mouse IGF-1, the concentration refers 
to the equivalent of mouse IGF-1. 
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Oxidative DNA damage 
The oxidation product 8OHdG is produced when reactive oxygen or nitrogen species oxidize 
DNA, and represents a common marker for oxidative stress372. We measured 8OHdG levels 
in cell culture media from primary striatal neurons using a commercially available ELISA kit 
(8-hydroxy-2-deoxy Guanosine EIA Kit, StressMarq Biosciences) and following the 
manufacturer’s instructions. 
For this, striatal neurons were seeded at a density of 200,000 per well on 24 well plates, 
culture media were collected on DIV 7 and diluted 1:10 with ELISA buffer. The sample was 
loaded on an antibody-coated plate competing with 8OHdG-acetylcholine-esterase-tracer for 
antibody binding. After incubation and washing steps, acetylcholine esterase substrate was 
added and the OD was measured at 412 nm. The signal is inversely proportional to the 
amount of sample 8OHdG.  
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Results 
Breeding efficacy 
A total of 41 breedings with two females each (i.e. 82 individual breeding events) were set up. 
Of these, 17 females conceived, giving a breeding success of 20 %. Vaginal smears 
(Figure 1) were prepared from 68 of the 82 females. Out of these, 24 showed signs of mating 
activity, while 45 did not. Thus, predicting pregnancy upon a positive result for mating activity 
had only a success rate of 52 %. In contrast, excluding rats due to the lack of indicators of 
mating activity was 96 % accurate. 
A better predictor of pregnancy was body weight development after breeding (Figure 3). 
Pregnant females differed significantly from non-pregnant females in body weight gain after 1 
week (25 ± 14 g versus 6 ± 11 g at day 6-9, P = 0.0006, Welch-corrected t-test). The difference 
increased further about 3-fold until the day of dissection, (66 ± 20 g versus 13 ± 13 g at day 
17-18, P <0.0001, Welch-corrected t-test). Only one female rat was found to have increased 
her body weight dramatically after breeding, while not carrying a litter after 18 days. During 
dissection, we found that this rat had accumulated large amounts of body fat, which might 
indicate a pregnancy that was aborted at an earlier time. 
 
Figure 3. Increased body weight gain in pregnant females after breeding. 
The body weight gain of females was measured on the day of breeding (day 0) and at different days after 
breeding. Mean values from 14 rats that did not conceive after breeding (not pregnant) and 13 rats that 
did conceive after breeding (pregnant) are shown. Two-way ANOVA, Sidak’s post-test, * P < 0.05, 
** P < 0.01, *** P < 0.001. 
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Viability of neuronal cultures 
Isolated cells were viable in culture, readily attached to the culture dish surface and formed 
axonal processes (Figure 4). 
When comparing the viability of primary cultures from BACHD rats and their WT littermates at 
DIV 3, we did not detect any differences regarding their mortality or cell metabolism, as 
measured by the LDH and MTT assays, respectively (Figure 5). 
Mutant huntingtin expression 
As published before358, we detected insoluble forms of mHTT in primary striatal and cortical 
neurons from BACHD rats at DIV 7 by filter trap assay (Figure 6). This result confirms the 
expression of mHTT in BACHD rat primary neurons as well as the presence of mHTT 
aggregates at that age. Cortex revealed more aggregated mHTT, consistent with a higher 
expression level and higher amount of aggregate formation in BACHD rats in vivo142 as well 
as in HD patient brains86 
 
Figure 4. Primary neuronal cultures. 
The photographs show primary striatal (A) and cortical (B) neurons at DIV 3 at a density of 200,000 cells 
per well in a 24 well plate. Cortical neurons are larger than striatal neurons and grow longer axonal 
processes. Images were taken with a light microscope at 400x magnification. 
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Figure 5. BACHD primary neuronal cultures do not show reduced cell viability. 
Cell viability was determined at DIV 7 based on the LDH release of dead cells (A, B) and the 
dehydrogenase-dependent MTT conversion (C, D). Neither cell mortality measured in the LDH test, nor 
cell metabolism measured in the MTT test, differed between WT and BACHD rat striatal (A, C) or cortical 
(B, D) primary neuronal cultures. The same individual embryos were used for the cultures for LDH and 
MTT assay (n = 3 WT and 5 BACHD for striatum, and n = 3 WT and 3 BACHD for cortex). Welch-corrected 
t-tests, * P < 0.05, ** P < 0.01, *** P < 0.001. 
 
Figure 6. BACHD rat primary neuronal cultures contain insoluble mHTT. 
SDS-insoluble proteins were trapped on a nitrocellulose membrane and probed with a polyQ-specific 
antibody. The presence of insoluble polyQ-containing protein in primary striatal and cortical cultures from 
BACHD rat embryos but not their WT littermates indicates the expression of aggregated forms of mHTT  
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in these neurons. Each dot is the extract from a separate neuronal culture prepared from an individual 
embryo (three embryos per genotype and brain region). 
Axonal mitochondrial transport 
Several studies report an impairment of axonal trafficking in HD46,288,431,432. Compromised 
mitochondrial transport in particular288,289,433 might contribute to deficits in cellular energy 
metabolism observed in HD398. Therefore, we tracked axonal transport of mitochondria in our 
primary cultures by measuring the amount of motile mitochondria within axonal processes. On 
average, WT cells contained 30–40 % of motile mitochondria, which is common for healthy 
cells434. On the other hand, a significant reduction of the percentage of motile mitochondria 
was detected in striatal (Figure 7A) and cortical neurons (Figure 7B) from BACHD rats 
compared to WT littermates, pointing to an HD-related transport defect. 
         A                                         B                                                                                
 
 
 
 
 
 
 
Figure 7. Axonal mitochondrial transport is impaired in BACHD rat neurons. 
BACHD rat striatal (left side) and cortical (right side) neurons have a lower percentage of motile 
mitochondria compared to neurons from their WT littermates. The graph displays mean plus SEM of 
neurons tracked from three independent measurements (striatum: n = 12 WT and 12 BACHD neurons; 
cortex: n = 18 WT and 21 BACHD neurons). Welch-corrected t-test, * P < 0.05, ** P < 0.01, *** P < 0.001. 
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IGF-1 levels 
It has been shown that the axonal transport defect is restored, if mHTT is phosphorylated at 
serine 421400. In HD, reduced IGF-1 levels197 lead to decreased Akt signaling435 and reduced 
phosphorylation of mHTT at serine 421400. Thus, we investigated the levels of IGF-1 in BACHD 
rat primary striatal cultures. We observed reduced levels of IGF-1 in these neurons (Figure 8). 
Interestingly, IGF-1 levels seemed to be slightly increased in BACHD rat cultures at DIV 3, 
while this trend changed into reduced IGF-1 levels at DIV 6 and 9, cumulating in a significant 
difference at DIV 12. 
 
Figure 8. IGF-1 levels are reduced in BACHD rat primary striatal neurons at longer cultivation 
times. 
BACHD rat primary striatal neurons show lower IGF-1 concentration in their culture media at 12 days in 
vitro (DIV). Samples were taken from cultures deriving from six individual embryos per genotype. Two-
way ANOVA, Sidak’s post-test, * P < 0.05, ** P < 0.01, *** P < 0.001. 
Oxidative DNA damage 
Oxidative stress, and associated DNA damage have been described as a part of mitochondrial 
dysfunction in HD246. These pathologies are considered to be related to a negative influence 
of mHTT on mitochondrial function265,269. Since we had found that striatal but not cortical 
neurons from BACHD rats display deficits in energy metabolism at DIV 7358, we were 
interested in assessing if oxidative stress as a result of profound mitochondrial damage would 
be present in these cells after longer cultivation times. However, we found that the levels of 
8OHdG released by dead cells did not differ between WT and BACHD rats, neither at DIV 3 
nor at the late DIV 12 (Figure 9). 
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Figure 9. BACHD rat primary striatal neurons do not show enhanced oxidative DNA damage. 
Levels of 8OHdG, measured by ELISA were similar in BACHD and WT rat striatal neurons at early and 
late cultivation times. Data points represent samples from four individual embryos per genotype and day 
in vitro (DIV). Two-way repeated measurements ANOVA, Sidak’s post-test. * P < 0.05, ** P < 0.01, 
*** P < 0.001. 
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Discussion 
We demonstrated that our protocol for isolation and cultivation of primary BACHD rat neurons 
revealed viable cultures, which were subsequently used for a variety of assays to analyze cell 
functions. BACHD rat primary neurons show impaired cell functions, which resemble the 
pathology found in the HD patient. Thus, BACHD rat primary neurons can be regarded a useful 
tool for the analysis of disease mechanisms, and to test the therapeutic efficacy of drugs or 
compounds for HD. 
The dissection of striatal and cortical tissue followed previous protocols established for mice. 
The original protocols were combined, adapted for rats and optimized for easier parallel 
application. Optimization was necessary, as the parallel preparation of primary striatal and 
cortical cultures would have otherwise been immensely time-consuming, since the original 
protocols differed on several steps. The combined protocol is sophisticated in the sense that 
it is more time-efficient and the procedures have higher practicability. In addition, it allows for 
direct comparison between striatum and cortex from a given embryo. 
It should be mentioned that our optimization strategy did not aim at increasing the yield in 
neuronal tissue. Our focus was to reduce the amount of time needed to perform the laborious 
procedures. In case that tissue yield is crucial, for instance if the model organisms are mice 
instead of rats, the dissection and trituration steps can be refined. Also, pooled samples might 
be chosen instead of keeping samples from individual embryos separate. 
Our protocol could in principle be varied or extended for the parallel culture of other brain 
regions such as for instance hippocampus, as the hippocampus can be easily identified and 
dissected in the embryonic brain at E 17.5 or E 18.5. Similarly, cerebellar neurons or glia cells 
from different areas could be cultured using our extraction protocol, simply by adapting the 
specific culture media required. This way, our approach is not only useful for studying 
molecular mechanisms of HD but also those of other neurological disorders. 
In our isolated neurons, we analyzed four interconnected parameters implicated in the cellular 
pathology of HD. We found that mHTT is expressed in primary neuronal cultures. Moreover, 
mHTT had formed aggregates in these cells at DIV 7, similar to primary striatal cultures from 
mice transfected with mHTT in vitro94. Aggregates of mHTT are not considered to be per se 
cytotoxic, however, they derive from N-terminal mHTT fragments which are highly toxic to  
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cells. Thus, the presence of mHTT aggregates in BACHD rat primary neurons indicates that 
mHTT is cleaved into toxic fragments, resembling the condition found in the HD brain. BACHD 
rat primary neurons further displayed HD-related pathologies. We found the cells to 
recapitulate a prominent molecular pathology of HD, an axonal transport defect induced by 
reduced IGF-1/Akt signaling197,400,435. We further analyzed the presence of oxidative DNA 
damage, to detect if BACHD rat primary neurons showed profound mitochondrial dysfunction. 
However, this was not the case. 
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Huntington disease (HD) is a hereditary brain disease. Although the causative gene has been found, the exact
mechanisms of the pathogenesis are still unknown. Recent investigations point to metabolic and energetic
dysfunctions in HD neurons.
Both univariate and multivariate analyses were used to compare proton nuclear magnetic resonance spectra
of serum and cerebrospinal ﬂuid (CSF) taken from presymptomatic HD transgenic rats and their wild-type
littermates. N-acetylaspartate (NAA), was found to be signiﬁcantly decreased in the serum of HD rats
compared to wild-type littermates. Moreover, in the serum their levels of glutamine, succinic acid, glucose
and lactate are signiﬁcantly increased as well. An increased concentration of lactate and glucose is also found
in CSF. There is a 1:1 stoichiometry coupling glucose utilization and glutamate cycling. The observed increase
in the glutamine concentration, which indicates a shutdown in the neuronal-glial glutamate-glutamine
cycling, results therefore in an increased glucose concentration. The elevated succinic acid concentration
might be due to an inhibition of succinate dehydrogenase, an enzyme linked to the mitochondrial respiratory
chain and TCA cycle. Moreover, reduced levels of NAA may reﬂect an impairment of mitochondrial energy
production. In addition, the observed difference in lactate supports a deﬁciency of oxidative energy
metabolism in rats transgenic for HD as well.
The observed metabolic alterations seem to be more profound in serum than in CSF in presymptomatic rats.
All ﬁndings suggest that even in presymptomatic rats, a defect in energy metabolism is already apparent.
These results support the hypothesis of mitochondrial energy dysfunction in HD.
© 2011 Elsevier B.V. All rights reserved.
1. Introduction
Huntington disease (HD) is an autosomal dominant neurodegen-
erative disorder, characterized by progressive motor, cognitive and
psychiatric dysfunctions. Although the disease can occur at any age,
the median age of onset is 40 years. Most patients die one to two
decades after disease onset.
HD is caused by a mutation in the gene coding for the protein
huntingtin. The exact function of this protein is still unknown. Normal
individuals have a CAG-trinucleotide repeat length of less than 37 [1].
People whose CAG repeat length exceeds this number will develop
HD. The length of the CAG expansion is proportional to the severity of
the disease and inversely proportional to the age of onset [2]. At
present, the exact mechanism of the HD pathology is still unknown.
However, recent evidence points to metabolic and energetic dysfunc-
tion in HD neurons [2–4]. Better knowledge about this mechanism is
expected to lead to more appropriate analyses, which in turn should
result in a better understanding of the disease. Moreover, this will
help to direct the quest for improved treatments in the proper
direction.
According to Nicholson et al. [5], metabolomics is deﬁned as ‘the
quantitative measurement of the dynamic multiparametric metabolic
response of living systems to pathophysiological stimuli or genetic
modiﬁcations’. Since 1999, applications of this technique have
emerged in other ﬁelds (e.g. environmental sciences) [6]. Metabolites
in bioﬂuids are in dynamic equilibriumwith those in cells and tissues.
A healthy individual attempts to retain the concentration of
metabolites in cells and tissues constant by homeostasis. Abnormal
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cellular processes due to sickness, toxins, etc. result in altered bioﬂuid
compositions. Various analytical techniques are available to detect
low molecular weight metabolites. The ones most commonly applied
in metabolomic studies are nuclear magnetic resonance spectroscopy
(NMR) and mass spectrometry (MS). The latter is frequently used in
combination with a chromatographic separation technique (liquid
chromatography, gas chromatography, etc.) [7]. Although NMR is less
sensitive thanMS, this technique offers some important advantages. It
is a high-throughput analysis that does not require any preceding
chromatographic separation or puriﬁcation procedure. Additionally,
sample preparation is very straightforward. Furthermore, it is a non-
destructive method capable of detecting all non-exchangeable pro-
tons, provided they are present above a certain threshold concentra-
tion (μM concentrations). Moreover, the measurements are very
reproducible and inexpensive on a per sample basis [8–10]. All these
advantages have contributed to the application of NMR spectroscopy
in clinical diagnoses of diseases and in the follow-up of subjects
participating in medical treatment studies [11].
The NMR spectrum of a bioﬂuid is generally extremely complex in
nature, since each molecule present in the bioﬂuid gives rise to one or
several peaks in most cases. Moreover, many peaks show some ﬁne
structure and splittings which cause a prominent overlap of signals
originating from different molecules [12]. Visual inspection of the
spectra will therefore only reveal a small percentage of the available
information [13].
Spectral interpretation can be simpliﬁed by applying automatic
data reduction methods. Subsequently, these reduced datasets can be
analyzed with univariate [2,14–22] or multivariate [13,23–27]
statistical methods.
In this study we applied 1H NMR spectroscopy in order to
disentangle the metabolic proﬁle of serum and cerebrospinal ﬂuid
(CSF) from a rat model for HD. Both univariate and multivariate
statistical analyses were applied in a search for pathology speciﬁc
differences. It is anticipated that these investigations lead to a gain in
knowledge about the pathogenesis of HD and make it possible to
identify some potential biomarkers.
2. Materials and methods
2.1. Animals
Transgenic HD rats carrying a truncated huntingtin cDNA fragment
with 51 CAG repeats under the control of the native rat huntingtin
promoter, and their wild-type littermates were used [28]. The
expressed gene product was 75 kDa, corresponding to 22% of the
full-length huntingtin (cDNA positions 324–2321, amino acid posi-
tions 1–709/825, corresponding to exons 1–16), which are under the
control of 886 bp of the rat huntingtin promoter (positions 900 to 15).
Genotyping was carried out as previously described [28]. The number
of CAG repeats was analyzed in a subset of transgenic rats using these
primers: cggctgaggcagcagcggctgt (forward) and ccttcgagtccct-
caagtccttc (reverse). The reverse primer is labelled at the 5′ end
with the ﬂuorescent dye Cy5. The PCR amplicon length was then
analyzed on the Beckman coulter sequencer (CEQ 8000 Cycle
Sequencer, Krefeld, Germany). In more than 15 generations only a
small variation of ±1–2 CAGs were observed in transgenic rats of HD.
Also for this study, in a subset of animals, the CAG-length was checked
and it was found to be 51±2 CAGs. After genotyping, rats were
housed in gender- and genotyped matched groups of two, according
to FELASA recommendations. All rats were kept under a 12:12 hours
light–dark cycle with lights on at 06.00 a.m. and food (Altromin lab
chow pallets, Altromin standard diet: 1320; Lage, Germany) and tap
water available ad libitum. All research and animal care procedures
had been approved by the district government of Tuebingen,
Germany, and followed principles described in the European Com-
munity's Council Directive of 24th November, 1986 (86/609/EEC).
For this study, we used serum and CSF from female, transgenic HD
rats (n=10 for serum and n=8 for CSF) at an age of two months and
compared these with age-matched wild-type (WT) littermates
(n=12 for serum and respectively 9 for CSF). We are aware of the
fact that the number of samples used in this study is rather small.
However, this was determined by keeping in mind the well-being of
animals and in order to reduce costs. Moreover, in the literature a lot
of studies where even less samples per group are investigated, can be
found [15,27,29–32].
2.2. Sample collection and preparation
2.2.1. CSF samples
Rats were sacriﬁced by CO2 inhalation and immediately exsangui-
nated. Subsequently, each animal was placed prone onto the
stereotaxic instrument. A sagittal incision of the skin was made
inferior to the occiput. The subcutaneous tissue and neck muscles
through the midline were bluntly separated. Next, the rat was laid
down in a way that the bodymade a 135° angle with the ﬁxed head. In
this angle, the dura mater of cisterna magna was exposed sufﬁciently.
The dura was then penetrated with an insulin syringe and CSF was
drawn. All samples were transferred into polypropylene tubes,
immediately snap frozen in liquid nitrogen and stored at −80 °C
until shipped for NMR analysis. Upon arrival, CSF samples were
immediately stored at −80 °C until measurement.
All CSF samples (40 μL) were simultaneously lyophilized. In cases
where less than 40 μL of CSF was available, the total available volume
was lyophilized. The freeze-dried samples were then stored at−20 °C
in sealed vials until analysis. In order to keep the time spent at room
temperature to a minimum, samples were randomly divided in ﬁve
batches. Samples gathered in one batch were prepared together. Prior
to NMR analysis, each sample was reconstituted in 8 μL sodium
phosphate buffer (50 mM dissolved in D2O, pH=7.05) containing
0.05 mM sodium azide in order to prevent bacterial contamination.
Finally, this volume was transferred to a 1 mm NMR tube.
2.2.2. Serum samples
Samples were taken as done previously [33]. In short: rats were
sacriﬁced with CO2 and blood was drawn directly from the heart. All
rats were tested for diabetes immediately after sample collection. The
blood was incubated for 1 h at 37 °C, followed by centrifugation for
30 min at 3000 ×g. The serum was collected and immediately stored
at −80 °C until shipped for NMR analysis. Upon arrival, serum
samples were immediately stored at −80 °C until measurement.
In order to keep the time spent at room temperature to a
minimum, samples were randomly divided in three groups. Samples
assembled in one group were prepared together. Just before their
acquisition, samples were thawed to room temperature. An aliquot of
serum (250 μL) from each sample was mixed with 300 μL of an
aqueous saline solution. In this way, each sample contains 0.1 M NaCl
and 10% D2O. The addition of an internal standard like DSS is
prohibited by its interaction with proteins present in the sample.
Subsequently, the total volume was transferred to a 5 mm NMR tube.
2.3.
1
H NMR spectroscopy
Prepared samples were analyzed on a Bruker Avance II-700
spectrometer, operating at a proton frequency of 700.13 MHz. The
spectrometer is equipped with a BACS-60 automatic sample changer
and a 5 mm inverse TXI-Z probe when measuring serum samples.
Since the brain volume of rats is rather small, the amount of CSF that
can be collected at once from one animal is too small to perform a
classical NMR analysis (N100 μL is necessary, prior to dilution to the
ﬁnal 550 μL measuring volume, in order to get a good S/N). Combining
CSF taken from different animals within a population is not advisable,
since this will remove the possibility to detect individual differences.
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Recently, Bach and co-workers [10,34] demonstrated that the use of a
1 mm probe setup provides an alternative to address the measure-
ment of such volume restricted samples. Therefore, CSF samples
were measured with a 1 mm inverse TXI-Z probe, requiring only 8 μL
of sample volume. The samples were held at room temperature
while on the sample changer and at 303 K during acquisition. Carr–
Purcell–Meiboom–Gill (CPMG) experiments were executed in order
to get 1D 1H NMR spectra of the samples. The individual CPMG spin
echo (in total 1 ms) was repeated 20 times, resulting in a total spin-
spin relaxation delay of 20 ms. Suppression of the water signal was
performed using 2.22 s presaturation during the relaxation delay. For
serum 64 scans (32 K data points each) were sampled whereas 1024
scans were needed for CSF. Each scan had an acquisition time of 0.78 s.
To keep variation due to sample handling to a minimum, tuning and
matching as well as shimming were performed automatically for each
sample. Digital ﬁltering was performed using the ‘baseopt’ option
available in Topspin 2.0 (Bruker Biospin Corporation) which results in
ﬂat baselines. Prior to Fourier transformation, the Free Induction
Decays (FIDs) were zero-ﬁlled to 64 K and an exponential window
function with a line broadening factor of 0.3 Hz was applied. The
acquired NMR spectra were consecutively processed for phase and
baseline correction. In the absence of an external reference (vide
supra 2.2.2), all serum spectra were referenced to the methyl doublet
of lactate at 1.33 ppm. After initial referencing of the CSF spectra using
the anomeric glucose 1H signal at 5.225 ppm, the spectra were still
shifted one against the other. They were aligned using an in house
developed spectral alignment algorithm (Vu T.N. et. al, submitted).
2.4. Data reduction of the NMR spectra
The 1H NMR spectra were automatically reduced into consecutive
integrated spectral regions (buckets) of an equal width (0.05 ppm)
applying R (version 2.7.2, http://www.r-project.org). In order to
eliminate spectral variations due to different quality of water
suppression from one spectrum to another, the region containing
the water resonance (4.5–5.0 ppm) was not included in the analysis.
In order to account for differences in concentration between samples,
the subdivided spectra were scaled to their total intensity.
2.4.1. Multivariate analysis
Prior tomultivariate analysis, the datawere scaled to unit variance.
Besides unit variance scaling, also pareto scaling and no scaling were
tested on the dataset. However, these did not generate signiﬁcant
differences. Since all the variables possess an equal weight, irrespec-
tive of their absolute magnitude in the original data when unit
variance scaling is applied, this method was preferred.
Principal component analysis (PCA) is used to project the data in
two or three dimension in order to be able to discern outliers. This
method transforms the original variables in new, uncorrelated
variables or principal components (PC) in such a way that the ﬁrst
PC represents most of the variation present in the original dataset.
Higher PC will subsequently contain less amount of the variance
[5,7,26].
Partial least squares-discriminant analysis (PLS-DA) is a multivar-
iate classiﬁcationmethod based on PLS, a regression extension of PCA.
This technique uses a priori knowledge about the data to maximize
the separation between samples belonging to different classes [7,35].
Here, it concerns information about the pathological condition
(healthy or HD) of each sample. The obtained scores plots are used
to visualize the separation between the samples based on their class
membership. The corresponding loading plots contain information
about the variables responsible for the observed separation. Both PCA
and PLS calculations were performed with R (R version 2.7.2, http://
www.r-project.org, packages FactoMineR version 1.14, caret version
4.76). A double cross-validation (2CV) strategy and permutation test
[36] were applied to estimate the quality of the developed PLS-DA
model. The data points were randomly divided into 5 fractions, of
which one was used for testing, whereas the others were used for
training and validation. Leave-one-out cross-validation (LOOCV) [36]
is used for validation in order to select the optimal model. LOOCV uses
all but one data point as the training set. The left-out data point is used
for validation. The data were randomly ordered 100 times. The
average of area under the ROC curve (AUROC) was used as the
criterion. In order to select the optimal number of components for
PLS-DA, different numbers were tested (from 1 to the number of
samples). Furthermore, the number of misclassiﬁcations and the Q²
value were collected. A distribution was generated for the H0
hypothesis that no difference exists between the two classes. In the
permutation test, the class labels of control and disease are
permutated by randomly assigning them to different individuals.
With ‘wrong’ class labels, a classiﬁcation model is again calculated.
The data were permutated 1000 times. For each permutated set, the
cross-validation was repeated 20 times and the average parameter
values were computed.
2.4.2. Univariate analysis
The bucket table created for the multivariate analysis was
exported to Excel (Microsoft Ofﬁce 2003) in order to carry out a
Student's t-test. P levels smaller than 0.05 were considered to be
signiﬁcant. An advanced classiﬁer, Support Vector Machine (SVM)
[37], was applied to classify the samples based on the signiﬁcantly
differential buckets. Each sample contains one out of two possible
labels, and is represented by a feature vector based on the values of
the signiﬁcant buckets. The data samples were randomly divided into
5 fractions, of which one was used for testing, whereas the others
were used for training and validation. The data were randomly
ordered 100 times. The average of area under the ROC curve (AUROC)
was used as the criterion. To estimate the quality of the developed
SVM model, the double cross-validation (2CV) strategy and permu-
tation test described in [36] used for PLS-DA were applied again. In all
experiments, the SVM function in the package e1071 (version 1.5-22)
in R (R version 2.7.2, http://www.r-project.org) was used with the
default setting parameters, e.g. linear kernel and cost equals 1.
3. Results
3.1. Visual inspection of NMR spectra
There is a lot of information comprised in 1HNMR spectra of serum
and CSF samples. Visual inspection of the spectra can already reveal
some interesting features in some cases. A representative 1H Carr–
Purcell–Meiboom–Gill (CPMG) serum spectrum of both a wild-type
and a transgenic HD rat is represented in Additional ﬁle A. The
projection of all available serum spectra onto each other makes a clear
differentiation between wild-type (WT) and HD rats possible. Peaks
representing glucose and succinic acid seem to be elevated in spectra
fromHD rats (Fig. 1). This indicates that both glucose and succinic acid
are increased in concentration in the serum of transgenic animals.
Visual examination of an overlay of the CSF spectra does not indicate
an immediate difference between WT and HD rats.
3.2. PCA to detect outliers
Principal component analysis (PCA) was applied on the data in
order to uncover inherent similarities and differences potentially
present within the spectral proﬁles. The scores plot of the ﬁrst two
principal components gives a representative overview of the data
(Fig. 2).
3.2.1. Serum samples
The ﬁrst principal component (PC1) accounts for 76.42% of the
total variation present in the dataset. The second principal component
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(PC2) accounts for an additional 10.02% of the total variation. Data
points lying outside the 95% conﬁdence ellipse (Hotelling T²) can be
considered as outliers, i.e. observations that have an aberrant
behaviour. As indicated in Fig. 2, two data point are laying outside
the Hotelling T² plot. Reconsidering these spectra reveals that the
water suppression technique, which has been used while acquiring
the spectra, has caused a shift of the baseline in comparison with the
other spectra. This slightly different prospect is revealed by this
multivariate statistical tool. However, these two spectra are not
discarded for further analysis, as their differences are not from a
biological nature.
3.2.2. CSF samples
The scores plot of the ﬁrst two principal components accounts for
45.57% of the total variation present in the CSF dataset. Possible
outliers present in the dataset were uncovered by spotting the data
points lying outside the 95% conﬁdence ellipse of this scores plot.
Consecutive PCA indicate three data points (one WT and two HD
samples) with an aberrant behaviour (see Additional ﬁle B, Additional
ﬁle C and Additional ﬁle D). Those spectra correspond with low
available volume samples (b40 μL lyophilized). For this reason, these
spectra were excluded from the dataset before further analysis.
3.3. Discrimination between normal and pathological samples using PLS-
DA
A partial least squares-discriminant analysis (PLS-DA) model was
developed in order to discriminate samples according to their class
membership, i.e. healthy or HD. The results of this analysis are
depicted in Fig. 3. The scores plot shows a reasonable separation
between both sample groups. The corresponding loading plot reveals
the metabolites that are responsible for the observed separation.
Annotation of the loadings was conﬁrmed by a comparison with
reference spectra of an in house database recorded at 700 MHz. A
Fig. 1. Visual comparison of serum spectra. An overlay of all acquired 1H NMR 700 MHz serum spectra, a some representative peaks of glucose b signal of succinic acid. Spectra of
wild-type rats are coloured black; those of HD rats blue.
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double cross-validation (2CV) strategy and permutation test were
applied to estimate the quality of the developed PLS-DA model, as
described in [36]. This yielded an area under the ROC curve (AUROC)
of 84.90% and 72.73% for serum and CSF respectively. For all
assessment parameters (Q² value and the number of misclassiﬁca-
tions), there is a clear distinction between the permutation distribu-
tion and the original classiﬁcation. This shows that the speciﬁc
classiﬁcation is signiﬁcant (see Additional ﬁles E1 for serum and E2 for
CSF).
3.3.1. Serum samples
The loading coefﬁcients responsible for the separation of the
serum samples according to their pathological condition correspond
to the metabolites glucose (δ3.28, δ3.38, δ3.43, δ3.48, δ3.53, δ3.73,
δ3.78, δ3.83, δ3.88, δ3.93 and δ5.23), lactate (δ1.33 and δ4.13), lipids
(δ0.83, δ0.88, δ1.23, δ1.28, δ1.58, δ2.03, δ2.23, δ2.73, δ2.78, δ5.28 and
δ5.33), succinic acid (δ2.43), glutamine (δ2.13 and δ2.43) and NAA
(δ2.03). An overview of these results is given in Table 1.
3.3.2. CSF samples
The most relevant loadings in the separation of CSF samples
according to their pathological condition are situated around δ3.38,
δ3.43, δ3.48, δ3.73, δ3.78, δ3.83 and δ3.88 (glucose) and δ1.33
(lactate).
3.4. Discrimination between normal and pathological samples using a
univariate analysis
A Student's t-test is used to uncover the metabolites that show a
statistically signiﬁcant concentration difference between the two
observed populations. Thus, these metabolites can be used to
differentiate HD from healthy samples. The bucket table, which was
created for the multivariate analysis, was used as input variable for
the univariate analysis. For each bucket, the corresponding p-value
was calculated. A p-value smaller than 0.05 was considered as
signiﬁcant.
3.4.1. Serum samples
The bucket comprising both the singlet peak of the methylene
groups of succinic acid and the multiplet peak of CH2CO of glutamine
was found to be signiﬁcantly different between WT and TG rats. In
order to assign this statistically signiﬁcant difference unambiguously
to the correct metabolite, both signals were integrated referenced to
the methylene singlet of creatine at 3.93 ppm. A visual representation
of these results is displayed in Fig. 4. These boxplots reveal that both
metabolites contribute to the differentiation of the samples according
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Fig. 3. PLS, clustering of samples according to their pathological condition. a PLS scores plot of
1
H NMR serum spectra of twelve wild-type (black squares) and ten HD (blue triangles)
rats (females, 2 months old). b The corresponding loading plot represents the variables attributable to the observed class separation. c PLS scores plot of 1H NMR CSF spectra of nine
wild-type (black squares) and eight HD (blue triangles) rats (females, two months old). d The loading coefﬁcient plot corresponding to the scores plot (c).
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Fig. 2. PCA to detect outliers. PCA scores plot of the ﬁrst and second principal component
mapping the serum spectra of twelve wild-type and ten HD rats (females, 2 months old).
The Hotelling T2 ellipse is used to elucidate outliers. Colour coding: black squares=wild-
type rats, blue triangles = HD.
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to their genotype. Both glutamine (pb0.05) and succinic acid
(pb0.005) were found to be signiﬁcantly increased in HD rats
compared to WT littermates. Glucose was found to be elevated in
HD rats as well (pb0.05). Furthermore, NAAwas decreased in HD rats
(pb0.05). Moreover, the bucket comprising the area between 4.30
and 4.25 ppm (see Fig. 5) is found to be signiﬁcantly decreased in HD
rats. At present, we have not been able to identify the component(s)
present in this bucket. These results are illustrated in Fig. 4. The
thirteenmost signiﬁcant buckets for whom the p-value is smaller than
0.05, able in discriminating between healthy and HD samples, were
used to build an SVM classiﬁer. An area under the ROC curve (AUROC)
of 71.44% could be obtained. For all the assessment parameters, a clear
distinction between the permutation distribution and the original
classiﬁcation is obtained. This demonstrates that the speciﬁc
classiﬁcation is signiﬁcant (see Additional ﬁle E3).
3.4.2. CSF samples
In CSF, a Student's t-test could not reveal any statistically
signiﬁcant metabolite concentration difference between WT and HD
rats.
4. Discussion
In this study we have shown that rats transgenic for the HD
mutation can be discriminated from healthy, wild-type littermates
Table 1
Overview of the metabolites responsible for the separation of serum samples according
to their pathological condition.
Metabolites
Higher concentration in TG animals Glucose
Lactate
Succinic acid
Glutamine
Lower concentration in TG animals NAA
Lipids
HD wt
0.
00
9
0.
01
0
0.
01
1
0.
01
2
glucose
HD wt
2.
8
3.
0
3.
2
3.
4
3.
6
glutamine
HD wt
0.
03
4
0.
03
6
0.
03
8
0.
04
0
NAA
HD wt
0.
00
55
0.
00
60
0.
00
65
0.
00
70
unknown
HD wt
0.
6
0.
8
1.
0
1.
2
1.
4
succinic acid
a b
c
e
d
Fig. 4. Visualization of the results obtained by univariate analysis. A boxplot is used to visualize the data of the Student's t-test. The boxplot is based on the ﬁve-number-summary,
i.e. the median (black line), 25% quartile (lower box line), 75% quartile (upper box line), minimum (lower whisker) and maximum (upper whisker). This means that 50% of the
data points are situated in the box. The range between the 25% quartile (Q25) and 75% quartile (Q75) is called the interquartile range (IQR). Subsequently, the whiskers are
calculated by the formula flower=Q25−1.5* IQR for the lower whisker and respectively fupper=Q75+1.5* IQR for the upper whisker. a glucose, b glutamine, c NAA, d the unknown
component in the bucket comprising the area between 4.30 and 4.25 ppm and e succinic acid. The boxplot of WT samples is coloured grey whereas the boxplot of TG samples has a
blue colour.
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even prior to the onset of motor deﬁcits [38]. A comparable study was
already executed by Tsang and co-workers on a different animal
model [27]. However, there are some inconsistencies between the
ﬁgures and text described in their paper. The metabolites they
indicated in the loading plot of the serum samples correspond to those
mentioned for urine samples in the text and vice versa.
We used three differentmethods for the analysis. Visual inspection
of the serum spectra already suggests that glucose as well as succinic
acid levels are elevated in HD rats. These results are statistically
conﬁrmed by means of a univariate analysis. Moreover, the Student's
t-test discloses that glutamine and NAA are able to discriminate
between HD and WT rats in serum samples. PLS, a supervised
multivariate statistical technique, was performed in order to reveal
the discriminative power of different metabolites between the
studied groups. For the serum samples, the loadings which are able
to separate healthy from pathological samples correspond to the
metabolites glucose, glutamine, lipids, lactate, succinic acid and NAA.
Regarding CSF spectra, visual inspection and univariate analysis are
not able to discriminate WT from HD rats. PLS, on the other hand,
distinguishes both glucose and lactate as discriminating metabolites.
In CSF as well as in serum samples, glucose is indicated as a
biomarker to detect Huntington disease presymptomatically. Al-
though the literature [2,4,39] exposes some evidence of diabetes in
subjects with HD, plasma glucose measurements in the same
transgenic rat model at different ages do not reach the threshold for
diabetes [28]. Thus, the observed difference in glucosemust have been
caused by a perturbation in another metabolic pathway. Some
evidence of a disturbed glucose metabolism in HD can be found in
the literature [4,40,41]. A possible explanation for the observed
increased concentrations of glutamine and glucose is also documen-
ted: according to Sibson et al. [32], there is a 1:1 stoichiometry
between the consumption of glucose and the formation of glutamate.
The observed increase in glutamine can reﬂect a decreased glutamin-
ase activity. Glutaminase is a mitochondrial enzyme found in neurons
that takes care of the conversion of glutamine in glutamate. A
perturbation of the glutamate–glutamine cycling may indicate an
impairment of energymetabolism andmitochondrial respiration [27].
Thus, a decrease in glutaminase activity precludes the conversion of
glutamine into glutamate. Owing to this, the neurons will have a lack
of glutamate for neurotransmission. Finally, this will result in an
elevated concentration of glutamine and glucose (due to decreased
glucose utilization) as observed in our experiments [4]. This theory
can be afﬁrmed by previous studies which also point to a disruption of
energy metabolism in HD [42,43].
In addition, the observed difference in lactate supports the theory
of a deﬁciency of oxidative energy metabolism in rats transgenic for
HD. The conversion of glucose to pyruvate during glycolysis involves
the concomitant reduction of 2 mol of NAD+ to NADH. In cells
undergoing an aerobic respiration, pyruvate is subsequently oxidized
to acetyl-Coenzyme A (Acetyl-CoA), which in turn, enters the citric
acid cycle. In this way, the NADH produced during glycolysis is
reoxidized through the mitochondrial electron transport chain.
However, a perturbation in the Krebs cycle or mitochondrial electron
transport chain might prevent pyruvate to enter the oxidative energy
metabolism. Since NADH needs to be reoxidized to NAD+ to maintain
a steady state condition, an alternative pathway to transfer electrons
is accomplished, i.e. the reduction of pyruvate to lactate by the
catalyzed reaction of lactate dehydrogenase. As a result, an increased
concentration of lactate, the end product of anaerobic glycolysis,
indicates a defect in energy metabolism as well [44].
An elevated concentration of succinic acid is probably due to an
inhibition of succinate dehydrogenase. This enzyme has two important
functions in the mitochondria. First, it supports the oxidation of succinic
acid to fumarate in the tricarboxylic acid (TCA) cycle. Second, it is linked to
the respiratory chain, i.e. complex II of the mitochondrial electron
transport chain [45,46]. A decrease in mitochondrial complex II activity
has already been observed in HD [3,47,48]. Our ﬁnding of an elevated
succinic acid concentration is therefore in linewith these previous results.
A decreased NAA concentration is known to be a marker of
neuronal dysfunction [27,49]. Reduced NAA levels have been well
documented for several neurological diseases, e.g. Alzheimer disease
[50], Huntington disease [4,27,51] and Parkinson disease [17,50].
Moreover, in HD it clearly correlates with the duration of symptoms
and the CAG repeat length [16,52]. The enzyme responsible for the
synthesis of NAA, L-N-acetylaspartyl transferase, is exclusively found
inmitochondria [50]. Since inhibitors of themitochondrial respiratory
chain seem to decrease the concentration of NAA [4], reduced NAA
levels may reﬂect an impaired mitochondrial energy production [27].
Obviously, a change in the concentration of eachof thesemetabolites
can be linked to a variety of conditions. However, the changes observed
for all metabolites combined could allow for amore narrow correlation,
i.e. with HD.
Fig. 5. Spectral region between 4.35 and 4.25 ppm. The univariate analysis indicates the bucket comprising the chemical shift region between 4.30 and 4.25 ppm as signiﬁcantly
different between WT and HD rats. The signals within this bucket are illustrated.
1377K.A. Verwaest et al. / Biochimica et Biophysica Acta 1812 (2011) 1371–1379
5. Conclusions
In conclusion, this study shows that metabolic alterations already
emerge in the serum and CSF of these rats before overt symptoms of
HD are manifested. In an early stage of the disease, metabolic
alterations seem to be more pronounced in serum compared to CSF.
All metabolites found being able at discriminating WT from HD rats
point to a disruption of the mitochondrial respiratory chain and
energymetabolism. These ﬁndings suggest that compounds which act
on mitochondria might have a positive effect on HD pathology.
Moreover, this study shows that 1H NMR spectroscopy is an
appropriate tool to investigate the metabolic disturbance occurring
in early stages of HD. A more profound knowledge of the disease
pathology can be obtained by performing a metabolomic analysis of
samples originating from more mature rats. Such an analysis could
give more insight into the development of this disease, which in turn
may lead to improved therapeutic interventions.
Supplementarymaterials related to this article can be found online
at doi:10.1016/j.bbadis.2011.08.001.
Conﬂict of interests statement
The authors declare that they have no competing interests.
Acknowledgements
KAV thanks the University of Antwerp (UA) and the FWO-
Vlaanderen for funding. AVDL, JCM and RD thank the FWO-Vlaanderen
for research funding (G.0064.07). The 700 MHz NMR spectrometer
(Ghent, Belgium) of the interuniversity NMR facility was ﬁnanced by
Ghent University, the Free University of Brussels (VUB) and the UA via
the ‘Zware Apparatuur’ FFEU Incentive of the Flemish Government. KL
and TNV are supported by an SBO grant (IWT-600450) and a BOF
interdisciplinary grant of the University of Antwerp. LC and HN are
supported by the European Community ‘RATstream STREP project’.
References
[1] The Huntington's Disease Collaborative Research Group, A novel gene containing
a trinucleotide repeat that is expanded and unstable on Huntington's disease
chromosomes, Cell 72 (1993) 971–983.
[2] O.A. Andreassen, A. Dedeoglu, R.J. Ferrante, B.G. Jenkins, K.L. Ferrante, M. Thomas,
A. Friedlich, S.E. Browne, G. Schilling, D.R. Borchelt, S.M. Hersch, C.A. Ross, M.F.
Beal, Creatine increases survival and delays motor symptoms in a transgenic
animal model of Huntington's disease, Neurobiol. Dis. 8 (2001) 479–491.
[3] S.J. Tabrizi, M.W.J. Cleeter, J. Xuereb, J.-W. Taanman, J.M. Cooper, A.H.V. Schapira,
Biochemical abnormalities and excitotoxicity in Huntington's disease brain, Ann.
Neurol. 45 (1999) 25–32.
[4] B.G. Jenkins, P. Klivenyi, E. Kustermann, O.A. Andreassen, R.J. Ferrante, B.R. Rosen,
M.F. Beal, Nonlinear decrease over time in N-acetyl aspartate levels in the absence
of neuronal loss and increases in glutamine and glucose in transgenic
Huntington's disease mice, J. Neurochem. 74 (2000) 2108–2119.
[5] J.K. Nicholson, J.C. Lindon, E. Holmes, ‘Metabonomics’: understanding the
metabolic responses of living systems to pathophysiological stimuli via
multivariate statistical analysis of biological NMR spectroscopic data, Xenobiotica
29 (1999) 1181–1189.
[6] J.G. Bundy, M.P. Davey, M.R. Viant, Environmental metabolomics: a critical review
and future perspectives, Metabolomics 5 (2009) 3–21.
[7] J.C. Lindon, J.K. Nicholson, E. Holmes, The Handbook of Metabonomics and
Metabolomics, Elsevier, Amsterdam, 2007.
[8] M.R. Viant, B.G. Lyeth, M.G. Miller, R.F. Berman, An NMR metabolomic
investigation of early metabolic disturbances following traumatic brain injury
in a mammalian model, NMR Biomed. 18 (2005) 507–516.
[9] O.A.C. Petroff, R.K. Yu, T. Ogino, High-resolution proton magnetic resonance
analysis of human cerebrospinal ﬂuid, J. Neurochem. 47 (1986) 1270–1276.
[10] P. Khandelwal, C.E. Beyer, Q. Lin, L.E. Schechter, A.C. Bach, Studying rat brain
neurochemistry using nanoprobe NMR spectroscopy: a metabonomics approach,
Anal. Chem. 76 (2004) 4123–4127.
[11] J.C. Lindon, J.K. Nicholson, J.R. Everett, NMR spectroscopy of bioﬂuids, Annu. Rep.
Spectrosc. 38 (1999) 1–88.
[12] A.D. Maher, D. Crockford, H. Toft, D. Malmodin, J.H. Faber, M.I. McCarthy, A.
Barrett, M. Allen, M. Walker, E. Holmes, J.C. Lindon, J.K. Nicholson, Optimization of
human plasma 1H NMR spectroscopic data processing for high-throughput
metabolic phenotyping studies and detection of insulin resistance related to type
2 diabetes, Anal. Chem. 80 (2008) 7354–7362.
[13] J.C. Lindon, E. Holmes, J.K. Nicholson, Pattern recognition methods and
applications in biomedical magnetic resonance, Prog. Nucl. Magn. Reson.
Spectrosc. 39 (2001) 1–40.
[14] R. Hewer, J. Vorster, F.E. Steffens, D. Meyer, Applying bioﬂuid 1H NMR-based
metabonomic techniques to distinguish between HIV-1 positive/AIDS patients on
antiretroviral treatment and HIV-1 negative individuals, J. Pharm. Biomed. Anal.
41 (2006) 1442–1446.
[15] M.A. Constantinou, A. Tsantili-Kakoulidou, I. Andreadou, E.K. Iliodromitis, D.T.
Kremastinos, E. Mikros, Application of NMR-based metabonomics in the
investigation of myocardial ischemia–reperfusion, ischemic preconditioning and
antioxidant intervention in rabbits, Eur. J. Pharm. Sci. 30 (2007) 303–314.
[16] B.G. Jenkins, H.D. Rosas, Y.C.I. Chen, T. Makabe, R. Myers, M. MacDonald, B.R.
Rosen, M.F. Beal, W.J. Koroshetz, 1H NMR spectroscopy studies of Huntington's
disease — correlations with CAG repeat numbers, Neurology 50 (1998)
1357–1365.
[17] H.M. Baik, B.Y. Choe, H.K. Lee, T.S. Suh, B.C. Son, J.M. Lee, Metabolic alterations
in Parkinson's disease after thalamotomy, as revealed by 1H MR spectroscopy,
Korean J. Radiol. 3 (2002) 180–188.
[18] A.R. Tate, S.J.P. Damment, J.C. Lindon, Investigation of the metabolite variation in
control rat urine using 1H NMR spectroscopy, Anal. Biochem. 291 (2001) 17–26.
[19] A. Bender, D.P. Auer, T. Merl, R. Reilmann, P. Saemann, A. Yassouridis, J. Bender, A.
Weindl, M. Dose, T. Gasser, T. Klopstock, Creatine supplementation lowers brain
glutamate levels in Huntington's disease, J. Neurol. 252 (2005) 36–41.
[20] S. Kasparová, Z. Sumbalová, P. Bystrický, J. Kucharská, T. Liptaj, V. Mlynárik, A.
Gvozdjáková, Effect of coenzyme Q10 and vitamin E on brain energy metabolism
in the animal model of Huntington's disease, Neurochem. Int. 48 (2006) 93–99.
[21] P. Verbessem, J. Lemiere, B.O. Eijnde, S. Swinnen, L. Vanhees, M. Van Leemputte, P.
Hespel, R. Dom, Creatine supplementation in Huntington's disease — a placebo-
controlled pilot trial, Neurology 61 (2003) 925–930.
[22] I. Tkác, C.D. Keene, J. Pfeuffer, W.C. Low, R. Gruetter, Metabolic changes in
quinolinic acid-lesioned rat striatum detected non-invasively by in vivo 1H NMR
spectroscopy, J. Neurosci. Res. 66 (2001) 891–898.
[23] E. Holmes, H. Antti, Chemometric contributions to the evolution of metabo-
nomics: mathematical solutions to characterising and interpreting complex
biological NMR spectra, Analyst 127 (2002) 1549–1557.
[24] T.M. Alam, M.K. Alam, Chemometric analysis of NMR spectroscopy data: a review,
Annu. Rep. Spectrosc. 54 (2005) 41–80.
[25] E.M. Lenz, J. Bright, I.D. Wilson, A. Hughes, J. Morrisson, H. Lindberg, A. Lockton,
Metabonomics, dietary inﬂuences and cultural differences: a 1HNMR-based study
of urine samples obtained from healthy British and Swedish subjects, J. Pharm.
Biomed. Anal. 36 (2004) 841–849.
[26] W. El-deredy, Pattern recognition approaches in biomedical and clinical magnetic
resonance spectroscopy: a review, NMR Biomed. 10 (1997) 99–124.
[27] T.M. Tsang, B. Woodman, G.A. Mcloughlin, J.L. Grifﬁn, S.J. Tabrizi, G.P. Bates, E.
Holmes, Metabolic characterization of the R6/2 transgenic mouse model of
Huntington's disease by high-resolution MAS 1H NMR spectroscopy, J. Proteome
Res. 5 (2006) 483–492.
[28] S. von Hörsten, I. Schmitt, H.P. Nguyen, C. Holzmann, T. Schmidt, T. Walther, M.
Bader, R. Pabst, P. Kobbe, J. Krotova, D. Stiller, A. Kask, A. Vaarmann, S. Rathke-
Hartlieb, J.B. Schulz, U. Grasshoff, I. Bauer, A.M.M. Vieira-Saecker, M. Paul, L. Jones,
K.S. Lindenberg, B. Landwehrmeyer, A. Bauer, X.J. Li, O. Riess, Transgenic rat model
of Huntington's disease, Hum. Mol. Genet. 12 (2003) 617–624.
[29] I.F. Duarte, B.J. Goodfellow, A. Barros, J.G. Jones, C. Barosa, L. Diogo, P. Garcia, A.M.
Gil, Metabolic characterisation of plasma in juveniles with glycogen storage
disease type 1a (GSD1a) by high-resolution 1H NMR spectroscopy, NMR Biomed.
20 (2007) 401–412.
[30] E. Brouillet, P. Hantraye, R.J. Ferrante, R. Dolan, A. Leroy-Willig, N.W. Kowall, M.F.
Beal, Chronic mitochondrial energy impairment produces selective striatal
degeneration and abnormal choreiform movements in primates, Proc. Natl.
Acad. Sci. U.S.A. 92 (1995) 7105–7109.
[31] I. Tkác, J.M. Dubinsky, C.D. Keene, R. Gruetter, W.C. Low, Neurochemical changes
in Huntington R6/2 mouse striatum detected by in vivo1H NMR spectroscopy,
J. Neurochem. 100 (2009) 1397–1406.
[32] N.R. Sibson, A. Dhankhar, G.F. Mason, D.L. Rothman, K.L. Behar, R.G. Shulman,
Stoichiometric coupling of brain glucose metabolism and glutamatergic neuronal
activity, Proc. Natl. Acad. Sci. U.S.A. 95 (1998) 316–321.
[33] P. Conforti, C. Ramos, B.L. Apostol, D.A. Simmons, H.P. Nguyen, O. Riess, L.M.
Thompson, C. Zuccato, E. Cattaneo, Blood level of brain-derived neurotrophic
factor mRNA is progressively reduced in rodent models of Huntington's disease:
restoration by the neuroprotective compound CEP-1347, Mol. Cell. Neurosci. 39
(2008) 1–7.
[34] P. Khandelwal, C.E. Beyer, Q. Lin, P. McGonigle, L.E. Schechter, A.C. Bach,
Nanoprobe NMR spectroscopy and in vivo microdialysis: new analytical methods
to study brain neurochemistry, J. Neurosci. Methods 133 (2004) 181–189.
[35] L. Eriksson, E. Johansson, H. Antti, E. Holmes, Multi-andmegavariate data analysis:
ﬁnding and using regularities in metabonomics data, in: D.G. Robertson, J. Lindon
(Eds.), Metabolomics in Toxicity Assessment, Taylor & Francis Group, Boca Raton,
2005, pp. 263–335.
[36] J.A. Westerhuis, H.C.J. Hoefsloot, S. Smit, D.J. Vis, A.K. Smilde, E.J.J. van Velzen,
J.P.M. van Duijnhoven, F.A. van Dorsten, Assessment of PLSDA cross validation,
Metabolomics 4 (2008) 81–89.
[37] N. Cristianini, J. Shawe-Taylor, An Introduction to Support Vector Machines and
Other Kernel-Based Learning Methods, Cambridge University Press, Cambridge,
2000.
1378 K.A. Verwaest et al. / Biochimica et Biophysica Acta 1812 (2011) 1371–1379
[38] H.P. Nguyen, P. Kobbe, H. Rahne, T. Wörpel, B. Jäger, M. Stephan, R. Pabst, C.
Holzmann, O. Riess, H. Korr, O. Kántor, E. Petrasch-Parwez, R. Wetzel, A. Osmand,
S. von Hörsten, Behavioral abnormalities precede neuropathological markers in
rats transgenic for Huntington's disease, Hum. Mol. Genet. 15 (2006) 3177–3194.
[39] M.S. Hurlbert, W. Zhou, C. Wasmeier, F.G. Kaddis, J.C. Hutton, C.R. Freed, Mice
transgenic for an expanded CAG repeat in the Huntington's disease gene develop
diabetes, Diabetes 48 (1999) 649–651.
[40] S.E. Browne, M.F. Beal, The energetics of Huntington's disease, Neurochem. Res. 29
(2004) 531–546.
[41] A. Ciarmiello, M. Cannella, S. Lastoria, M. Simonelli, L. Frati, D.C. Rubinsztein, F.
Squitieri, Brain white-matter volume loss and glucose hypometabolism precede
the clinical symptoms of Huntington's disease, J. Nucl. Med. 47 (2006) 215–222.
[42] B.G. Jenkins, W.J. Koroshetz, M.F. Beal, B.R. Rosen, Evidence for impairment of
energy metabolism in vivo in Huntington's disease using localized 1H NMR
spectroscopy, Neurology 43 (1993) 2689–2695.
[43] M. Gu,M.T. Gash, V.M.Mann, F. Javoy-Agid, J.M. Cooper, A.H.V. Schapira, Mitochondrial
defect in Huntington's disease caudate nucleus, Ann. Neurol. 39 (1996) 385–389.
[44] C.K. Mathews, K.E. van Holde, K.G. Ahern, Carbohydrate Metabolism I: Anaerobic
Processes in Generating Metabolic Energy, Biochemistry, Addison Wesley Long-
man, San Francisco, 2000, pp. 446–482.
[45] B.R. Underwood, D. Broadhurst, W.B. Dunn, D.I. Ellis, A.W. Michell, C. Vacher, D.E.
Mosedale, D.B. Kell, R.A. Barker, D.J. Grainger, D.C. Rubinsztein, Huntington
disease patients and transgenic mice have similar pro-catabolic serummetabolite
proﬁles, Brain 129 (2006) 877–886.
[46] C. Dautry, F. Condé, E. Brouillet, V. Mittoux, M.F. Beal, G. Bloch, P. Hantraye, Serial
1H-NMR spectroscopy study of metabolic impairment in primates chronically
treated with succinate dehydrogenase inhibitor 3-nitropropionic acid, Neurobiol.
Dis. 6 (2006) 259–268.
[47] S.E. Browne, A.C. Bowling, U. MacGarvey, M.J. Baik, S.C. Berger, M.M.K. Muqit, E.D.
Bird, M.F. Beal, Oxidative damage and metabolic dysfunction in Huntington's
disease: selective vulnerability of the basal ganglia, Ann. Neurol. 41 (1997)
646–653.
[48] M. Gu, M.T. Gash, V.M. Mann, F. Javoy-Agid, J.M. Cooper, A.H.V. Schapira,
Mitochondrial defect in Huntington's disease caudate nucleus, Ann. Neurol. 39
(1996) 385–389.
[49] C. Demougeot, C. Marie, M. Giroud, A. Beley, N-acetylaspartate: a literature review
of animal research on brain ischaemia, J. Neurochem. 90 (2004) 776–783.
[50] J.K. Choi, A. Dedeoglu, B.G. Jenkins, Application of MRS to mouse models of
neurodegenerative illness, NMR Biomed. 20 (2007) 216–237.
[51] A. van Dellen, J. Welch, R.M. Dixon, P. Cordery, D. York, P. Styles, C. Blakemore, A.J.
Hannan, N-acetylaspartate and DARPP-32 levels decrease in the corpus striatum
of Huntington's disease mice, Neuroreport 11 (2000) 3751–3757.
[52] J.C.H. van Oostrom, P.E. Sijens, R.A.C. Roos, K.L. Leenders, 1H magnetic resonance
spectroscopy in preclinical Huntington disease, Brain Res. 1168 (2007) 67–71.
1379K.A. Verwaest et al. / Biochimica et Biophysica Acta 1812 (2011) 1371–1379

Neurobiology of Disease
A Novel BACHD Transgenic Rat Exhibits Characteristic
Neuropathological Features of Huntington Disease
Libo Yu-Taeger,1 Elisabeth Petrasch-Parwez,2 Alexander P. Osmand,3 Adriana Redensek,1 Silke Metzger,1
Laura E. Clemens,1 Larry Park,4 David Howland,5 Carsten Calaminus,6 Xiaofeng Gu,7 Bernd Pichler,6 X. William Yang,7
Olaf Riess,1 and Huu Phuc Nguyen1
1Department of Medical Genetics, University of Tuebingen, 72076 Tuebingen, Germany, 2Department of Neuroanatomy and Molecular Brain Research,
Ruhr-University Bochum, 44801 Bochum, Germany, 3Department of Medicine, University of Tennessee Graduate School of Medicine, Knoxville, Tennessee
37920, 4CHDI Management/CHDI Foundation, Los Angeles, California 90045, 5CHDI Management/CHDI Foundation, Princeton, New Jersey 08540,
6Laboratory for Preclinical Imaging and Imaging Technology of the Werner Siemens-Foundation, University of Tuebingen, 72076 Tuebingen, Germany,
and 7Department of Psychiatry and Biobehavioral Sciences, David Geffen School of Medicine, University of California at Los Angeles, Los Angeles,
California 90095
Huntington disease (HD) is an inherited progressive neurodegenerative disorder, characterized by motor, cognitive, and psychiatric
deficits as well as neurodegeneration and brain atrophy beginning in the striatum and the cortex and extending to other subcortical brain
regions. The genetic cause is an expansion of the CAG repeat stretch in the HTT gene encoding huntingtin protein (htt). Here, we
generated an HD transgenic rat model using a human bacterial artificial chromosome (BAC), which contains the full-length HTT genomic
sequence with 97 CAG/CAA repeats and all regulatory elements. BACHD transgenic rats display a robust, early onset and progressive
HD-like phenotype including motor deficits and anxiety-related symptoms. In contrast to BAC and yeast artificial chromosome HD
mouse models that express full-length mutant huntingtin, BACHD rats do not exhibit an increased body weight. Neuropathologically, the
distribution of neuropil aggregates and nuclear accumulation of N-terminal mutant huntingtin in BACHD rats is similar to the observa-
tions in human HD brains. Aggregates occur more frequently in the cortex than in the striatum and neuropil aggregates appear earlier
than mutant htt accumulation in the nucleus. Furthermore, we found an imbalance in the striatal striosome and matrix compartments in
early stages of the disease. In addition, reduced dopamine receptor binding was detectable by in vivo imaging. Our data demonstrate that
this transgenic BACHD rat line may be a valuable model for further understanding the disease mechanisms and for preclinical pharma-
cological studies.
Introduction
Huntington disease (HD) is an autosomal dominant, progressive
neurodegenerative disorder commonly manifesting in adulthood
(Harper, 1991). Clinical features include motor deficits, cognitive
decline, and psychological disturbances (Vonsattel and DiFiglia,
1998). The hallmark of HD neuropathology is initial striatal at-
rophy, which expands at later stages to the cerebral cortex and
other subcortical brain regions (Bruyn, 1979; Vonsattel et al.,
1985). Interestingly, neuropil and nuclear huntingtin (htt) aggre-
gates are abundant in the cortex, but are only sparsely observed in
the striatum of HD-affected brains (Gutekunst et al., 1999; Kue-
mmerle et al., 1999).
Expansions of the CAG repeat (38) in exon 1 of the gene
encoding htt were first discovered in 1993 and represent to date
the sole genetic cause for the disease (The Huntington’s Disease
Collaborative Research Group, 1993). A number of mouse mod-
els expressing full-length htt or truncated htt fragments were
developed for therapeutic studies and to better understand the
pathogenesis of disease (Menalled and Chesselet, 2002; Ehrnhoe-
fer et al., 2009; Crook and Housman, 2011; Munoz-Sanjuan and
Bates, 2011). However, mouse models are in general limited for
studying certain functional and behavioral measurements
(Tecott and Nestler, 2004; Rodriguiz and Wetsel, 2006; Herr-
mann et al., 2012). The limitations of mouse models as well as
pharmacogenomic differences between the species (Toutain et
al., 2010) necessitate either the laborious development of test
designs appropriate for mouse models or the use of additional
species to generate HD models in which these test designs are
readily available.
Rat models have made substantial contributions to our un-
derstanding of biological function and behavior. Numerous rat
disease models have successfully proven their utility for modeling
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the human condition (Hammer et al., 1990; von Ho¨rsten et al.,
2003; Yamada et al., 2004; Liu et al., 2008). Although learning and
memory can be studied with some restrictions in mice, the cur-
rent scientific knowledge concerning the complexity of learning
and memory, as well as the multiplicity of brain systems support-
ing it, has come largely from behavioral research using rats (Re-
port of the NIH Rat Model Priority Meeting, 1999, http://www.
nhlbi.nih.gov/resources/docs/ratmtg.pdf). Compared to mice,
rats show excellent learning abilities, a mandatory requirement
for the identification of the subtle cognitive deficits that may be
present in the early stages of HD. Another practical advantage of
rats is their larger brain size, which facilitates direct invasive pro-
cedures. In addition, miniaturized physiological in vivo ap-
proaches, such as structural and functional imaging of small
brain structures, are more difficult in mouse models due to size
limitation.
We have previously generated an HD transgenic rat line
(tgHD rats), which expresses a fragment of mutant htt (von
Ho¨rsten et al., 2003). This rat model demonstrated many aspects
of HD, but lacking the full-length mutant htt (fl-mhtt) protein
certain aspects of the human disease would be imperfectly repli-
cated.
In this study, we generated and characterized a new bacterial
artificial chromosome (BAC) HD transgenic rat model express-
ing fl-mhtt under the control of the human HTT promoter and
all its regulatory elements to determine its similarity to the hu-
man condition across the molecular, behavioral, and anatomical
domains.
Materials and Methods
Animals
Generation of transgenic rats. BACs, containing human genomic DNA
spanning the full-length HTT gene with 97 CAG/CAA repeats and in-
cluding all regulatory elements (Gray et al., 2008), were microinjected
into oocytes of Sprague Dawley rats. Genotyping and determination of
BAC transgene integrity were performed via PCR analysis using genomic
DNA extracted from ear biopsy tissue (High Pure PCR Template Prepa-
ration Kit; Roche). Two primer pairs were designed, one pair binding to
exon 1 (FW: 5-ATGGCGACCCTGGAAAAGC-3; RV: 5-AGGTCGGT
GCAGAGGCTCCTCTG-3) of both endogenous Htt and exogenous
mutant HTT with different amplicon lengths, while the second primer
pair binds specifically to the last exon of the HTT transgene (FW: 5-TG
TGATTAATTTGGTTGTCAAGTTTT-3;RV:5-AGCTGGAAACATCA
CCTACATAGACT-3).
To estimate relative transgene copy number of the BAC insertion and
number of integration sites, probe-based real-time PCR (TaqMan PCR)
was performed using genomic DNA. Briefly, primers and probe were
designed to bind specifically to intron 29 of the HTT transgene (FW:
5-ACCGACCTTCTGAAGCCTACTTCT-3;RV:5-TTCTCCTCCAAA
GGATCACAACTC-3; probe: 5FAM-CTAAGTGGCGCTGCGTAGTG
CGAA-3Bhq). The Ct values of all samples were normalized to -actin
serving as reference gene (FW: 5-AGCCATGTACGTAGCCATCCA-3;
RV: 5-TCTCCGGAGTCCATCACAATG-3; probe: 5CY-TGTCCCTG
TATGCCTCTGGTCGTACCAC-3Bhq). The relative copy number of
all F1 rats was compared within and between each line.
RNA analysis. Expression levels of mRNA from each line were ana-
lyzed via real-time PCR using QuantiTect SYBR Green PCR Kits (Qia-
gen). Total mRNA was extracted from whole brain using the RNeasy
Lipid Tissue Midi Kit (Qiagen) and cDNA was synthesized using a Quan-
tiTect Reverse Transcription Kit (Qiagen) following the manufacturer’s
instructions. The relative mRNA expression levels were compared with
endogenous wild-type (WT) htt. The primers were designed for trans-
genic HTT (FW: 5-GTGGAGGTTTGCTGAGCTG-3; RV: 5-GCAAAA
TTGCCAAAAGAAGC-3) and rat Htt (FW: 5-ATCTTGAGCCACAG
CTCCAGCCA-3; RV: 5-TCTGAAAACGTCTGAGACTTCACCAGA-
3) spanning at least one exon– exon junction.
Measurement of the CAG-CAA repeat length in BACHD rats
To verify the conservation of the polyQ repeat length, we analyzed the
PCR fragment length of DNA samples extracted from 100 peripheral
tissues and different brain regions. DNA extractions were performed as
described before and rat samples were collected considering different rat
generations, gender, and ages of the rats. PCRs were performed using a
Cy5labeled forward primer and a reverse primer amplifying a fragment
of HTT exon 1 including the CAG-CAA repeats (forward primer: 5-
GAT GAA GGC CTT CGA GTC CCT CAA GTC CTT CT-3, reverse
primer: 5-CGG CTG AGG CAG CAG CGG CTG T-3). The fragment
lengths of the amplicons were determined and analyzed using the
fluorescence-based capillary electrophoresis Sequencer CEQ8800 and
genetic analysis system software in a complete set from Beckman Coulter.
CAG-CAA repeat numbers were calculated according to the individual
fragment length and the human HTT sequence published on the NCBI
database.
Identification of alternative HTT splicing variants in BACHD
transgenic rats
Splicing variants may possess a considerable effect on protein function with
two or more splicing products fulfilling distinct functions in the expressing
cells. Therefore, BACHD transgenic rats carrying the genomic sequence with
upstream and downstream flanking regions instead of cDNA sequence were
generated. Two protein-encoding splicing variants of the human mRNA
have been identified and listed in the Ensemble Genome Browser (http://
www.ensembl.org/Homo_sapiens/Gene/Summary?gENSG00000197386;
r4:3076408-3245676) so far (HTT-001, transcript ID: ENST00000355072
and HTT-011, transcript ID: ENST00000509618). The longer one (HTT-
001) includes all 67 exons encoding for the full-length huntingtin; the
smaller one (HTT-011) consists only of 3 exons, the last 31 bases of exon 29,
exon 30, and 31 as well as the 96 bases of the following intron 31–32. A
forward primer was designed to bind to both transcripts in exon 31 of HTT-
001 and reverse primers were chosen to bind specifically to each variant. For
HTT-001, the reverse primer binds to exon 32 whereas for HTT-011, the
primer was directed against a region within the last 96 nucleotides. Brain
samples from the striatum, the cortex, and the cerebellum were taken and
after purification of the mRNA subjected to real-time PCR using the Quan-
tiTect SYBR Green PCR Kit (Qiagen).
Western blotting. Expression levels of transgenic mhtt in different lines
and different brain regions were quantified using Western blot and Im-
ageJ (National Institutes of Health, NIH) analysis. One-month-old rat
brains were homogenized with a homogenizer at a speed of 30,000 rpm in
modified radioimmunoprecipitation assay buffer (Gray et al., 2008). The
lysates were centrifuged at 4°C for 15 min at 16,200  g, and the super-
natant was removed and stored at 80°C for Western blot analysis.
Western blot analysis was performed as described previously (Gray et
al., 2008). The blots were probed with two monoclonal antibodies:
MAB2166 (1:2000; Millipore) recognizing the N-terminal region of both
human and rat htt, and 1C2 (1:2000; Millipore) binding to the expanded
polyQ sequence of human htt but not to the nonexpanded polyQ se-
quence of the endogenous rat htt.
Behavioral assessment
Rats were group-housed with mixed genotypes in a constant temperature-
humidity room (22  1°C, 55  10% relative humidity) with a 12 h light/
dark cycle (lights on/off at 2:00 A.M./P.M.). Food and water were provided
ad libitum. All behavioral tests were performed only with male rats during
the dark phase, which is the physiological activity period of the rats. Controls
were an equal mix of WT littermates from both lines and the experimenters
were blind to the individual animals’ genotype. All animal procedures were
approved by the state government of Baden–Wu¨rttemberg, Germany, and
are in accordance with animal protection guidelines.
Rotarod test. Rotarod experiments (Accelerated rotarod for rats 7750,
Ugo Basile) were used to measure forelimb and hindlimb motor coordi-
nation. BACHD transgenic rats and WT littermates were trained on 3
consecutive days with four trials per day. Directly after training they were
tested on 2 consecutive days with two trials per day and an interval of 1 h
between individual trials. During the training period, the rats were placed
on the rotating rod at a constant speed of 12 rpm for 2 min. Rats were
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returned to the rod after falling during the
training period up to 10 falls per trial. Individ-
ual tests were assessed for a maximum of 5 min
with accelerating speed from 4 to 40 rpm over a
period of 4 min, and the latencies to fall were
recorded. Rats from the same cohort (n  12)
were tested every month from 1 to 15 months
of age. Three rats were excluded from the anal-
ysis because already at younger ages they fell off
the rotarod immediately when placed on it, de-
spite extensive training.
Footprint test. We used a footprint test to
analyze gait abnormalities in BACHD rats.
BACHD transgenics and WT littermates were
evaluated in this task at 14 months of age (n 
11). The front and hindpaws of the animals
were painted with nontoxic paint of different
colors. On the day before testing, the rats were
trained in three sessions. The best performance
out of three tests with each rat was selected for
data analysis. The stride width of the hindpaw,
the step length (left paw to left paw), and the
overlap (distance between front and hindpaw)
were measured in three consecutive steps, and
the average was taken for further analysis.
Elevated plus maze. An elevated plus maze
was used to assess the anxiety of BACHD rats.
To eliminate the possibility of habituation ef-
fects, different cohorts of rats were tested at 1
(n  13 per genotype), 4 (n  13 per geno-
type), and 12 (TG5:WT  8:11) months of age
as described previously (Nguyen et al., 2006).
Rats were placed at the center of an elevated
plus maze (with two open and two closed
arms) facing an open arm and were monitored
for 5 min. The time spent in the open arms was
recorded as a percentage of the total time for
analysis.
Locomotor activity and food intake. Rats were
monitored using the PhenoMaster system
(TSE Systems), which represents a modular
setup that screens rats in a home cage-like en-
vironment for their ambulatory activity and
rearing as well as feeding and drinking behav-
ior. The activity detection is achieved using in-
frared sensor pairs arranged in horizontal (x,y
level for ambulatory activity) and vertical (z
level for rearing) strips. Food and water con-
sumption were recorded by two weighting sen-
sors. The same cohort of animals (TG5:TG9:
WT  16:19:18) was individually screened for
22 h every 3 months until the age of 18 months.
Data were automatically collected with 1 min
intervals and analyzed either entirely or only
for the dark (active) phase. Rats, which did not
drink 3 ml of water within 24 h were excluded
from the data analysis since this might have con-
founded feeding behavior and activity.
Light and electron immunohistochemistry
Rats were deeply anesthetized with ketamine/
xylazine (100/10 mg/kg, i.p.) and transcardially
perfused with 4% paraformaldehyde in 0.1 M
sodium cacodylate buffer, pH 7.4, followed by postfixation of the brains
in the same fixative overnight. For lightmicroscopical immunohisto-
chemistry 16 rat brains were embedded in one gelatin block; 40 m
coronal sections were freeze-cut and collected into 24 series (NeuroSci-
ence Associates). Free-floating staining was performed as previously de-
scribed (Osmand et al., 2006). Sections were incubated with the
polyclonal S830 antibody (1:15,000; 10 ng/ml, kindly provided by G.
Bates), EM48 (1:300, MAB5374; Millipore Bioscience Research Re-
agents) or the polyclonal anti-calbindin D-28K antibody (1:50,000;
Swant Swiss antibodies) followed by the respective secondary antibodies:
biotinylated rabbit anti-sheep IgG antibody (1:1000, BA-6000; Vector
Laboratories), biotinylated goat anti-mouse IgG antibody (1:1000, BA-
9200; Vector Laboratories), or biotinylated goat anti-rabbit IgG antibody
Figure 1. Generation of BACHD transgenic rats. A, BACHD construct was designed using a BAC containing the entire 170 kb of
the HTT genomic locus with 20 kb upstream and 50 kb downstream flanking sequences. The mutant HTT exon 1 including 97
CAA-CAG trinucleotide repeats in place of endogenous HTT exon 1 is flanked by two loxP sites. B, Western blot analysis of mhtt
expression in different transgenic rat lines and compared with BACHD mouse expression. Both mhtt and endogenous WT rat htt are
recognized by MAB2166 showing bands of 360 and 330 kDa, respectively (arrows). Line 5 presents the highest mhtt expres-
sion and line 9 shows a comparable mhtt expression level to the BACHD mouse. C, Western blot analysis of mhtt expression in
various brain regions in transgenic line 5 (TG5) and transgenic line 9 (TG9) using antibody 1C2. In TG5 rats mhtt is abundantly
present in cerebellum (Crb), striatum (Str), and cortex (Ctx), whereas olfactory bulb (Bulb), brainstem (Brs), and hypothalamus
(Hyp) show a relatively reduced expression of mhtt. In TG9 rats higher expression levels were found in striatum, olfactory bulb, and
hypothalamus compared with cerebellum, cortex, and brainstem. WB, Whole brain.
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(1:1000, BA-1000; Vector Laboratories). Then sections were treated with
an avidin– biotin–peroxidase complex (Vector Laboratories), and ex-
posed to nickel-DAB-H2O2 (0.6% nickel sulfate, 0.01% DAB, and
0.001% hydrogen peroxide) until a suitable staining intensity had devel-
oped. S830 staining was routinely amplified using a single round of bio-
tinylated tyramine amplification before the final ABC step. Images were
taken using an Axioplan 2 Microscope (Zeiss) with a digital camera
(AxioCam MRm; Zeiss) and imaging acquisition software (AxioVi-
sion-6; Zeiss). Quantification was performed using ImageJ (NIH).
For electron microscopy BACHD and control rat brains (13 and 16.5
months of age) were adjusted in Plexiglas frames according to the coor-
dinates of a rat brain atlas (Paxinos and Franklin, 2006), embedded in 2%
agarose, and cut into 3 mm coronal brain blocks. Blocks were cut into
series of 50 m vibratome sections and immunostained with the mono-
clonal EM48 antibody (1:100, MAB5374; Millipore Bioscience Research
Reagents) the specificity of which was controlled in WT rats. Immuno-
stained sections were photodocumented for later detection of the reac-
tion product and flat embedded in Araldite (Serva) as described
previously (Petrasch-Parwez et al., 2007). Ultrathin sections (90 nm)
were contrasted with 5% aqueous uranyl acetate and lead citrate (pH 12).
Quantitative assessment of morphological changes in the
striosome compartment
Calbindin immunostaining of rats at 6 months of age was used (TG5:
TG9:WT  5:4:5) to perform a relative quantification of the striatal
striosome compartment. Four striata of each rat were measured in cor-
onal 40-m-thick brain sections between bregma 1.44 and 0.24 mm
(Paxinos and Franklin, 2006). The striatum was outlined medially adja-
cent to the lateral ventricle, dorsolaterally below the corpus callosum,
and ventrally by a line through the ventral tip of the ventricle as the region
of interest (ROI) using ImageJ (NIH). The striosomal area was deter-
mined within the ROI by outlining the faintly stained calbindin areas.
The ratter was blind to the rat’s genotype.
[11C]raclopride positron emission tomographic imaging
For longitudinal positron emission tomography (PET) experiments,
transgenic BACHD and control rats were imaged at 6, 12, and 18 months
of age (n  6 of each genotype at each time point) using an Inveon
dedicated small-animal PET scanner (Siemens Preclinical Solutions),
yielding a spatial resolution of 1.3 mm in the reconstructed image.
Conscious animals were lightly restrained and injected with 29.6 MBq
[ 11C]raclopride via one of the lateral tail veins. A 60 min dynamic PET
scan was obtained immediately after tracer injection followed by a 15 min
attenuation correction. During imaging, the animals were anesthetized
with a mixture of 1.5% isoflurane in 100% oxygen. The animals were
centered in the field of view of the PET scanner. Anesthesia was moni-
tored by measuring respiratory frequency, and the body temperature was
kept at 37°C by a heating pad underneath the animal. PET data were
acquired in list mode; graphed in time frames of 4  60 s, 3  120 s, 7 
300 s and 2  450 s; and reconstructed using a filtered backprojection
algorithm with a matrix size of 256  256 and a zoom factor of two.
Image files were analyzed using PMOD and AsiPro software (Siemens
Preclinical Solutions). The PMOD image fusion software allowed for
linear transformation and rotation to overlay the PET and magnetic
resonance (MR) template images. The fusioned PET/MR images were
analyzed to calculate specific ROIs in different brain areas with reference
to the stereotactic brain atlas of Paxinos and Franklin (2006). With the
PMOD software we also analyzed the [ 11C]raclopride uptake in two
brain areas including cerebellum and striatum. The cerebellum was cho-
sen as a reference region, to correlate the unspecific uptake with the tracer
uptake in the striatum.
Statistical analysis
Standard two-way ANOVA (data not matched) and repeated-measures
two-way ANOVA (repeated or matched data) were conducted to assess
the effects of genotype and age and genotype  age interaction. Bonfer-
roni post hoc tests were conducted to compare individual genotype effects
at individual ages. For the analysis of the rotarod test results, only data
until 10 months were taken into account because most TG5 rats fell
immediately from the rotarod during the final 5 months (from age 11 to
15 months) leading to a non-normal distribution of the data in the final
5 months. For data where only one time point was assessed (such as the
footprint test and matrix/striosome analysis), one-way ANOVA was con-
ducted to evaluate the effects of genotype, followed by Tukey’s post hoc
test for multiple comparisons. Data are presented as mean  SEM. Dif-
ferences were considered significant if p  0.05.
Results
Generation and establishment of BACHD rats
BACHD rats expressing full-length mutant human htt, were gen-
erated with BACs containing human genomic DNA spanning the
full-length HTT gene and the flanking genomic sequences of 20
kb upstream and 50 kb downstream, which included all regula-
tory elements (Yang et al., 1997; Kazantsev et al., 1999; Gray et al.,
2008). WT HTT exon 1 was replaced by mutant HTT exon 1
containing 97 mixed CAA/CAG repeats flanked by two LoxP sites
(Fig. 1A). Thereby, the BAC construct allows for a conditional
and inducible elimination of the mutant HTT exon 1 by Cre
recombinase activity. Following microinjection, 21 of 24 trans-
genic founder rats generated F1 progeny, which was used to eval-
uate the integrity of the transgene. Two different primer pairs
were used in the PCR analysis elongating a fragment of the first
and last exon of the HTT gene. Of 21 founder rats, 18 possessed
the full-length HTT gene; three founders had to be withdrawn
as they were lacking at least the last exon (data not shown).
Genomic transgene copy number was analyzed using TaqMan
real-time PCR (data not shown). Three lines had multiple inser-
tion sites of the BAC constructs and were therefore excluded from
further experimentation. mRNA expression levels were quanti-
fied with SYBR Green quantitative PCR, indicating that line
LY.005 had the highest mRNA expression of mutant htt (data not
shown). Htt protein levels of 1-month-old transgenic rats were
Figure 2. Alternative splicing variants in BACHD transgenic rats. Real-time PCR was per-
formed using one common forward primer binding to both variants of HTT-001 and HTT-011;
the reverse primers were chosen specifically to bind to each variant. A, Image of gel electropho-
resis. The BACHD rats TG5 and TG9 exhibit both transcription variants HTT-001 and HTT-011 in
cerebellum (Crb), cortex (Ctx), and striatum (Str). Whole-brain (WB) mRNA of a WT rat was
taken as negative control. B, Quantification of the proportion of HTT-001/HTT-011 in different
brain regions of both transgenic lines. The ratios of HTT-001 and HTT-011 vary between 2.49
and 4.40 in all brain regions investigated in both TG5 and TG9, except in the cortex of TG9 rats,
where an equal expression of HTT-001 and HTT-011 is present.
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quantified by Western blot analysis with
the antibody MAB2166, which recognizes
both human and rat htt. Highest protein
expression was also found in line LY.005,
consistent with the mRNA results (data
not shown), whereas line LY.009 dis-
played a comparable level of mRNA and
protein as the well characterized
BACHD mice (Fig. 1 B) (Gray et al.,
2008). Consequently, these two lines,
which contain a single insertion site and
express intact full-length htt were se-
lected for subsequent phenotypic
characterization.
The relative fold of transgene expres-
sion compared with endogenous rat htt
was estimated by semiquantitative anal-
ysis of mhtt in each line with respect to
the calibration line LY.001, which ex-
pressed the same level of mhtt mRNA as
endogenous htt mRNA. The estimated
expression level of mhtt is 4.5 times
higher than the endogenous in the
transgenic line LY.005 (TG5), and 2.5
times higher than endogenous htt in line
LY.009 (TG9).
To assess the expression pattern of
mhtt in different brain regions of the
transgenic BACHD rats, protein ex-
tracts of 6 brain subregions (cerebellum,
cortex, striatum, olfactory bulbs, brain-
stem,andhypothalamus)from1-month-
old TG5 and TG9 rats were analyzed
using Western blot analysis (Fig. 1C).
The blots were stained with antibody
1C2 to visualize the signal of mhtt. The
results revealed that in TG5 rats mhtt is
most expressed in the cerebellum, stria-
tum, cortex, and olfactory bulb, whereas
the hypothalamus and brainstem show a
lower abundance (Fig. 1C). In TG9 rats
higher expression levels were found in
striatum, olfactory bulb, and hypothal-
amus compared with cerebellum, cor-
tex, and brainstem.
Stable CAG repeat number and alternative splicing variants of
mutant human huntingtin in BACHD rats
The stability of CAG repeat expansions is of critical importance
for therapeutic studies, since the age of onset of HD inversely
correlates with the number of CAG repeats (Duyao et al., 1993;
Stine et al., 1993). In total, 100 samples from different brain
regions or peripheral tissue were collected from transgenic rats
with ages of up to 18 months of four generations and both gen-
ders to verify the stability of the polyglutamine stretch in
our transgenic rat model. Our analysis revealed stability of the
polyQ encoding sequence in both germlines and in different
brain regions at different ages, gender, and rat generations as
observed in BACHD mice (data not shown) (Gray et al.,
2008).
Real-time PCR was performed to determine alternative splic-
ing variants of the transgene mRNA. Samples of different brain
regions of BACHD rats were analyzed for the presence of both
mhtt protein-encoding variants, which have been previously
identified (transcript HTT-001 and HTT-011 in Ensemble Ge-
nome Browser). Both the small (HTT-011) and the 67 exons
spanning large transcript (HTT-001) were identified in all an-
alyzed brain samples and the ratio of the transcript variants
present in the different brain regions were similar (Fig. 2 A, B).
BACHD rats do not exhibit an increased body weight
compared with WT littermates
Since it has been shown that an increased expression of fl-mhtt
in mice is associated with a dose-dependent increase in body
weight (Van Raamsdonk et al., 2006), we have monitored body
weight in both lines of BACHD rats and their WT litter-
mates weekly (Fig. 3A). All rats gained body weight until 64
weeks of age with neither significant interaction between ge-
notype and age, nor main effect of genotype (repeated-
measures ANOVA, p  0.05).
Figure 3. Motor function analysis of BACHD rat lines TG5 and TG9 compared with WT littermates. A, Comparison of body
weights of BACHD rats and WT littermates (WT:TG5:TG9, N  20:16:22). The body weight was measured once a week and was not
significantly different between genotypes over an observation period of 64 weeks. B, Rats underwent four test sessions each
month on an accelerating rod (4 – 40 rpm in 4 min). Mean latencies to fall ( SEM) were compared among different genotypes
over 15 months (n  12). TG5 rats displayed a progressive decrease in performance from 1 month of age, whereas TG9 showed an
impaired performance at 3 and 4 months. Starting with the fifth test month, TG9 rats adapted an alternative strategy to remain on
the rotating rod, which yielded comparable performances compared with WT rats. C, Footprints at 14 months of age. Stride width:
continuous line; step length: dotted line; and overlap between front and hindlimbs: two directional arrows. D, Statistical analysis
of footprints examined at 14 months of age. TG5 exhibited a significantly abnormal gait with increased stride width, decreased
overlap as indicated by a greater distance between hind and front paw placement, and decreased step length. E, Hindlimb clasping
in BACHD transgenic rats at 3 weeks of age. Data are expressed as means  SEM, *p  0.05; **p  0.01; ***p  0.0001.
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Early onset and progressive motor deficits in BACHD rats
Motor deficits are an important clinical feature of HD patients
including involuntary movements, motor dyscoordination, and
gait disturbances. To assess motor dysfunction in our transgenic
animals, we performed rotarod tests and footprint analyses and
looked for clasping behavior.
Four trials on an accelerated rotarod were conducted with
1-month-old rats and repeated every month until the age of 15
months. The average latency until the animal fell off the rotating
rod was measured and analyzed. Repeated-measures ANOVA
revealed a highly significant main effect of genotype (F(2,270) 
22.86, p  0.0001) and a statistically significant genotype  age
interaction (F(18,270)  1.67, p  0.0448), reflecting a significant
difference between the performance of BACHD rats and WT rats
with increasing age. Subsequent post hoc analysis with Bonferroni
tests demonstrated a progressive decline in rotarod performance
in the TG5 group relative to both WT and TG9 animals (Fig. 3B).
Significant differences were already evident at 1 month of age
(p  0.01). Here, TG5 rats exhibited significant difficulties in
maintaining balance on the rod at higher rotation speeds and
were unable to remain on the rod longer than 97.31  19.45 s. In
comparison, WT rats showed an average latency to fall of
156.88  8.48 s. At 4 months of age, the performance of TG5 rats
dropped drastically, but it was maintained over the next 4
months. A similar drastic reduction in performance was observed
again between 9 and 11 months of age, when most of the TG5 rats
were unable to walk on the rod even at the lowest velocity (4 rpm)
(Fig. 3B).
Video recordings provided additional insight into the rats’
performance on the rotarod. At young ages (3 months), both
transgenic and WT rats displayed similar
walking behavior on the rotarod. Starting
with 3 and 5 months of age, respectively,
TG5 and TG9 transgenic rats adopted an
abnormal walking strategy. After being
placed on the rod, the transgenic animals
turned 180° and instead of performing a
coordinated walk, they started to jump
backwards. The number of transgenic rats
adapting this unusual strategy increased
with age, which partly compensated for
the decline in rotarod performance. None
of the WT littermates displayed this ab-
normal movement strategy. Together, the
results of the rotarod test demonstrated
an early onset and progressive motor
function deficit in BACHD transgenic rats
of line TG5.
To investigate the gait of BACHD
transgenic rats, footprints from all geno-
types (n  11 each) were analyzed at 14
months of age. The stride width of the
hindlimbs as well as the step length and
the overlap of hindlimbs and forelimbs of
each individual rat were measured. One-
way ANOVA revealed that 14-month-old
transgenic TG5 rats made significantly
shorter steps with forelimbs and
hindlimbs (p  0.0001) than TG9 and
WT. Furthermore, TG5 rats showed an
increased stride width (p  0.01) and a
reduced overlap between forelimb and
hindlimb placement (p  0.0001) (Fig.
3C,D) compared with the other groups, indicating that BACHD
transgenic rats TG5 have gait abnormalities at older ages com-
pared with WT rats.
Additionally, characteristic hindlimb clasping behavior was
observed during tail suspension in both transgenic lines starting
at 3 weeks of age (Fig. 3E).
Decreased anxiety, initial hypoactivity, and reduced food
intake in BACHD rats
Additional clinical features of HD patients involve multiple psy-
chiatric symptoms. To score the anxiety level of the BACHD
transgenic rats, we used the elevated plus maze test. Independent
cohorts of TG5 rats and WT littermates were used at 1, 4, and 12
months of age. One- and four-month- old BACHD TG5 rats
spent significantly more time on the open arms compared with
WT (10.30 and 9.55% at 1 and 4 months of age, respectively, p 
0.05 at each time point), (Fig. 4A). At 12 months of age, the
difference between TG5 and WT rats further increased with a
mean difference of 13.43% (p  0.01). The significance of these
observations was confirmed by two-way ANOVA, which indi-
cated a highly significant main effect of genotype (F(1,65)  25.56,
p  0.0001) as well as a main effect of age (F(2,65)  37.7, p 
0.0001). However, there was no significant interaction between
genotype and age (F(2,65)  0.26, p  0.7753) because the per-
centage of time spent on the open arms of the maze decreased in
both genotypes with increasing age.
Locomotor activity and food consumption of BACHD rats
were registered in an automated, home cage-like environment
(PhenoMaster; TSE Systems). Measurements were taken from
one cohort of each rat line (TG5:TG9:WT  16:19:18) every 3
Figure 4. Emotional changes, reduced food intake, and initial hypoactivity in BACHD rats. A, Independent cohorts of TG5 and
WT control rats were tested in the elevated plus maze at 1, 4, and 12 months of age. Data are reported as mean  SEM for the
percentage of time spent in the open arms. TG5 rats exhibited significantly increased open-arm exploration compared with WT
controls, which was evident at 4 months of age. The time spent in the open arms decreased in both genotypes throughout the
study. Over an 18 month period with 3 month intervals, a cohort of TG5 (n  16), TG9 (n  19), and WT rats (n  18) were
measured for food intake (B), ambulatory activity (C), and rearing (D) during 12 h of a dark phase. We found significant decreased
food consumption in both transgenic lines over a period of 18 months (asterisks), and a highly significant interaction effect
between genotype and ambulatory activities. Both ambulatory activity and rearing decreased in all three genotypes over time,
whereas significantly lower activity and rearing in both TG5 and TG9 compared with the WT rats were only observed up to 6 months
of age. Data are expressed as means  SEM, *p  0.05; **p  0.01; ***p  0.0001.
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months over a period of 15 months. At each time point, ambulatory
activity over 22 h as well as rearing activity during the dark phase
were analyzed. Both transgenic and WT rats showed a pronounced
dark/light cycle in their behavioral activities with their main activity
taking place during the dark phases. The activity pattern did not
differ between different genotypes (data not shown).
Highly significant differences in ambulatory activity were found
at early time points in both transgenic rat lines compared with WT
Figure 5. Htt aggregates were investigated using polyclonal sheep antibody S830 and monoclonal mouse antibody EM48 showing similar brain regional distribution pattern. Mutant htt
immunoreactivity is widely distributed throughout the cerebrum of BACHD rats by 12 months of age. Nickel-DAB (black) visualizes immuno-activity of mhtt, and the counterstaining with thionin
(blue) marks nuclei. In both TG5 and TG9 rats, aggregates varying in size and formation were abundant in the cortex (a– d), nucleus accumbens (e– h), and hippocampus (i–l ) and strongly
expressed in the stratum lucidum of CA3 area (arrow in k and l ), bed nucleus of stria terminals (m–p), and amygdala (q–t). Few aggregates were found in caudate–putamen (u–x). Most aggregates
were localized in the neuropil, some of which arranged in a linear array (arrows in the insert of c). Nuclear htt staining (arrowheads in the insert of c) was only detected in layer II/III of the cortex, a
few in caudate–putamen, and in the granule cells of dentate gyrus at 12 months of age. Scale bars: inlay showing high-magnification images, 20 m; in low-magnification images, 200 m.
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(both TG5 and TG9 p  0.001 at 3 and 6 months of age) (Fig. 4C,D).
The reduction in rearing activity was only observed in TG5 com-
pared with WT control rats at early time points (p  0.05 at 3
months of age, p  0.0001 at 6 months of age). The significance of
these observations was confirmed by two-way ANOVA, which indi-
cated a highly significant interaction effect (genotype  age: F(10,259)
 4.22, p  0.0001) in ambulatory activity, a main effect of genotype
in both ambulatory activity (F(2,259)  22.32, p  0.0001) and rear-
ing activity (F(2,248)  15.11, p  0.0001) as well as a main effect of
age (F(5,259)  217.89, p  0.0001 in ambulatory activity; F(5,248) 
23.23, p  0.0001 in rearing activity).
The total food consumption during the dark phase was com-
pared between the three genotypes over 15 months. Analysis with
two-way ANOVA revealed a highly significant main effect of geno-
type (F(2,259) 67.80, p0.0001). BACHD rats of both lines showed
a reduced food intake throughout the study, which was due to re-
duction in food intake in both transgenic rat lines compared with
WT littermates with a mean value of 8.79 g in TG5 and 4.90 g in TG9
(Fig. 4B) compared with 20.71 g in WT. However, there was no
significant interaction between genotype and age (F(10,259)  1.06,
p  0.3965).
Huntingtin aggregates increase over time and are widely
distributed in BACHD rats
To investigate the regional distribution pattern of mhtt-positive ag-
gregates in BACHD transgenic rats, we used the polyclonal sheep
antibody S830 and the monoclonal mouse antibody EM48 in serial
brain sections at 12 months of age (Fig. 5). Immunohistological
staining with both antibodies demonstrated a similar distribution
pattern in BACHD transgenic rats. However, mEM48 staining
was weaker and may exhibit an unspecific immunoreactivity with
blood vessels (Fig. 5h). For this reason, the results obtained with
the S830 antibody are described in more detail in the following. In
TG5 and TG9 brains, the aggregates were found to be widely
distributed in all regions with prominent expression in the neo-
cortex and in limbic areas including nucleus accumbens, hip-
pocampus (specifically in the CA3 region), bed nucleus of the
stria terminalis, and the amygdala (Fig. 5). A lower expression
was observed in the hypothalamus and in most thalamic nuclei
(data not shown). In comparison, very few aggregates were de-
tected in the dorsolateral caudate–putamen, the lateral globus
pallidus, and the substantia nigra (data not shown). The cerebel-
lar cortex showed a few small aggregates throughout all three
layers (data not shown). Both the size and
number of aggregates increased with age,
showing the largest and most abundant
aggregates in amygdala, in the CA3 region
of the hippocampus, and in the cerebral cor-
tex, indicating that aggregate formation
continued to progress in these regions (Fig.
6). Nuclear accumulation of N-terminal
huntingtin was only observed in outer layers
of cerebral cortex, in striatum, and in the
granule cells of the dentate gyrus in older
rats (after 9 months of age) and increased
thereafter (Figs. 5, 6). Mhtt aggregates were
more prominent in TG5 than in TG9 rats at
all ages investigated. No immunoreactivity
was observed in WT rats.
Subcellular localization of N-terminal
htt aggregates and neurodegeneration
Using light microscopy, aggregates vary-
ing in size and form as well as chain-like structures were observed
throughout the brain areas with abundant mhtt. These data indi-
cate that mhtt aggregates are primarily located in the neuropil
(Figs. 5, 6). Subcellular localization of N-terminal htt aggregates
and neurodegeneration were further investigated ultrastructur-
ally in TG5 rat brains at advanced ages by EM48 immunohisto-
chemistry (Fig. 7) when aggregates were abundantly expressed.
Electron microscopy confirmed that most aggregates were local-
ized in the neuropil. Htt deposits were predominantly detected in
axons (Fig. 7C,K) and synaptic terminals (Fig. 7D,G,L). Dark
degenerating neurons and dark dendrites were also identified in
these areas as documented in the nucleus accumbens (Fig. 7B),
bed nucleus of the stria terminalis (Fig. 7F), and the cortex (Fig.
7J). Dark neurons with condensed nucleus and cytoplasm were
often localized adjacent to normal light neurons (Fig. 7B,F).
Dark degenerating terminals were seen in apposition to large
pallidal dendrites (Fig. 7H). Some dark cortical neurons dis-
played a fine granular immunoreaction product (Fig. 7J) similar
to that seen by light microscopy in the respective area (Fig. 6).
The prominent S830 immunoreactivity in the stratum lucidum
of the CA3 region of the hippocampus (Fig. 5) corresponded to
immunopositive unmyelinated mossy fibers (Fig. 7K) and their
terminals, some of which were engulfed by lamellated structures
as a sign of degeneration (Fig. 7L).
Reduced dopamine receptor binding potential in aged
BACHD transgenic rats
A specific uptake of the D2-receptor antagonist [11C]raclopride was
demonstrated in dynamic PET scans in the striatum of WT and
BACHD TG5 rats, while there was no specific tracer uptake in the
corresponding cerebella. Longitudinal measurements up to 18
months of age revealed a significant decrease in the striatal uptake of
[11C]raclopride in BACHD rats (two-way ANOVA for the main
effect of genotype, F(1,24)  8.77, p  0.01). This reduction of dopa-
mine receptor binding potential was evident at 18 months of age
( p  0.01), as confirmed by Bonferroni post hoc multiple-
comparison test (Fig. 8). However, there was no significant inter-
action between genotype and age (F(2,24)  2.33, p  0,1185).
Imbalance of striosome and matrix compartments in early
disease stages of BACHD rats
Calbindin immunostaining was performed to determine changes
in the striosome and matrix compartments, as calbindin is
Figure 6. Spatiotemporal accumulation of mhtt in amygdala (Amg) and cortex (Ctx) of TG5 rat brains. An increase in both
number and size of neuropil aggregates (arrows) was observed in both regions during aging; nuclear accumulation of mhtt
(arrowheads) appeared only in cortex at 9 months of age becoming more abundant at 15 months of age. Scale bar, 20 m.
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strongly expressed in the matrix surrounding the Calbindin-poor
striosomes (Fig. 9A). The intensity of the calbindin staining nei-
ther in the matrix nor in the irregular-shaped striosomes (Fig.
9A) was altered in BACHD rats compared with WT littermates.
One-way ANOVA demonstrated that both total matrix area and
number of the striosomes in BACHD transgenic animals did not
differ from that of their WT littermates (Fig. 9B). However, the
total striosome area (Fig. 9C) and the mean area of the striosomes
(Fig. 9D) were significantly different among the three genotypes,
which subsequent Tukey’s multiple-comparison test determined
was due to the reduction in total and mean striosomal area in
TG5 transgenic rats compared with WT littermates (29% in total
area, p  0.0359; 34% in mean area, p  0,0196). This imbalance
in the striosome-matrix compartments in TG5 rats may affect the
equilibrium of inhibitory and excitatory output from the stria-
tum to downstream neurons.
Discussion
BACHD transgenic rats expressing fl-mhtt, exhibit several robust
HD-like behavioral phenotypes as well as changes at the molecu-
lar and cellular levels (Fig. 10). Importantly, there was no signif-
icant difference in body weight between BACHD rats of both
lines and WT littermates (Fig. 3A). This is in contrast to what has
been reported in BACHD mice and YAC128 mice (Menalled et
al., 2009), where overexpression of fl-mhtt is associated with a
significantly increased body weight. It has been postulated that
body weight is modulated by levels of fl-htt with increased levels
of fl-wthtt or fl-mhtt leading to an increased body and organ
weight in mice, while a decrease of fl-htt is associated with body
weight loss (Van Raamsdonk et al., 2006). The increase of
body weight in mice resulted from an increase of both total fat
mass and fat-free mass and was associated with increased levels of
plasma IGF-1 (Pouladi et al., 2010). Interestingly, we also ob-
served an increase in body fat mass in BACHD rats. But in con-
trast to the published mouse data a decrease in organ weight in
BACHD rats of line TG5 was found resulting in a comparable
body weight between BACHD rats and WT rats (preliminary
results, data not shown). This discrepancy is especially intriguing
since the same construct was used to generate BACHD mice and
Figure 7. Neurodegeneration and subcellular localization of mhtt aggregates in TG5 brains (A, E, I ). Vibratome sections (50 m) show the areas investigated by EM48 immune-electron
microscopy (B, F, J ). Dark degenerated neurons (DN) and dendrites (B, arrowheads) were detected in the nucleus accumbens (Acb), bed nucleus of the stria terminalis (BNST), and cortex (Ctx), the
latter with punctate nuclear htt reactivity as seen adjacent to the nucleolus (N) at higher enlargement (N, inlay in J ). DNs were seen localized near normal neurons, MSN (B), or myelinated nerve fibers
showing evidence of degeneration (arrow in J ). Htt aggregates (*) were observed in axons (arrow in C) and synaptic terminals (T in D and G) often contacting dendrites (De). Dark terminals (DT in
H ) were seen in the globus pallidus (GP) apposing pallidal dendrites (PDe). In the hippocampal CA3 region of hippocampus mossy fiber bundles (MF) emerging from the dentate gyrus (DG) exhibited
immunoreactive unmyelinated fibers (K, arrows); htt reactivity engulfed by lamellated structures was also observed in mossy fiber terminals (MFT in L), adjacent to neuronal dendrites (De).
Caudate–putamen (CPu); anterior commissure (ac). Scale bars: (in A, E, I ), 0.5 mm; (in B, F, J ), 5 m; (in C, H, K, L), 1 m; (in D, G), 0.5 m.
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rats. It might be attributed to species-specific differences and
is less likely caused by integration site effects as we did not
observe an increased body weight in any of the 18 full-length
BACHD rat lines. Furthermore, there is a proportional correla-
tion between the severity of the HD phenotype and the protein
expression level in the two BACHD lines arguing against an inte-
gration site effect. As progressive rotarod deficits are readily ap-
parent in BACHD rats of line TG5 these are very likely motor
defects rather than a consequence of increased body weight. Also,
we can exclude that differences in body weight confound other
behavioral tests in BACHD rats rendering this model valuable for
further phenotype studies.
Another advantage of the BACHD rat
is its strong phenotype. Compared with
the already existing fragment tgHD rats
BACHD rats show an earlier onset and a
faster progression of motor deficits with-
out the need to breed for homozygosity as
heterozygous tgHD rats show only subtle
deficits (Nguyen et al., 2006; Brooks et al.,
2009). Recently, a milder phenotype in
tgHD rats as originally described has been
reported (Casteels et al., 2011; Antonsen
et al., 2012; Blockx et al., 2012). Also,
while striatal atrophy was found in some
groups of old tgHD rats (von Ho¨rsten et
al., 2003; Ka´ntor et al., 2006; Nguyen et al.,
2006), other studies revealed little or no
evidence for atrophy (Winkler et al., 2006;
Bode et al., 2008; Blockx et al., 2011).
In addition, the expression of fl-mhtt
compared with a fragment of mhtt may
add important features. For example,
transgenic HTT in BACHD rats under-
goes natural splicing as confirmed by
the presence of the two naturally occur-
ring mRNA isoforms. Even though the
small splicing variant does not contain a
polyQ stretch, it may fulfill additional func-
tions relevant for the disease process. Since
both of these isoforms were found in hu-
mans (www.ensembl.org/Homo_sapiens/
Gene/Summary?gENSG00000197386;r
4:3076408-3245676), the BACHD rat
model closely resembles the HD patient
condition in this respect.
In BACHD rats, we found a signifi-
cantly decreased D2 receptor binding po-
tential by [11C]raclopride PET, which is
in accordance with findings in HD pa-
tients and has been proposed as a neuro-
imaging biomarker for HD (Pavese et al.,
2003; van Oostrom et al., 2005). Due to
the relatively large size of the rat brain, in
vivo MRI and PET imaging are more prac-
ticable than in mice, thus providing an ex-
cellent tool to study disease progression.
To our knowledge, this is the first study
showing clear longitudinal changes by
[11C]raclopride PET in an HD animal
model, making the BACHD rats a valu-
able model for noninvasive neuroimaging
studies with novel ligands to be subse-
quently translated into the clinics.
Remarkably, the BACHD rat model reflects many aspects of
the aggregation pattern of mhtt found in HD patients. The aggre-
gates occur more frequently in the cortex than in the striatum and
neuropil aggregates appear earlier than mhtt accumulation in the
nucleus (DiFiglia et al., 1997; Gutekunst et al., 1999). In contrast,
R6/2 mice display mainly diffusible mhtt throughout the nucleus
with intensively stained nuclear aggregates (Kosinski et al., 1999;
Wang et al., 2008). In the fragment rat model for HD, cortical
aggregates are far less expressed than in the limbic striatum (von
Ho¨rsten et al., 2003; Nguyen et al., 2006). BACHD mice display a
similar mhtt aggregate distribution pattern as our BACHD rats
Figure 8. [11C]raclopride PET imaging reveals D2 receptor loss in striatum of BACHD rats TG5. [11C]raclopride uptake was
measured as standard uptake volume (SUV) of different brain areas. PET time activity curves of target (striatum) and reference
region (cerebellum) are plotted for the control (A) and BACHD rats (B). C, Corresponding binding potential (BPND) values are shown
in the striatum. There was no significant difference in BPND between the first two time points in transgenic and control rats. After
18 months the BPND of BACHD was significantly lower than in control littermates. Representative images of [11C]raclopride uptake
at each age is shown in D. Data are expressed as means  SEM, **p  0.01.
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with prevalence of neuropil aggregates
and paucity of intranuclear inclusions,
but both are less abundant than in
BACHD rats and appear at a later time
point; the diffuse nuclear mhtt accumula-
tion was not detected until 18 months of
age (Gray et al., 2008). In comparison,
YAC128 mice display both neuropil ag-
gregates and intranuclear inclusions,
which were present at 15 months of age,
particularly in ventral striatum, amygdala,
and cortex (Bayram-Weston et al., 2012).
Interestingly, neuropil aggregates are
much more common in HD patients with
an adult onset than in juvenile onset pa-
tients, and the number of neuropil aggre-
gates correlates with the extent of disease.
While intranuclear aggregates were not
detected in the presymptomatic patient,
neuropil aggregates were observed in the
cortex of the same presymptomatic pa-
tient (DiFiglia et al., 1997; Gourfinkel-An
et al., 1998; Gutekunst et al., 1999). This
difference in the aggregation pattern might be explained by se-
quence differences in the human mutant HTT transgenes har-
bored by the BACHD models and the YAC128 mice, including
single nucleotide polymorphisms as well as differences in the
nature of CAA interruptions of the CAG tract (Pouladi et al.,
2012).
However, whether the extent of aggregation or numbers of ag-
gregates predict neuronal death remains controversial. The forma-
tion of neuropil aggregates can induce axonal degeneration (Li et al.,
2001). Additionally, they can influence the mitochondrial trans-
port along both axons and dendrites, thereby impairing energy
supply within neuronal processes (Chang et al., 2006). Importantly,
BACHD rats show mhtt deposits prominently expressed in axons
and synaptic terminals (Fig. 7). In contrast, other studies have sug-
gested that aggregation may exert beneficial effects by protecting
against polyglutamine toxicity, since the aggregation of N-terminal
htt reduces the amount of monomeric and oligomeric N-terminal
htt, which possesses a higher toxicity (Arrasate et al., 2004; Lajoie and
Snapp, 2010; Miller et al., 2010). In BACHD rats, numerous dark
degenerating neurons and dendrites were found in brain regions,
where prominent numbers of aggregates were present. Furthermore,
dark neurons and dendrites containing aggregates were frequently
observed together suggesting a connection between aggregate for-
mation and neurodegeneration. However, further studies would be
needed to investigate this association.
Figure 10. Progression of various phenotypes in BACHD TG5 rats. The findings of this study are summarized according to the
earliest onset or appearance of each phenotype.
Figure 9. Striosome abnormalities in the striatum of BACHD rats. The ROI is outlined by a dotted black line. A, Calbindin immunostained sections of WT, TG5, and TG9 rats at 6 months of age show
striosomes visible by faint calbindin staining (arrows and outlined by a continuous white line), while the intense staining visualizes the matrix surrounding the striosomes. Scale bar, 0.5 cm. B, The
total matrix area and number of striosomes was similar in WT, TG5, and TG9 rats. A significant decrease in both total (C) and mean striosome areas (D) was only observed in TG5 rats compared with
WT littermates. Data are expressed as means  SEM, *p  0.05.
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The striatum is composed of two interdependent compart-
ments: the striosome (patch) and the matrix, which can be dis-
tinguished by the differential expression of neurotransmitter-
related molecules (Goldman-Rakic, 1982; Graybiel et al., 1990;
Holt et al., 1997). Discriminative input and output connections
suggest that the striosome and matrix compartments participate
in limbic-based and sensorimotor/associative forebrain circuits,
respectively (Donoghue and Herkenham, 1986; Gerfen, 1992). In
HD patients, an imbalanced loss of neurons in the striosome and
matrix compartments has been described leading to a reduced
total matrix area whereas the volume of the striosome is not
affected (Ferrante et al., 1987; Seto-Ohshima et al., 1988; Hersch
and Ferrante, 1997). Conversely, it has also been reported that
this imbalance in neuron loss is initially found in the striosomes
but affects both compartments equally in later stages of the dis-
ease (Reiner et al., 1988; Hedreen and Folstein, 1995; Lawhorn et
al., 2008). Striosomes exchange information with the surround-
ing matrix, the integrated signal will be subsequently sent
through D1 (excitatory) and D2 (inhibitory) medium spiny neu-
rons (MSNs) via direct and indirect pathways to the thalamocor-
tical circuits. However, the striosome and matrix compartments
contain disproportionate amounts of D1 and D2 neurons and the
imbalance of those two compartments influence the proportion
of excitatory and inhibitory signaling in limbic-based and senso-
rimotor/associative forebrain circuits. Thus, a change in the es-
tablished equilibrium, as is the case in HD, causes a disorder of
the basal ganglia. In BACHD rats, we observed early changes in
the pattern of striosome and matrix compartments, as well as a
decrease in the total and mean striosome area. This could cause
alterations in the basal ganglia and lead to neuronal dysfunction
and clinical signs of HD. However, the exact mechanism behind
this is unknown and how this is linked to the neuropil aggregates
within the sensorimotor circuit and the limbic-based circuits still
needs to be answered.
In summary, we have developed a novel transgenic rat model
for Huntington disease, which expresses fl-mhtt with 97 polyQ
repeats under the control of the human htt promoter and regu-
latory elements. These BACHD rats display a robust, early onset
and progressive HD-like phenotype combined with characteris-
tic neuropathological features of Huntington disease making
them a valuable model for further understanding the disease
mechanisms and for preclinical pharmacological studies.
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Behavioral characterization is an important part of estab-
lishing novel animal models, but classical behavioral
tests struggle to reveal conclusive results due to prob-
lems with both reproducibility and validity. On the con-
trary, automated homecage observations are believed to
produce robust outcomes that relatemore to natural ani-
mal behavior. However, information on the behavior of
background strains from such observations, which could
provide important referencematerial, is rare. For this rea-
son, we compared the behavior of the commonly used
Lister Hooded, Lewis, Fischer 344 and Wistar rats during
70h of exposure to an automated homecage system at 2,
4 and 6months of age. We found considerable strain dif-
ferences in metabolic parameters, novelty-induced and
baseline activity-related behavior as well as differences
in the development of these parameters with age. The
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vantages of the system compared to classical behavioral
tests, as well as the system’s ability to recreate common
findings in literature.
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Detailed behavioral characterization is an important part of
establishing novel animal models in a variety of research
fields. For this purpose, the animals’ behavior is often
assessed in a range of classical behavioral tests such
as the open field, elevated plus maze or the Morris
water maze. Although this enables the comparison with
previously published results, there are known problems
with classical tests of this kind. Many classical tests are
based on running brief trials in non-homecage setups.
This enables the researcher to control many aspects of
the test, but it has also been suggested that the results
mainly reflect the confrontation with an unfamiliar situation
and environment rather than a baseline behavior (Tecott
& Nestler 2004). Furthermore, many classical tests rely
on non-standardized equipment and protocols. This low
level of standardization can lead to difficulties in replication
and generalization of study outcomes (Chesler et al. 2002;
Izídio et al. 2005; Mandillo et al. 2008; Tucci et al. 2006;
van der Staay & Steckler 2002; Vyssotski et al. 2002;
Wahlsten et al. 2003a,b). Finally, classical tests involve direct
handling of the animals by the experimenter prior to the test
session. The experimenter has been shown to influence the
outcome of some tests (Chesler et al. 2002) and might
be considered a source of variation, even if equipment
and procedures are carefully standardized (Crabbe et al.
1999).
Automated homecage observation has been promoted
to provide a good solution to the problems stated above
(Kas & van Ree 2004) and a series of systems for
computer-based acquisition of homecage activities of rats
and mice as well as analysis software are in use (e.g.
de Visser et al. 2006; Goulding et al. 2008; Hu¨bener et al.
2011; Jhuang et al. 2010; Voikar et al. 2010; Zarringhalam
et al. 2012). Such systems offer a standardized testing
environment, while also allowing standardized customization
to run specific protocols. As the animals are housed in
a homecage-like environment, their behavior is thought to
better reflect a natural state (de Visser et al. 2006; Tecott &
Nestler 2004). In addition, as the measurements are highly
computerized, behavioral data is gathered objectively. The
systems are further able to measure a broad spectrum of
behaviors including activity, food and water intake as well
as cognitive aspects. Thus, a well-functioning automated
homecage system could in theory be used for the complete
behavioral characterization of an animal model. But there
is currently a lack of literature on automated homecage
behavior of background strains, in contrast to classical
behavioral tests (e.g. Berton et al. 1997; Brooks et al.
2004, 2005; Richards et al. 2013; Wilhelm & Mitchell
2009). Studies that focus on the behavior of background
strains constitute important reference material and can aid
researchers in their choice of both background strain and
behavioral test setup. Due to this, we conducted a study
aimed at evaluating the practicality and sensitivity of an
automated behavioral testing system in differentiating the
four commonly used rat strains Lister Hooded, Lewis, Fischer
344 and Wistar.
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Figure 1: Rat strains. For our study, the common laboratory rat strains Lister Hooded (a), Lewis (b), Fischer 344 (c) and Wistar (d)
were obtained from Charles River Laboratories, Germany.
Animals and methods
Rats
We used 12 male rats from each of the four strains Lister Hooded
(Crl:LIS), Lewis (Crl:LEW), Fischer 344 (F344/DuCrl) and Wistar
(Crl:WI) (Fig. 1). The animals were obtained from Charles River
(Charles River Laboratories, ResearchModels and Services, Germany
GmbH, Sulzfeld, Germany) at the age of 4weeks.
All experiments were approved by the commission for animal
experiments at the Regierungspra¨sidium Tu¨bingen in accordance
with the guidelines of the German animal welfare act. The behavioral
experiments were all carried out by the same experimenter, trained
and experienced in laboratory animal research.
Housing conditions followed the recommendations of the
European Union (ETS 123 A). The environmental conditions in the
housing roomwere kept at 21–23◦C ambient temperature, 55± 10%
humidity and a 12/12 h light/dark cycle with lights off at 1400 h and
lights on at 0200h. Animals were kept in groups of four animals of
the same genotype in type IV autoclavable plastic cages with high lid
(38×55 cm wide, 24.5 cm high) (Fig. 2b). Cages contained 1000g of
autoclaved wooden bedding and were cleaned twice a week. Food
(ssniff V1534-000 standard rat chow) and tap water were delivered
ad libitum.
The animalswereweighed and inspectedweekly in order to assess
their general health status and accustom them to human handling.
The rats were given 2weeks of acclimatization in our animal facility
prior to the start of the experiments.
Measurements
Body weight
The animals were weighed weekly using a kitchen balance (accuracy
was ±1g) in order to record body weight development.
Body weight and body length at 10weeks of age
At 10weeks of age, we measured the body length and body weight
of the animals in order to assess differences in body size. For the
measurement of body length, the animals were briefly anesthetized
with isoflurane and the length from the tip of the nose to the base
of the tail (head-trunk length) was measured, using a ruler (accuracy
was ±0.1 cm).
Automated homecage observations
Measurements were carried out at the age of 2, 4 and 6months.
For this purpose, the animals were transferred to the testing cages,
where they were housed individually. The measurements started
40± 5min before the onset of the dark phase. Data were collected
in 20-min sample intervals during a total of 70 h of recording. The
animalswere assigned to one of the 12 cages in a pseudo-randomized
manner. Each run of 12 animals contained four animals from three
strains, respectively, so that each time point comprised four runs and
lasted 12 days in total.
During testing, the animals were inspected daily for proper food
and water intake and the system for accurate functioning.
In between runs, the system was cleaned thoroughly and new
bedding as well as fresh water and food pellets was supplied.
Automated homecage system
For the behavioral analysis, we used the automated homecage
system PHENOMASTER (PM) (TSE Systems, Bad Homburg, Germany)
(Fig. 2a) with the software version 1.3.7 (2010). Our customized
setup included a set of 12 homecage-like autoclavable plastic cages
(37.5×48 cm wide, 20 cm high) plus a reference cage. All cages
were equipped with a frame with infrared light beams for activity
detection (Actimot2, 302020 series). Our setup further included
metabolic units for measurement of water and food consumption
(Drink/Feed, 259980 series) and the analysis of respiratory gases
(CaloSys, 994600 series). For this purpose, the cages contained a
drinking bottle and a food basket suspended from high-precision
sensors. The cages were further sealed with an airtight plastic lid
containing an input tube for air supply and an output tube for gas
sampling.
Activity
Infrared light beams were installed at two different height levels
around the cage and spaced1.5 cm apart from each other. The lower
set was located at a height of 3 cm (2-month-old animals) or 4 cm
(4- and 6-month-old animals) to measure activity in the x- and y -axis
(locomotion). A higher set of beams at 8 cm (2-month-old animals)
or 12 cm (4- and 6-month-old animals) detected activity in the z-
axis (rearing). The height of the beams was initially evaluated using
Sprague Dawley rats. We decided on having fixed setups for all rat
strains, but differing between the ages, since the biggest difference
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Figure 2: PHENOMASTER metabolic cage and homecage. The homecage-like PM cages (a, c) differ from standard housing cages for
rats (b, d). Differences concern cage dimensions, constitution of the lid and presentation of water and food. The PM cages have a
moderately smaller floor area and a considerably lower height due to their flat lids. The airtight lids of the metabolic cages further
isolate the inner of the cage to a larger degree from the surroundings. Water and food bins are hanging lower than in the homecage
and the food baskets offer a substantially smaller surface for feeding.
in size did not occur between strains but between the youngsters at
2months of age and the adult animals at 4 and 6months of age. For
more accurate measurements, the amount of bedding placed in the
cages during the measurements was set to 250 g.
Locomotion was further subdivided into overall ambulatory activity
(ambulation), finemovements and ambulatory activity in the periphery
and the center of the cage. The system recorded a movement as
ambulatory activity, when three or more different light beams were
disrupted consecutively, whereas it was recorded as fine movement,
when adjacent light beams were disrupted alternately. In order to
analyze activity in specific parts of the cage, a peripheral and central
area was defined with the software. The center accounted for the
inner 16.5×12 cm (198 cm2) of the total 48× 37.5 cm (1800 cm2).
From this, we calculated the ratio of periphery to center activity
(per/cen). The sensors were scanning activity with a rate of 100Hz
and were programmed to a refractory period of 0.8 seconds. The
activity measurement relied on the number of beam breaks (counts)
made by the animal. It is important to note that as each animal was
always breaking several light beams at a given time, the number of
beam breaks was much higher than the number of events underlying
the recorded counts. The software also provided the option to count
all beam breaks detected at a time as one single event. However,
having it counted as only one event would disregard the quality (i.e.
duration, intensity) of the event. For this reason, we decided to have
all beam breaks counted separately.
Novelty-induced behavior
Analysis of activity levels during the first hour served as a measure
for the behavioral response to a novel environment. Ambulatory
and rearing activity were regarded as exploratory-related behaviors,
whereas per/cen was considered to be anxiety-related.
Water and food intake
Water and food intake was measured with high-precision sensors.
The water bottle contained 150ml of fresh tap water and the food
basket was loaded with 150 g of ssniff V1534-000 standard rat chow.
Water and food intake are given in ml per hour (ml/h) and g per hour
(g/h) or in ml per hour per kg of body weight (ml/h/kg) and g per
hour per kg of body weight (g/h/kg), respectively in order to account
for body weight differences between the individuals and the groups.
Containers were filled before the start of the measurement and the
amount of food and water was sufficient for the 70-h measurement.
A minimum consumption of 0.01ml of water and 0.01 g of food as
well as a maximum consumption of 0.1ml of water and 0.1 g of food
were set in order to exclude values caused through spillage or leaky
bottles.
Indirect calorimetry
In order to obtain data on respiratory gases, the PM cages were
fed with room air via an in-bound tube with a constant air flow of
1.8 l per min. Every 20min, an out-bound tube conducted 0.25 l of
sample air first to a cooling unit, where the sample was dried, and
further to the measuring unit containing O2- and CO2-electrodes.
Subtraction of the respective gas pressure from that of a reference
cage revealed the VO2 and VCO2 (carbon dioxide production). From
these values, the software further calculated the respiratory quotient
(RQ=VCO2/VO2). VO2 and RQ are only presented for the age of 2
and 4months, since a problem with the gas calibration occurred at
the last age.
Data analysis
Processing of raw data with R statistics
The PM software itself includes an analysis and graphing function.
However, in order to conduct a detailed statistical analysis, we
decided to export the data table and use additional software.
By means of R statistics (R: A Language and Environment for
Statistical Computing, R Development Core Team, R Foundation for
Statistical Computing, Vienna, Austria, 2011, ISBN 3-900051-07-0,
Genes, Brain and Behavior (2014) 13: 305–321 307
Clemens et al.
http://www.R-project.org), we developed a script that sorted the data
from all recordings according to animal number (1–12), study groups
(strains) and time point of measurement (age 2, 4 or 6months). From
this, it created either an hourly sum of the respective parameter
(ambulation, fine movements, rearing, per/cen) or an hourly mean
(VO2, RQ). The data were separated into a habituation period (first
hour of measurement) and a long-term measurement of additional
69 h. For this 3-day observation period, the script further calculated
mean values for light and dark phase separately.
Graphs
Graphs were created using GRAPHPAD PRISM 6.00. Illustrations on
the basis of photographic images were arranged with Adobe
Photoshop CS3.
Statistical analysis
For statistical evaluation of the development of the four strains
over time, we performed analyses of variance (ANOVA). Body size
at 10weeks of age was compared with a one-way ANOVA (ANOVA1)
and Tukey’s multiple comparison test (Tukey post-test), while all
the parameters obtained at more than one age were analyzed with
a repeated measurements two-way ANOVA (rmANOVA2). Differences
between strains in these parameters were investigated using
Tukey post-test. Age effects were analyzed with Dunnett’s multiple
comparisons test (Dunnett post-test), comparing the second and
third measurement to the first one. Body weight gain before and
during the PM were compared using Sidak’s multiple comparisons
test (Sidak’s post-test).
Statistics were performed with GRAPHPAD PRISM version 6.00
for Windows (GRAPHPAD Software, San Diego, CA, USA,
http://www.graphpad.com). Values given in the text refer to
group mean and standard deviation. The α-level was set to 0.05.
Respective P-values are given in the text or in the figures down to a
level of 0.0001 as reported by GRAPHPAD PRISM.
We excluded a total of 88 of 1968 data sets from the two-way
analysis of variance (ambulation (7/384), rearing (9/384), per/cen
activity (20/96), fine movements (2/144), drinking (16/144), feeding
(10/144)), because 88 out of the 5904 individual values in these
data sets were most likely erroneous due to hardware problems.
For activity, we found the system to register very high counts for
some animals. This might have been due to bedding that was shifted
around by the animal. We only excluded values that were more than
three times higher than the group mean and did not occur repeated
times for the same animal. Measuring per/cen activity revealed a
special problem: After the initial exploration of the test cages, we
found some of the rats to lie down and sleep, usually in a corner of
the cage, leading to low ambulatory activity counts in general and
even lower or zero activity counts for the central area. Thus, such
an animal displayed either a very high per/cen value or no value at
all in case of zero center activity. For food and water intake, it was
detected that drinking bottles were leaking from time to time (leading
to unreasonably high values for water intake) and the food got stuck
in the food basket, so that the animal was not able to reach it (leading
to unreasonably low values for food intake). For activity, drinking and
feeding, the values that were excluded are spread equally among
groups and testing cages, suggesting that they are not the result
of a systematic error or having a biological meaning. In contrary,
the number of values that had to be taken out of the analysis of
per/cen activity differ between rat strains and are clearly related to a
difference in behavior.
Results
Because of the large amount of data obtained, values for
group means and standard deviation as well as most of
the statistics obtained from post hoc analysis are listed in
separate tables. Only the statistical results from the ANOVAs
are given in the text, together with the description of the
results.
Part I: morphology
The four rat strains showed morphological differences. Lister
rats were the only pigmented rats, while the others were
albinos (Fig. 1).
Furthermore, there were differences in body weight and
size (Fig. 3). At 10weeks of age, body weight was highest
in Wistar followed by Lister and Lewis rats and Fischer rats
weighed least (F3,44= 106.3, P < 0.0001, Fig. 3a).
Similarly, body length at 10weeks of age was highest
in Wistar rats, Lister and Lewis rats were medium sized
and Fischer rats were smallest (F3,44= 57.12, P <0.0001,
Fig. 3b).
Further investigation showed that significant differences
between strains remained after relating body weight to body
length (F3,44= 79.93, P < 0.0001, Fig. 3c).
The weekly measurements of body weight revealed
significant differences between the strains (F3,44=178.6,
P < 0.0001) as well as a significant development of body
weight with age (F72,1056=70.68, P < 0.0001, Fig. 3d,e).
Wistar rats weighed significantly more than the other strains
at any time throughout the study, while the three other
strains did not differ at young ages. From 8weeks on, Fischer
rats showed a significantly lower body weight than all other
strains. At the age of 25weeks, Lister rats separated from
Lewis rats, with Lister being the heavier ones. The exact
level of significance for these comparisons varied with age
(Fig. 3e).
Part II: behavioral observations in the automated
homecages
As described above, we used an automatic homecage
system to monitor activity and metabolism in Lister, Wistar,
Lewis and Fischer rats. The rats’ behavior was assessed
during a 70-h experiment. The first hour of observation
was used to investigate the response to the novel
environment, while activity-related andmetabolic parameters
were followed for another 69 h. Group means and standard
deviation are given in Table 1 for activity-related parameters
and in Table 2 for metabolic parameters; P-values from post-
testing are displayed in Tables 3 (activity) and 4 (metabolism).
Novelty-induced behavior
The first hour of measurement
Ambulatory and rearing activity as well as the activity in the
periphery relative to the activity in the center of the cage
(per/cen) were analyzed during the first hour in the PM. Rats
showed a similar change in behavior during the first hour
at all ages (Fig. S1). For convenience, only the results from
2-month-old rats are displayed and discussed here (Fig. 4,
Table 1).
Ambulation decreased significantly from the first to the
second 20-min interval and remained at a low level during
the third 20-min interval in most animals (F2,88=47.95,
P < 0.0001, Fig. 4).
Rearing activity also decreased within the first hour of
observation (F2,88=15.14, P < 0.0001). However, this only
reached statistical significance for Lewis and Fischer rats,
although Lister andWistar rats also showed a gradual decline
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Figure 3: Body size. Body length (a), body weight (b) and weight/length ratio at 10weeks of age (c) as well as body weight
development from 4 to 28weeks of age (d) are shown for the four rat strains Lister, Wistar, Lewis and Fischer. The (a)–(c) show values
for individual animals with the group mean being indicated by a horizontal line. (d) Displays weekly mean and standard deviation for
the four rat strains. Statistics: ANOVA1 (a–c), P-values for group comparison are given as lowercase letters with one letter=P < 0.05,
two letters=P <0.01, three letters=P < 0.001, four letters=P < 0.0001 and meaning a= significantly different from Lister rats,
b= significantly different from Wistar rats, c= significantly different from Lewis rats and d= significantly different from Fischer rats.
rmANOVA2 (d–e), P-values for strain, time and strain*time differences (d) and P-values for the Bonferroni post-test (e) are given as
asterisks with *P < 0.05, **P <0.01, ***P < 0.001 and ****P < 0.0001. For the group comparison (e), the additional information on
the time point, the P-value was observed for is added (w=weeks).
in rearing (Fig. 4). Per/cen activity did not significantly change
during the first hour (Fig. 4).
It appeared that some animals decreased their ambulatory
and rearing activity to a very low level or even to zero within
the first hour. Observations by the experimenter revealed
that a part of the animals went to sleep after an initial
exploration of the cage. While no animals were found with a
particularly low activity during the first 20min, the number of
animals with a low level of activity differed between strains
during the following 40min. The frequency was highest for
Lewis rats (9/12), followed by Fischer (6/12) and Wistar rats
(4/12 animals), and did not occur at all in Lister rats.
Strain differences during the first 20min of testing
Because of the decrease in activity, which can be regarded as
habituation effect, only the behavior during the initial 20min
was used to assess differences in novelty-induced behavior
between the different rat strains.
Novelty-induced ambulation and rearing decreased
with age (ambulation: F2,88= 35.72, P < 0.0001; rearing:
F2,88= 39.60, P <0.0001, Fig. 5). Age also influenced
per/cen activity, with older rats showing a lower per/cen
ratio (F2,86= 25.59, P <0.0001, Fig. 5). Significant strain
differences were observed in all three parameters (ambu-
lation: F3,44= 4.571, P = 0.0072; rearing: F3,44=5.407,
P = 0.0030; per/cen: F3,43= 7.224, P = 0.0005). Post hoc
analysis indicated that these were mainly based on Lister
rats differing from the other strains in ambulatory and
rearing activity, while Lewis rats differed in per/cen activity.
Lister rats showed higher mean values for ambulatory
activity compared to the other strains at all ages. Significant
differences were found between Lister and Wistar rats at
2months (P < 0.05) and between Lister and Fischer rats at
6months of age (P <0.01, Fig. 5). Lister rats also appeared
to rear more than the other strains at 4 and 6months of age,
reaching statistical significance compared to Fischer rats at
4months (P < 0.01) and compared to Lewis (P < 0.05) and
Fischer rats (P < 0.05) at 6months of age (Fig. 5). Significant
differences in per/cen activity occurred between Lister and
Lewis rats at 2months (P <0.05) and 4months of age
(P < 0.05), whereat Lewis rats showed highest mean values
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for per/cen activity of all strains. However, we detected a
very high individual variability in this parameter (Fig. 5).
3-Day observation of activity-related and metabolic
parameters
Following the first hour of observation, the animals were
monitored for an additional 69-h period. Ambulation, fine
movements, rearing, water intake, food intake, VO2 and
RQ were assessed and analyzed for the overall three-day
observation as well as for light and dark phase separately.
Circadian rhythm
Time series analysis indicated that all rats showed a circadian
rhythm entrained by the 12/12 h dark/light cycle. In line with
this, all four rat strains showed higher levels of ambulation,
rearing, drinking, feeding, VO2 and RQ during the dark phase
compared to the light phase. Since the results were similar
for all parameters at all ages, only the data for ambulation are
displayed as an example (Figs. 6,S2).
Ambulatory activity
Total values for ambulation revealed moderate differences
between the rat strains (F3,43= 3.680, P = 0.0191), but
showed a clear age effect, with older animals having
a lower ambulatory activity (F2,86= 352.6, P < 0.0001) as
well as a significant strain difference in the influence of
age on ambulation (F6,86= 3.226, P = 0.0066, Fig. 7). Total
ambulatory activity was highest in Wistar and Fischer rats at
2months of age. No significant differences between strains
were detected at 4months of age, while Fischer rats were
again most active at 6months of age.
Separate analysis of light and dark phases revealed similar
significant age effects as seen for the total observation
period (F2,88= 172.1, light phase: P < 0.0001; dark phase:
F2,86= 147.5, P <0.0001) but showed highly significant
strain effects (light phase: F3,44=24.37, P < 0.0001; dark
phase: F3,43=9.793, P <0.0001) as well as strain*age
interactions (light phase: F6,88= 9.486, P < 0.0001; dark
phase: F6,86= 8.032, P <0.0001, Fig. 7). Strain differences
were based to a large degree on Lister rats, being
significantly more active during the light phase and in
turn less active during the dark phase at 2months
and 4months of age. Wistar rats on the other hand
were least active during the light phase, becoming
significantly different from Lister and Fischer rats at 6months
of age.
Fine movements
Analysis of the total amount of fine movements
revealed minor differences between strains (F3,43=3.401,
P = 0.0260, Fig. 7). Fine movements were also found to
decrease with age in all strains (F2,86= 180.5, P < 0.0001).
The development over time did not differ between strains.
Strain differences in fine movements resulted from an
increased amount in Fischer rats at 6months of age.
Analysis of the distribution of fine movements during
the light and dark phase revealed more pronounced
strain differences (light phase: F3,44= 13.89, P <0.0001;
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Automated homecage observation of wild type rat behavior
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Figure 4: Habituation to the PHENOMASTER cages. Ambulation, rearing and per/cen activity are shown for Listar, Wistar, Lewis and
Fischer rats during the first, second and third 20min time interval in the PHENOMASTER. Values are group mean and standard deviation of
the sum of beam break counts over 20min. Statistics: rmANOVA2, Dunnett’s post-test, P-values for the comparison of the second and
third 20-min time interval with the first 20-min time interval are given as lowercase letters (a= Lister rats, b=Wistar rats, c=Lewis
rats and d=Fischer rats) with one letter=P <0.05, two letters=P < 0.01, three letters=P <0.001 and four letters=P <0.0001.
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Figure 5: Novelty-induced behavior. Ambulation, rearing and per/cen activity are shown for Listar, Wistar, Lewis and Fischer rats
at the age of 2, 4 and 6months. Values are group mean and standard deviation of the sum of beam break counts over 20min.
Statistics: rmANOVA2, Dunnett’s post-test, P-values for the comparison of activity at 4 and 6months with the activity at 2months of
age are given as lowercase letters (a=Lister rats, b=Wistar rats, c= Lewis rats and d=Fischer rats) with one letter=P <0.05, two
letters=P <0.01, three letters=P < 0.001 and four letters=P < 0.0001.
dark phase: F3,43=10.85, P < 0.0001) and a significant
age effect (light phase: F2,88= 56.68, P <0.0001; dark
phase: F2,86= 146.4, P < 0.0001) as well as strain*age
interaction (light phase: F6,88= 8.242, P <0.0001; dark
phase: F6,86=6.015, P < 0.0001, Fig. 7). Lister rats showed
significantly more finemovements during the light phase and
less fine movements during the dark phase at 2months of
age. The increased total amount of finemovements found for
Fischer rats at 6months of age was based on a moderately
higher number of counts during the dark phase and a more
prominently higher number of counts during the light phase.
Rearing activity
Total rearing activity decreased with age (F2,84=178.7,
P < 0.0001) and the strains developed differently over time
(F6,84= 4.780, P < 0.0001) (Fig. 7). Strain differences were
present (F3,42=4.239, P = 0.0028), but appeared only at
2months of age according to post-test results. At that
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Figure 6: Ambulatory activity over the three observation days. Ambulatory activity is displayed as sum of counts per hour over
the 70-h observation period at 2months of age. Each point represents the group mean of Lister, Wistar, Lewis and Fischer rats. Error
bars are not shown in order to enable a better visual comparison. The dark phase is indicated by the black bars below the x-axis.
age, Wistar rats reared in total significantly more than the
other rats.
Looking at light and dark phase also revealed sig-
nificant differences between strains at 2months of
age (light phase: F3,42= 12.09, P < 0.0001; dark phase:
F3,43=5.626, P = 0.0002) as well as a significant age
effect (light phase: F2,84=131.7, P < 0.0001; dark phase:
F2,86=148.2, P <0.0001) as well as strain*age interac-
tion (light phase: F6,84= 3.848, P =0.0019; dark phase:
F6,86=8.497, P < 0.0001, Fig. 7). The higher total amount
of rearing found for Wistar rats at 2months of age, was
based on a significantly higher rearing activity during the
dark phase. Similar as it was found for ambulation and fine
movements, Lister rats reared more than the other strains
during the light phase at 2months of age. Fischer rats reared
least during the light phase.
Water intake
Total water intake differed significantly between strains
at each age (F3,37= 48.83, P <0.0001) (Fig. 8). It further
developed differently over time in the three rat strains
(F6,74= 5.626, P < 0.0001) with Wistar, Lewis and Fischer
rats showing a decrease in water consumption from 2 to
6months of age (mean difference in water intake between
2 and 6months Wistar: 22.4ml, P < 0.0001; Lewis: 11.9ml,
P >0.001; Fischer 13.9ml, P < 0.0001), while Lister rats
increased their water consumption from 2 to 4months of age
(mean difference in water intake between 2 and 4months:
−9.1ml, P <0.01). Strain differences in the overall amount
of water consumed during the 3-day experiment reflected
the differences in body size of the animals. In total, Wistar
rats drank significantly more than the other strains at all
ages. Lister and Lewis rats did not differ in their overall water
intake and Fischer rats drank least at any time.
The amount of water consumed during the light
and dark phase was also found to differ significantly
between strains (light phase: F3,37=33.10, P <0.0001;
dark phase: F3,37= 33.86, P < 0.0001) with a significant
effect of age (light phase: F2,74=45.78, P < 0.0001;
dark phase: F2,74= 15.46, P < 0.0001) and a significant
strain*age interaction (light phase: F6,74= 9.520, P < 0.0001;
dark phase: F6,74= 11.94, P <0.0001, Fig. 8). The strain
differences in total water intake were mostly recapitulated
in the results for dark phase water intake. During the light
phase, Lister rats had the highest water intake at all ages
and Wistar rats drank more than Lewis and Fischer rats at
4months of age.
Total water intake relative to body weight [ml/kg]
decreased with age in all strains (F2,74= 653.4, P < 0.0001),
but also showed differences in the exact development over
time between the strains (F6,74= 3.475, P = 0.0044, Fig. 8).
Strain differences in relative water intake resulted from
differences at 2months of age (F3,37= 6.165, P = 0.0017).
At that age, Lewis and Wistar rats consumed most, while
Fischer rats consumed least.
Relative water intake during light and dark phase both
decreased with age in all strains (light phase: F2,82=111.5,
P < 0.0001; dark phase: F2,76= 363.8, P < 0.0001), but not in
a similar manner (light phase: F6,82= 13.78, P < 0.0001; dark
phase: F6,76=16.91, P < 0.0001, Fig. 8). Strain differences
were found at 2months only (light phase: F3,41=22.48,
P < 0.0001; dark phase: F3,38= 10.66,P < 0.0001)with Lister
and Lewis rats consuming significantly more water relative
to body weight than Wistar rats, which in turn consumed
more than Fischer rats during the light phase. During the
dark phase, Lister rats drank the least amount of water per
kg body weight compared to the other strains.
Food intake
The three rat strains differed significantly in their total
food consumption (F3,40= 194.6, P < 0.0001, Fig. 8). The
strains further developed differently with age (F6,80=5.396,
P < 0.0001), with Wistar and Fischer rats decreasing their
food consumption from 2 to 6months of age (mean
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Figure 7: Light phase, dark phase and total amount of activity-related parameters. Ambulatory activity, fine movements and
rearing activity are given per light phase, dark phase and total 70-h observation period for Lister, Wistar, Lewis and Fischer rats. Each
data point represents group mean and standard deviation at 2months, 4months and 6months of age.
difference in food intake between 2 and 6months Wistar:
7.1 g, P < 0.01; Fischer 12.0 g, P < 0.0001), while Lister and
Lewis rats kept a constant consumption level (age effect:
F2,80=5.502, P = 0.0036). Strain differences in food intake
resembled body weight to a lesser degree than water intake:
At 2months of age, the results for food intake were in
accordance with body weight, with Wistar rats eating most,
Fischer rats eating least and Lister and Lewis rats eating the
same amount of food during the 3-day observation period.
At 4 and 6months of age though, the difference between
Wistar, Lister and Lewis rats disappeared due to the drop in
food intake in Wistar rats.
Significant strain differences appeared as well when
looking at light and dark phases separately (light
phase: F3,40= 33.73, P <0.0001; dark phase: F3,41=77.85,
P < 0.0001) with a significant effect of age on food
intake (light phase: F2,80= 10.05, P = 0.0001; dark phase:
F2,82= 6.121, P = 0.0033) and a significantly different devel-
opment of the strains with age (light phase: F6,80=6.431,
P < 0.0001; dark phase: F6,82= 13.85, P <0.0001, Fig. 8). As
it was found for water intake, food intake during the dark
phase was reflecting differences in total food consumption,
while during the light phase differences between groups
were smaller and were based on Lister rats eating most at
2months of age and Fischer rats eating least at all ages.
Food intake relative to body weight (g/kg) decreased
with age in all strains (F2,80= 1077, P < 0.0001) showing a
significant strain*age interaction (F6,80=13.20, P <0.0001,
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phase and total amount of
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Fig. 8). Lister and Lewis rats had a higher food intake
relative to body weight compared to Wistar rats at all ages
(F3,40= 49.98, P < 0.0001) and Wistar rats ate more than
Fischer rats at 2months of age.
The decrease in the relative amount of food intake (light
phase: F2,80= 259.2, P < 0.0001; dark phase: F2,82= 812.5,
P <0.0001) as well as the difference in strain*age inter-
action was also found for both light and dark phase (light
phase: F6,80= 4.425, P = 0.0007, dark phase: F2,82= 10.63,
P <0.0001, Fig. 8). At 2months of age, Lister rats showed
the highest relative food consumption during the light phase,
in accordance with their absolute amount of food intake;
at the same age, Lewis rats consumed more food than all
other strains, followed by Lister rats, while Fischer rats ate
least. Differences were less pronounced at older ages, but
mean values of Lister and particularly Lewis rats remained
above Wistar and Fischer rats.
VO2
The relative hourly consumption of oxygen (ml O2/kg/h)
showed significant strain differences (F3,44= 16.72,
P <0.0001; Fig. 8), a significant decrease of VO2 relative
to body weight with age (F1,44=1277, P <0.0001) and a
significant strain* age interaction (F3,44= 3.876, P < 0.0152).
Strain differences comprised a higher metabolic rate of
Lewis over Lister rats and in turn Lister over Wistar and
Fischer rats at 2months of age. At 4months of age,
metabolic rates converged, leaving only Lewis rats at a
slightly higher level.
Strain differences (light phase: F3,44= 20.16, P < 0.0001;
dark phase: F3,44= 12.68, P < 0.0001), age effect (light
phase: F1,44= 831.9, P <0.0001; dark phase: F1,44=1752,
P <0.0001) and strain*age interaction (light phase:
F3,44=6.73, P < 0.0008; dark phase: F3,44= 2.304,
P =0.0900) were also found for light and dark phase sep-
arately and were mainly based on differences at 2months
of age (Fig. 8). The higher VO2 of Lister rats resulted from
an increase during the light phase, while Lewis rats showed
high VO2 levels during both light and dark phase.
Respiratory quotient
Strains differed significantly in their mean RQ during the
experiment (F3,44= 23.82, P < 0.0001), based on Wistar rats
having a significantly lower RQ compared to all other strains
(Fig. 8). Respiratory quotient further decreased with age in
all strains (F1,44= 172.1, P <0.0001), but in a moderately
different manner (F3,44=4.8914, P < 0.0051).
Strain differences in RQ were also found during the light
(F3,44= 34.13, P <0.0001) and dark phase (F3,44=10.46,
P < 0.0001) and were consistent with the differences
observed for food intake (Fig. 8). Lister rats had a significantly
higher RQ during the light phase, while the RQ was
significantly reduced in Wistar rats during both light and
dark phase compared to the other strains. The decrease
of RQ with age was also present for light (F1,44=144.3,
P < 0.0001) and dark phase (F1,44= 98.61, P <0.0001)
with a moderate difference in strain*age interaction (light
phase: F3,44= 4.214, P < 0.0105; dark phase F3,44=2.984,
P < 0.0413).
Weight gain before and during the experiment
A comparison of the average weight gain one week prior to
the experiment with the weight gain during the experiment
revealed a significant drop in body weight gain during the
experiment in Wistar and Fischer rats (Wistar: F1,22=32.76;
P < 0.0001; Fischer: F1,22=41.74; P < 0.0001; Fig. 9). Lister
and Lewis rats seemed to be less affected in their weight gain
during the experiment, but showed a significantly decreased
weight gain at least at 4months of age (Lister: F1,18=17.25;
P = 0.0006; Lewis: F1,22= 8.671; P < 0.0075).
Discussion
The PHENOMASTER system
Automated homecage systems are of particular interest for
the behavioral phenotyping of laboratory animals, as these
systems are believed to provide more robust and valid
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measurements of behavior compared to classical tests. Our
study provides basic data on the behavior of four commonly
used rat strains in an automated homecage system and
reveals some important aspects to consider when using
such a system.
The PHENOMASTER system as replacement for other tests
The PM software offers the measurement of activity in
specific parts of the cage. In order to investigate, if these
measurements could provide a valid replacement for an
open field (OF) test, we measured ambulatory, rearing and
per/cen activity during the first 60min of testing. The drop
in ambulation and rearing after the first 20min indicates
that the animals initially explored and later habituated to the
test cage in a similar fashion as it would be expected in an
OF (Daenen et al. 2001; Hoy et al. 1999; Simon et al. 1994;
Thiel et al. 1999). Habituation behavior was also found in
a characterization study of a mouse model using both OF
and PM (Painsipp et al. 2008). In contrast to ambulation and
rearing, per/cen activity remained constant throughout the
first hour of measurement. Although there are indications of
habituation effects on similar parameters in the OF (Fonio
et al. 2012; Ossenkopp et al. 1994; Simon et al. 1994; Thiel
et al. 1999), it is at the moment unclear how the PM results
would relate to those, as the smaller size of the cages and
the presence of food and water baskets could affect the rats’
tendency for thigmotaxis (Eilam 2003; Russell & Williams
1973).
The PHENOMASTER as a homecage
A large part of the promotion of automated behavioral testing
systems such as the PM focuses on their homecage-like
aspects. It is believed that testing animals in a known
environment reduces stress and offers results that better
represent natural behavior (de Visser et al. 2006; Lipp et al.
2005; Tecott & Nestler 2004). However, the PM system
differs notably from the typical homecage environment in our
animal facilities. Themost profound difference is the demand
of single housing. Housing the animals individually is usually
avoided because of ethical considerations, but also because
it is known to influence performance in behavioral tests
(reviewed in Hall 1998; Lukkes et al. 2009). Other aspects
concern the cage setup itself. The airtight lids used in our
setup are lower than the lids of the actual homecages and
might therefore restrain rearing in old or big rats. Further, the
lids likely create different acoustic and olfactory conditions
compared to the homecages. Finally, food and water is not
provided in the same way as in a typical homecage. It might
be tempting to neglect these differences and consider the
conditions close enough to the normal homecage. However,
our measurements suggest that the rats experience some
form of stress during testing as indicated by the drop in
weight gain. Since this is a general phenomenon we observe
with both mouse and rat PM systems using different setups
in different animal facilities, it is an important issue for further
evaluation. Indeed, it is known from metabolic cages, where
the animals are also transferred to a different cage setup and
isolated for the duration of the test, that these conditions
are stressful to mice and rats (Gil et al. 1999; Kalliokoski
et al. 2013). From the current study, it cannot be concluded
whether the stress experienced during the PM experiment
is a result of the testing conditions per se or rather due
to the change in housing conditions. Thus it is possible that
keeping the rats in the PM system constantly, or adapting the
homecages to better approximate the PM setup, might avoid
a stress response. However, as either option would include
long-term social isolation, obtained data wouldmost likely not
reflect the natural behavior of a social animal. In this regard,
it might be better to work with other automated homecage
systems like the commercially available PhenoTyper (Noldus
Information Technology, Wageningen, The Netherlands) or
IntelliCage (NewBehavior AG, Zurich, Switzerland), which
allow the assessment of group-housed animals.
Comparison of four common background rat strains
Novelty-induced behavior
The first 20min of exposure to the PM cages could constitute
a replacement at least for the activity parameter of an
OF. Our results indicate that Lister rats are generally more
active in terms of total ambulation and rearing counts. These
findings might reflect a general trait among pigmented rats,
suggesting that they are exploratory rather than anxious
when exposed to a new environment (Broersen & Uylings
1999; Onaivi et al. 1992; Ramos et al. 1997; Rex et al. 1996;
van der Staay et al. 1996, 2009; Weiss et al. 2000). Although
post hoc analysis did not reveal significant strain differences,
per/cen ratio indicated that Lewis rats had a stronger
preference for sticking to the periphery of the PM cages.
However, Lewis rats also showed the steepest decline
in ambulatory activity and the highest number of animals
with almost no ambulatory and rearing activity after the
initial 20min. Thus, we conclude that the high per/cen ratio
might have resulted rather from a reduced exploratory activity
than from increased anxiety, again pointing to difficulties in
using the PM for the assessment of anxiety parameters.
Accordingly, Lewis rats have previously been found to
be less explorative (Rex et al. 1996) and either more or
equally anxious compared to Fischer rats (Chaouloff et al.
1995; van der Staay et al. 2009). However, it is important
to note that different anxiety tests are known to reveal
different phenotypes and comparisons to classical anxiety
tests might at this time be premature. A more thorough
investigation of the per/cen measurement and potential
anxiogenic factors of the PM system must be made to
provide better understanding of which studies it can be
expected to replicate.
3-Day observation period
The data obtained from each 3-day test period were divided
into light phase, dark phase and total activity. The total
values for ambulation, fine movement and rearing did not
reveal any consistent differences between the rat strains.
However, when analyzing light and dark phase separately,
it became apparent that Lister rats were more active in all
three parameters during the day. Furthermore, they showed
the least amount of activity during the night. This finding is in
line with a comparative study on behavioral pharmacology,
revealing a higher diurnal and lower nocturnal homecage
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locomotor activity during a 24-h observation in Lister Hooded
compared to Sprague Dawley and Wistar rats (McDermott &
Kelly 2008). As the total level of activity was largely similar
between Lister rats and the other strains, this indicates that
Lister rats have a different circadian rhythm of activity.
Drinking and feeding differed significantly between the
rat strains, and absolute values seemed to recapitulate
differences in body size. However, looking at food and
water intake relative to body weight revealed that Wistar
and Fischer rats ate less than the others. Comparing
weight gain before and during testing further showed that
Wistar and Fischer rats did not grow properly during PM
exposure. Accordingly, oxygen consumption, and even more
meaningful respiratory quotient, was lower in Wistar rats
compared to the other strains, pointing to inappropriate food
supply. Lewis rats had the highestmetabolic rate and showed
the least effect on bodyweight gain during the test, indicating
them to be least affected by the testing conditions. This idea
is supported by literature on Lewis rats being less susceptible
to stress due to physiological alterations (Chaouloff et al.
1995; Dhabhar et al. 1993). Lister rats once again showed
higher diurnal activity in food and water intake and
consistently in oxygen consumption and RQ, which further
reinforces the differences seen in their activity pattern.
Summary notes
Automated homecage observation has been promoted as
a powerful tool to study animal behavior. The essential
advantage lies in the possibility to assess behavioral
parameters over long periods of time, which in turn enables
analysis across circadian phases as well as separate analysis
of both novelty-induced and baseline homecage behavior.
In this study, data on the behavior of wild type rat strains
was collected with the commercially available automated
homecage system PHENOMASTER. The first hour of observation
revealed strain differences in novelty-induced behavior,
which recreate common findings in literature. In a following
3-day observation period, further differences in circadian
activities were identified, which offer new results that can
be a useful reference for further studies.
It has to be noted that although the system allowed for
minimal animal handling, a range of other stressors appeared
to be present. Thus, further investigation is needed in order to
establish optimal protocols for behavioral assessment, and
to better judge the potential of the PM system.
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Abstract
In Huntington disease (HD), there is increasing evidence for a link between mutant huntingtin expression,
mitochondrial dysfunction, energetic deficits and neurodegeneration but the precise nature, causes and order of
these events remain to be determined. In this work, our objective was to evaluate mitochondrial respiratory function
in intact, non-permeabilized, neurons derived from a transgenic rat model for HD compared to their wild type
littermates by measuring oxygen consumption rates and extracellular acidification rates. Although HD striatal neurons
had similar respiratory capacity as those from their wild-type littermates when they were incubated in rich medium
containing a supra-physiological glucose concentration (25 mM), pyruvate and amino acids, respiratory defects
emerged when cells were incubated in media containing only a physiological cerebral level of glucose (2.5 mM).
According to the concept that glucose is not the sole substrate used by the brain for neuronal energy production, we
provide evidence that primary neurons can use lactate as well as pyruvate to fuel the mitochondrial respiratory chain.
In contrast to glucose, we found no major deficits in HD striatal neurons’ capacity to use pyruvate as a respiratory
substrate compared to wild type littermates. Additionally, we used extracellular acidification rates to confirm a
reduction in anaerobic glycolysis in the same cells. Interestingly, the metabolic disturbances observed in striatal
neurons were not seen in primary cortical neurons, a brain region affected in later stages of HD. In conclusion, our
results argue for a dysfunction in glycolysis, which might precede any defects in the respiratory chain itself, and these
are early events in the onset of disease.
Citation: Gouarné C, Tardif G, Tracz J, Latyszenok V, Michaud M, et al. (2013) Early Deficits in Glycolysis Are Specific to Striatal Neurons from a Rat
Model of Huntington Disease. PLoS ONE 8(11): e81528. doi:10.1371/journal.pone.0081528
Editor: Hemachandra Reddy, Oregon Health & Science University, United States of America
Received May 22, 2013; Accepted October 14, 2013; Published November 26, 2013
Copyright: © 2013 Caroline Gouarné. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which
permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: Funding was provided by Trophos and by the European Union under the 7th Framework Program for RTD - Project MitoTarget - Grant
Agreement HEALTH-F2-2008-223388. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the
manuscript.
Competing interests: The authors have the following interests. This study was partly funded by Trophos, the employer of CG, GT, JT, VL, MM, TB and
RMP and who hold Trophos shares or stock options. There are no patents, products in development or marketed products to declare. This does not alter
the authors' adherence to all the PLOS ONE policies on sharing data and materials, as detailed online in the guide for authors.
* E-mail: rpruss@trophos.com
Introduction
Huntington disease (HD) is a hereditary neurodegenerative
disorder caused by a CAG repeat extension in the coding
region of the huntingtin gene, leading to striatal atrophy which
later expands to the cerebral cortex and other subcortical brain
regions [1,2]. Clinically, the disease is characterized by
psychiatric symptoms, movement disorders, progressive
dementia and also by pronounced weight loss despite
sustained caloric intake [3] supporting to the hypothesis of
impaired ATP synthesis in HD [4,5]. This was further confirmed
by the detection of significant alterations in the glucose
concentration by brain imaging [6-8] and in the concentration of
energetic metabolites (mainly N-acetylaspartate, glutamine/
glutamate, and lactate) in brain or in the cerebrospinal fluid of
HD patients [9-15]. Whether this results from reduced
mitochondrial ATP synthesis and/or reduced glycolytic ATP
levels is not known. The observation of a severe reduction in
the activity of the mitochondrial respiratory chain complexes
II/III and a milder reduction in the activity of complex IV in the
caudate/putamen from post-mortem brain samples suggested
that mitochondrial abnormalities may underlie HD pathogenesis
[16-18]. However, whether respiratory chain impairment is the
cause or the consequence of neuronal loss in HD remains
unclear, since such defects were not observed in pre-
symptomatic patients [19,20].
To further address the precise nature and the role of
metabolic and mitochondrial dysfunction in HD, studies were
performed in genetic models of HD, particularly in mice
expressing full-length mutant huntingtin (fl-mHtt). As observed
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in pre-symptomatic and early HD patients, no major impairment
in the enzymatic activity of the mitochondrial respiratory chain
complexes I–IV was evidenced in either the striatum or the
sensorimotor cortex of these mice [19]. By contrast, deficits in
respiration rate and ATP production reported in STHdh Q111
striatal cell lines derived from knock-in mice with 111 CAG
repeats introduced into the mouse HTT homologue Hdh
[21-23]. However, the impairment could not be assigned to
defects in individual respiratory complexes in these cells.
Moreover, differences in mitochondrial respiratory rates were
no longer present when using isolated mitochondria from the
same cell lines [24], suggesting that detection of some
mitochondria deficits may only be detected in intact cells. In
that sense, Oliveira and colleagues measured mitochondrial
respiratory rates in intact, non-permeabilized, primary striatal
neurons from Hdh150 knock-in mice and did not find any deficit
under resting condition when compared to wild type controls
[25]. However, when challenged with an energy-demanding
stimulus (NMDA-receptor activation) and incubated in
pyruvate-based media to accentuate mitochondrial metabolism,
Hdh150 neurons were more vulnerable to calcium overload
than neurons from their wild-type littermates [26]. These results
highlight the importance of assessing mitochondrial function in
the cellular environment including both neuronal cell bodies
and neurites. It is also important to survey the use of various
glycolytic and oxidative substrates to better understand how
cells cope with metabolic demands in situ.
To pursue these questions, we investigated mitochondrial
respiration in specific primary neuronal subpopulations cultured
from a new HD transgenic rat model expressing fl-mHtt and all
regulatory elements integrated from a bacterial artificial
chromosome (BACHD rats). These rats display a robust, earlier
onset and faster progressive HD-like phenotype even in
heterozygous transgenic rats compared to previously described
HD rats expressing a mHtt fragment [27]. Oxygen consumption
rates and anaerobic glycolysis were measured using a variety
of substrates in situ, directly in the culture well, preserving the
neuronal network integrity.
Materials and Methods
Ethics statement
All experiments were approved and performed in accordance
with internal institutional guidelines; Trophos is an accredited
institution for animal experimentation in France (French
ministry of Agriculture, Agreements No. B-13-055-15) and in
strict accordance with national and European regulations
(Directive 86/609/EEC of the European Economic Community
regarding the protection of animals used for experimental and
other scientific purposes). All efforts were made to avoid or
minimize animal suffering and to reduce and refine the
experimentation.
Animals
Male heterozygous transgenic BACHD rats (HD) expressing
high levels of fl-mHtt protein containing 97 CAG/CAA repeats
(line LY.005) [27] were bred with female wild type (WT) rats
obtained from Elevage Janvier (Le Genest Saint Isle, France).
The rats were housed in a controlled environment (room
temperature 22°C ± 2; reverse 12h light dark cycle, 50% ± 5
humidity) with food and water available ad libitum. Pregnant
female rats were euthanized at embryonic day 17 (E17) by
gradual fill CO2 overdose. Rats were placed in a hermetic box
then exposed to a mixture of O2/CO2 (40-60% respectively)
until sleep was induced. The % CO2 was then progressively
increased up to 100% while O2 was decreased (0.5L/min every
30 sec. for 3 min up to 5L/min) and then maintained for 4-5
min.
Genotype identification
Rat embryos from a single pregnant female rat were used for
each independent experiment. All embryos were genotyped to
identify WT and HD animals. During genotyping, brains were
maintained in Hibernate® conservation medium (BrainBits) at
4°C. The embryos were genotyped with a PCR-based assay
using DNA from tail tissue. The mHTT gene product was
detected using the primers 5’-
ATGGCGACCCTGGAAAAGCTG-3’ and 5‘-
AGGTCGGTGCAGAGGCTCCTC-3’ (Eurofins). PCR
conditions were: 30 cycles at 94°C (30 s), 60°C (30 s), 72°C (1
min).
Primary neuronal cultures
E17 primary striatal neurons were prepared by an adapted
method previously described [28]. Briefly, striata were
thoroughly minced into 1 mm sections, washed in HBSS
medium (Invitrogen) complemented with 7 mM HEPES
(Invitrogen) and 0.45% glucose (w/v) (Sigma) and incubated for
15 min at 37°C with 0.25% of trypsin (Invitrogen). The tissues
were mechanically dissociated by several pipetting and
centrifugation steps (5 min at 250 x g). Primary striatal neurons
were seeded onto poly-ornithine (Invitrogen) and laminin (BD)
coated Seahorse 24-well plates at a density of 150,000 cells/
well in Neurobasal™ media (Invitrogen), complemented with
2% B-27 supplement (Gibco) and 1 mM pyruvate (Invitrogen).
The two cell populations (WT and HD) were seeded in different
wells of the same plate with 4 to 8 replicates per plate
depending on the protocol. The cells were incubated for 7 days
at 37°C in a humidified incubator in an atmosphere of 95% O2,
5% CO2. E17 primary cortical neurons were prepared using a
similar protocol and seeded at a density of 110,000 cells/well.
Striatal and cortical neuronal culture purity was controlled by
immunofluorescence using NeuN antibody (Millipore) to identify
neurons, GFAP (Millipore) for astrocytes and F4/80 (Santa
Cruz) for microglial cells. Both striatal and cortical neuronal
cultures were 98% pure. The presence of mHtt, already in the
form of aggregates, was confirmed in primary striatal and
cortical neuronal cultures derived from HD rats (see in Protocol
S1 and Figure S1).
Oxygen consumption rate and extracellular
acidification rate measurements-
Cellular oxygen consumption and extracellular acidification
rate (ECAR) reflecting lactate release were concomitantly
measured using a XF24 extracellular flux analyzer (Seahorse
Bioscience) as previously described [29].
Metabolic Deficits in HD Primary Striatal Neurons
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Respiration experiments in substrate-rich medium
Experiments in substrate-rich media were performed using
Dulbecco’s Modified Eagle’s Medium (DMEM) containing 25
mM glucose without bicarbonate (Invitrogen) and
complemented with 1 mM fresh pyruvate (assay medium). One
hour before the start of the respiration measurements, the
original culture medium was replaced by assay medium and
plates were placed into the XF analyzer calibrated at 37°C.
After 10 min of equilibration, OCR was measured for 1.5 min to
establish a baseline rate. The medium was then gently mixed
for 2 min followed by a 3 min pause to restore normal oxygen
tension in the microenvironment surrounding the cells. After
baseline measurements, oligomycin (final concentration 0.5
µg/ml) (Sigma) was injected into each well in order to inhibit
mitochondrial ATP synthase to determine proton leak-
dependent OCR (State 4o). After this, the uncoupling agent
carbonilcyanide p-triflouromethoxyphenylhydrazone (FCCP;
final concentration 2 µM) (Sigma) was injected to determine
maximal OCR (state 3u). Finally, rotenone (final concentration
75 nM) (Sigma) and antimycin A (final concentration 150 ng/ml)
(Sigma) were injected to inhibit complex 1 and complex 3
respectively and to completely abolish mitochondrial
respiration. After each injection step, two measurement cycles
(measurement + mix + pause) were performed (Figure 1) and
after rotenone and antimycin A injection, 4 measurement
cycles were performed. Preliminary experiments determined
the optimal concentration of these agents to optimally inhibit or
stimulate respiration without inducing toxicity.
Substrate-dependent respiration experiments
To assay the ability of different substrates to support
respiration, experiments were designed using a simple
substrate-free modified Krebs Henseleit Buffer (KHB) (NaCl
111 mM, KCl 4.7 mM, MgSO4 2 mM, Na2HPO4 1.2 mM, pH
7.4), complemented with 2 mM GlutaMAX™ (Invitrogen). One
hour before the start of the assay, the original culture medium
was replaced by KHB and the plates were placed in an
incubator at 37°C without CO2 and then in the XF analyzer.
After 10 min of equilibration in the instrument, OCR was
measured for 1.5 min to establish a substrate free basal rate.
Medium was then gently mixed for 2 min followed by a 3 min
pause to restore normal oxygen tension in the
microenvironment surrounding the cells. After baseline
measurements, the substrates D-glucose (Sigma), pyruvate
(Sigma) or lactate (Sigma) were injected and OCR was
measured for 1.5 min followed by injections of oligomycin,
FCCP and rotenone plus antimycin A as described above. After
each injection, two or three measurement cycles
(measurement + mix + pause) were performed.
Respiration parameters calculation
When oxygen consumption rate measurements ended, cells
were incubated for 20 minutes with 2 µg/ml calcein-AM to
measure the relative neuronal cell density and viability in each
well. Only experiments with a similar cell density based on
calcein fluorescence between WT and HD (Student’s t test p >
0.05) were validated and analyzed. Respiration parameters
were calculated from data obtained during the steps of OCR
measurement. For basal respiration and oligomycin respiration,
the last OCR measurement of the cycle was selected for
calculation. For FCCP the first OCR measurement of the cycle
was selected to avoid the effect of substrates depletion on
maximal OCR. For further details please refer to the legend of
the respective figures. Because non-mitochondrial oxygen
consumption rate (measured after antimycin A injection) was
overestimated due to the fact that FCCP injection activated
non-mitochondrial oxidase and because the rate was negligible
(according to preliminary assays), we decided to not remove
non-mitochondrial OCR from all measurements. Cell
respiratory control ratio (RCR) was calculated by dividing the
maximal rate (uncoupled) by the oligomycin rate (proton leak).
Spare respiratory capacity was calculated by subtracting the
basal rate from the maximal (uncoupled) rate. Coupling
efficiency was calculated by dividing the fraction of basal
mitochondrial oxygen consumption used for ATP synthesis
(basal rate minus oligomycin rate) by the basal rate. The
substrate response was determined by dividing the OCR
obtained after substrate addition (glucose, pyruvate, lactate, or
combinations) by the substrate-free basal rate in KHB.
Statistical analysis
Data are expressed as means ± SEM. Comparisons
between two groups were performed using an unpaired
Student’s t test. Comparisons of several groups or differences
between treatments and experimental groups were conducted
using a one way or two way analysis of variance (ANOVA)
followed by Dunnett’s post test. A p-value of less than 0.05 was
considered statistically significant.
Results
Characterization of WT and HD striatal neuron
respiration in substrate-rich medium
E17 primary striatal neurons from HD and WT rat embryos
were cultured for 7 days in Neurobasal™ medium and then
placed in DMEM with similar concentrations of amino acids,
vitamins and glucose (25 mM) to measure OCR. Their
response to the respiration analysis paradigm in substrate rich
medium is shown in Figure 1A. Basal OCR is strongly
controlled by ATP turnover and to a lesser extent by substrate
oxidation and proton leak [30]. Addition of oligomycin induced a
decrease in OCR and under this condition (state 4o),
respiration is strongly controlled by proton leak kinetics and
partially by substrate oxidation [30]. In contrast, OCR sensitive
to oligomycin is strongly driven by the proton flux
accompanying ATP synthesis. Addition of the uncoupler
(FCCP) caused an increase in OCR until the maximum
respiration rate was reached (state3u). This respiratory rate
reflects the maximal respiratory chain activity as well as the
maximal substrate oxidation rate that is achievable [30]. Finally,
addition of rotenone (complex 1 inhibitor) and antimycin A
(complex 3 inhibitor) totally blocked the respiratory chain and
the residual OCR represented non-mitochondrial respiration,
probably driven by NADPH oxidase activity [30]. In these
experiments performed in substrate rich DMEM, no differences
in OCR or respiratory parameters were detectable between WT
Metabolic Deficits in HD Primary Striatal Neurons
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Figure 1.  No differences in respiratory parameters are detected between HD and WT striatal neurons incubated in
substrate-rich medium.  OCR measurements were performed in bicarbonate- and HEPES-free DMEM containing 25 mM glucose
complemented with pyruvate (1 mM) and began 10 min after cell plate installation in the Seahorse analyser. A) OCR was measured
sequentially in basal conditions (time points 1-3), after injections of oligomycin (oligo; time points 4 and 5), FCCP (time points 6 and
7), rotenone (time points 8 and 9) and then antimycin A (AA; time points 10 and 11) at the indicated times. Data shown are mean ±
SEM from a representative experiment (eight replicates). Respiratory parameters were derived from OCR measured during each
phase of the experiment as shown in A: B) respiratory control ratio = [FCCP rate (time point 6) / oligo rate (time point 5)]; C)
coupling efficiency = [basal rate (time point 3) – oligo rate (time point 5)] / basal rate (time point 3); D) spare respiratory capacity =
[FCCP rate (time point 6) – basal rate (time point 3)]. Respiratory parameters shown in panels B-D are mean ± SEM calculated from
all replicates (eight replicates in each of three independent experiments).
doi: 10.1371/journal.pone.0081528.g001
Metabolic Deficits in HD Primary Striatal Neurons
PLOS ONE | www.plosone.org 4 November 2013 | Volume 8 | Issue 11 | e81528
and HD striatal neurons (Figure 1). Similarly, HD striatal
neurons showed no deficits in RCR, which detects substrate
oxidation efficiency and respiration due to proton leak, but not
driven by ATP synthesis (Figure 1B), coupling efficiency, which
is strongly controlled by ATP turnover and proton leak (Figure
1C) or spare respiratory capacity, which reflects the capacity of
the respiratory chain to respond to an increase in energy
demand and the ability of substrates to provide fuel (Figure
1D).
Glucose supported respiration in striatal neurons
In first experiments, the medium used to measure respiration
contained 25 mM glucose to mimic their original culture
conditions. This is a high, supra-physiological concentration
compared to the glucose concentrations found in brain that are
estimated to be around 2.5 mM in rats [31]. To check whether
there was any difference in the ability of HD striatal neurons to
use more physiological levels of glucose as well as various
other substrates to support oxidative phosphorylation, we
performed a series of experiments adding specific substrates to
cells incubated in KHB. Different concentrations of glucose
were injected (final concentrations of 2.5 - 25 mM) followed by
oligomycin, FCCP, and rotenone + antimycin A injections
(Figure 2A). In the absence of glucose, neurons were able to
maintain basal respiration but they were not able to respond to
FCCP stimulation (Figure 2A). All concentrations of glucose
between 2.5 and 25 mM induced a similar increase in basal
OCR (Figure 2B) but even though basal respiration was similar
in the presence of physiological and supra-physiological
glucose concentrations (Figure 2B), FCCP-stimulated
respiration and RCR were glucose-concentration dependent
(Figure 2C). These results suggest that the physiological
glucose concentration found in brain, although sufficient to
support respiration under basal conditions (low energy
demand) may be limiting under conditions of high respiratory
demand.
Neurons can use lactate and pyruvate to support
respiration
Increasing evidence supports the idea that glucose is not the
sole energy substrate for neurons in the brain. Oxidative
substrates such as pyruvate or even lactate provided by glial
cells could be supplementary fuel for neurons [32]. Results
presented in Figure 3 reinforced this hypothesis. WT neurons
were incubated for 1 hour in KHB medium lacking metabolic
substrates then provided with various concentrations of
pyruvate (Figure 3A) or lactate (Figure 3B). Then respiratory
parameters were derived following injection of oligomycin,
FCCP, and rotenone + antimycin A. As observed in the
previous study assaying the response to glucose, in the
absence of substrates, neurons were able to maintain basal
respiration but were not able to respond to FCCP stimulation
(Figure 3A; 3B). Addition of either pyruvate or lactate increased
basal respiration as previously seen with glucose and restored
the neurons’ capacity to respond to FCCP stimulation (Figure
3A, 3B). In the case of pyruvate, a similar basal respiration rate
was detected over the concentration range tested (1-30 mM)
but maximal respiration and RCR reached a plateau between 1
and 10 mM (Figure 3A, 3C, 3E). Addition of 1 or 10 mM lactate
resulted in a similar basal respiration rate, which was
significantly increased in the presence of 30 mM lactate (Figure
3B-F). FCCP stimulated respiration was also supported by
lactate but to a lesser extent than pyruvate. This can be
explained by the observation that 30 mM lactate induced a
significant increase in proton leak respiration in addition to ATP
synthesis-driven respiration (Figure 3G). This was not the case
for 30 mM pyruvate (Figure 3D). Because 30 mM lactate
increased mitochondrial proton leak, potentially disturbing
mitochondrial function, this concentration was not considered in
further analysis of RCR as a function of pyruvate and lactate
concentrations (Figure 3I). We observed a concentration-
dependent increase in RCR for both lactate and pyruvate,
plateauing at 10 mM for pyruvate. Comparing the RCR
between 10 mM pyruvate and lactate shows that pyruvate is
clearly a better substrate, most likely due to the fact that lactate
must first be converted to pyruvate.
Comparison of respiratory parameters in WT and HD
striatal neurons in the presence of a physiological
glucose concentration
To see whether there is any difference in the capacity of WT
and HD striatal neurons to use physiological glucose
concentrations, OCR was measured in KHB as shown in
Figure 2. First, OCR was measured after one hour of substrate
deprivation. Although there were some differences noted
during the equilibration period seen in some experiments,
overall, there were little or no significant differences detected
between the two genotypes following more than one hour in
this challenging condition, suggesting that intracellular
substrates and neurons’ capacity to mobilize them were similar
between WT and HD striatal neurons (Figure 4A). Furthermore,
as observed in Figure 2, addition of 2.5 mM glucose increased
OCR to a similar basal level in both WT and HD striatal
neurons (Figure 4A) and oligomycin injection induced a similar
reduction in OCR and in proton leak respiration in the two
genotypes (Figure 4A). These results show that there is no
underlying mitochondrial dysfunction in HD striatal neurons or
their ability to use glucose to support basal respiration and ATP
synthesis. By contrast, when respiration was stimulated with
FCCP, OCR deficits associated with lower RCR and spare
respiratory capacity were detected in HD striatal neurons
compared to WT (Figure 4B, 4C), suggesting mitochondrial
respiratory chain dysfunction and/or a defect in glucose
metabolism that generates pyruvate (glycolysis) under
stimulated conditions.
Respiration in WT and HD striatal neurons supported
by pyruvate or lactate
We also evaluated HD and WT striatal neurons’ capacity to
use alternative substrates, pyruvate and lactate according the
protocol set up in Figure 3. The concentration chosen for this
exploration was 10 mM for each substrate, which was the
concentration inducing the maximal OCR response under
stimulated conditions without causing proton leak. As
previously shown in Figure 4, after more than one hour of
substrate deprivation, OCR was similar between WT and HD
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Figure 2.  Respiration parameters measured in WT striatal neurons as a function of glucose concentration.  On the day of
the respiration experiments, medium was replaced with substrate-free KHB and cells were incubated for 1 h at 37°C. OCR
measurements began 10 min after cell plate installation in the Seahorse analyser. A) After measuring the initial OCR in the absence
of substrates, various concentrations of glucose in KHB (vehicle; Veh) were injected (final concentrations: 0, 2.5, 5 or 25 mM). OCR
was then measured in the presence of substrate and following successive injections of oligomycin (oligo), FCCP, then rotenone and
antimycin A (rot + AA) at the indicated times. Data are expressed as the percentage of the basal value measured at the time point 3
(four replicates). § p < 0.05, §§ p < 0.01, §§§ p < 0.001 (0 mM vs. 2.5 mM glucose); # p < 0.05, ## p < 0.01, ### p < 0.001 (0 mM
vs. 5 mM glucose); * p < 0.05, ** p < 0.01, ***p < 0.001 (0 mM vs. 25 mM glucose). Respiratory parameters were derived from OCR
measured during each of these phases; B) glucose response = [basal glucose rate (time point 6) / basal free substrate rate (time
point 3)]; C) respiratory control ratio = [FCCP rate (time point 9) / oligomycin rate (time point 8)]. * p < 0.05 compared to 2.5 mM
glucose.
doi: 10.1371/journal.pone.0081528.g002
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neurons (Figure 5A, 5D). Pyruvate addition induced a
significant increase in basal OCR and restored neurons’
capacity to respond to FCCP (Figure 5A). No significant
differences were detected in HD striatal neurons compared to
WT (Figure 5A-C). Lactate addition induced a similar increase
in basal OCR as pyruvate, which was again not different
between WT and HD neurons (Figure 5D). Even though
respiration in the presence of 10 mM lactate was similar or only
slightly lower in HD neurons, the resulting RCR and spare
respiratory capacity appeared to be significantly lower in
FCCP-stimulated HD neurons compare to WT (Figure 5E-F).
Figure 3.  Striatal neurons can use alternative substrates to glucose to support respiration.  On the day of the respiration
experiments, medium was replaced with substrate-free KHB and cells were incubated as described in Figure 2. After measuring the
initial OCR in the absence of substrates, various concentrations of pyruvate (A) or lactate (B) in KHB (vehicle; Veh) were injected
(final concentrations: 0, 1, 10 or 30 mM). OCR was then measured in the presence of substrate and following successive injections
of oligomycin (oligo), FCCP, then rotenone and antimycin A (rot + AA) at the indicated times. Data are expressed as the percentage
of the basal value measured at time point 3 (four replicates). § p < 0.05, §§ p < 0.01, §§§ p < 0.001 (0 mM vs. 1 mM pyruvate or
lactate); # p < 0.05, ## p < 0.01, ### p < 0.001 (0 mM vs. 10 mM pyruvate or lactate); * p < 0.05, ** p < 0.01, ***p < 0.001 (0 mM vs.
30 mM pyruvate or lactate). Respiratory parameters were derived from the various phases following pyruvate (C-E) or lactate (F-H)
injection: substrate response = [basal pyruvate or lactate rate (time point 6) / basal substrate free rate (time point 3)]; proton leak
rate (time point 7); respiratory control ratio = [FCCP rate (time point 9) / oligomycin rate (time point 8)]. * p < 0.05, ** p < 0.01
compared to 1 mM pyruvate (C-E) or lactate (F-H). I). Respiratory control ratio expressed as a function of pyruvate (1, 3, 10 or 30
mM) or lactate (1, 3 or 10 mM) concentration.
doi: 10.1371/journal.pone.0081528.g003
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To see how neurons respond to a mixture of metabolic
substrates, OCR was measured in WT and HD striatal neurons
in the presence of 2.5 mM glucose followed by addition of 10
mM lactate or pyruvate (Figure 6). Neither pyruvate nor lactate
Figure 4.  OCR measurements performed using a physiological glucose concentration revealed respiratory deficits in HD
striatal neurons.  OCR measurements were performed as described in Figures 2. A) OCR measurements were taken following
injection of glucose (final concentration, 2.5 mM), oligomycin (oligo) then FCCP at the indicated times. Data shown are mean ± SEM
from a representative experiment. Respiratory parameters were derived from the various phases following glucose injection (B-C):
respiratory control ratio = [FCCP rate (time point 10) / oligo rate (time point 9)]; glucose spare respiratory capacity = [FCCP rate
(time point 10) – glucose rate (time point 7)]. Data shown are mean ± SEM from all replicates (six replicates in each of three
independent experiments). * p < 0.05, ** p < 0.01 comparing HD vs. WT.
doi: 10.1371/journal.pone.0081528.g004
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increased basal OCR further when neurons were already
supplied with a physiological glucose concentration (Figure 6A-
D), suggesting that glucose alone was sufficient to support
basic neuron energy requirements. Moreover, this result
confirmed that under basal conditions, respiration is probably
strongly controlled by the rate of mitochondrial ATP turnover or
proton leak and is not limited by the rate of substrate oxidation.
FCCP injection induced a large increase in OCR in the two
conditions tested. In the presence of glucose and pyruvate,
RCR was higher compared to glucose or pyruvate alone (9.2 ±
0.8, 5.4 ± 0.4, 3.5 ± 0.4; glucose + pyruvate RCR, pyruvate
RCR, glucose RCR, respectively; mean ± SEM). Similar results
were obtained with lactate, with higher RCR in the presence of
glucose and lactate compared to glucose or lactate alone (6.2
± 0.5, 3.3 ± 0.2, 3.5 ± 0.4; glucose + lactate RCR, lactate RCR,
glucose RCR, respectively; mean ± SEM). These results
suggest that in the presence of a physiological glucose
concentration, maximal respiration can be improved when
alternative substrates such as pyruvate or lactate are available.
However, it can be seen that FCCP-stimulated OCR was
significantly lower in HD compared to WT striatal neurons when
supplied with either pyruvate or lactate in addition to a
physiological glucose concentration (Figure 6A-D). This shows
that the respiratory defects observed under stress conditions in
Figure 5.  Comparison of HD and WT striatal neurons’ ability to use pyruvate and lactate in the absence of glucose.  OCR
measurements were performed as described in Figure 3. OCR measurements were taken following injection of 10 mM pyruvate (A)
or lactate (D), oligomycin (oligo) and FCCP (2 µM) at the indicated times. Data shown are mean ± SEM from a representative
experiment (six or ten replicates for pyruvate or lactate, respectively). Respiratory parameters were derived from the various phases
following pyruvate (B-C) or lactate (E-F) injection: respiratory control ratio = [FCCP rate (time point 9) / oligo rate (time point 8)];
spare respiratory capacity = [FCCP rate (time point 9) – pyruvate or lactate rate (time point 6)]. Data for respiratory parameters are
mean ± SEM calculated from all replicates (three independent experiments). * p < 0.05 comparing HD vs. WT.
doi: 10.1371/journal.pone.0081528.g005
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the presence of physiological concentration of glucose (Figure
4) were not completely compensated by the presence of
alternative substrates, such as pyruvate or lactate.
Comparison of ECAR in WT and HD primary striatal
neurons
To investigate if OCR deficits observed in the presence of
2.5 mM glucose in HD primary striatal neurons were associated
with a defect in anaerobic glycolysis, we measured ECAR in
HD and WT striatal neurons. First, we observed under basal
conditions that ECAR in WT striatal neurons remained stable
regardless of the glucose concentration used (Figure 7A). After
oligomycin injection, the inhibition of ATP synthesis by the
respiratory chain resulted in ECAR activation as previously
described [29]. Interestingly, this activation was glucose
concentration dependent (Figure 7A). Because FCCP
increases H+ extrusion, ECAR could not be used as a measure
of glycolysis under uncoupling conditions; therefore, data
Figure 6.  HD striatal neurons have a lower capacity to use glucose under high respiratory demands, even when
supplemented with pyruvate or lactate.  Striatal neurons were cultivated for 7 days as described in Figure 1. One hour before the
start of the respiration experiments, medium was replaced with substrate-free KHB complemented with 2.5 mM glucose. OCR
measurements were performed as described in Figure 3. OCR measurements following injection of 10 mM pyruvate (A) or lactate
(D), oligomycin (oligo) and FCCP (2 µM) at the indicated times. Data shown are mean ± SEM from a representative experiment (five
or four replicates for pyruvate or lactate, respectively). Respiratory parameters were derived from the various phases following
pyruvate (B-C) or lactate (E-F) injection: respiratory control ratio = [FCCP rate (time point 9) / oligo rate (time point 8)]; spare
respiratory capacity = [FCCP rate (time point 9) - pyruvate or lactate rate (time point 6)]. Data for respiratory parameters are mean ±
SEM calculated from all replicates (three independent experiments). * p < 0.05, ** p < 0.01 comparing HD vs. WT.
doi: 10.1371/journal.pone.0081528.g006
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obtained after FCCP injection was not analyzed. Then, ECAR
was measured in WT and HD primary striatal neurons
incubated either in rich substrate DMEM or in KHB containing
2.5 mM glucose (Figure 7B). Under basal conditions, no
significant difference was observed between WT and HD
neurons. In contrast, oligomycin-stimulated ECAR as an
indicator of glycolysis was significantly lower in HD neurons
both in rich and low glucose medium, suggesting a specific
defect in their maximal anaerobic glycolysis capacity. At the
same time, intracellular pH measured using 2',7'-Bis-(2-
Carboxyethyl)-5-(and-6)-Carboxyfluorescein (BCECF
Invitrogen, 0.3µM) was similar in WT and HD neurons
suggesting no difference in lactate release between the two
genotypes (data not shown).
Comparison of respiration parameters in WT and HD
cortical neurons
To investigate if the deficits seen in HD striatal neurons were
common to all types of neurons, we performed similar
experiments using primary cortical neurons, a brain region
affected later in Huntington disease [33]. In contrast to striatal
neurons, no respiratory deficits were detected in the presence
of 2.5 mM glucose alone under basal or uncoupling conditions
(Figure 8A) and RCR was similar between HD and WT cortical
neurons. Additionally, in the presence of glucose (2.5 mM) and
pyruvate (10 mM) or lactate (10 mM), no defect was detected
in HD cortical neurons in any of the respiratory parameters
(Figure 8B-C). ECAR measurements were also performed in
presence of 2.5 mM glucose in primary cortical neurons and
results did not show any defects in HD compared to WT
(Figure 8D).
Discussion
In this study, we measured the ability of various substrates to
support mitochondrial respiration in intact primary striatal and
cortical neurons obtained from WT and HD rat embryos. These
studies were designed to detect potential metabolic differences
in HD neurons that could contribute to the pattern of
neurodegeneration found in HD. We detected no specific
mitochondrial respiratory chain defects in either cortical or
striatal neurons from HD rats. By contrast, we found defects in
glycolysis that are present even in cells prepared from
embryos, but only in primary striatal and not cortical neurons
derived from this rat HD model even though mHtt aggregates
are present in both types of neurons (see Figure S1).
As previously mentioned, most of the studies exploring
mitochondrial defects in HD models were done using brain
extracts containing heterogeneous mixtures of neuronal and
glial mitochondria, which may have precluded clear
conclusions. In this study, we monitored metabolic rates in
specific primary neuronal subpopulations (cortical or striatal)
attached to the culture plates after 7 days in culture using
extracellular flux measurement technology [29]. This allowed
us to measure OCR in intact cells including all mitochondria
populations located in neuronal cell bodies as well as neurites.
Indeed, mitochondria localized in dendrites, axon shafts and
presynaptic terminals play a key role in neuronal metabolism
and in neuroplasticity [34] and these structures are largely left
behind when neurons are detached from their culture surface
for respiration measurements; this mitochondrial fraction is
important especially when considering that axonal transport is
disturbed in HD [35]. In addition, these studies highlighted the
importance of alternate substrates to support neuronal
respiration along with physiological glucose concentrations
found in brain, particularly when respiration demand is high.
The normal plasma glucose concentration is around 4.5 mM;
however, the glucose concentration in the CNS is only about
2.5 mM [31,36]. Neurobasal™ medium, commonly used to
culture primary neurons contains 25 mM glucose, a supra-
physiological concentration. We found that glucose dose-
dependently increased neuronal spare respiratory capacity and
RCR and that 2.5 mM glucose was clearly suboptimal to
support neurons under high respiratory demand. We then
found that both lactate and pyruvate were individually able to
support mitochondrial respiration in intact neurons and that
these alternative substrates could provide additional respiratory
capacity beyond that provided by CNS levels of glucose when
neurons were challenged with an uncoupling agent. These
results highlight the importance of neuronal glial coupling
whereby glucose utilization by astrocytes results in the release
of lactate that can then be taken up and used by neurons to
support respiration [37-39]. Lactate conversion to pyruvate may
take place preferentially in nerve terminals depending on
differential distribution of LDH isoforms found in neuron cell
bodies and terminals [40]. Furthermore, MCT1 transporters
have recently been implicated in lactate exchange between
oligodendrocytes and neuronal axons [41]. Interestingly, we
observed an additive effect of glucose and pyruvate on
maximal, FCCP-stimulated OCR (refer to maximal OCR in
Figures 4, 5, 6). These results support the existence of a
glucose dependent but pyruvate independent system
transferring electrons to the respiratory chain in neurons.
Indeed, the glycerol 3-phosphate shuttle directly transfers
electrons to coenzyme Q in the mitochondrial inner membrane.
This shuttle, active in neurons, is regulated by NADH/NAD+
and calcium and depends on the first step of glycolysis [42-44].
When HD striatal neurons were incubated in substrate-rich
media containing a supra-physiological glucose concentration,
no respiratory deficits were detected. These results are
consistent with previous results obtained in HD knock-in mouse
primary striatal neurons [25] where mitochondrial respiration
was monitored in medium containing 15 mM glucose. In
addition to these results, we now show that when the
respiration demand is high, HD striatal neurons exhibit
respiratory deficits when supplied with 2.5 mM glucose either
alone or when supplemented with lactate or pyruvate. When
pyruvate was the sole substrate present in the assay media, no
significant respiratory deficits were observed in HD striatal
neurons. These results argue for an alteration in glucose
uptake and/or in glycolysis in HD rather than any defects in the
respiratory chain itself. This hypothesis is further supported by
the fact that deficits were only detected in the presence of
physiological glucose concentrations but not when glucose was
abundant. Moreover, because glucose defects in OCR were
not compensated by pyruvate addition, it appears that a
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Figure 7.  HD striatal neurons have a lower capacity to use anaerobic glycolysis in the presence of high and low glucose
concentrations.  Striatal neurons were cultivated for 7 days in Neurobasal™ medium containing 25 mM glucose and
complemented with B27 and pyruvate (1 mM). A) On the day of the respiration experiments, medium was replaced with substrate-
free KHB and WT cells were incubated for 1 h at 37°C. ECAR was measured after injection of different concentrations of glucose
then oligomycin. Data are mean ± SEM and derived from the same experiment presented in Figure 2. * p < 0.05, ** p < 0.01 vs. 2.5
mM glucose. B) On the day of the respiration experiments, cells were incubated in 2.5 mM glucose in KHB medium or bicarbonate-
and HEPES-free DMEM containing 25 mM glucose complemented with pyruvate (1 mM) for 1 h at 37°C. ECAR was measured
under basal conditions and after oligomycin stimulation. Data are mean ± SEM from all independent experiments (2.5 mM glucose:
five replicates in each of five experiments, n=25; 25 mM glucose: eleven replicates in each of seven experiments, n=77). . * p<0.05,
** p < 0.01 comparing WT vs. HD.
doi: 10.1371/journal.pone.0081528.g007
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glucose-dependent but pyruvate independent electron transfer
pathway is down regulated in HD primary striatal neurons.
Extracellular acidification is a valid indicator of the anaerobic
glycolysis rate (metabolic pathway converting glucose into
lactate) and a valuable tool for analysing cellular bioenergetics
[29,45]. Here, we observed that ECAR deficits were detected in
HD striatal neurons both when incubated in culture medium
containing a supra-physiological glucose concentration but also
in KHB containing 2.5 mM glucose. Taken together, the OCR
and ECAR data strongly support the hypothesis that striatal
glycolysis deficits occur early in HD pathogenesis.
Dysregulation in glycolysis has been reported in several
studies in animal and cellular HD models or in patients
[20,46-48]. Additionally, Powers and colleagues reported a
preserved mitochondrial oxidative metabolism in early HD
patients with striatal atrophy, indicating that defects in
respiratory chain enzymes observed in post mortem brain are
either not sufficient to explain oxidative phosphorylation
impairments or are not present early in the time course of the
disease [20]. They also reported in the same early HD patients
Figure 8.  HD cortical neurons had no metabolic deficits regardless of the substrate supplied.  HD and WT cortical neurons
were cultivated for 7 days in Neurobasal™ medium complemented with B27 and pyruvate (1 mM). One hour before the start of
respiration experiments, medium was replaced with substrate-free KHB and incubated at 37°C before being placed in the Seahorse
analyser. OCR measurements were performed as described in Figures 2 and 3. OCR measurements following injection of (A) 2.5
mM glucose, (B) 10 mM pyruvate or (C) 10 mM lactate followed by oligomycin (oligo) and FCCP (2 µM) at the indicated times. D)
ECAR was measured in the presence of 2.5 mM glucose under basal conditions and after oligomycin stimulation. Data shown in
panels A-C are from representative experiments while data in panel D is the mean ± SEM calculated from all replicates (eight
replicates for each substrate in each of two independent experiments)..
doi: 10.1371/journal.pone.0081528.g008
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a decrease in cerebral glucose metabolism indicating a
selective impairment of striatal glycolytic metabolism [20]. Very
recently, Zala et al. showed that the glycolytic enzyme,
GAPDH, is located on neuron vesicles and that local glycolysis
powers vesicular fast axonal transport. Additionally, the authors
demonstrated that huntingtin is a scaffold that joins GAPDH to
these vesicles, suggesting that mutations in huntingtin could
perturb glycolysis-generated ATP necessary for vesicle motility
[49].
Interestingly, in our study, even though mHtt aggregates are
present in both cell types, metabolic defects were only detected
in embryonic striatal neurons and not in cortical neurons, a
brain region affected later in Huntington disease progression.
Indeed, cortical neurons showed neither OCR deficits nor
ECAR alterations in the presence of a physiological
concentration of glucose. These results provide additional
insight into the mechanisms of selective striatal
neurodegeneration and into the relative metabolic vulnerability
of different cellular populations to mHtt toxicity. In the light of
the present study, it might be argued that striatal neurons seem
to have different metabolic requirements compared to cortex
and may have a reduced capacity to manage substrate
deprivation. Indeed, we can observe in Figures 4A and 8A that
glucose injection did not have the same impact on basal OCR
in striatal and cortical neurons. In striatal neurons a significant
increase of 31.5 ± 5.8% was observed in response to glucose
injection; for cortical neurons, which had a higher basal OCR in
the absence of glucose, the response was only 9 ± 2.9%.
In summary, early glycolysis defects are found specifically in
HD striatal neurons. These subtle defects, observed only with
levels of glucose found in brain, may only have adverse
consequences after prolonged stress or in combination with
other age-related declines in metabolism, explaining why
neurodegeneration only becomes evident in HD gene carriers
in middle age. These results can be related to new insights in
pre-symptomatic carriers of apolipoprotein E4, who show
reduced cerebral glucose metabolism even before Aβ
aggregation and decades before the onset of AD pathology
[50,51]. These brain functional abnormalities in
neurodegenerative disease gene carriers argue for early
prevention therapies, decades before the onset of cognitive or
motor symptoms.
Supporting Information
Protocol S1.  Methods for assessing mhtt expression in
primary neuronal cultures.
(DOC)
Figure S1.  Confirmation of mhtt expression in primary
neuronal cultures. Primary striatal and cortical neurons from
HD rats express mhtt. SDS-insoluble and thus aggregated
proteins were trapped on a nitrocellulose membrane and
probed with a polyQ-specific antibody. The presence of
aggregated polyQ-containing protein in primary striatal and
cortical cultures from HD rat embryos but not their WT
littermates indicates the expression of aggregated forms of
mhtt in these neurons. Each dot is the extract from a separate
neuronal culture, prepared from an individual WT or HD
embryo.
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Protocol S1
Striatal and cortical neurons prepared from 
individual HD and WT embryos were cultured in 
6-well plates at a density of 1,000,000 cells/well 
for cortex and 2,000,000 cells/well for striatum. 
After 7 days in vitro, cells were harvested by 
trypsinization (1 ml of 0.25 % trypsin with EDTA 
(Gibco) per well) and centrifugation (10 min at 
400xg). Proteins were extracted from cell 
pellets by incubation in 100 µl RIPA buffer (50 
mM Tris-HCl, pH 8.0, 150 mM NaCl, 1 % IGPAL 
(NP-40 substitute), 0.5 % 
sodiumdesoxychelate, 0.1 % SDS) containing 4 
% cOmplete ULTRA Protease Inhibitor-Cocktail 
with EDTA (Roche) for 30 min at 4 °C and 
subsequent centrifugation for 15 min at 4 °C at 
16.400xg. Supernatant was collected and 
protein content for each sample was measured 
using a Bradford assay. The samples were 
stored at -80 °C until further use. For the 
analysis of mhtt expression in these samples, 
we performed a filter trap assay [1] optimized 
for the detection of mhtt. The method is based 
on the SDS-insolubility of mhtt aggregates, 
which are retained when filtered through a 
nitrocellulose membrane. For this purpose, 20 
µg of lysate protein was mixed with SDS (final 
concentration 2 %) and filtered using a dot 
blotter (Dot blotter SRC 96 D, S&S Minifold I, 
Schleicher & Schuell, Germany). The 
membrane (Protran Nitrocellulose Membrane, 
Whatman) was afterwards probed with 1C2 
anti-polyQ-antibody (MAB1574, Millipore, 
1:2000) overnight at 4 °C and on the next day 
incubated for 1 hour at room temperature with 
the secondary, horse-radish-peroxidase-linked 
anti-mouse IgG antibody (NA931, Amersham 
Biosiences, 1:2500). Chemiluminescence was 
created using ECL Western Blotting Detection 
Reagent (Amersham Biosciences) and 
detected with the Odyssey FC (LI-COR 
Biosciences), showing aggregated forms of 
polyQ-containing protein (mhtt) (Fig S1).
 
1. Wanker EE, Scherzinger E, Heiser V, Sittler A, Eickhoff H, et al. (1999) Membrane filter assay for detection of amyloid-like polyglutamine-
containing protein aggregates. Methods Enzymol 309: 375-386. 
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Abstract Huntington disease (HD) is a fatal neurodegenera-
tive disorder caused by a CAG repeat expansion in exon 1 of
the huntingtin gene (HTT). One prominent target of the mutant
huntingtin protein (mhtt) is the mitochondrion, affecting its
morphology, distribution, and function. Thus, mitochondria
have been suggested as potential therapeutic targets for the
treatment of HD. Olesoxime, a cholesterol-like compound,
promotes motor neuron survival and neurite outgrowth
in vitro, and its effects are presumed to occur via a direct
interaction with mitochondrial membranes (MMs). We exam-
ined the properties of MMs isolated from cell and animal
models of HD as well as the effects of olesoxime on MM
fluidity and cholesterol levels. MMs isolated from brains of
aged Hdh Q111/Q111 knock-in mice showed a significant
decrease in 1,6-diphenyl-hexatriene (DPH) anisotropy, which
is inversely correlated with membrane fluidity. Similar in-
creases in MM fluidity were observed in striatal STHdh
Q111/Q111 cells as well as in MMs isolated from brains of
BACHD transgenic rats. Treatment of STHdh cells with
olesoxime decreased the fluidity of isolated MMs.
Decreased membrane fluidity was also measured in
olesoxime-treated MMs isolated from brains of HD knock-in
mice. In both models, treatment with olesoxime restored HD-
specific changes in MMs. Accordingly, olesoxime significant-
ly counteracted the mhtt-induced increase in MM fluidity of
MMs isolated from brains of BACHD rats after 12 months of
treatment in vivo, possibly by enhancing MM cholesterol
levels. Thus, olesoxime may represent a novel pharmacolog-
ical tool to treat mitochondrial dysfunction in HD.
Keywords BACHD rat . Huntington disease .Membrane
cholesterol . Membrane fluidity . Mitochondrial membrane
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Introduction
Huntington disease (HD) is a fatal neurodegenerative disorder
caused by a single genetic mutation—a CAG repeat expan-
sion in exon 1 of the gene coding for the huntingtin protein
(Htt) [1]. The disease is manifested mostly around the age of
40–50 [2] with symptoms including involuntary movements,
psychiatric abnormalities, cognitive decline and metabolic
disturbances, inevitably leading to the death of the patient
[3]. To date, there is no effective treatment available to ame-
liorate the symptoms or prevent disease progression.
HD research has recently been focused on mitochondrial
dysfunction. Mitochondria are complex organelles composed
of two phospholipid bilayer membranes: the inner mitochondrial
membrane (IMM) and outer mitochondrial membrane (OMM)
[4]. Like other membranes, MMs are dynamic two-dimensional
fluids consisting mainly of proteins and lipids [5]. The fluidity of
the phospholipid bilayer modulates numerous essential cell func-
tions, including the interaction and regulation of membrane-
associated enzymes, receptors, and ion channels [6–9].
Membrane fluidity is mainly dependent on the protein and lipid
composition, which in turn is determined by the types of unsat-
urated fatty acids and phospholipids as well as the cholesterol
content [10].Mitochondria generally contain only small amounts
of cholesterol, concentrated in the OMM [11]. There is evidence
that mitochondrial membrane fluidity regulates or modulates the
function of essential proteins within the mitochondrial mem-
brane and vice versa. The IMM harbors the proteins of the
electron transfer chain (ETC.), and its integrity is critical for
the activity of the ETC. complexes, which drive ATP production.
Accordingly, a correlation between membrane fluidity and the
mobility and function of single complexes of the ETC. has been
established [12–15]. Recent studies also revealed that changes in
mitochondrial membrane fluidity might have a direct impact on
membrane-based processes such as fission-associated morpho-
logical changes, recruitment of pro-apoptotic factors, and mito-
chondrial permeability transition (mPT) [16, 17].
In HD, mitochondria are strongly affected by the presence of
mutant htt (mhtt). Early mitochondrial impairments seem to
concern defects in glycolysis [18, 19], while during disease
progression, the functioning of the whole mitochondrial network
is compromised (for review, please refer to [20–24]). N-terminal
mhtt fragments have been shown to bind to the OMM [25–28],
altering the activity of the fission and fusion proteins Drp1 and
Mfn2 and leading to a fragmentation of the mitochondrial net-
work [28–32] as well as an impairment of axonal mitochondrial
transport [27, 31–33]. In the presence of mhtt, mitochondria
further seem to be more susceptible to oxidative stress and have
a lower Ca2+ uptake capacity, lower respiratory capacity, and
decreased ATP production rates [26, 34, 35].
Based on the strong evidence for mitochondrial impairments
in HD, mitochondria-targeting molecules as coenzyme Q10, N-
acetyl-L-cysteine, carnitine, or bezafibrate have been evaluated in
therapeutic approaches with beneficial effects [36–41]. Another
promising compound has been identified in a phenotypic screen-
ing approach to promote the survival of primary motor neurons
[42]. Olesoxime (cholest-4-en-3-one, oxime) is a cholesterol-like
molecule that was found to interact with the voltage-dependent
anion channel (VDAC) and the translocator protein (TSPO)
[42]. VDAC and TSPO are two proteins of the outer mitochon-
drial membrane that are involved in Ca2+ homeostasis [43],
metabolite exchange [44], and cholesterol transport [45]. Both
proteins are further involved in mPT. Consistent with this,
olesoxime was able to rescue cortical neurons from apoptotic
cell death induced by camptothecin [18]. Furthermore,
olesoxime has shown beneficial effects in disease models of
amyotrophic lateral sclerosis [42, 46] and peripheral neuropa-
thies [47, 48]. Furthermore, olesoxime is readily taken up by
cells and accumulates in mitochondria [49].
Based on the initial finding of changed fluidity parameters
in membranes isolated from Hdh Q111/Q111 knock-in mice
[50], this study was carried out in order to evaluate membrane
fluidity as a common feature for mitochondrial dysfunction in
HD and to test the efficacy of olesoxime in targeting changes
in membrane properties of mitochondria using in vitro and
in vivo models of HD.
Materials and Methods
Chemicals
Chemicals were purchased from Sigma-Aldrich, Hamburg,
Germany, cell culture media were purchased from Invitrogen
Mol Neurobiol
GmbH, Karlsruhe, Germany, and olesoxime (TRO19622) was
kindly provided by Trophos SA, Marseille, France.
Animal and Cell Models of HD
All experiments were carried out by individuals with
appropriate training and experience according to the
requirements of the Federation of European Laboratory
Animal Science Associations and the European
Communities Council Directive (Directive 2010/63/
EU). The commission for animal experiments at the
“Regierungspräsidium Tübingen” in accordance with
the guidelines of the German Animal Welfare Act ap-
proved all experiments.
STHdh Cells In our experiments, we used a striatal cell line
derived from Hdh Q111/111 knock-in mice (detailed descrip-
tion below) containing homozygous huntingtin gene (htt) loci
with a humanized exon 1 with 111 CAG repeats (STHdh
Q111/Q111) and a striatal cell line derived from wild-type
mice containing endogenous htt with 7 CAG repeats (STHdh
Q7/Q7). STHdh cell lines were purchased from Coriell Cell
Repositories and originate from the laboratory of Dr. Marcy
MacDonald (Harvard Medical School, Boston, USA).
Cell Culture
Both cell lines were cultured in Dulbecco’s modified Eagle’s
medium (DMEM), supplemented with 10 % heat-inactivated
fetal calf serum (FCS), 100 units/ml penicillin, 100 μg/ml
streptomycin, and 0.4 mg/ml G418. The cells were cultured
at 37 °C in a humidified incubator containing 5 % CO2.
Differentiation of STHdh Cells and Olesoxime Treatment
Cells were grown in T175 flasks with a complete medium
until they reached 70 % confluence. Cells were treated with
fresh media including 1.0, 3.0, or 10.0 μM olesoxime (in
dimethylsulfoxide (DMSO)) or fresh media including
0.05 % DMSO only for control. After 18 h of olesoxime
treatment, differentiation was initiated by adding 7 ml of
dopamine cocktail (Forskolin 50 μmol/l, 3-isobutyl-1-meth-
ylxanthine (IBMX) 250 μmol/l, TPA 0.2 μmol/l, dopamine
10 μmol/l, and α-FGF 10 ng/ml in DMEM). Morphological
changes were visible as early as 30 min after induction of
differentiation. After 6 h, cells were harvested in ice-cold
phosphate-buffered saline (PBS; pH 7.4) at 4 °C. The cell
suspension was centrifuged for 10 min at 600×g. The super-
natant was discarded, and the cell pellets were stored at
−20 °C until membrane isolation was performed.
HD Knock-in Mice Hdh Q111/111 knock-in mice (C57BL/
6 J-Hdh(111Q)KI-MacD) were obtained from Dr. Marcy
MacDonald (Harvard Medical School, Boston, USA) and
bred for more than ten generations in our facility before the
study. They were kept at 21–23 °C ambient temperature, 55±
10 % humidity, and a 12:12-h light/dark cycle with lights on
from 3:00 a.m. to 3:00 p.m. According to the ETS 123,
Appendix A, animals were kept in groups of two to five
animals of the same sex and mixed genotype in type IV,
autoclavable plastic cages with high lid, containing autoclaved
wooden bedding and nesting material. Cages were cleaned
once a week. Food and water were delivered ad libitum. The
mice were weaned at 21 days of age and kept without any
behavioral testing until they were sacrificed at the age of 3–
9 months (adult) or 18–20 months (aged).
BACHD Rats The SPRD-BACHDflhtt97Q-TG5 rat [51] was
generated with a BAC construct, previously implemented to
generate the BACHD mouse [52]. BACHD rats express the
full-length human mutant huntingtin gene (mHTT) with 97
mixed CAA-CAG repeats. BACHD rat line TG5, which was
used in this study, is characterized by a high copy number of
mHTTas well as a high RNA and protein expression. BACHD
rats display behavioral abnormalities and neuropathology sim-
ilar to HD patients [51].
Housing conditions followed the recommendations of the
European Union (ETS 123, Appendix A). The environmental
conditions in the housing room amounted to 21–23 °C ambi-
ent temperature, 55±10 % humidity, and a 12:12-h light/dark
cycle with lights off at 2:00 p.m. and lights on at 2:00 a.m.
Animals were kept in groups of four animals of mixed geno-
type (two wt to two mut) in type IV, autoclavable plastic cages
with high lid, containing autoclaved wooden bedding. Cages
were cleaned twice a week. Food and water were delivered ad
libitum.
Animals were weaned at 21 days of age. At 5 weeks of age,
the foodwas changed from a standard rat housing chow (ssniff
V1534-000, SSNIFF Germany) to either a control diet
(Altromin C1000, Altromin Germany) or the same diet loaded
with 600 mg/kg olesoxime. At 13 months of age, after
12 months of olesoxime treatment, the rats were sacrificed,
and mitochondrial parameters were measured.
Membrane Isolation from Cells
For the isolation of cellular mitochondrial and plasma mem-
branes, harvested cell pellets were homogenized in 5 mmol/l
trishydroxymethylaminomethan-hydrochloride (Tris–HCl)
(pH 8.5) applying 15 strokes with a Teflon® pestle at
1,100 rpm. The homogenate was lysed on ice for 1 h and
15 min and vortexed vigorously every 15 min. After lysis, the
homogenate was centrifuged at 20,000 rpm, and the pellet was
resuspended in ice-cold deionized water and homogenized
once more as described above (15 strokes, 1,100 rpm). The
homogenate was under-layered with a sucrose solution
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(1.5 mol/l sucrose, 10 mmol/l 4-2-hydroxyethyl-1-
piperazineethanesulfonic acid (HEPES), 0.25 mmol/l
ethylenediamine tetra acetic acid (EDTA)) and centrifuged at
68,000×g. The resulting pellet containing mitochondrial
membranes was resuspended in 5 mmol/l Tris–HCl (pH 7.4)
and stored at −20 °C. The interface was collected, washed
with ice-cold deionized water, and centrifuged at 20,000×g.
The pellet containing the plasmamembranes was resuspended
in 5 mmol/l Tris–HCl (pH 7.4) and stored at −20 °C.
Membrane Isolation from Brain Tissue
The isolation of mitochondrial and synaptosomal plasma
membranes (SPMs) was performed according to Eckert et al.
[53]. Two mouse brains or one rat hemisphere (without brain
stem and cerebellum) were homogenized in buffer I (0.32 M
sucrose, 10 mM HEPES; 1 mM EDTA, pH 7.4) and centri-
fuged at 585×g at 4 °C. The supernatant was centrifuged
twice at 17,400×g at 4 °C. Pellets contained synaptosomes
and mitochondria. The pellets were resuspended in buffer I
and layered over a density gradient of 7.5 and 13 % Ficoll
solution (wt/vol). The gradients were centrifuged for 60min at
87,300×g. The pellet containing enriched brain mitochondrial
membranes was resuspended in 5 mmol/l Tris–HCl and stored
at −20 °C. After centrifugation, the lower interface of the
gradient was collected, suspended in buffer I, centrifuged first
at 17,400×g, and after resuspension in buffer I, centrifuged
again at 14,600×g for washing. The resulting synaptosomal
pellet was resuspended in buffer II (5 mmol/l Tris–HCl;
pH 8.5). For lysis, the synaptosomes were kept on ice for
1 h while vortexing every 10 min. After this, the suspension
was centrifuged for 20 min at 43,000×g. The pellet was
resuspended in ice-cold deionized water, under-layered with
a sucrose solution (1.5 M sucrose, 10 mM HEPES, 0.25 mM
EDTA), and centrifuged for 45 min at 41,000×g. The synap-
tosomal plasma membranes at the interface were carefully
removed, suspended in 50 mM Tris–HCl buffer, and stored
at −20 °C.
Membrane Fluidity Measurement
Membrane fluidity was assessed using the lipophilic probe
1,6-diphenyl-hexatriene (DPH) and fluorescence polariza-
tion spectrometry [10]. Hereby, fluorescence anisotropy is
inversely correlated with membrane fluidity. DPH mainly
localizes in the hydrocarbon core and intercalates prefer-
entially axial, between the acyl chains of the phospholipid
bilayer. Thus, steady state polarization of DPH provides an
overall measure of the structural order of the membrane
interior. For DPH measurements, 30 μl of membrane
suspension (in 5 mM Tris–HCl, pH 7.4) with a protein
concentration of 30 μg/100 μl (protein concentration was
determined according to the Lowry method [54]) was
incubated with 250 μl Tris–HCl (5 mM, pH 7.4). Then,
350 μl of a 1:150 diluted DPH stock solution (5 mM in
tetrahydrofuran) and either 70 μl of Tris–HCl (5 mM,
pH 7.4) as a control or 70 μl of olesoxime suspension
(in case of mouse brains) were added and incubated at
37 °C for 45 min. Steady state anisotropy was directly
measured at 37 °C in a quartz cuvette (Hellma analytics,
Mül lheim Germany) in a SLM Luminescence
Spectrometer Aminco-Bowman® Series 2 (SLM Aminco,
Urbana, USA) using excitation and emission wave lengths
of 360 and 450 nm (slits 4 nm), respectively. The detector
signal was adjusted to a maximum photomultiplier voltage
of 80 %. Steady state fluorescence polarization (PS) was
expressed as the anisotropy rS of the probe according to
the equation: rS=2PS / 3−PS.
Cholesterol Determination
Cho l e s t e ro l was de t e rm ined acco rd ing to the
cholesteroloxidase-peroxidase-aminophenazon-phenol
(CHOD-PAP) method with slight modifications according to
Kirsch et al. [55]. In brief, 0.5% (w/v) methyl-β-cyclodextrine
(MβCD) in combination with Brij 35 as a 15% (w/v) aqueous
solution was used to improve cholesterol extraction from the
membrane. After 2 h of incubation, cholesterol was measured
in triplicates at 490 nm in a micro-plate reader (DigiScan,
ASYS Hitech GmbH).
Solubilization of Olesoxime
For in vitro application, olesoxime was freshly solubilized
before each experiment in low amounts of MβCD. Briefly,
10 μl of olesoxime stock solution (20 mM in DMSO) was
mixed with 990 μl of 0.5 mM MβCD in Tris–HCl, vortexed
vigorously, and mixed on a thermomixer for 24 h at 1,400 rpm
and 37 °C in order to reveal a homogenous, stabilized suspen-
sion. MβCD is known to extract cholesterol from biological
membranes [56]. Thus, we carefully assessed the effects of
MβCD on the parameters determined in the study and ap-
proved that the maximum concentration applied did not exert
any effects per se.
Statistical Analysis
The data are given as the mean ± standard error of the
mean (SEM). For statistical comparison, unpaired and
two-sided t-tests and two-way ANOVA followed by
Bonferroni post hoc test for multiple comparisons were
used (GraphPad Software for Mac 5.0, San Diego,
USA), since all data proved to be normally distributed.
p values <0.05 were considered to be statistically
significant.
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Results
Mitochondrial dysfunction is a prominent pathological feature
observed in HD disease models as well as HD patients.
However, the properties of the mitochondrial membrane have
not been addressed yet. For this reason, we measured mem-
brane fluidity and cholesterol levels as its main determinant in
mitochondrial membranes (MMs) and plasma membranes
(PMs) or synaptosomal plasma membranes (SPMs) isolated
from STHdh cells as well as 18–20-month-old HD knock-in
mice and 13-month-old BACHD rats and their wild-type
littermates.Membrane fluidity was assessed spectrophotomet-
rically using the fluorescent probe DPH, which correlates
inversely with the acyl-chain flexibility of fatty acids in the
hydrocarbon core of lipid bilayers.
Mitochondrial Membrane Fluidity Is Altered in HD
Isolated MMs from differentiated STHdh cells showed a
significant increase in mitochondrial membrane fluidity in
the mutant STHdh Q111/Q111 cells compared to STHdh
Q7/Q7 control cells (Fig. 1(a)).
We had reported before that mitochondrial mem-
branes but not synaptosomal plasma membranes isolated
from brains of adult (3–9-month-old) HD knock-in mice
showed a similar increase in membrane fluidity, as we
have now shown for STHdh cells, the cell line originat-
ing from these mice [50]. In order to investigate a
potential progressive nature of mitochondrial membrane
fluidity changes, we here analyzed membrane fluidity in
aged (18–20-month-old) HD knock-in mice (Fig. 1(b)).
A comparison between the previously obtained data of
adult mice with the new data of aged mice (Fig. 2)
showed that age had a significant impact on membrane
fluidity but influenced the two genotypes in a different
manner. Wild-type mice showed a significant increase in
both mitochondrial membrane fluidity (Fig. 2(a)) and
synaptosomal membrane fluidity (Fig. 2(b)), which is
typically observed with aging [50, 53, 57]. On the
contrary, no change in synaptosomal plasma membrane
fluidity was observed in HD knock-in mice with aging
(Fig. 2(a)), which leads to a significant genotype differ-
ence in synaptosomal plasma membrane fluidity in aged
mice. Moreover, mitochondrial membrane fluidity fur-
ther increased in aged HD knock-in mice (Fig. 2(b)).
Overall, these findings point towards a disease-specific,
progressive impairment in mutant mice.
In accordance with the results obtained from HD knock-in
mice and STHdh cells, MMs isolated from BACHD rats also
exhibited a disease-specific increase in membrane fluidity
(Fig. 1(c)).
In contrast to MMs, the fluidity of PMs and SPMs was
unchanged in HD cell and animal models (Fig. 1(a–c)).
HD-Related Alterations in Mitochondrial Membrane Fluidity
Are Not Reflected by Changes in Cholesterol Content
Cholesterol represents a major modulator of membrane fluid-
ity [58]. In line with our previous data, showing that plasma
and mitochondrial membranes noticeably differ in cholesterol
levels [50], MMs contained only a small amount of cholester-
ol compared to plasma membranes (Fig. 1(d–f)). Higher cho-
lesterol levels in SPMs may account for their lower fluidity
compared to MMs (Fig. 1(a–c)). In the HD models studied, a
significant reduction of MM cholesterol was found only in
BACHD rats (Fig. 1(f)). Cholesterol levels were unchanged in
STHdh cells and HD knock-in mice (Fig. 1(d, e)). Thus,
cholesterol levels might not be the major determinant of
membrane fluidity changes found in MMs or SPMs isolated
from different HD models.
Olesoxime Restores Membrane Fluidity and Cholesterol
Levels Affected in HD Models
Olesoxime has cholesterol-like structure, enters the cell, and
concentrates in mitochondria [42, 49], thus representing a
possible modulator of mitochondrial membrane fluidity.
Treatment of differentiated HD cells with olesoxime for
24 h led to a disease-unspecific and dose-dependent decrease
in mitochondrial membrane fluidity (Fig. 3). In both cell lines,
10 μM olesoxime decreased the fluidity of isolated MMs
(Fig. 3(a, b)). In addition, olesoxime significantly enhanced
the cholesterol content in MMs isolated from HD mutant and
control cells (Fig. 3(c, d)). In contrast, olesoxime significantly
reduced the cholesterol content in PMs isolated from HD
mutant (1, 3, and 10 μM) and control cells (10 μM)
(Fig. 3(e, f)).
Incubation of MMs isolated from brains of aged HD
knock-in mice with olesoxime in vitro led to a dose-
dependent increase in anisotropy, indicative of a decrease in
membrane fluidity. As it was found for STHdh cells, a con-
centration of 10 μM olesoxime restored MM fluidity to con-
trol levels (Fig. 4a). Incubation of SPM isolated from brains of
adult and aged HDmice with 30 μM olesoxime in vitro led to
an increase in anisotropy, indicative of a decrease in mem-
brane fluidity (Fig. 4b). Incubation of MMs and SPMs with
olesoxime had no effect on cholesterol levels (data not
shown).
In order to investigate if the effect of olesoxime on
membrane fluidity found in vitro for MMs isolated from
cells or mouse brains could also be demonstrated
in vivo, membrane fluidity and cholesterol content were
measured in MM and SPM fractions prepared from
BACHD rats pretreated with olesoxime for 12 months.
We found olesoxime restored brain MM fluidity as well
as cholesterol content (Fig. 5), without affecting the
fluidity or cholesterol content of SPM (Fig. 5b, d).
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Fig. 2 Membrane fluidity in adult and aged mice. DPH anisotropy,
which correlates inversely with membrane fluidity, was measured in
mitochondrial membranes (MM) (a) and synaptosomal plasma mem-
branes (SPM) (b) from Hdh Q111/111 knock-in mice and their wild-type
littermates (control) (b) at younger (adult, 3–9 months) and older (aged,
18–20 months) age. Bars show mean ± SEM, n=6/group, *p<0.05;
**p≤0.01; ***p≤0.0001,two-way ANOVA and Bonferroni post hoc
analysis
Fig. 1 Membrane properties of cell and animal models of HD. Mito-
chondrial membranes (MM) and plasma membranes (PM) from cell
samples or synaptosomal plasma membranes (SPM) from brain samples
were isolated by gradient centrifugation. a–c Membrane anisotropy of
DPH was measured, which correlates inversely with membrane fluidity.
Graphs show the DPH anisotropy of isolated membranes from STHdh
Q7/Q7 and Q111/Q111 cells after 6 h of differentiation (a), DPH anisot-
ropy of isolated membranes from the brains of Hdh Q111/111 knock-in
mice and their wild-type (WT) litter mates at 18–20 months of age (b), as
well as BACHD rats and their WT litter mates at 13 months of age (c). d,
e Membrane cholesterol content was assessed by the CHOD-PAP meth-
od. Graphs display the cholesterol content of isolated membranes from
STHdh Q7/Q7 and Q111/Q111 cells after 6 h of differentiation (d),
cholesterol content of isolated membranes from the brains of Hdh
Q111/111 knock-in mice and their WT litter mates at 18–20 months of
age (e), as well as BACHD rats and their WT litter mates at 13 months of
age (f). Bars show mean ± SEM, n=4–7/group. *p<0.05; **p≤0.01
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Unexpectedly, we found olesoxime decreased SPM flu-
idity in wild-type control rats (Fig. 5a, c), while no
change in cholesterol content was observed in these
animals (Fig. 5c, d).
Discussion
Mitochondrial dysfunction has been studied intensely during
the last decade in HD research [20–24]. The impact of mhtt on
Fig. 3 In vitro effects of
olesoxime on membranes from
STHdh cells. Mitochondrial
membranes (MM) and plasma
membranes (PM) were isolated
from control STHdh Q7/Q7
(plain bars) or mutant STHdh
Q111/Q111 cells (striped bars)
after 6 h of differentiation and 24 h
of treatment with olesoxime (1–
10μM). Controls were treatedwith
DMSO only. a, b The graphs
display the influence of olesoxime
on DPH anisotropy of MM from
STHdh Q7/7 (a) and Q111/111
cells (b) as well as its influence on
cholesterol content of MM from
STHdh Q7/7 (c) and Q111/111
cells (d) and plasma membranes
from STHdh Q7/7 (e) and Q111/
111 cells (f).Bars represent mean ±
SEM, n=5/group, *p≤0.05;
**p≤0.01; ***p≤0.0001, t-test
Fig. 4 In vitro effects of olesoxime on brainmembranes fromHDknock-
in mice. Isolated mitochondrial membranes (MM) (a) and synaptosomal
plasma membranes (SPM) (b) from the brains of aged (18–20 months
old) Hdh Q111/111 knock-in mice were incubated with 3, 10, or 3 µM
olesoxime. DPH anisotropy, which correlates inversely with membrane
fluidity, was measured. Bars show mean ± SEM; n=6/group, plus sign =
compared to untreated wild-type litter mates, asterisk = compared to
untreated knock-in mouse samples (co). *,+p<0.05; **,++p≤0.01;
***,+++p<0.0001, t test
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mitochondrial integrity is manifold, affecting mitochondrial
shape [28–32, 59, 60], intracellular distribution [27, 31–33],
and functioning [61]. mhtt thereby acts either directly [25–28]
or indirectly through transcriptional dysregulation of genes
involved in mitochondrial function. Mitochondrial network
dysfunction has been considered a key player in HD patho-
genesis, since mitochondria orchestrate energy supply and
Ca2+ homeostasis in healthy cells but also trigger apoptosis
when their buffering capacity becomes insufficient. However,
it could not yet be clarified whether mitochondrial damage is
the primary cause for the neuronal cell degeneration observed
in HD or whether it is secondary to other events. Furthermore,
mitochondria have been suggested as potential therapeutic
targets, and various HD animal and cellular models have been
used to identify treatments that improve specific mitochondri-
al defects implicated in HD [36–41].
Mitochondrial Membrane Fluidity as a Common Pathological
Feature in HD
Inner and outer mitochondrial membranes constitute an im-
portant interface of phospholipid bilayers, containing proteins
and lipid rafts that control signal transduction, energy produc-
tion, and apoptosis initiation [50]. Decreased membrane flu-
idity has been observed previously in synaptosomal and mi-
tochondrial membranes isolated from the brains of aged or
Alzheimer disease (AD) mouse models and is considered to
play a key role in the pathogenic events in AD and aging [50,
53]. We had also provided the first results on changes in
mitochondrial membrane fluidity in HD [50]. In contrast to
aging and AD, we found membrane fluidity to be significantly
increased in mitochondrial membranes isolated from HD
knock-in mice of relatively young age (3–9 months).
Consistent with this finding, aged HD knock-in mice
showed a significant increase in membrane fluidity of brain
mitochondria compared to their wild-type littermates. This
effect was even more pronounced compared to our initial
finding of increased fluidity in the younger mice.
Importantly, while wild-type mice display a decrease in mem-
brane fluidity in both plasma and mitochondrial membranes
common to aging [50, 53, 57], HD knock-in mice show a
further increase in mitochondrial membrane fluidity and do
not follow the decrease in plasma membrane fluidity observed
in wild types. This suggests a progressive impairment of
mitochondrial membrane properties in these animals.
Importantly, the specific increase in mitochondrial mem-
brane fluidity was also identified in STHdh Q111/111 cells as
well as BACHD rats. Thus, the change in mitochondrial
membrane fluidity is robustly observed across different spe-
cies, strongly suggesting a direct or indirect involvement of
mhtt in mitochondrial membrane perturbation. Recent results
argue for a direct interaction of mhtt with proteins of the
mitochondrial membrane [25, 34, 62, 63] and mitochondrial
raft-like micro-domains [64]. In particular, it has been shown
that the first 17 amino acids (N17) of htt control its mitochon-
drial localization. It appears that N17 has lipid-binding prop-
erties and also enhances aggregate formation, and together
with the expanded polyQ repeat, it acutely disrupts calcium
Fig. 5 In vivo effects of
olesoxime on brain membranes
from BACHD rats. Mitochondrial
membranes (MM) and
synaptosomal plasma membranes
(SPM) were isolated from
13-month-old BACHD rats and
their wild-type (WT) litter mates
treated with either control diet or
600 mg/kg olesoxime for 12
months. DPH anisotropy, which
correlates inversely with
membrane fluidity, was measured
in MM (a) and SPM (c).
Membrane cholesterol levels
were determined by the CHOD-
PAP method in MM (b) SPM (d).
Bars represent mean ± SEM,
n=4–7/group. *p<0.05;
**p<0.01; ***p<0.0001,
t test
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homeostasis, leading to mitochondrial dysfunction [65].
Furthermore, cells overexpressing htt with 74 or 138
polyglutamine repeats were more sensitized to oxidative
stress-induced mitochondrial fragmentation, had reduced
ATP levels, and showed altered mitochondrial dynamics [28].
It was shown previously that synaptosomal plasma mem-
branes isolated from the brains of rats pretreated with 3-
nitropropionic acid (3-NP, rat model of HD) displayed de-
creased membrane fluidity selectively in striatal membranes
[66]. In our study, we did not observe significant differences in
the fluidity of synaptosomal plasma membranes. Since 3-NP
is a mitochondrial toxin, 3-NP treatment severely damages
mitochondria, leading to cell death and specific striatal lesions
[67]. Therefore, it is likely that the mitochondrial phenotype in
a 3-NP model exceeds the one in most of our genetic disease
models. In accordance with this idea, membrane fluidity data
obtained from patient fibroblasts also did not reveal changes
in plasma membrane fluidity [68].
The Role of Cholesterol for Determining Membrane Fluidity
in HD
Changes in membrane fluidity also affect membrane lipid
micro-domains [69, 70], which have recently been identified
to play a role in mitochondrial impairments in HD [64]. The
fluidity of biological membranes is determined by the mem-
brane lipid composition and individual phospholipids, includ-
ing their interaction with cholesterol and their level of satura-
tion [10]. Cholesterol is one of the major regulators of mem-
brane fluidity [71], and changes in cellular cholesterol metab-
olism have been associated with HD (summarized in
[72–75]). Valenza et al. [76] have demonstrated decreased
levels of specific sterols in HD model systems including one
of our HD rat models. Reduced mitochondrial cholesterol
levels in HD were presumed to be linked to inhibitory effects
of mhtt on the expression of 3-hydroxy-3-methyl-glutaryl-
CoA (HMG-CoA) reductase in astrocytes and neurons and/
or on ABCA1 transporters in astrocytes. Here, we report a
reduction in cholesterol levels in brain mitochondrial mem-
branes isolated from BACHD rats, but not HD knock-in mice
or STHdh cells. However, Marullo et al. [77] pointed out that
outcomes on cholesterol levels might crucially depend on the
method used for detection. A more detailed follow-up study
on the concentration and distribution of cholesterol in HD
would be required in order to draw final conclusions.
Olesoxime as a Therapeutic Drug for Mitochondrial
Dysfunction in HD
Based on the strong evidence for mitochondrial impairments
in HD [78, 79], mitochondria have been identified as targets
for therapeutic approaches [80, 81]. Herein, we tested the
effect of olesoxime on mitochondrial membrane properties
in vitro and in vivo. We found olesoxime to specifically
decrease mitochondrial membrane fluidity when applied in
either condition. In vitro treatment of STHdh Q111/111 and
Q7/7 cells revealed a genotype-nonspecific effect of the drug.
However, the decrease in membrane fluidity changed the
membrane properties in the direction of untreated controls.
Intriguingly, olesoxime specifically affected mitochondrial
membrane fluidity when administered per os (via the food)
in BACHD rats. Mitochondrial membrane fluidity was de-
creased almost down to normal levels in olesoxime-treated
transgenic rats and did not affect mitochondrial membranes of
wild-type littermates.
That olesoxime specifically affects the mitochondrial and
not the plasma membranes is consistent with the observation
of its entering the cell and concentrating at mitochondria in
primary cortical neurons [49]. Furthermore, previous obser-
vations revealed that olesoxime interacts with TSPO and
VDAC in the outer mitochondrial membrane [42]. Both pro-
teins are involved in multiple key cellular processes [82].
TSPO is primarily localized in the outer mitochondrial mem-
brane. One of its main functions is the transport of cholesterol
into mitochondria [83] and its delivery to the inner mitochon-
drial membrane [45]. The TSPO ligand PK11195 induces
changes in the distribution of intracellular cholesterol, which
is removed from membranes and accumulates into lipid drop-
lets [84]. The same TSPO ligand increases mitochondrial
membrane fluidity [85]. However, whether or not the effects
of olesoxime on cholesterol distribution and mitochondrial
membrane fluidity are linked to TSPO needs further investi-
gation. TSPO is, together with VDAC, also involved in mito-
chondrial homeostasis, such as energy production or calcium
signalling. VDAC acts as a gatekeeper for the entry and exit of
mitochondrial metabolites and thus plays a crucial role in the
regulation of metabolic and energetic functions of mitochon-
dria [44]. It is also recognized to function in mitochondria-
mediated apoptosis by the release of pro-apoptotic factors,
such as cytochrome c [82]. Interestingly, mPT was found to
be associated with increased membrane fluidity [86]. Thus,
VDAC appears to be a convergence point for a variety of cell
survival and cell death signals. Even though there are still
multiple models and viewpoints regarding mitochondrial per-
meability transition and mPT pore components, the preven-
tion of mPT has been shown to provide neuroprotection in
different paradigms [87] and might be relevant for the
olesoxime mechanism of action. This pharmacological char-
acteristic of olesoxime could be of relevance for HD, as
inhibitors of cytochrome c release have been proposed to have
therapeutic potential in HD [88–90]. Olesoxime had demon-
strated therapeutic efficacy for the treatment of mitochondrial
dysfunction and mitochondria-related disease pathology in
cell and animal models of amyotrophic lateral sclerosis [42,
46], multiple sclerosis [91], and peripheral neuropathy [47].
Chemically, olesoxime is a cholesterol oxime that shares
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structural analogy with tauroursodeoxycholic acid (TUDCA),
a cholesterol derivative with anti-apoptotic function [92] that
was found to be beneficial in 3-NP models of HD [93, 94].
Thus, steroids may represent potent molecules for the devel-
opment of disease-specific drugs targeting mitochondrial dys-
function in HD.
Summary Notes
Our study reveals alterations in mitochondrial membrane flu-
idity to be a common pathological feature related to mitochon-
drial dysfunction in HD. Mitochondrial membrane fluidity is
consistently increased in cell and animal models of HD, a
condition which has been linked to the initiation of apoptosis.
A detailed investigation of the connection between mitochon-
drial membrane fluidity changes and other mitochondrial im-
pairments, which are abundant in HD, is required in order to
understand when the changes occur and what the underlying
mechanisms are. Evaluation of the modulatory effect of the
mitochondria-targeting drug olesoxime, which inhibits apo-
ptosis, further revealed a decrease in membrane fluidity, con-
sistent with a rescue of mitochondrial membrane fluidity
changes in HD. Further studies need to be conducted in order
to uncover the mechanism of action and potential benefits for
the behavioral and neuropathological disease phenotype.
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Abstract
Huntington disease (HD) is an inherited neurodegenerative disease characterized by motor, cognitive, psychiatric and
metabolic symptoms. Animal models of HD show phenotypes that can be divided into similar categories, with the
metabolic phenotype of certain models being characterized by obesity. Although interesting in terms of modeling
metabolic symptoms of HD, the obesity phenotype can be problematic as it might confound the results of certain
behavioral tests. This concerns the assessment of cognitive function in particular, as tests for such phenotypes are often
based on food depriving the animals and having them perform tasks for food rewards. The BACHD rat is a recently
established animal model of HD, and in order to ensure that behavioral characterization of these rats is done in a reliable
way, a basic understanding of their physiology is needed. Here, we show that BACHD rats are obese and suffer from discrete
developmental deficits. When assessing the motivation to lever push for a food reward, BACHD rats were found to be less
motivated than wild type rats, although this phenotype was dependent on the food deprivation strategy. Specifically, the
phenotype was present when rats of both genotypes were deprived to 85% of their respective free-feeding body weight,
but not when deprivation levels were adjusted in order to match the rats’ apparent hunger levels. The study emphasizes the
importance of considering metabolic abnormalities as a confounding factor when performing behavioral characterization of
HD animal models.
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Introduction
Huntington disease (HD) is an autosomal dominantly inherited
neurodegenerative disease with a prevalence of 6 per 100,000 in
Europe and North America [1]. Development of HD is dependent
on a single mutation that results in the extension of the CAG
repeat sequence present in the gene for the Huntingtin protein [2].
HD patients display a range of symptoms that can be grouped into
motor, psychiatric, cognitive and metabolic symptoms. Symptoms
gradually worsen as the disease progresses, and due to the lack of
disease modifying treatments HD is invariably fatal.
There are numerous transgenic animal models of HD [3], and
as with any disease model, a major focus of working with these is to
assess how well their phenotypes mirror symptoms found in HD
patients. This is complicated due to the multitude of phenotypes
that are often present, and the potential risk of some phenotypes
confounding the assessment of others. The metabolic phenotypes
are especially interesting in this regard. While HD patients
typically lose weight [4,5,6,7,8,9], the body weight and body
composition phenotypes of transgenic animal models of HD vary
[3]. Animals that express the full-length mutant huntingtin gene
typically show an increased body weight, due to increased fat mass
[10,11]. Although this is interesting in terms of modeling the
metabolic symptoms of HD, an increase in body weight has been
suggested to result in reduced performance on the rotarod [12,13],
a common test of motor capacity and limb coordination.
Metabolic phenotypes are also of interest when considering tests
of cognitive function, as these are often based on having food
deprived animals perform certain tasks to retrieve food rewards
[14]. Ideally, animals should be equally hungry and interested in
food rewards when performing such tests, as studies where
motivational differences are present can give misleading results
[15]. Changes in body composition, such as the ones seen in HD
models, are likely to either be caused by or lead to a change in ad
libitum food consumption. Unless careful adjustments are made,
such phenotypes might persist even after food deprivation. One
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proposed method to avoid this when working with HD models is
to adjust food deprivation levels until animals show similar
consumption rates in tests where they are given brief access to food
[16,17]. Similar tests are occasionally used to assess hunger and
food interest, [18,19,20,21] although in HD research one should
also consider that a slowed consumption rate could be caused by
motor impairments. Thus, detailed knowledge about body
composition and feeding behavior of an animal model, both when
deprived and ad libitum fed, is important for planning and
interpreting a variety of behavioral tests.
The BACHD rat is a recently established animal model for HD.
These rats carry a large construct containing the full-length gene
for human mutant Huntingtin, with its endogenous regulatory
sequences [22]. Previous studies have shown that BACHD rats
have motor impairments and neuropathological phenotypes
reminiscent of symptoms seen among HD patients [22]. In
addition, BACHD rats appear to be impaired in some cognitive
tests [23]. Previous studies have indicated that BACHD rats eat
less than WT rats [22], although the setup used for that particular
study demanded social isolation, and its validity for assessing
natural behavior has been questioned [24]. Further, although it
has been pointed out that BACHD rats appear obese [22], there
has not been any study on their body composition. Therefore, we
performed a longitudinal study where food intake was measured in
a social homecage setup, and body composition was assessed
through detailed dissections. As further behavioral characteriza-
tion of the BACHD rats will be dependent on tests that require
food deprivation, we also sought to evaluate an optimal food
deprivation strategy for BACHD rats. For this, consumption rate
of reward pellets and regular food, as well as performance in a
progressive ratio test with prefeedings was assessed at different
levels of food deprivation.
Materials and Methods
Animals
A total of 168 male rats were used for the study. These were
acquired from three separate in-house breeding events, with
heterozygous BACHD males from the TG5 line [22] paired with
WT females. All animals were on Sprague Dawley background.
Animals were genotyped according to previously published
protocols [22] and housed in type IV cages (38655 cm), with
high lids (24.5 cm from cage floor), and free access to water. Food
availability and social conditions differed between the experimen-
tal groups. Rats used for ad libitum food intake and body
composition measurements were housed in genotype-matched
pairs, and had free access to food (SNIFF V1534-000 standard
chow) during the entire length of their respective test. Importantly,
food was provided on the cage floor and not on the cage top. Body
weight was measured weekly to assess general health, and cages
were changed twice per week. Rats used for hunger assessment
and PR tests were housed in genotype-matched groups of three
rats per cage. They had free access to food from the cage top until
the age of ten weeks. At that point, the rats were food deprived as
described below. Body weight was measured daily in order to
assess food deprivation levels, and cages were changed weekly.
The animal facility kept 21–23uC, 55–10% humidity, and was set
to a partially inverted light/dark cycle with lights on/off at 02:00/
14:00 during summer, and 01:00/13:00 during winter.
The seven groups of animals were used in different tests, as
described below. An overview of the animal groups, and the tests,
is shown in Figure 1. All experiments were approved by the local
ethics committee (Regierungspraesidium Tuebingen) and carried
out in accordance with the German Animal Welfare Act and the
guidelines of the Federation of European Laboratory Animal
Science Associations, based on European Union legislation
(Directive 2010/63/EU).
Ad libitum food consumption in a social homecage
environment
Ad libitum food consumption was measured using a total of 72
rats, acquired from one breeding event. At the age of five weeks,
all rats were arranged into genotype-matched pairs, and housed as
described above. This gave a total of 36 cages, 18 cages per
genotype. Cages with WT and BACHD rats were evenly
distributed over two racks, which were placed next to each other
in the same housing room. Food and water intake was assessed
Figure 1. Overview of study groups. A total of seven groups of rats were used in the current study. These were derived from different breeding
events and used in different tests, as shown in the figure. The ‘‘n’’ indicates the number of animals used from each genotype. Note that a total of two
animals were excluded during analysis, as explained in detail under ‘‘Statistical analysis’’.
doi:10.1371/journal.pone.0105662.g001
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twice weekly, when cages were changed. Cages were changed on
Mondays and Thursdays during the last two hours of the light
phase. At each cage-changing event, a known amount of food was
placed inside each new cage, and the fresh water bottles were
weighed. The weights of the old water bottles as well as the weight
of the food left in each old cage were then measured to assess the
amount of food and water consumed since the last cage change.
The food was manually collected from the bedding of the old
cages. After removing large food pieces, the bedding was sifted in a
homemade sieve with a 1 mm mesh in order to collect small food
pieces generated by food grinding. The animals’ food and water
consumption was followed in this way until the age of 26 weeks.
Sifting of bedding materials started when animals were 15 weeks
old.
Dissection for body composition assessment
A detailed dissection was performed in order to study the body
composition of BACHD rats. Five different rat groups were
sacrificed at 1, 3, 6, 9, and 12 months of age respectively, with
each group being composed of 12 WT and 12 BACHD rats. The
rat groups used for dissection at 6, 9, and 12 months of age were
the same rats that were followed during the ad libitum food
consumption test. The rat groups used for dissection at 1 and 3
months of age were acquired from a separate breeding. Housing
conditions were identical for all animals, and according to the
description above. Aside from the weekly food and water
consumption assessment made during the ad libitum food intake
test, food and water consumption were measured monthly as
animals aged. When rats reached an age of interest, a dissection
group was arranged based on the animals’ food consumption,
water intake, and body weights, so that the dissected group well
represented the full group.
Rats were sacrificed in a carbon dioxide chamber two to four
hours before dark-phase onset. Blood samples were collected after
sacrifice, through retro-orbital bleeding. Body lengths and body
weights were measured on the intact animals, with body length
measured from nose tip to tail tip. Additional measurements of
head, trunk, and tail lengths were measured from nose tip to back
of the head, back of the head to anus, and anus to tail tip,
respectively. After these external measurements, skin and subcu-
taneous adipose tissue deposits were removed and weighed. Then,
internal organs and adipose deposits located in the abdomen and
chest cavities were removed and weighed. The remaining carcass
was weighed before removal of the brain. By later subtracting the
brain weight, a measurement of bone and muscle weight (denoted
bone/muscle) was acquired for each rat. Dissection of a given age
group was carried out during four to six days, with rats of both
genotypes being assessed on each day.
Hunger assessment tests
Two tests were used to assess hunger levels in WT and BACHD
rats at three different food deprivation levels. A group of 24
animals with equal numbers of WT and BACHD rats was used for
both tests. This group was acquired from a breeding separate from
the ones used for the ad libitum food consumption and body
composition measurements. As mentioned above, food deprivation
started when the rats were ten weeks old. Body weights were
compared to control data from age- and genotype-matched free-
feeding animals, on a weekly basis, in order to acquire
measurements of food deprivation levels (relative body weight).
It should be noted that the control data was not gathered in the
current study, but in previous tests. Rats were given small daily
amounts of food inside their social homecages, approximately four
hours after dark phase onset, to maintain food deprivation. During
the first week of food deprivation, animals were habituated to the
reward pellets (Bio-Serv, Dustless Precision PelletsH F0021,
purchased through Bilaney Consultants, Duesseldorf, Germany)
by daily giving each cage a spoon-full of reward pellets together
with the daily amount of food. Behavior assessment started one
hour after dark phase onset, and was performed in the animals’
housing room, using soft red light. Rats were 13 weeks old when
behavioral assessment started.
Rats were assessed in both tests on each given testing occasion.
The first test assessed the rats’ interest in consuming 100 reward
pellets. The test used a glass cage (28.5629629.5 cm) with
mirrors, which allowed a good view of the feeding animals. At the
start of each trial, a rat was placed inside the cage, and was
allowed two explore it freely during two minutes. Afterwards, a
glass Petri dish containing 100 reward pellets was placed inside the
cage, in one of the corners that faced the experimenter. The rats
were then given a total of five minutes to consume the reward
pellets, while the experimenter scored their behavior. The
experimenter used two timers to separately record the total time
taken to consume the reward pellets, and the time each rat actually
spent eating. Thus, one timer was started when the rat first
discovered the pellets, and stopped either when all pellets were
consumed or when five minutes had passed. The second timer was
also started when the rat first discovered the pellets, but was
stopped whenever the rat stopped eating, and explored the test
arena. Roughly three hours were needed to assess all 24 rats. The
test schedule was arranged so that entire cages of BACHD and
WT rats were assessed in an alternating manner. Thus, three rats
of a given genotype were assessed in sequence, followed by three
rats of the other genotype. The experimenter was blinded to the
animals’ genotypes.
The second test assessed the rats’ interest in regular food. In this
test, rats were given free access to a large amount of food in their
homecages. Food was made available to the rats when four hours
remained of the dark phase. Identical amounts of food were placed
in the cage tops, with one-minute spacing between cages,
alternating between BACHD and WT cages. The remaining food
was then measured each half hour, until the end of the dark phase.
A final measurement was made at the end of the subsequent light
phase. At each measurement, the cages were briefly inspected for
larger pieces of food, as they occasionally dropped between the
bars of the cage lids.
The rats were assessed in these two tests on three separate
occasions. On the first, both WT and BACHD rats were deprived
to 85% of their respective free-feeding body weights. In an attempt
to reverse the phenotypes that were found, the food deprivation
levels were then adjusted so WT and BACHD rats were at 95 and
80% of their respective free-feeding body weights. On the final
trial, the previous deprivation levels were switched, so that WT
and BACHD rats were at 80 and 95% of their respective free-
feeding body weights. Each test occasion was separated by a week
of food deprivation, to allow gradual adjustment of deprivation
levels.
Progressive ratio test
A progressive ratio (PR) test was run to assess the rats’
motivation to work for a food reward at two different food
deprivation settings. A group of 24 animals with equal numbers of
WT and BACHD rats was used for the test. This group was
acquired from the same breeding as the group used for the hunger
tests described above. Food deprivation was initiated and
maintained as described above. Behavioral assessment started 30
minutes after dark phase onset, in a room separate from the
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animals’ housing room, using soft red light. Rats were 11 weeks old
when behavioral assessment started.
A bank of six operant conditioning chambers (Coulbourn
Instruments, H10-11R-TC with H10-24 isolation boxes, pur-
chased through Bilaney Consultants, Duesseldorf, Germany) was
used to run the test. Each chamber was equipped with two
retractable levers, placed 6 cm above the chamber floor,
protruding 2 cm from the wall. The levers were placed on either
side of a central pellet receptacle trough, which was placed 2 cm
above the chamber floor. The pellet receptacle trough contained a
yellow light, which was used to signal the delivery of a reward
pellet in all protocols described below. The chambers also
contained a red house light, on the wall opposite from the levers
and pellet receptacle trough, which shined during the full duration
of the training sessions. A water bottle was also available on this
wall, to ensure ad libitum access to water during testing. All
protocols were designed and run with Graphic State 4.1.04. Rats
were given single daily sessions, meaning that a total of four daily
runs with all six operant chambers were needed to assess the whole
group. Each run assessed three WT and three BACHD rats in a
determined order, so that a given rat was trained on the same time
of day through the entire test. Each rat was assigned to a specific
operant chamber, although this was arranged so that each operant
chamber was used to assess equal numbers of WT and BACHD
rats. Rats received their daily regimen of regular food four hours
after the completion of the last run of the day.
During initial training, rats of both genotypes were deprived to
85% of their respective free-feeding body weights. Afterwards, all
rats received two habituation sessions in the conditioning
chambers. During these, both levers were retracted and a single
reward pellet was delivered to the pellet trough at 10, 15, 20, 25,
or 30-second intervals. The pellet delivery interval varied in a
pseudo-randomized fashion so that each set of five deliveries used
each given interval once. Pellet retrieval, or failure to retrieve the
pellet within five seconds after delivery, lead to the start of the next
pellet delivery interval. After the habituation sessions, rats were
trained to lever push for a pellet reward. During these sessions,
both levers were extended into the chamber, but only one was
reinforced. Rats were either trained to push the right or the left
lever, with the reinforced lever position being counter-balanced
within the genotype groups. During training, the experimenter
would reward rats for approaching, sniffing and touching the
reinforced lever, until rats started to reliably push the lever on their
own. During this, each lever push was rewarded with one pellet.
Training continued until rats completed 100 lever pushes within a
30-minute session, without any help from the experimenter. The
rats were then trained on an FR3 protocol, where they had to push
the reinforced lever three times before being rewarded with a
pellet. When a rat completed 100 ratios within a 30-minute
session, it progressed to an FR5 protocol. Rats now had to push
the reinforced lever five times before being rewarded with a pellet.
Training on the FR5 protocol continued until rats completed 100
ratios within a 30-minute session, on three consecutive sessions.
Afterwards, rats were trained on a PR protocol adapted from [16].
In the current protocol, the ten first ratios were of FR5 type.
Afterwards, the required number of lever pushes increased after
each completed ratio. During this progression, the required
number of lever pushes increased in an arithmetic fashion within
each block of ten ratios, but also changed between the blocks, to
give an overall exponential progression. Thus, during the first,
second and third block of ten ratios, the ratio requirement
increased with one, three and five pushes per completed ratio,
respectively. The PR sessions lasted 80 minutes. The main
behavioral parameter of interest was a set of break points, defined
as the first ratio where a rat made no responses on the reinforced
lever during 10, 25, 50, 100, 300 or 600 seconds. Rats were
trained until both genotype groups reached a stable performance,
which in this case required 18 sessions. Performance during the six
last sessions was defined as baseline performance.
Once stable PR performance had been reached, the rats were
challenged in a set of four prefeeding tests. During these tests, the
rats were fed specific amounts of reward pellets or regular food,
just prior to their daily PR session. Rats were prefed by placing
them in individual cages that contained the specified amount of
food. Each prefeeding condition was assessed once, in the
following order: 100 reward pellets, 250 reward pellets, 4.5 g of
regular food, 11.25 g of regular food. Each prefeeding test was
separated by two regular PR sessions to ensure that rats returned
to their baseline performance.
After completion of the first round of prefeeding tests, the food
deprivation level of WT rats was adjusted until they consumed
food at the same rate as BACHD rats. Consumption rate was
assessed daily by measuring the amount of food consumed during
15 minutes of free access to regular food, placed in the cage tops of
the rats’ homecages. The rats were still given daily PR sessions
during food deprivation adjustments. The food consumption tests
were run four hours after completion of the last PR run, i.e. at the
time when the rats were usually given their daily food ration.
When WT rats had reached a consumption rate equal to that of
BACHD rats, six additional PR sessions were run to establish a
new baseline. The prefeeding tests were then repeated in the same
manner as described above. Rats were 20 weeks old at the end of
the test.
Statistical analyses
All statistical analyses were conducted using GraphPad Prism
v.6.01 (GraphPad Software, San Diego California USA, http://
www.graphpad.com).
Food consumption in the ad libitum food consumption test was
analyzed both in terms of the absolute amount of food consumed
and the amount of food consumed relative to the animals’ body
weight. The main analysis of food consumption was based on the
weight of large food pieces, as the food debris gathered through
sifting of the bedding material also contained hair and bedding
pieces. A separate analysis where food consumption was corrected
for the amount of food debris was still performed. For this, the
mean amount of food debris was calculated for each cage, based
on their longitudinal data. This was then added to the weight of
the large food pieces measured at each cage changing. For the
relative food consumption, rats in a given cage were assumed to
eat equal amounts of food. The approximate amount of food
consumed by one of the rats was subsequently related to the mean
body weight of the two rats. Two-way repeated measures
ANVOAs were used to analyze body weight as well as absolute
and relative food consumption. Age was used as within-subject
factor, and genotype as between-subject factor.
For data gathered in the dissection study, body weight, absolute
weight of adipose and bone/muscle tissues, as well as bone/muscle
weight relative to body length were analyzed using regular two-
way ANOVAs. The factors of interest were still age and genotype.
The weights of adipose tissue, bone/muscle tissue and internal
organs relative to body weight were analyzed in individual t-tests,
or Mann-Whitney tests, between genotypes, within each age
group. As the observed phenotypes did not vary between different
adipose tissue deposits, only the combined weight of all deposits
will be addressed here. One BACHD rat meant for the dissection
of six months old animals died before the dissection, making that
particular age group 12 WT and 11 BACHD rats.
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Results from the two hunger tests were analyzed both within
and between each testing occasion. For each test occasion of the
reward pellet consumption test, the time needed to consume the
pellets was analyzed with t-tests to compare the two genotypes.
The time spent exploring the test arena was only analyzed on the
first test occasion, using t-test, as rats showed essentially no interest
in exploring the arena on later trials. One BACHD rat was
excluded from the analysis of the last trial, as he failed to consume
all reward pellets within the maximum trial time. The amount of
food consumed during the food consumption test was on each test
occasion analyzed with two-way repeated measures ANOVA,
using time as within-subject factor, and genotype as between-
subject factor. To better understand the effect of repeated testing
and food deprivation levels, the time needed to consume 100
reward pellets, and the amount of food consumed during the first
30 minutes of the food consumption test were analyzed in
additional detail. Thus, data from all three test-occasions were
analyzed in two-way repeated measures ANOVAs, using genotype
as between-subject factor, and either session number or food
deprivation level as within-subject factor. Analysis of baseline
performance during the PR test was also made with repeated
measures two-way ANOVAs, with break point as within-subject
factor, and genotype as between-subject factor. Drops in
motivation during prefeeding sessions were analyzed for the 600-
seconds break point, as a percentage of the ratio reached during
the two preceding PR sessions. Once again, repeated two-way
ANOVAs were used to analyze the results, using prefeeding
condition as within-subject factor, and genotype as between-
subject factor. Separate analyses were performed for prefeeding
with reward pellets, and regular food. Bonferroni post-hoc test was
used to follow up any significant effects of genotype, or interaction
effects found in the two-way ANOVAs. Alpha for all analyses was
set to 0.05.
Results
Ad libitum food consumption
To assess BACHD rats’ growth and food consumption in a low-
stress and social environment, we housed genotype-matched rats
in pairs (Figure 2A), and measured their weekly body weight and
food consumption. Rats of both genotypes grew steadily during the
test, as indicated by the significant effect of age on body weight
(p,0.0001, F(21,1449) =2766) (Figure 2B). BACHD and WT rats
grew at a similar rate, and showed similar body weights through
the entire test, with no significant genotype effect or age x
genotype interaction. The rats’ food consumption also changed
with age (p,0.0001, F(20,680) =110.5) (Figure 2C). In general,
food consumption increased gradually until the age of nine weeks,
and then slowly dropped. Importantly, WT and BACHD rats
consumed equal amounts of food between six and eight weeks of
age, but there were a number of differences seen at older ages. At
nine and ten weeks of age, BACHD rats appeared to consume
more food that WT rats, although this did not reach statistical
significance. Directly following this, food consumption dropped
steadily among BACHD rats, while WT rats remained arguably
stable until the age of 16 weeks. Due to this, BACHD rats
eventually ate less than WT rats, as indicated by the significant
results from the post-hoc analysis at 17 weeks of age and onwards
(p,0.05–0.01). The difference in how food consumption changed
with age among BACHD and WT rats was also evident in a
significant age x genotype interaction (p,0.0001, F(20,680) =
19.06). Relating food consumption to the rats’ body weight gave
largely the same results, with a significant age effect (p,0.0001,
F(60,680) =1930) and age x genotype interaction (p,0.0001,
F(20,680) =12.99) (Figure 2D). However, this analysis made the
increased food intake among young BACHD rats more apparent,
with the post-hoc test indicating significant differences between
BACHD and WT at seven to ten weeks of age (p,0.01–0.0001).
In contrast, the decreased food consumption among old BACHD
rats was less apparent, with the post-hoc test only indicating a few
significant data points at 18 to 21 weeks of age (p,0.05–0.01). It
should be noted that BACHD rats produced less food debris
compared to WT rats (Figure S1A and B). Correcting for this did
not dramatically affect the food consumption phenotype, although
the genotype differences became less apparent (Figure S1C).
Finally, BACHD rats consumed dramatically less water compared
to WT rats (Figure S1D).
Body composition of BACHD rats
In order to assess BACHD rats’ body composition, we dissected
BACHD and WT rats at five different ages. As expected, older rats
weighed more, leading to a significant age effect on body weight
(p,0.0001, F(4,109) =444.1) (Figure 3A). In line with previous
data, there were no differences in body weight between the
genotypes in any age group, and also no significant difference in
apparent growth. The body composition of BACHD rats was
however different from that of WT rats. BACHD rats had
significantly lower percentage of bone and muscle (p,0.001, all
ages), and higher percentage of adipose tissue (p,0.05–0.001) in
all age groups (Figure 3B). These differences were also apparent
when analyzing the absolute weights of the respective tissues. Both
WT and BACHD rats gained adipose tissue with age, as indicated
by a significant age effect on the weight of total adipose tissue (p,
0.0001, F(4,109) =142) (Figure 3C). However, BACHD rats carried
an excess amount of adipose tissue, as indicated by both a
significant genotype effect (p,0.0001, F(1,109) =81.25), and
significant results from the post-hoc analysis of all groups, except
the one-month old rats (p,0.05–0.0001). There was also a
significant age x genotype interaction (p,0.0001, F(4,109) =7.686)
that was dependent on data from the one and three months old
groups. The bone/muscle weight also increased with age for both
genotypes (p,0.0001, F(4,109) =555.4) (Figure 3D). However,
BACHD rats were found to have significantly less bone/muscle
tissue compared to WT rats in all but the one-month old age
groups. This was indicated both by a significant genotype effect
(p,0.0001, F(1,109) =70.69), and significant results from the post-
hoc analysis (p,0.01–0.0001). A significant age x genotype
interaction (p,0.001, F(4,109) =4.18) also indicated that there
was a difference in the rats’ growth. Importantly, this effect was
dependent on the data of the one–month old group.
The rats’ body length also increased with age for both genotypes
(p,0.0001, F(4,109) =1517), although a significant genotype effect
(p,0.0001, F(1,109) =86.46) and post-hoc tests (p,0.01–0.0001)
revealed that BACHD rats were smaller than WT (Figure 3E).
This was apparent in all age groups except the one-month old
animals. It should, however, be noted that one-month old
BACHD rats were shorter than WT rats when analyzing litter-
matched groups (data not shown). The reduced body length
among BACHD rats was mainly due to them having shorter tails
and heads compared to WT rats (Figure S2).
BACHD rats also showed a lower amount of bone/muscle
tissues in relation to their body length (Figure 3F). Rats of both
genotypes gained relative amounts of bone and muscle with age
(p,0.0001, F(4,109) =570.6). However, BACHD rats had lower
relative amounts of bone and muscle from three months of age, as
evident from a significant genotype effect (p,0.0001, F(1,109) =
47.32) and post-hoc analysis (p,0.05–0.0001).
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Assessment of hunger during food deprivation of BACHD
rats
Two tests based on voluntary consumption of reward pellets and
regular food, were run to assess BACHD rats’ hunger level at
different levels of food deprivation (Figure 4A). When both WT
and BACHD rats were deprived to 85% of their respective free-
feeding body weights, BACHD rats were found to consume both
reward pellets and regular food at a slower rate than WT rats
(Figure 4B). In the pellet consumption test, BACHD rats needed
longer time to eat the reward pellets (p,0.01), but did not spend
more time exploring the arena, compared to WT rats. The slower
feeding speed led to a significant increase in trial time for BACHD
rats (data not shown). In the food consumption test, BACHD rats
were found to have eaten less than WT rats at almost all
investigated intervals, as evident from the significant genotype
effect (p,0.01, F(1,6) =14.62), and the significant results from the
post-hoc analysis (p,0.05–0.01). It should be noted that a
difference in actual consumption rate was only seen during the
first 30 minutes, resulting in an initial difference in the amount of
food consumed, which then persisted through the remaining part
of the test. This difference in behavior gave a significant time x
genotype interaction (p,0.01, F(9,54) =2.840) in the amount of
food consumed by the rats.
In an attempt to reverse the phenotypes described above, the
food deprivation levels were adjusted so that BACHD and WT
rats were at 80 and 95% of their respective free-feeding body
weights (Figure 4C). In the pellet consumption tests, BACHD rats
now needed a similar amount of time to consume the reward
pellets, although there was a borderline significant trend towards
BACHD rats needing more time (p= 0.0535). With the exception
of one WT rat, all rats spent the entire trial eating, and showed
minimal interest in exploring the test arena. In the food
Figure 2. Body weight and food consumption. (A) Housing conditions during the ad libitum food consumption test. (B) Body weight of rats
plotted against their age. (C) Approximate daily food consumption per rat (calculated from weekly food consumption per cage), plotted against the
age of the animals. (D) Relative daily food consumption per rat (calculated from weekly food consumption and average body weight per cage),
plotted against the age of the animals. The graphs show group mean plus standard error of the mean. Two-way ANOVA results are displayed above
each graph, and significant results from post-hoc analysis are displayed for individual data points. Genotype differences are indicated by (p,0.05)
*, (p,0.01) **, (p,0.001) *** and (p,0.0001) ****.
doi:10.1371/journal.pone.0105662.g002
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consumption tests, BACHD and WT rats consumed food at the
same rate during the first 150 minutes. During the remaining part
of the test, WT rats ate more, eventually leading to a significant
difference in the total amount of food consumed during the test
(p,0.01). The behavioral differences led to a significant time x
genotype interaction effect (p,0.0001, F(9,54) =8.642).
In a final test, the food deprivation levels were adjusted so that
BACHD and WT rats were at 95 and 80% of their respective free-
feeding body weights (Figure 4D). At this point, BACHD rats
consumed the reward pellets at the same rate as WT rats, as the
aforementioned trend was no longer present. With the exception
of two BACHD rats, all rats spent the entire trial eating, and
showed minimal interest in exploring the test arena. One BACHD
rat did not consume all reward pellets within five minutes. In the
food consumption test, BACHD rats were once again found to
have consumed less food than WT at all investigated intervals,
resulting in a significant genotype effect (p,0.001, F(1,6) =42.52),
and significant results from the post-hoc analysis (p,0.05–0.0001).
BACHD rats ate at a slower rate during the first hour. The
consumption rate gradually declined among WT rats, while it
gradually increased among BACHD rats, ending up at similar
levels after 150 minutes. This difference in behavior gave a
significant time x genotype interaction (p,0.0001, F(9,54) =8.47)
in the amount of food consumed by the rats.
A more detailed analysis of the results was performed with the
aim of better assessing the impact of food deprivation levels on the
consumption rate in the two tests. Separate two-way ANOVA
analysis of the time needed to consume 100 reward pellets, using
genotype as between-subject factor, and either food deprivation
level or the number of test sessions as within-subject factor,
revealed similar statistical results (Figure 5A). In either case, there
was a significant genotype effect (p,0.05, F(1,21) =5.476), and
performance on the first session, where both genotypes were
deprived to 85%, differed significantly between genotype groups
(p,0.05). Both analyses also revealed a significant effect of their
respective within-subject parameter (p,0.01, F(2,42) =7.861 and
6.6333 for session and deprivation level, respectively). However,
inspection of the graphed data indicated that the time needed to
consume the reward pellets did not clearly decrease with
increasing food deprivation levels, but did so with increased
numbers of test sessions. Performing the same analyses on the
amount of food consumed during the first 30 minutes of the food
consumption test revealed different results (Figure 5B). Both
analyses once again revealed a significant genotype effect (p,
0.01, F(1,6) =15.59), and significant effects of their respective
within-subject parameters (p,0.01, F(2,12) =8.220 and 17.04 for
session and deprivation level, respectively). Post-hoc analysis of
data analyzed in terms of food deprivation level revealed a
significant difference in consumption rate when rats of both
genotypes were deprived to 85% of their free-feeding body weight.
This was also found when analyzing the data in terms of the
number of test sessions given to the rats, although that analysis also
revealed a significant difference in consumption rate during the
third session. In contrast to the results from the pellet consumption
test, the consumption rate in the food consumption test appeared
to gradually increase with an increased food deprivation level,
while not showing any gradual change during repeated testing.
Progressive ratio performance during different levels of
food deprivation
To better assess differences in the motivational state among the
rats, a progressive ratio test was run with two different food
deprivation settings. All rats learned to push the lever in order to
obtain a reward pellet, although there were some discrete
behavioral differences between WT and BACHD rats during the
initial training steps. During habituation, BACHD rats made
fewer entries into the pellet receptacle (Figure S3A, B) and were
initially slower at retrieving the pellets (Figure S3C). During CRF,
FR3 and FR5 training, BACHD rats were generally slower at both
retrieving the pellets, and returning to the reinforced lever (Figure
S4 and S5).
During the fixed ratio part of the PR protocol, BACHD rats
were still slower at retrieving the reward pellets, but they no longer
showed an increase in lever return latencies (Figure S6). These
results were largely unaffected when food deprivation levels were
adjusted. WT rats tended to take longer time to complete the FR5
ratios, although this became significant only after adjustment of
their deprivation level (Figure S6). Importantly, there were no
overt differences between genotypes in the overall response
frequency on the rewarded lever during the fixed ratios (Figure
S6). The same was true for the mean number of lever pushes made
on the non-reinforced lever during the entire PR session (Figure
S7).
Analysis of how the rats reached a series of break points, when
all were deprived to 85% of their free-feeding body weight,
revealed both a significant genotype effect (p,0.01, F(1,22)
=10.66) and differences in the three highest break points (p,
0.01), with BACHD rats reaching lower ratios (Figure 6A). These
differences were not present when the food deprivation level of
WT rats had been adjusted so that their food consumption rate
matched that of BACHD rats. Similarly, when all rats were
deprived to 85% of their free-feeding body weight, BACHD rats
responded with more pronounced drops in motivation during
prefeeding of both reward pellets and regular food, as indicated by
significant genotype effects (p,0.01, F(1,22) =9.461 and p,0.01,
F(1,21) =8.343 for reward pellet and regular food prefeeding,
respectively) and prefeeding x genotype interactions (p,0.001,
F(2,44) =11.19 and p,0.05, F(1,21) =8.341 for reward pellet and
regular food prefeeding, respectively) (Figure 6B). Once again,
these phenotypes were not present when the food deprivation level
of WT rats had been adjusted, leading to identical responses in the
prefeeding tests. It should be noted that only the last break point,
break point 600, was suitable for prefeeding analysis. Prefeeding
induced a strong interest in water among WT rats, which
dramatically affected their early break points (data not shown). It
should also be noted that there was a significant difference in body
weight once the food deprivation levels had been adjusted, with
WT rats being significantly heavier than BACHD rats (data not
shown). The WT rats weighed roughly 50 g more than BACHD
rats, resulting in them being at 95% of their free-feeding body
weight.
Figure 3. Body composition assessed through dissection. (A–F) Data from the dissection groups as stated in the graph titles. The graphs
show group mean plus standard error of the mean. Two-way ANOVA results are displayed above each graph, and significant results from post-hoc
analysis are displayed inside each graph. Significant genotype differences are indicated by (p,0.05) *, (p,0.01) **, (p,0.001) *** and (p,0.0001) ****.
For (B), ANOVA was not performed, and the indicated differences concern single comparisons between WT and BACHD rats within the age groups.
Significant differences are indicated with ‘‘a’’ and ‘‘b’’ for differences in the relative amount of adipose and bone/muscle tissue respectively, written
according to the same grading as above.
doi:10.1371/journal.pone.0105662.g003
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Figure 4. Hunger and food interest assessment. Setups (A) and performance in the two consumption tests during the first (B), second (C) and
third test session (D), with the different food deprivation levels stated in the title of each figure panel. The time needed to eat 100 reward pellets and
the time spent exploring in the reward pellet consumption setup, are displayed in the top left and right graphs of each panel, respectively. The
bottom graph of each panel shows the cumulative food consumed per rat during the regular food consumption test. Scatter plots for reward pellet
consumption test results indicate individual values and group mean. Line graphs for regular food consumption indicate group mean plus standard
error of the mean. Statistical test results are given inside the graphs. For the regular food consumption test, two-way ANOVA results are displayed in
the bottom right corner, and results from post-hoc analysis are shown for individual data points. Significant genotype differences are indicated by
(p,0.05) *, (p,0.01) **, (p,0.001) *** and (p,0.0001) ****.
doi:10.1371/journal.pone.0105662.g004
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Discussion
Body composition and food intake of BACHD rats
Many transgenic animal models of HD show an altered body
weight compared to their WT littermates. Animals that express a
fragment of the disease-causing gene typically have a reduced
body weight [25,26,27], while the ones that express the full-length
gene typically have an increased body weight [10,11]. We show
here, that although BACHD rats did not differ from WT rats in
terms of body weight, they displayed several changes in body
composition. Strikingly, BACHD rats carried an excess amount of
adipose tissue. This is in line with phenotypes of other full-length
models of HD, as the increased body weight of BACHD and
YAC128 mice has been shown to at least in part be due to an
increase in adipose tissue mass [28,29]. It should be pointed out
that R6/2 and N171-82Q mice, which only express a fragment of
the disease-causing gene, also carry excess amounts of adipose
tissue [25,30]. R6/2 mice have further been shown to maintain
this increased fat mass even when they start to lose weight [25].
Thus, the increase in adipose tissue seems to be a common
phenotype of transgenic HD models, although it does not always
result in obesity.
Increased amounts of adipose tissue could theoretically be the
result of increased food intake, decreased home cage activity,
metabolic disturbances, or a combination of the three. While
BACHD mice have been shown to eat more than their WT
littermates [28], R6/2 and YAC128 mice have been found to have
unchanged food intake [25,29]. A previous study on BACHD rats,
in which food intake was followed from three to eighteen months
of age, indicated that the transgenic rats ate less than their WT
littermates [22]. These results were well reproduced here, despite
the different housing conditions. The current study also assessed
food intake at ages younger than three months, where BACHD
rats appeared to consume more food compared to WT rats. It
should be noted, however, that the appearance of the food
consumption phenotypes was to some degree dependent on
whether or not the weight of the consumed food was normalized to
the animals’ body weight. The aim of this normalization was to
relate the rats’ food intake to a measurement of their body size,
and through this investigate if the reduced food intake among
Figure 5. Impact of repeated testing and food deprivation on consumption tests. (A) The time needed to consume 100 reward pellets is
plotted against the deprivation level (left graph) and session number (right graph). (B) The food consumed during the first 30 minutes of the regular
food consumption test is plotted against the deprivation level (left graph) and session number (right graph). The graphs show mean plus standard
error of the mean. Two-way ANOVA results are displayed above each graph, and results from post-hoc analysis are shown for individual data points.
Significant genotype differences are indicated by (p,0.05) *, (p,0.01) **, (p,0.001) *** and (p,0.0001) ****.
doi:10.1371/journal.pone.0105662.g005
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Figure 6. Progressive ratio test performance. Performance in the PR test is shown for when animals of both genotypes were deprived to 85% of
their free-feeding body weight (graphs to the left in each figure panel) and when the deprivation level of WT rats had been adjusted to achieve equal
food consumption rates between genotypes (graphs on the right of each figure panel). (A) Baseline performance during six consecutive PR sessions
preceding the prefeeding tests. The ratio, where a given break point was reached, is indicated. (B) Performance during prefeeding with reward pellets
(top panel) and regular food (bottom panel). The drop in motivation is displayed as percentage of baseline performance for break point 600. The
graphs show group mean plus standard error of the mean. Two-way ANOVA results are displayed above each graph, and results from post-hoc
analysis are shown for individual data points. Significant genotype differences are indicated by (p,0.05) *, (p,0.01) **, (p,0.001) *** and (p,0.0001)
****.
doi:10.1371/journal.pone.0105662.g006
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BACHD rats could be due to them being smaller than WT rats.
Using body weight as an approximation of body size is, however,
probably only suitable at young ages, as the body weight of older
BACHD rats is distorted due to obesity. Thus, further studies are
needed to reach conclusions on this matter. In addition, as food
intake phenotypes are unlikely to explain the increase in adipose
tissue, metabolic parameters of BACHD rats need to be further
characterized. In this regard, it is important to note that the
obesity phenotype of BACHD mice was abolished when the
expression of mutant Huntingtin was silenced in the hypothalamus
[28]. Interestingly, hypothalamic lesions can induce obesity that is
not always associated with increased food intake, but can persist
despite unchanged or even reduced food intake [31,32,33,34,35].
The differential effects appear to depend on which specific
neuronal population is damaged [35,36], which might relate to the
common phenotype of increased fat mass, but varied food intake
seen across HD animal models.
In the current study, BACHD rats were shown to have a smaller
body size and disproportionately lower amount of bone/muscle
tissue compared to WT rats. Information about similar parameters
is scarce for other HD models, although YAC128 mice have been
shown to have unchanged lean body mass [29], while R6/2 mice
show a progressive reduction in lean body mass as they age [25].
These are both in contrast to the bone/muscle phenotype seen in
BACHD rats, as the lower amount of bone/muscle tissue seen in
the current study did not seem to progress with age. Instead, the
body size and bone/muscle phenotypes seen in the BACHD rats
appeared to be caused by discrete developmental deficits and
stunted growth. It is unlikely that these phenotypes were the result
of malnutrition during testing, as food was available ad libitum on
the cage floor. It is possible, however, that BACHD pups might
have had difficulties when competing for mothers’ milk, leading to
malnutrition at early ages. Such factors have been shown to affect
the growth of animals from large litters [37]. Alternatively, the
growth of BACHD rats might be disturbed on a molecular level, as
Huntingtin has been shown to be important during fetal
development [38]. The fact that BACHD rats had smaller heads
compared to WT rats is particularly interesting, as similar
symptoms have been seen in HD gene-carriers [39]. Thus, the
discrete developmental deficits found in the BACHD rats might be
closely connected to developmental deficits of human patients.
Food deprivation and motivation of BACHD rats
Behavioral assessment of HD animal models through the use of
operant conditioning tests is of interest, as cognitive symptoms are
common in HD patients and might become valuable to clinically
track disease progression and treatment effects [40,41,42]. Many
conditioning protocols require food deprivation in order to both
efficiently train the animals to perform a given task and to
maintain high performance. However, food deprivation of HD
models requires extra care as they can be expected to have
changes in body composition. To better understand how to
optimally food deprive BACHD rats, we assessed their interest in
food in a total of three different tests.
Free intake of reward pellets and regular food is sometimes used
to assess an animal’s hunger level and interest in food
[18,19,20,21]. In the current study, WT and BACHD rats
deprived to 85% of their free-feeding body weight did not seem to
differ in their interest in consuming 100 reward pellets, although
BACHD rats needed more time to eat all pellets. Food deprivation
levels were then adjusted in an attempt to reverse the phenotypes,
however, this did not seem to affect the rats’ behavior. Instead,
both the time spent exploring the arena and the time needed to
consume all pellets decreased with repeated testing. The training
effect on the consumption rate eventually led to BACHD rats
consuming the reward pellets at an equal rate compared to WT
rats. There were indications that rats deprived to 95% of their
free-feeding body weight spent more time exploring the arena
compared to rats deprived to 80%, but this generally concerned
one or two rats of an entire group of twelve. As the current
protocol did not appear to be sensitive even to large changes in
food deprivation levels, it is unlikely to be a suitable test for
assessing discrete differences in food interest. It is also clear that
the apparent training effect could be misinterpreted as a food
deprivation effect, if one assessed a given group of animals
repeatedly with the aim of gradually adjusting their food
deprivation level. The slowed consumption speed seen among
BACHD rats in the pellet consumption test is, however, an
interesting phenotype on its own. While eating, rats typically stood
on all four paws and used their tongue to pick up the pellets. Thus,
the slower feeding rate among BACHD rats is likely due to
impairments in quite basic processes that are needed for eating.
These could include impaired chewing, swallowing or tongue
movements as well as reduced saliva production. It is tempting to
hypothesize that the slower feeding speed among BACHD rats
could be due to phenotypes similar to the tongue protrusion
symptoms that are often seen among HD patients [43,44].
Interestingly, there are protocols for measuring tongue protrusion
[45] in rats, although these tests must be performed carefully, as
the smaller head size of BACHD rats likely means that they have
shorter tongues as well.
In the regular food consumption test, BACHD rats consumed
less food than WT rats when both groups were deprived to 85% of
their respective free-feeding body weight. Consumption rate
during the first 30 minutes of the test changed in a predictable
way when deprivation levels were adjusted, with more deprived
rats eating at a faster rate. This suggests that the protocol was well
suited for the assessment of food interest and hunger levels. Our
results further showed that when BACHD and WT rats were
deprived to 80 and 95% of their respective free-feeding body
weights, they consumed food at an identical rate for the initial 150
minutes, indicating that the rats were equally hungry. As the test
session continued, BACHD rats once again ate less than WT rats,
which likely reflected differences in the rats’ satiety levels. It should
be noted that the feeding behavior of either genotype did not
significantly differ when comparing their 80 and 85% food
deprivation test sessions. Thus, although the test seems suitable to
assess food interest, it does not appear to be very sensitive.
Assessing food consumption in single animals, rather than in
groups, would most likely improve the test’s sensitivity. It would
further allow separate scoring of the time spent eating and the time
spent not eating, as it was done in the reward pellet consumption
test. However, despite extensive habituation, we have found it
difficult to get our rats to efficiently consume regular food in any
other setup than their home cages. As the test did not allow
separate scoring of the time the rats spent feeding and doing other
activities, it was not possible to conclude if the difference in
consumption rate was strictly due to a difference in hunger and
food interest. This idea is especially difficult to support when
considering the results of the pellet consumption test. In an
attempt to reach a conclusion on the matter, we ran a PR test with
prefeedings.
When both WT and BACHD rats were deprived to 85% of
their respective free-feeding body weight, BACHD rats were
clearly less motivated to work for food rewards in the PR test.
Similar phenotypes have been found in other HD models [16,46]
and they are typically discussed in terms of apathy, which is a
common symptom among HD patients [47,48]. However,
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BACHD rats also responded with more pronounced drops in
motivation during the prefeeding tests, which would typically be
interpreted as BACHD rats being less hungry compared to WT
rats [49,50,51]. This would also support the idea that the BACHD
rats’ lower consumption rate in the first session of the food
consumption test was to some degree caused by lower hunger and
food interest. When the food deprivation level of WT rats was
adjusted to achieve equal food consumption rates to those of the
BACHD rats, all genotype differences that were previously seen in
the PR test disappeared. As WT and BACHD rats did not differ
during prefeeding tests, it is reasonable to assume that they were
equally hungry and that the food consumption test was suitable for
establishing food deprivation levels that ensured this. As they also
no longer differed in baseline performance, the motivational deficit
seen in the first PR test was likely dependent on a difference in
hunger levels, rather than an apathy-related phenotype. It is
interesting to note that after the food deprivation levels had been
adjusted, BACHD rats weighed approximately 50 g less than WT
rats. This difference was similar to the one found in bone/muscle
tissue, suggesting that WT and BACHD rats carried a similar
amount of adipose tissue. Secretion of leptin, which affects satiety
and food intake [52,53], is proportional to adipose tissue mass
[54], and it is possible that the food deprivation adjustment led to
equal hunger and food interest due to equal levels of leptin.
Importantly, higher leptin levels have been shown to reduce
motivation in PR tests [55], which gives a possible explanation for
the initial motivational difference.
Most of the conclusions above are based on the idea that
prefeeding responses depend exclusively on hunger levels and not
on other aspects of motivation. One could argue that animals that
suffer from motivational deficits not related to hunger, might also
respond stronger on the prefeeding tests. Thus, seeking a situation
where animals respond equally to prefeeding could in itself lead to
the lack of differences in PR performance. It is therefore important
to note that other studies have found motivational differences
despite identical responses on prefeeding tests [51], and that
motivational deficits have been found in BACHD mice after
adjusting deprivation levels until animals consumed food at the
same rate [16]. It should also be noted that the true nature of the
motivational phenotype seen here is mainly of importance when
such phenotypes are being characterized. If one simply wishes to
minimize motivational differences when working with BACHD
rats, regardless if these are due to hunger levels or other aspects of
motivation, adjusting deprivation levels so that WT and BACHD
rats consume regular food at a comparable rate should suffice.
Still, the current study only considered quite young animals. It is
possible that older BACHD rats suffer from motor impairments
that could affect the validity of the food consumption test. Also,
motivational phenotypes not related to hunger might become
apparent among older BACHD rats. We aim at addressing these
ideas in a longitudinal study of PR performance.
Summary
In the current study, BACHD rats were found to have
metabolic disturbances, which is in line with other animal models
of HD. We further found that unless these phenotypes were taken
into consideration during food deprivation, BACHD rats were less
motivated than WT rats in a progressive ratio test. Thus,
metabolic phenotypes are important to consider as possible
confounding factors when assessing apathy-related phenotypes of
BACHD rats. The same is likely true for other HD animal models
with metabolic abnormalities.
Our results further indicated that basing the animals’ food
deprivation levels on their consumption rates of regular food was a
convenient way to avoid motivational differences between
BACHD and WT rats. Thus, previous studies that applied this
method when studying apathy in HD animal models [16] likely
avoided hunger-based motivational differences, and our results
support the future use of this method. It is also important to
consider its use in behavioral tests where the main readout is not
directly related to apathy or motivation, such as [17], as
motivational differences have been shown to affect animals’
behavior in such tests too [15].
Supporting Information
Figure S1 Food debris and water consumption during
the ad libitum food consumption test. (A) The approximate
daily amount of food debris produced per cage (calculated from a
three- to four-day average), plotted against the age of the rats. (B)
The approximate amount of food debris per cage relative to the
average food consumption per cage, plotted against the age of the
rats. (C) The approximate daily food consumption per rat
(calculated from the weekly food consumption per cage) after
accounting for food debris left in the cages, plotted against the age
of the rats. (D) The approximate daily water consumption per rat
(calculated from the weekly water consumption per cage), plotted
against the age of the rats. The graphs indicate group mean plus
standard error of the mean. Two-way ANOVA results are
displayed above each graph, and results from post-hoc analysis
are shown for individual data points. Significant genotype
differences are indicated by (p,0.05) *, (p,0.01) **, (p,0.001)
*** and (p,0.0001) ****. For (D), WT and BACHD rats differed
highly significant (****) for all data points between 11 and 26
weeks of age.
(TIF)
Figure S2 Body length measurements. (A–D) Data from
length measurement as stated in the graph titles. The graphs show
group mean plus standard error of the mean. Two-way ANOVA
results are displayed above each graph, and significant results from
post-hoc analysis are displayed inside each graph. Significant
genotype differences are indicated by (p,0.05) *, (p,0.01) **, (p,
0.001) *** and (p,0.0001) ****.
(TIF)
Figure S3 Habituation to the operant conditioning
boxes. (A) The total number of head entries made into the pellet
receptacle during habituation sessions. (B) The total time spent
with the head inside of the pellet receptacle during habituation
sessions as a measurement of the duration of receptacle visits. (C)
The mean latency to enter the pellet receptacle after the delivery
of a reward pellet. The graphs indicate group mean plus standard
error of the mean. Two-way ANOVA results are displayed above
each graph, and results from post-hoc analysis are shown for
individual data points. Significant genotype differences are
indicated by (p,0.05) *, (p,0.01) **, (p,0.001) *** and (p,
0.0001) ****.
(TIF)
Figure S4 Performance on the CRF protocol. Results from
the final session of CRF training are shown as indicated by graph
titles. Session duration measured the time the rats needed to
complete 100 ratios. Retrieval latency measured the time between
the release of the reinforced lever and the entry into the pellet
receptacle. Lever return latency was defined as the interval
between the first receptacle entry following reward delivery and
the lever push that followed. Graphs indicate the performance of
individual rats and group mean. Results from t-tests or Mann-
Whitney tests are indicated in the graphs. Significant genotype
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differences are indicated by (p,0.05) *, (p,0.01) **, (p,0.001) ***
and (p,0.0001) ****.
(TIF)
Figure S5 Performance on fixed ratio protocols. Results
for several basic parameters of FR3 and FR5 protocols are shown
as indicated by the graph titles. Session duration measured the
time the rats needed to complete 100 ratios. Ratio duration
measured the time between the first and last lever push of each
ratio. Ratio interval was defined as the time between the last lever
push of one ratio and the first lever push of the ratio that followed.
Retrieval latency measured the time between the release of the
reinforced lever and the entry into the pellet receptacle. Lever
return was defined as the interval between the first receptacle entry
following reward delivery and the first lever push of the ratio that
followed. Scatter plots of FR3 results indicate the performance of
individual rats and group mean. Results from t-tests or Mann-
Whitney tests are indicated in the graphs. Only results from the
final session, where rats performed at criterion, are displayed. Line
graphs of FR5 results indicate group mean plus standard error of
the mean, plotted against the training session. Only the three final
sessions, where rats performed at criterion, are included. Two-way
ANOVA results are displayed at the top right corner of each FR5
graph, and significant results from post-hoc analysis are shown for
individual data points. Significant genotype differences are
indicated by (p,0.05) *, (p,0.01) **, (p,0.001) *** and (p,
0.0001) ****.
(TIF)
Figure S6 Performance on the fixed ratio part of the
progressive ratio protocol. Results for the basic parameters of
the ten FR5 ratios run at the start of each PR session. (A) Data
from sessions where BACHD and WT rats were both deprived to
85% of their respective free-feeding body weights. (B) Data from
sessions where food deprivation was adjusted to match the food
consumption rate of BACHD and WT rats. Details for each
parameter are described in the figure legend of Figure S4 and S5.
Lever push frequency was calculated based on the pushes made on
the reinforced lever during the full length of a ratio, i.e. the ratio
duration plus interval to subsequent ratio. Results displayed were
obtained from the sessions used for baseline curves in Figure 6A.
The graphs indicate group mean plus standard error of the mean.
Two-way ANOVA results are displayed at the top right corner of
each graph, and results from post-hoc analysis are shown for
individual data points. Significant genotype differences are
indicated by (p,0.05) *, (p,0.01) **, (p,0.001) *** and (p,
0.0001) ****.
(TIF)
Figure S7 Mean number of errors for the fixed ratio
part of the progressive ratio protocol. Errors made by the
rats during the ten FR5 ratios run at the start of each PR session.
(A) Data from sessions where BACHD and WT rats were both
deprived to 85% of their respective free-feeding body weights. (B)
Data from sessions where food deprivation was adjusted to match
the food consumption rate of BACHD and WT rats. Results were
obtained from the sessions used for baseline curves in Figure 6A.
Graphs indicate the performance of individual rats and group
mean. Results from t-tests or Mann-Whitney tests are indicated in
the graphs. Significant genotype differences are indicated by (p,
0.05) *, (p,0.01) **, (p,0.001) *** and (p,0.0001) ****.
(TIF)
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Huntington’s disease is a fatal human neurodegenerative disorder caused by a CAG repeat expansion in the HTT gene, which
translates into a mutant huntingtin protein. A key event in the molecular pathogenesis of Huntington’s disease is the proteolytic
cleavage of mutant huntingtin, leading to the accumulation of toxic protein fragments. Mutant huntingtin cleavage has been linked
to the overactivation of proteases due to mitochondrial dysfunction and calcium derangements. Here, we investigated the thera-
peutic potential of olesoxime, a mitochondria-targeting, neuroprotective compound, in the BACHD rat model of Huntington’s
disease. BACHD rats were treated with olesoxime via the food for 12 months. In vivo analysis covered motor impairments,
cognitive deficits, mood disturbances and brain atrophy. Ex vivo analyses addressed olesoxime’s effect on mutant huntingtin
aggregation and cleavage, as well as brain mitochondria function. Olesoxime improved cognitive and psychiatric phenotypes,
and ameliorated cortical thinning in the BACHD rat. The treatment reduced cerebral mutant huntingtin aggregates and nuclear
accumulation. Further analysis revealed a cortex-specific overactivation of calpain in untreated BACHD rats. Treated BACHD rats
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Introduction
Huntington’s disease, a fatal human neurodegenerative dis-
order, results from a CAG repeat expansion in exon 1 of
HTT (The Huntington’s Disease Collaborative Research
Group, 1993). The mutation translates into an elongated
polyglutamine tract close to the N-terminus of the mutant
huntingtin protein (HTT) (Persichetti et al., 1995). Patients
with Huntington’s disease suffer from a broad range of
symptoms including motor, psychiatric, cognitive and meta-
bolic disturbances (Vonsattel and DiFiglia, 1998), which
are associated with neuronal dysfunction, and the selective
degeneration of cortical and striatal projection neurons
(Tabrizi et al., 2011; Poudel et al., 2014).
The intrinsic toxicity of mutant HTT has been linked to the
formation of N-terminal protein fragments (Rigamonti et al.,
2000; Nagai et al., 2007;Wang et al., 2008). These fragments
interfere with important intracellular pathways (Zuccato
et al., 2010), accumulate in the nucleus (Landles et al.,
2010), and form protein aggregates in nucleus and cytoplasm
(Cooper et al., 1998; Li and Li, 1998), which is a hallmark of
Huntington’s disease (Gutekunst et al., 1999). Mutant HTT
fragments derive from proteolytic cleavage of the full-length
protein. Several classes of proteolytic enzymes have been
identified to mediate this process, including calpains (Gafni
and Ellerby, 2002), caspases (Goldberg et al., 1996), cathe-
psins (Kim et al., 2006) andmatrix metalloproteinases (Miller
et al., 2010). Calpains, which play a general role in neurode-
generative processes (Yang et al., 2013), are overactivated in
Huntington’s disease (Gafni and Ellerby, 2002), and inhib-
ition of the calpain-mediated cleavage of mutant HTT has
been found to ameliorate Huntington’s disease-related
pathologies (Gafni et al., 2004).
Calpains are activated in response to cytosolic Ca2 + cur-
rents (Goll et al., 2003), and Ca2 + homeostasis is disrupted
at several levels in Huntington’s disease (Miller and
Bezprozvanny, 2010). Moreover, Ca2 + derangements
have been considered to be causal for the neuronal
damage in Huntington’s disease, as the selective demise of
vulnerable neurons is thought to result from their particular
sensitivity to excitotoxicity, which is characterized by
intracellular Ca2 + overload and subsequent cell death
(Fan and Raymond, 2007). Mitochondria are particularly
involved in this process, as they are crucial for maintaining
low intracellular Ca2 + levels, and pivotal for triggering cell
death programs when their buffering capacity is exhausted
(Calı` et al., 2012). Mutant HTT affects mitochondrial func-
tion by directly binding to the outer mitochondrial mem-
brane (Panov et al., 2002; Choo et al., 2004; Rockabrand
et al., 2007; Gellerich et al., 2008; Wang et al., 2009) and
by disturbing the transcription of nuclear-encoded mito-
chondrial effector genes (Bae et al., 2005; Cui et al.,
2006). As a consequence, mitochondrial Ca2 + handling
ability is impaired, making cells more susceptible to exci-
totoxic insults (Panov et al., 2003; Tang et al., 2005).
The current study was designed to evaluate the thera-
peutic potential of the orphan drug candidate, olesoxime
(Bordet et al., 2007), on disease-related phenotypes of the
BACHD rat model of Huntington’s disease (Yu-Taeger
et al., 2012). Olesoxime is a small cholesterol-like molecule
that accumulates at the site of mitochondria (Bordet et al.,
2010). Olesoxime’s mechanism of action is not fully under-
stood, although it has been shown to inhibit mitochondrial
permeability transition (Bordet et al., 2010; Gouarne´ et al.,
2013, 2015), which is a Ca2 + -sensitive process that can
trigger cell death (Lemasters et al., 2009). Olesoxime has
demonstrated therapeutic efficacy in several neurodegenera-
tive diseases (Bordet et al., 2007; Sunyach et al., 2012;
Eckmann et al., 2013; Richter et al., 2014) and peripheral
neuropathies (Bordet et al., 2008; Xiao et al., 2009, 2012;
Rovini et al., 2010), and just recently yielded impressive
beneficial effects on motor function in a phase II clinical
trial in patients with spinal muscular atrophy (Dessaud
et al., 2014).
Here, we found that olesoxime treatment ameliorated psy-
chiatric and cognitive abnormalities in the BACHD rat. The
treatment further increased their frontal cortex thickness and
improved mitochondrial function. Prominently, it appeared
that the main effect of olesoxime was to reduce Huntington’s
disease-related calpain overactivation. Thereby, the forma-
tion of mutant HTT fragments was drastically decreased.
This yet undiscovered function opens a new view on
Olesoxime suppresses calpain BRAIN 2015: 138; 3632–3653 | 3633
 by guest on January 8, 2016
http://brain.oxfordjournals.org/
D
ow
nloaded from
 
olesoxime’s mechanism of action, and highlights it as a novel
tool for reducing calpain activation and the accumulation of
toxic mutant HTT fragments.
Materials and methods
Ethical statement
Behavioural experiments were performed at the University of
Tuebingen, by individuals with appropriate training and ex-
perience. Experiments were approved by the local ethics com-
mittee at Regierungspraesidium Tuebingen, and carried out in
accordance with the German Animal Welfare Act and the
guidelines of the Federation of European Laboratory Animal
Science Associations, based on European Union legislation
(Directive 2010/63/EU).
The BACHD rat
The BACHD rat of line TG5 [Crl:CD(SD)-
Tg(HTT*97Q)21.2Hpn/Hpn], hereafter referred to as the
BACHD rat, overexpresses full-length HTT with 97 CAA/
CAG repeats on a BAC (bacterial artificial chromosome)
(Yu-Taeger et al., 2012). The construct has previously been
used to generate the BACHD mouse (Gray et al., 2008).
General husbandry and genotyping
All rats were bred at the University of Tuebingen and study
groups derived from a total of 24 different breedings to
reduce possible litter bias. Male BACHD rats, hemizygous
for mutant HTT, and male wild-type littermates from re-
spective breedings were spread across study groups. The
rats were weaned and genotyped at 21 days of age.
Genotyping was confirmed at the end of the study when
the animals were sacrificed, and followed established proto-
cols (Yu-Taeger et al., 2012). From weaning onwards, the
animals were kept in autoclavable plastic cages with high
lids (38 cm  55 cm wide  24.5 cm high). Cages contained
3 l of autoclaved wooden bedding and were cleaned twice
a week. Food (initially standard rat chow: Ssniff V1534-000,
SSNIFF Germany, later changed to: Altromin C1000,
Altromin; details in the next section) and tap water were
delivered ad libitum. Housing conditions followed the
European Convention for the Protection of Vertebrate
Animals used for Experimental and other Scientific
Purposes (ETS 123, Appendix A: Guidelines for accommoda-
tion and care of animals). The environmental conditions in
the housing room were kept at 21–23C ambient tempera-
ture, 55  10% humidity and a 12/12 h light/dark cycle with
lights off at 1:00 p.m. and lights on at 1:00 a.m. during
winter, or with lights off at 2:00 p.m. and lights on at
2:00 a.m. during summer.
Olesoxime treatment and
experimental groups
The study included two cohorts of rats. Cohort I served a
longitudinal study to assess the treatment effect on relevant
behavioural, neuropathological and molecular phenotypes
(Supplementary Fig. 1). This cohort was composed of 30
wild-type (15 treated, 15 non-treated) and 30 BACHD rats
(15 treated, 15 non-treated), kept in groups of four of mixed
genotype (two wild-type rats and two BACHD rats per cage).
Two weeks after weaning (5 weeks of age), food was changed
from regular rodent chow (as stated above) to either control
diet or the same diet loaded with 0.6mg/g olesoxime (provided
by Trophos SA). Behavioural characterization was carried out
until the age of 13 months and was followed by MRI and
post-mortem analyses.
Cohort II was used for the measurement of olesoxime con-
centration in plasma and brain as well as its distribution in
different brain areas (nine olesoxime-treated and three non-
treated control animals per genotype). These rats were kept
in groups of three of the same genotype. Olesoxime-containing
or control diet was administered for 2 weeks starting at the
age of 4 months.
Body weight and food intake were measured as safety
parameters for the olesoxime treatment. Body weight was mea-
sured weekly. For food intake measurements, the rats were
housed individually for 70 h in an automated behavioural
test system (PhenoMaster, TSE Systems) at 2, 4, 6, 8 and 12
months of age. Test protocol, system specifications and data
analysis were the same as described in detail in Clemens et al.
(2014).
Clasping behaviour
Clasping behaviour was investigated as a measure of a stri-
atum-based motor dysfunction (Soll et al., 2013). To detect
hind limb clasping, each animal was lifted on its tail for
2 s. The test was performed weekly from 5 weeks until the
age of 10 months (33 observations). The clasping frequency in
per cent of all observations was analysed.
Rotarod test
The animals were trained to walk on an accelerating rod (Rat
Rotarod 7750, Ugo Basile) to assess fore limb/hind limb co-
ordination at 2, 4 and 8 months of age as a measure of stri-
atum-based motor dysfunction (Bergeron et al., 2014). Rats
were given four daily trials at 2 months of age, or three
daily trials at older ages, during a total of five consecutive
days. Trials were separated by 1-h intervals. The experiments
were run during the dark phase. During the first 3 days, the
rats were trained to a stable performance. At this stage, the
maximum rotation speed of the rod was set to 12 rpm
(increasing from 2 to 12 rpm over 30 s), and trials lasted
either 120 s, or until the rat had fallen off the rod a total of
five times. The number of falls served as the performance read-
out. On the last 2 days, the rats’ maximum motor capacity
was tested. For this, the rotation speed of the rod increased
from 4 to 40 rpm over 240 s and the trials lasted either 300 s
or until the rat had fallen off the rod for a total of five times.
The total amount of time the animals spent on the rod
(excluding the time spent not running during falls) was mea-
sured and analysed as the animals’ running capacity. The
number of rats included in the analysis decreased, as an
increasing number of particularly BACHD rats refused to
stay on the rod at older ages (as discussed previously in
Yu-Taeger et al., 2012; Abada et al., 2013b).
3634 | BRAIN 2015: 138; 3632–3653 L. E. Clemens et al.
 by guest on January 8, 2016
http://brain.oxfordjournals.org/
D
ow
nloaded from
 
Simple swim test
At the age of 7 months, cognitive abilities were investigated
using a simple swim test. The animals were trained to swim to
a hidden platform placed at one end of a rectangular water
tank of 150  25  40 cm (adapted from Van Raamsdonk
et al., 2005). Training was carried out in dimmed red light
during the dark phase, alternating between cages with placebo-
and olesoxime-treated rats. During an initial training phase,
the animals were placed into the middle of the tank facing
away from the platform, forcing them to turn around to
reach it. The training was carried out on two consecutive
days in 3  3 trials on the first and three trials on the follow-
ing day. On the third day, the platform was repositioned to the
opposite side (‘reversal’) and the rats’ performance was mea-
sured again on two consecutive days. In this reversal training,
the rats needed to swim straight ahead in order to reach the
platform. The rats were trained in 3  3 trials on the first day
and three trials on the second day. Individual blocks of trials
were separated by 1 h. The water was kept at room tempera-
ture, and coloured with non-toxic black paint (Marabu
Fingerfarbe). The water tank was virtually divided into four
areas: the starting area, the area opposite to the platform, the
area towards the platform, and the platform. The trials were
videotaped and tracked using TSE VideoMot 2 equipment
(TSE Systems). Raw data on time and distance covered
before reaching the platform as well as swim speed were ex-
ported from the software, sorted according to genotype and
treatment, and analysed as average values for each block of
three trials, using a script for R statistics developed at the
University of Tuebingen.
Elevated plus maze
The rats’ preference for exploring the closed rather than the
open arms of an elevated plus maze was assessed as a meas-
urement of anxiety-like behaviour at 13 months of age. The
setup comprised four arms (12-cm wide and 42-cm long), con-
nected by a 12  12 cm central area. Two of the arms were
enclosed by 42-cm high walls (closed arms), while the other
two arms had no walls (open arms). The arena was positioned
52 cm above ground. The experimental room was lit with
white light, leaving the open arms exposed to light, while
the closed arms remained substantially darker. The test was
carried out for all rats on one day during the early dark phase,
and cages with placebo- and olesoxime-treated rats were tested
in an alternating order. At the start of each trial, a rat was
placed inside the central area of the maze, facing one of the
open arms, and allowed to freely explore the maze for a total
of 5min. The time spent in the open arms of the elevated plus
maze was measured and subsequently analysed as per cent of
the total trial duration.
Magnetic resonance imaging
MRI was performed at the Werner Siemens Imaging Center
(Tuebingen, Germany). For this purpose, the rats were anaes-
thetized with 2% isoflurane and maintained at 1.2% vaporized
in 100% O2 at a flow rate of 1.5 l/min. Body temperature and
ventilation rate were monitored throughout the MRI acquisi-
tion, with body temperature kept in the stable range of
37  0.5C. Anatomical T2-weighted images were acquired
with a rat brain surface coil using a 3D-spoiled turbo spin
echo sequence (256  160 matrix, 25  25 mm2 field of
view, repetition time = 3000ms, echo time = 205ms, slice
thickness = 0.22mm). For MRI data evaluation, image analysis
was performed using Inveon Research Workplace software
(Siemens Healthcare) and referring to the rat brain atlas
(The Rat Brain in Stereotaxic coordinates, 6th edition,
2006). Size differences in whole brain, cerebellum and striatum
were determined with high accuracy by measuring the respect-
ive volume, as these brain regions have a clear delimitation in
MRI. By contrast, differences in the size of the cerebral cortex
were evaluated more accurately by measuring the thickness of
the frontal part at 1.56mm relative to bregma at the most
dorsal point of the corpus callosum.
Measurement of olesoxime
concentration
The concentration of olesoxime in plasma and brain samples
was measured via HPLC-MS at Trophos SA using the
Alliance HPLC System (Waters S.A.S.). Samples were col-
lected as explained below and thawed at room temperature.
Plasma was mixed with 150ml of acetonitrile, vortexed for 10 s
and centrifuged for 10min at 13 200g. Brain tissue was first
homogenized at a concentration of 1 g/ml in Hank’s balanced
salt solution (10mM HEPES, 141mM NaCl, 4mM KCl,
28mM CaCl2, 1mM MgSO4, 1mM NaH2PO4).
Homogenates were then mixed with 300 ml dichloromethane,
vortexed for 10 s and centrifuged for 10min at 13 200g. The
organic phase was collected, evaporated at low pressure and
40C and resolubilized in 110ml acetonitrile. Assays were run
once. Calculations were performed against a calibration curve
prepared from olesoxime-spiked, normal rat plasma or brain
homogenate, respectively.
Blood sampling
Blood was collected from rats of Cohort I during the longitu-
dinal study at 3, 6, 9 and 13 months of age, and from rats of
Cohort II after 2 weeks of olesoxime treatment at 4 months of
age. For Cohort I, blood was collected by puncturing the ani-
mals’ tail veins (the procedure did not require anaesthesia),
while for Cohort II, blood was sampled retro-orbitally post-
mortem. In either case, sampling was carried out within 2 h
during the late light phase to minimize variation based on
circadian rhythms. Blood was collected into EDTA-coated
tubes on ice. Samples were centrifuged at 1500g for 10min,
plasma was removed, transferred into cryotubes and stored
at 80C.
Brain tissue sampling
For immunohistochemical techniques, the rats were deeply
anaesthetized with an intraperitoneal injection of ketamin/
xylazin (100mg/kg or 5–8mg/kg, respectively) and perfused
transcardially with 4% paraformaldehyde in phosphate-
buffered saline (pH 7.4). Brains were removed and stored at
4C in 0.5% paraformaldehyde in phosphate-buffered saline
(pH 7.4).
For all other analyses, the animals were sacrificed by CO2
inhalation. Brains were immediately dissected on ice and whole
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brain, or brain regions, were sampled. Tissue was shock-frozen
in liquid nitrogen and either stored at 80C or immediately
processed to obtain live mitochondria for high-resolution
respirometry. Tissue sampling was performed within 2 h
during the late light phase to minimize variation based on
any circadian phase-related changes.
Isolation of mitochondria and high
resolution respirometry
Mitochondria were isolated from the frontal brain and respir-
ation was measured at the Department of Pharmacology,
Goethe University Frankfurt, Germany. For this purpose,
tissue samples were homogenized in respiration media
(20mM HEPES, 110mM sucrose, 0.5mM EGTA, 3mM mag-
nesium dichloride, 60mM lactobionic acid, 20mM taurine,
10mM potassium dihydrogenphosphate and 1 g/l essentially
fatty acid-free bovine serum albumin, pH 7.4) containing
4% protease inhibitors (Complete Protease Inhibitor,
Roche). Homogenates were centrifuged at 1400g for 7min,
supernatant was collected and centrifuged at 1400g for 3min
and finally recollected and centrifuged at 10 000g for 5min to
pellet the mitochondria-containing fraction. Pellets were gently
resuspended in respiration media, aliquots for the determin-
ation of protein concentration and citrate synthase activity
(procedure described below) were collected, frozen in liquid
nitrogen and stored at 80C, while respiration was recorded
immediately.
Respiration was measured with the Oxygraph (Oroboros),
which allows the measurement of mitochondrial respiration in
two samples simultaneously. Analysis was made using sample
pairs of different genotypes (wild-type and BACHD) but iden-
tical treatment (placebo or olesoxime). Data were acquired
with DatLab software, version 4.3.2.7. The rate of mitochon-
drial respiration was monitored at 37C according to a proto-
col by Prof. Dr Erich Gnaiger (University of Innsbruck,
Austria) (Kuznetsov et al., 2002). A series of substrates and
inhibitors were added to the samples in sequence to assess the
function of different components of the mitochondrial respira-
tory chain. The capacity for OXPHOS (oxidative phosphoryl-
ation) was measured after addition of the complex I substrates
(CIOXPHOS) glutamate (5mM), malate (2mM) and ADP
(2mM), followed by the addition of succinate, the substrate
for complex II (CI + IIOXPHOS). Blocking the ATP synthase by
addition of oligomycin, further allowed for the measurement
of respiration driven by the mitochondrial proton leak only.
Subsequent titration of the artificial uncoupler FCCP (trifluor-
ocarbonylcyanide phenylhydrazone), injected in steps of 1mM
up to 4 mM until saturation occurred revealed the maximum
capacity of the electron transport system (ETS). Afterwards,
addition of the complex I inhibitor rotenone revealed
uncoupled CII activity (CIIETS). Residual oxygen consumption
(oxygen consumption caused by enzymes not belonging to the
ETS) was measured after inhibition of complex III with 2.5mM
antimycin A, and subtracted from all measurements.
Cytochrome C oxidase (complex IV) activity was determined
after addition of 0.5mM TMPD (tetramethylphenylenedia-
mine), an artificial substrate and 2mM ascorbate, which
keeps TMPD in the reduced state. Complex IV respiration
was corrected for the auto-oxidation rate of TMPD, deter-
mined by addition of azide (5100mM).
Respiration data were normalized to citrate synthase activ-
ity, a marker for mitochondrial mass (Kuznetsov et al., 2002).
Citrate synthase activity was assessed spectrophotometrically.
For this purpose, samples were thawed and diluted 1:2 in
deionized water. Reaction media [0.1M Tris-HCl, 0.1mM
DTNB (5,5-dithiobis-2-nitrobenzoic acid), 0.5mM oxaloace-
tate, 50 mM EDTA, 0.31mM acetyl coenzyme A, 5mM
triethanolamine hydrochloride] were warmed for 5min at
30C, samples were added, and the formation of TNB
(5-thio-2-nitrobenzoic acid) was measured immediately via ab-
sorbance at 412 nm.
Immunohistochemistry
Paraformaldehyde-fixed brains were embedded in gelatin
blocks (16 brains per block) and cut serially into 40-mm
thick coronal sections (performed by NeuroScience
Associates). Sections were stored in antigen-preserve solution
(Fisher Scientific) at 20C. Free-floating staining was per-
formed at room temperature, as described previously
(Osmand et al., 2006). Briefly, a series of 24 sections were
warmed up at room temperature for 2 h and incubated for
30min in 0.5% NaBH4 for blocking purpose. After washing,
the sections were probed overnight with sheep polyclonal S830
antibody (1:20 000, kindly provided by Prof. Dr Gillian Bates,
King’s College London, UK) for the detection of N-terminal
mutant HTT. On the next day, the sections were incubated
with biotinylated rabbit anti-sheep IgG secondary antibody
(1:1000, BA-6000, Vector Laboratories) for 2 h and subse-
quently with avidin-enzyme complex (Vectastain Elite ABC
Kit Rabbit IgG, Linaris) for 1 h. To further enhance the
signal, biotinylated thyramine plus 0.001% H2O2 was added
for 10min and the sections were once more incubated with
avidin-biotin complex. Colour development was achieved with
nickel-DAB-H2O2 (0.6% nickel, 0.01% DAB and 0.001%
H2O2) dissolved in TI buffer (0.05M Tris, 0.05M imidazole).
Nissl staining was performed using 1% thionine acetate to
visualize nuclei. Sections were mounted and stored at room
temperature.
Images were acquired using a Zeiss Axioplan microscope
(Pl 10 ocular, Plan-NEOFLUAR 40/0.75 objective,
AxioCam MRc) and Axiovision 4.8 software (Zeiss). Images
were exported from Axiovision in tiff format, and imported
into Corel Draw X5, where they were cropped to display the
region of interest, and moderately adjusted in brightness, con-
trast and saturation to better visualize the structures of inter-
est. The aforementioned adjustments did in no way change the
information that was subject to analysis, namely the total
number of S830-positive nuclei and cytoplasmic aggregates.
The quantification, i.e. counting the number of cytoplasmic
aggregates and the number of nuclei positive for mutant
HTT staining, was performed manually.
Immunoblotting
Immunoblotting was performed with striatal and cortical tissue
as well as mitochondrial membranes isolated from cerebral
hemispheres.
Striata and cortices were thawed and homogenized on ice in
TES buffer (50mM Tris, 2mM EDTA, 100mM NaCl, pH 7.5)
containing protease inhibitors (4% Complete Protease
Inhibitor, Roche). Homogenates were diluted 1:10 in TNES
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buffer (90% TES buffer, 10% Igepal CA630), incubated for 1 h
at 4C and centrifuged 2  30min at 16100g. Supernatant (cell
lysates) were collected and stored at 80C in 10% glycerin.
Mitochondria-enriched heavy membrane fractions were iso-
lated from cerebral hemispheres (brain stem, cerebellum and
olfactory bulbs had been removed). Tissue was homogenized
on ice in HEPES buffer (10mM HEPES, 0.32M sucrose,
1mM EDTA, pH 7.4) and centrifuged at 585g for 10min.
Supernatant was collected and further centrifuged twice at
17 400g for 20min. Pellets were resuspended and layered
over a Ficoll density gradient (7.5% and 13%, w/v). After
60min of ultracentrifugation at 87 300g, the pellet, which
at this point contained the mitochondrial fraction,
was sampled, resuspended in 5mM Tris-HCl and stored at
20C.
At the time of immunoblotting, all samples were thawed on
ice, and the protein concentration was measured spectrophoto-
metrically using Bradford reagent. Western blot analysis was
performed according to standard procedures. Briefly, 15 mg of
mitochondrial protein or 30 mg of protein from tissue lysates
were assayed using sodium dodecyl sulphate (SDS) polyacryl-
amide gel electrophoresis on Tris-glycine or purchased Tris-
acetate gels (Life Technologies). Proteins were transferred on
nitrocellulose or polyvinyl difluoride membranes, and probed
overnight at 4C with the primary antibody (Supplementary
Table 1). One hour of incubation with a horseradish peroxid-
ase-conjugated secondary or IRDye antibody (Supplementary
Table 1) at room temperature followed. Chemiluminescence
and fluorescence signals were detected with the LI-COR
ODYSSEY FC Imaging system (LI-COR Biosciences). Protein
levels were quantified by densitometry using ImageJ (Abra`moff
et al., 2004).
Filter retardation assay
For the detection of SDS-insoluble HTT species, 30 mg of cor-
tical or striatal proteins were diluted in 100ml DPBS (Life
Technologies) with 2% SDS and incubated for 5min at
room temperature. A nitrocellulose membrane (0.45 mm; Bio-
Rad) was equilibrated in 0.1% SDS in DPBS and samples were
filtered through this membrane using a Minifold II Slot Blot
System (Schleicher & Schuell). The membrane was then
washed twice with DPBS and blocked with 5% SlimFast
(Unilever) in Tris-buffered saline for 1 h at room temperature.
Retained SDS-insoluble HTT was detected using anti-HTT pri-
mary antibody (1:1000; clone 1HU-4C8, MAB2166, EMD
Millipore) and the respective anti-mouse horseradish peroxid-
ase-conjugated secondary antibody. Chemiluminescence signals
were detected with the LI-COR ODYSSEY FC Imaging system
and quantified using the ODYSSEY Server software version
4.1 (both LI-COR Biosciences).
Calpain activation assays
In vitro calpain activation assays of brain lysates were per-
formed as previously described (Hu¨bener et al., 2013).
Briefly, 30 mg of protein from TNES lysates were diluted in
40 ml calpain reaction buffer (20mM HEPES/KOH pH 7.6,
10mM KCl, 1.5mM MgCl2, 1mM dithiothreitol). The posi-
tive control was incubated with 20 ng of recombinant calpain-
1 (EMD Millipore), and 2mM CaCl2 for indicated times at
room temperature, while the negative control was pretreated
with 100mM of the calpain inhibitor CI-III (carbobenzoxy-
valinyl-phenylalaninal) (EMD Millipore) prior to calpain-1
addition. Calpain activity of all samples was quenched by
addition of 4 NuPAGE LDS sample buffer (Life
Technologies) and heat denaturation for 10min at 70C.
Samples were subsequently assayed by immunoblotting, as
described above.
Time-resolved ﬂuorescence energy
transfer for soluble mutant HTT
detection
Time-resolved fluorescence energy transfer (TR-FRET) was
performed with cortical and striatal lysates (sampled as
described in the ‘Immunoblotting’ section), and conducted ac-
cording to Baldo et al. (2012) at Novartis. Briefly, samples
were ultracentrifuged at 80 000g for 90min. Supernatant was
transferred to 384-microtitre plates, diluted 1:5 in detection
buffer (50mM NaH2PO4, 400mM NaF, 0.1% bovine serum
albumin, and 0.05% Tween) and probed with fluorophore-
labelled antibodies 2B7-Tb and MW1-d2 in a ratio of 1:10.
TR-FRET was read with an EnVision Reader (PerkinElmer).
After the excitation of the donor fluorophore Tb at 320 nm
and a time delay of 100ms, the resulting Tb and d2 emission
signals were read at 620 nm and 665 nm, respectively.
Experimental design
Sample size estimation was based on behavioural data previ-
ously obtained for the BACHD rat. Fifteen animals per geno-
type and treatment group were assigned to the Rotarod test,
12 to the simple swim test, five to the elevated plus maze and
10 to MRI analysis. Ex vivo analyses were planned with five
rats per group. The final assignment differed slightly from this,
as one cage of placebo-treated rats originally intended for the
elevated plus maze and mitochondrial respiration analysis was
used in addition for MRI measurements. Furthermore, three
animals died during the study (without any bias regarding
genotype or treatment groups). For ex vivo analyses, a final
number of three to five rats per group were used, as sample
material was limited.
During behavioural studies, the experimenter was blind to
the animals’ genotype, but not treatment, as the cages had to
be labelled to ensure that the right kind of food, either placebo
or olesoxime-loaded pellets, was provided at all times.
Aggregate count was performed by one observer, who was
blind to genotype and treatment group.
The n analysed, refers to the biological replicate of individ-
ual animals of a given genotype and treatment group, except
for drug concentration analysis in brain regions, where sam-
ples from two to three individuals were pooled in order to
reach a proper amount of sample material.
Statistical analysis
Data were analysed and graphed using GraphPad Prism 6.00
for Windows (GraphPad Software, San Diego California USA,
http://www.graphpad.com). Values refer to group mean and
standard error of the mean (SEM) for all figures, and group
mean and standard deviation (SD) for Table 1. The -level was
set to 0.05. Complete data sets proved to be normally
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distributed. Longitudinal data were analysed using repeated
measurements two-way ANOVA, with time (e.g. age or trial)
as a within-group factor and group (e.g. genotype and treat-
ment) as between-group factor. Single data sets were analysed
using regular two-way ANOVAs to identify genotype and
treatment effects. For both, two-way repeated measures
ANOVA and two-way ANOVA, the results are implemented
in each graph and specify the respective between-group factors.
Fisher’s least significant difference (LSD) was performed as
ANOVA post-test, and did not account for multiple compari-
sons, favouring false positive over false negative results in this
first evaluation of olesoxime effects on Huntington’s disease-
related phenotypes. There was one two-group comparison
(treatment effects specific to BACHD rats), which was ana-
lysed using a Student’s t-test. Results from two-way
ANOVAs and Fisher’s LSD post-test, and post-test as well as
t-test results for the comparisons *wild-type versus BACHD
rats; #untreated versus treated wild-type rats; and +untreated
versus treated BACHD rats are indicated in respective figures,
with ns = not significant, */#/+P5 0.05; **/##/++P4 0.01; and
***/###/+++P40.001.
Some behavioural data were excluded from the analysis
based on predefined criteria or technical problems.
Concerning technical problems, the data could either not be
properly acquired or the acquired data were inconclusive (as
explained in detail below). We did not predefine exclusion
criteria for outliers, or exclude data in order to reach a
normal distribution. Moreover, the values we excluded were
spread equally among groups, suggesting that it did not have a
biological meaning or exclusion was skewing the results. Food
intake measurements: nine of the 60 animals were excluded
from the analysis because in at least one of the five measure-
ments (at 2, 4, 6, 8 or 12 months of age), the food became
stuck in the food basket leaving the animal unable to reach it
and resulting in unreasonably low values for food intake
during the respective night. Rotarod test: no data were
excluded, but the number of rats available for analysis
decreased with age, as an increasing number of mainly
BACHD rats refused to stay on the rod at older ages (as dis-
cussed previously in Yu-Taeger et al., 2012; Abada et al.,
2013b). Simple swim test: the tracking software produced a
variety of errors, which made it necessary to exclude animals
with individual erroneous runs. Elevated plus maze: one of the
20 animals was excluded from the analysis, as it did not move
at all during the test. MRI: two of the 40 animals were
excluded from the analysis, as they moved their heads during
measurements and no sharp images could be acquired. Drug
concentration analysis: two of the 16 samples were excluded
as they had far higher drug concentrations than the rest of the
rats. The high drug load in the two animals is considered to be
due to food intake just prior to blood sampling, as we did not
food deprive the animals. Ex vivo analyses: no data were
excluded. Numbers of animals analysed in each experiment
are listed in Supplementary Table 2.
Results
A timeline and overview of the parameters assessed in this
study are given in Supplementary Fig. 1.
Olesoxime ameliorates cognitive
and psychiatric phenotypes of
BACHD rats
We previously reported that BACHD rats show a broad
range of behavioural abnormalities reminiscent of the
symptoms found in patients with Huntington’s disease
(Yu-Taeger et al., 2012; Abada et al., 2013a, b). The cog-
nitive phenotype of the BACHD rat is characterized by
difficulties in strategy shifting (Abada et al., 2013a).
Accordingly, we found that 7-month-old BACHD rats dis-
played reversal learning deficits in a simple swim test.
Untreated, but not olesoxime-treated BACHD rats,
needed longer to find a hidden platform after the platform
had been relocated (Fig. 1A). Swim speed did not differ
between groups (data not shown), suggesting that
BACHD rats’ general ability to swim was not impaired.
Anxiety-related changes were assessed by measuring the
time spent on the open arms of an elevated plus maze at 13
months of age. In line with our previous findings (Yu-Taeger
et al., 2012), BACHD rats spent a significantly longer amount
of time on the open arms thanwild-type rats. Olesoxime treat-
ment clearly ameliorated this phenotype (Fig. 1B).
Longitudinal assessment of clasping behaviour and rotarod
performance were carried out as common tests of striatum-
based motor dysfunction (Soll et al., 2013; Bergeron et al.,
2014). BACHD rats showed hind limb clasping, similar to
previous cohorts (Yu-Taeger et al., 2012) (Fig. 1C).
Furthermore, rotarod performance, which is among the ear-
liest pathological phenotypes detected in the BACHD rat (Yu-
Taeger et al., 2012), was found to be impaired at 2, 4 and 8
months of age (Fig. 1D). Olesoxime treatment, which started
when the motor abnormalities were already manifest, did not
reverse the pathology (Fig. 1C and D).
Olesoxime increases frontal cortex
thickness
Olesoxime has been ascribed with neuroprotective proper-
ties, as it was found to increase the survival of neurons
expressing disease proteins (Bordet et al., 2010; Gouarne´
et al., 2013, 2015). We performed MRI scans in 13-month-
old rats to evaluate if olesoxime was able to ameliorate
brain atrophy observed in BACHD rats (Yu-Taeger et al.,
2012). BACHD rats had significantly smaller cerebra
(Fig. 1E), striata (Fig. 1F) and prefrontal cortices
(Fig. 1G) compared to their wild-type littermates. While
olesoxime treatment did not significantly affect cerebral
or striatal volume (Fig. 1E and F), frontal cortex thickness
was significantly increased, pointing to a region-specific
neuroprotective effect of olesoxime (Fig. 1G).
Olesoxime is enriched in prefrontal
and frontal cortex
After finding significant beneficial, but apparently region-
specific effects of olesoxime, we analysed the drug
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concentration in plasma and brain regions in a separate
cohort of rats after 2 weeks of olesoxime treatment at 4
months of age (Cohort II). Analysis revealed similar plasma
levels as found for the main cohort at 3 months of age
(Cohort I) (Fig. 1H), which were presumed to lie in the
pharmacologically active range of olesoxime based on the
results of previous studies (Bordet et al., 2007, 2010;
Richter et al., 2014). Furthermore, BACHD rats tended
to have higher plasma (Fig. 1H) and brain (Fig. 1I) olesox-
ime levels than wild-type rats. In addition, we detected sig-
nificant differences in the olesoxime concentration among
brain regions, with highest concentrations measured in
prefrontal and frontal cortex (Fig. 1I). The general trend
to higher olesoxime concentrations in BACHD rats was not
the result of increased food intake (data not shown) and
there was no difference in body weight between genotype
or treatment groups, thus the results might point to altered
pharmacokinetics of olesoxime in the BACHD rat.
Olesoxime reduces mutant HTT
aggregates and nuclear accumulation
Aggregation and nuclear accumulation of mutant HTT are
prominent neuropathological features of Huntington’s
Figure 1 Olesoxime accumulates in the frontal cortex and exerts speciﬁc beneﬁcial effects on behavioural and neuropatho-
logical phenotypes of the BACHD rat. (A) A simple swim test was used to assess cognitive flexibility at 7 months of age. The graph shows
the time the animals needed to find a hidden platform after the position of the platform had been changed (reversal training). (B) Anxiety-related
behaviour was assessed in an elevated plus maze at 13 months of age. The graph shows the time the animals spent on the open arms of the maze
relative to trial duration. (C) Clasping behaviour was assessed weekly as an indicator for motor dysfunction. The graph displays the clasping
frequency between the age of 1 and 10 months. (D) Motor abnormalities were further investigated longitudinally using a Rotarod test. The graph
displays the mean running capacity during tests. (E–G) MRI was performed at 13 months of age. Images in the lower left corner illustrate the site
of measurement. (H and I) Plasma olesoxime levels were measured in the main cohort of rats used for all in vivo and ex vivo analyses (Cohort I) at
3 months of age, after 7 weeks of treatment. In addition, plasma and brain olesoxime levels were determined in a second cohort of rats (Cohort
II) at 4 months of age, after 2 weeks of treatment. Olsx = olesoxime, EPM = elevated plus maze; WT = wild-type; ns = not significant.
*/#/ +P5 0.05; **/##/++P4 0.01 and ***/###/+++P4 0.001.
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disease (Gutekunst et al., 1999). Consistent with our pre-
vious results (Yu-Taeger et al., 2012), 13-month-old
BACHD rats show mutant HTT aggregates (reflected by
distinct S830-positive punctae) and nuclear accumulation
(reflected by S830-positive nuclei) in variable magnitude
throughout the brain (Figs 2, 3A and B). Aggregates were
found predominantly in cortex, hypothalamus and amyg-
dala. Mutant HTT nuclear accumulation prevailed in the
cortex, lateral striatum and hippocampus. Similar to pa-
tients with Huntington’s disease (Gutekunst et al., 1999),
cerebral cortex hosted a high amount of mutant HTT ag-
gregates and nuclear accumulation of mutant HTT, while
neither form was abundant in the central caudate putamen,
the major part of the striatum. Olesoxime-treated BACHD
rats showed a significant reduction in both aggregate load
and nuclear mutant HTT accumulation (Figs 2, 3A and B).
Moreover, not only the number of aggregates and mutant
HTT-positive nuclei was reduced due to olesoxime treat-
ment, but also aggregate size and the density of mutant
HTT in the nuclei of olesoxime-treated BACHD rats
seemed to be lowered.
The results from immunohistochemical staining were
validated using a filter retardation assay to detect the
amount of non-soluble, and thus aggregated, mutant
HTT in cortical and striatal lysates from untreated and
olesoxime-treated BACHD rats. In both cortical and striatal
samples, aggregated mutant HTT was significantly reduced
due to olesoxime treatment (Fig. 3C).
Olesoxime decreases mutant HTT
fragments and increases full-length
mutant HTT by reducing calpain-
mediated cleavage
To further investigate the cause and consequences of
reduced mutant HTT aggregate formation and nuclear ac-
cumulation, we analysed the levels of soluble full-length
and truncated forms of mutant HTT in cortical and striatal
lysates from 13-month-old BACHD and wild-type rats.
Total levels of soluble mutant HTT were measured by
TR-FRET analysis as described previously (Baldo et al.,
2012). Consistent with the reduction of aggregated
mutant HTT throughout the cortex, soluble mutant HTT
levels were highly increased in the cortices but not striata
from olesoxime-treated BACHD rats (Fig. 3D).
As mutant HTT fragments are particularly prone to ag-
gregate formation (Cooper et al., 1998; Li and Li, 1998;
Martindale et al., 1998) and nuclear accumulation (Davies
et al., 1997; DiFiglia et al., 1997; Zhou et al., 2003), we
further quantified the levels of truncated mutant HTT by
western blot analysis (Fig. 3E–G). By using the
HTT-specific D7F7 antibody (epitope around proline
1220 of human HTT) to detect mutant HTT, as well as
endogenous rat HTT, and the polyglutamine-specific 1C2
antibody to detect mutant HTT only, we obtained a variety
of protein fragments in cortex and striatum of both wild-
type and BACHD rats (Fig. 3E). Untreated BACHD rats
showed clearly enhanced fragmentation of mutant HTT in
cortex (Fig. 3E and F) but not striatum (Fig. 3E and G). In
addition, the cortex samples from untreated BACHD rats
contained a variety of shorter HTT fragments that were not
detectable in cortical samples from wild-type rats, or
striatal samples of either genotype (Fig. 3E). Olesoxime
treatment reduced HTT fragmentation in BACHD rats
below wild-type level in both cortex and striatum
(Fig. 3E–G). Similar to the TR-FRET analysis, olesoxime-
treated BACHD rats showed a significant increase in
full-length mutant HTT, specifically in cortex (Fig. 3E
and F).
Based on the apparent influence of olesoxime on mutant
HTT proteolysis, we then investigated the origin of mutant
HTT fragments by analysing the activity of calpains and
caspases, the main contributors to proteolytic cleavage of
mutant HTT (Goldberg et al., 1996; Gafni and Ellerby,
2002). We did not find marked differences between geno-
type or treatment groups in the expression levels of cas-
pase-3, or the activation status of caspase-6 in either
cortex or striatum (data not shown). On the other hand,
strong activation of the calpain system was detected
specifically in cortex (Fig. 4A) but not striatum (Fig. 4B)
of untreated BACHD rats. While the expression levels of
full-length calpain-1, calpain-2 and calpain-10 were un-
changed (data not shown), overactivation of the calpain
system was evidenced by a distinct increase in processed
calpain-1, elevated levels of the cleaved form of the calpain
substrate -spectrin, and decreased levels of the endogenous
calpain inhibitor calpastatin (Fig. 4A). Olesoxime treatment
reversed the dysregulation by decreasing active calpain-1,
increasing calpastatin levels, and reducing -spectrin cleav-
age (Fig. 4A). Even though calpain activity was not
increased in the striata of untreated BACHD compared to
wild-type rats, olesoxime reduced calpain-1 activation and
spectrin cleavage also in this brain region, while no signifi-
cant effects on calpastatin levels were detected (Fig. 4B).
To validate that the cortical mutant HTT fragments
reduced by olesoxime treatment were calpain-derived, we
performed in vitro calpain cleavage assays on cortical
lysates (Fig. 4C and D). Incubation with recombinant
calpain-1 resulted in increased fragmentation accompanied
by a decrease in the levels of both full-length HTT and
mutant HTT (Fig. 4C). The accumulation of calpain-
derived wild-type and mutant HTT fragments was time-
dependent, and concerned a variety of N-terminal and C-
terminal fragments as detected by double-immunostaining
with D7F7 and the N-terminal 4C8 antibody (epitope
between amino acids 181 and 810) (Fig. 4D). Calpain de-
pendency was further confirmed by addition of the specific
calpain inhibitor CI-III, which abolished the fragmentation.
In vitro calpain activation resulted in a clear fragmentation
of HTT in wild-type rats, resembling the fragmentation
pattern found in BACHD rats. Fragmentation was also
enhanced in BACHD rats, although the effect was less
strong due to high basal fragmentation of mutant HTT.
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Figure 2 Effects of olesoxime on mutant huntingtin aggregates and nuclear accumulation in different brain regions. Aggregation
and nuclear accumulation of mutant HTTwere investigated in coronal brain sections from 13-month-old rats, stained with S830 N-terminal mutant
HTTantibody. Images were taken from prefrontal, frontal and parietal brain areas. Columns display series of images from individual rats [wild-type
(WT) n = 1, BACHD, n = 4]. Distinct punctae represent mutant HTT cytoplasmic aggregates and large circular staining represents mutant HTT
nuclear accumulation. Black–purple staining = S830 huntingtin signal; blue staining = thionine nuclear signal. Magnification: 400; Scale bar = 10mM.
Olsx = olesoxime; PL = prelimbic cortex; M1 = motor cortex 1; Cg = cingulate cortex; CPu = caudate putamen; S = somatosensory cortex;
Th = thalamus; Hyp = hypothalamus; VMH = ventro-medial hypothalamus; Hip = hippocampus; DG = dentate gyrus; Am = amygdala.
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Figure 3 Olesoxime reduces mutant HTT aggregation, nuclear accumulation and fragmentation, and increases soluble full-
length forms of mutant HTT. (A and B) Total numbers of S830-positive punctae [mutant HTT (mHTT) aggregates] and nuclei (nuclear
accumulation of mutant HTT) were counted manually from the brain regions displayed in Fig. 2. Images on the right illustrate the structures
counted, with arrows pointing to mutant HTT aggregates or mutant HTT-positive nuclei, respectively. Nc = not counted; np = not present;
PL = prelimbic cortex; M1 = motor cortex 1; Cg = cingulate cortex; CPu = caudate putamen; S = somatosensory cortex; Th = thalamus;
Hyp = hypothalamus; VMH = ventro-medial hypothalamus; Hip = hippocampus; DG = dentate gyrus; Am = amygdala. (C) SDS-insoluble proteins
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These results suggest that calpain cleavage constituted the
major contributor to proteolytic cleavage in the
BACHD rat and that the additional small fragments
found in BACHD rat cortex, which were cleared by olesox-
ime treatment, derived from enhanced calpain-mediated
cleavage.
Olesoxime reduces mitochondria-
associated HTT fragments and
improves mitochondrial function
Given that olesoxime accumulates at the site of mitochon-
dria (Bordet et al., 2010), we investigated the impact of
olesoxime on mitochondrial properties.
First, we analysed the activation status of the calpain
system in mitochondria-enriched heavy membrane fractions
isolated from the cerebra of 13-month-old, placebo- and
olesoxime-treated, wild-type and BACHD rats (Fig. 5A),
as calpains are also located in mitochondria (Arrington
et al., 2006; Badugu et al., 2008; Smith and Schnellmann,
2012). Enrichment in mitochondrial protein in the mito-
chondrial fractions is demonstrated by higher citrate syn-
thase levels compared to whole cell lysate (Fig. 5A and B).
Calpain activation was not increased in the mitochondrial
fractions of untreated BACHD rats (Fig. 5A). However,
olesoxime treatment repressed mitochondrial calpain activ-
ity in both BACHD and wild-type rat samples, as indicated
by a reduced amount of active calpain-1 and cleaved
-spectrin, as well as increased amounts of calpastatin
(Fig. 5A).
As HTT and mutant HTT are known to associate with
mitochondria (Choo et al., 2004; Gellerich et al., 2008; Orr
et al., 2008), we further investigated their presence and
cleavage in the mitochondrial fractions from wild-type
and BACHD rats (Fig. 5B). Full-length protein as well as
truncated forms of endogenous rat HTT and mutant HTT
were detected. More mitochondria-associated fragments of
HTT were found in untreated BACHD compared to wild-
type rats. Olesoxime treatment reduced the amount of HTT
fragments associated with mitochondria, in both wild-type
and BACHD rats. In the BACHD rat, olesoxime addition-
ally increased mitochondria-associated full-length endogen-
ous rat HTT and mutant HTT. Together with the results
on whole cell lysate, these findings indicate that olesoxime
mediates a genotype-independent reduction in mitochon-
drial calpain activation, and reduces tissue-specific, whole
cell calpain overactivation in the Huntington’s disease con-
text of the BACHD rat.
To test if olesoxime affected mitochondrial function, we
further investigated mitochondrial respiratory chain activity
(Fig. 5C) and the expression of mitochondrial proteins
(Table 1). Mitochondrial function has not been assessed in
the BACHD rat previously. Mitochondria isolated from 13-
month-old untreated BACHD rat cerebra showed an overall
lower oxygen consumption rate compared to wild-type rats,
and olesoxime treatment reduced this respiration deficit
(Fig. 5C). Expression levels of mitochondrial proteins were
not strikingly altered in 13-month-old untreated BACHD
compared to wild-type rats, but olesoxime strongly affected
the protein expression in BACHD and wild-type rats in a
differential manner (Table 1). While we observed a general
increase in the expression of many mitochondrial proteins in
cortex and striatum of olesoxime-treated wild-type rats, indi-
cative of an overall increase in mitochondrial mass, we de-
tected more specific effects in BACHD rats with olesoxime
treatment. In cortex, olesoxime increased the expression of
ATP synthase and the fusion-promoting proteins MFN1,
MFN2 and OPA1, while the expression of fission-promoting
proteins was either unaffected (FIS1) or decreased (DRP1),
suggesting a higher capacity for respiration and fusion pro-
cesses in this tissue due to olesoxime treatment. Olesoxime
further dramatically increased the expression of the outer
mitochondrial membrane transporter TOMM20, in both
cortex and striatum of the BACHD rat. This finding led us
to consider a general effect of olesoxime on transport across
the mitochondrial membrane, and particularly the exchange
of Ca2 + , as the overactivation of calpain found in BACHD rat
cortexmight be due to amitochondrial Ca2 + buffering deficit.
Olesoxime affects the expression of
proteins involved in Ca2+ homeostasis
It had been demonstrated that calpain-derived fragments of
mutant HTT are formed in response to Ca2 + stress (Gafni
et al., 2004). Olesoxime might influence Ca2 + homeostasis,
as it interacts with voltage-dependent anion channels
(VDACs) (Bordet et al., 2007), which are involved in intra-
cellular Ca2 + translocation (Gincel et al., 2001; Szabadkai
et al., 2006; Min et al., 2012). Western blot analysis revealed
no alteration in VDAC1/VDAC2 expression in 13-month-old
untreated BACHD rats compared to wild-type rats, but a dra-
matic increase in the expression of both isoforms in cortex
(Fig. 6A) and striatum (Fig. 6B) from olesoxime-treated
BACHD rats. The strong effect on VDAC expression was
also seen in the cortex of wild-type rats (Fig. 6A).
Figure 3 Continued
from cortical and striatal lysates were trapped on a nitrocellulose membrane and probed with the HTT-specific 4C8 antibody to quantify the
amount of aggregated mutant HTT. (D) Levels of soluble mutant HTTwere measured in cortical and striatal lysates from untreated and
olesoxime-treated BACHD rats via TR-FRET analysis. (E–G) Full-length and fragment forms of mutant HTTwere assessed in cortical and striatal
lysates using the HTT-specific D7F7 and the polyglutamine-specific 1C2 antibodies. Black arrowheads = full-length mutant HTT; grey arrow-
head = full-length endogenous rat HTT; red arrowheads = HTT fragments (1C2-positive bands in wild-type rats label polyglutamine-containing
proteins other than mutant HTT); VCP/p97 = loading control; Olsx = olesoxime; ns = not significant. */#/ +P5 0.05; **/##/++P4 0.01 and ***/###/
+++P4 0.001.
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Figure 4 Olesoxime reduces the calpain-mediated cleavage of HTT, the major source of HTT fragments in the BACHD rat. (A
and B) Calpain activation was investigated by western blot analysis of the protease calpain-1, its endogenous inhibitor calpastatin and cleavage
substrate -spectrin, in cortical and striatal lysates from 13-month-old rats. Arrowhead 1 = full-length -spectrin; arrowhead 2 = -spectrin
fragment; arrowhead a = full-length calpain-1; arrowhead b = processed calpain-1; arrowhead c = further processed calpain-1 (active calpain1
refers to the ratio c/b); -tubulin = loading control. (C) The dependency of HTT cleavage on calpain activity was assessed qualitatively in a calpain
activation assay performed with cortical lysates from untreated, 13-month-old wild-type (WT) and BACHD rats. Samples were treated with
recombinant calpain-1 and CaCl2 (rcalpain-1) for 15min, or additionally pretreated with calpain inhibitor III (CI-III) to demonstrate calpain-1
specificity. HTT fragments were detected with the HTT-specific D7F7 antibody. Black arrowhead = full-length mutant HTT; grey arrowhead = full-
length endogenous rat HTT; red arrowheads = HTT fragments. Shorter exposure of the membrane was used to distinguish high molecular weight
bands, while longer exposure revealed low molecular weight HTT fragments. (D) Another calpain activation assay was performed with cortical
lysates from one untreated, 13-month-old wild-type and one BACHD rat, respectively, to illustrate the variety of N-terminal and more C-terminal
HTT fragments. For this, the samples were first treated with recombinant calpain-1 and CaCl2 (rcalpain-1) for an increasing amount of time or
pretreated with calpain inhibitor III (CI-III) to demonstrate calpain-1 specificity. Samples were then probed with the HTT-specific D7F7 antibody as
well as the HTT-specific 4C8 antibody, labelling central and N-terminal mutant HTT, respectively. The figure shows the overlay of the two
detections with exclusive staining of HTTwith D7F7 in blue, exclusive staining of HTTwith 4C8 in red and double-staining of HTTwith both
antibodies in pink. Black arrowhead = full-length mutant HTT; grey arrowhead = full-length endogenous rat HTT; blue, red and pink
arrowheads = HTT fragments; ns = not significant. Shorter exposure of the membrane was used to distinguish high molecular weight bands, while
longer exposure revealed low molecular weight HTT fragments. */#/ +P5 0.05; **/##/++P4 0.01 and ***/###/+++P4 0.001.
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We further analysed the levels of the endoplasmic reticu-
lum-associated Ca2 + -transporter IP3R1, as it is implicated
in neurodegenerative diseases (Stutzmann and Mattson,
2011). Specifically, IP3R1 (encoded by ITPR1) protein ex-
pression is upregulated in response to elevated Ca2 + levels
(Genazzani et al., 1999), and excessive IP3R1-mediated
Ca2 + -release into the cytosol primes apoptosis (Stutzmann
and Mattson, 2011). Furthermore, both interaction with
mutant HTT and calpain cleavage have been shown to fa-
cilitate IP3R1 activity upon stimulation, and render neu-
rons more vulnerable to excitotoxic stimuli (Tang et al.,
2003; Kopil et al., 2012). We found the levels of IP3R1
to be increased in cortex (Fig. 6A) of untreated BACHD
compared to wild-type rats. While no significant effect of
Figure 5 Olesoxime reduces the activation of mitochondrial calpains and mitochondria-associated HTT fragments and re-
stores mild respiratory deﬁcits in BACHD rats. (A) Calpain activation was investigated in cerebral mitochondria-enriched heavy mem-
branes (mitochondrial fraction) from 13-month-old rats by western blot analysis of the protease calpain-1, its endogenous inhibitor calpastatin and
cleavage substrate -spectrin, in cortical and striatal lysates. Arrowhead 1 = full-length -spectrin; arrowhead 2 = -spectrin fragment; arrowhead
a = full-length calpain-1; arrowhead b = processed calpain-1; arrowhead c = further processed calpain-1 (active calpain-1 refers to the ratio c/b);
citrate synthase (CS) = loading control. (B) Full-length and fragment forms of mutant HTTwere assessed in cortical and striatal lysates from 13-
month-old rats using the HTT-specific D7F7 and the polyglutamine-specific 1C2 antibodies. Black arrowheads = full-length mutant HTT; grey
arrowhead = full-length endogenous rat HTT; red arrowheads = HTT fragments. One sample of wild-type cortex lysate was loaded to dem-
onstrate the enrichment of the mitochondrial marker citrate synthase in the mitochondrial fraction. (C) Mitochondrial respiratory chain activity
was assessed by measuring oxygen consumption of isolated cerebral mitochondria from 13-month-old rats. Addition of substrates and inhibitors
was performed as indicated in the figure and described in detail in the ‘Materials and methods’ section. CIOXPHOS = complex I-fueled respiration;
CI + IIOXPHOS = complex I- and II-fueled respiration; CI + IILEAK = membrane leakage; CI + IIETS = maximum respiratory capacity;
CIIETS = maximum capacity dependent on complex II; CIVETS = maximum capacity dependent on complex IV; ns = not significant. Oxygen con-
sumption rates were normalized to citrate synthase activity. */#/ +P5 0.05; **/##/++P4 0.01 and ***/###/+++P4 0.001.
Olesoxime suppresses calpain BRAIN 2015: 138; 3632–3653 | 3645
 by guest on January 8, 2016
http://brain.oxfordjournals.org/
D
ow
nloaded from
 
olesoxime treatment on IP3R1 was found in wild-type rats,
olesoxime normalized IP3R1 expression in the cortex from
BACHD rats (Fig. 6A and B).
Discussion
Olesoxime is a mitochondria-targeting neuroprotective
compound (Bordet et al., 2007, 2010) that has shown po-
tential as a treatment for several neurodegenerative diseases
(Bordet et al., 2008; Xiao et al., 2009, 2012; Rovini et al.,
2010; Sunyach et al., 2012; Eckmann et al., 2013; Richter
et al., 2014). We show here that olesoxime exhibited highly
beneficial effects on disease-related phenotypes in a
Huntington’s disease animal model. Importantly, the treat-
ment effects appeared to be conveyed through a previously
unknown function of olesoxime, to reduce proteolysis. In
Huntington’s disease, proteolytic cleavage of mutant HTT
results in the generation and accumulation of toxic mutant
HTT fragments (Goldberg et al., 1996; Gafni and Ellerby,
2002; Kim et al., 2006; Miller et al., 2010), which are
thought to be crucial for disease pathogenesis (Rigamonti
et al., 2000; Nagai et al., 2007; Wang et al., 2008).
Consistent with this, olesoxime-treated BACHD rats
showed reduced activation of the calpain system, reduced
amounts of mutant HTT fragments, aggregates and nuclear
mutant HTT accumulation, as well as behavioural and
neuropathological improvements. Inhibition of mutant
HTT cleavage has previously been targeted in
Huntington’s disease models by genetic manipulations
(Gafni et al., 2004; Graham et al., 2006; Miller et al.,
2010), or the use of protease inhibitor (Bizat et al.,
2003), revealing beneficial effects (Bizat et al., 2003;
Gafni et al., 2004; Graham et al., 2006; Miller et al.,
2010). However, olesoxime is the first small molecule iden-
tified to reduce the level of mutant HTT fragments in a safe
and simple approach: the compound can be administered
orally, has been shown to be safe and well-tolerated clinic-
ally (Lenglet et al., 2014), and its neuroprotective activity
has recently been demonstrated in a pivotal clinical trial in
patients with spinal muscular atrophy (Dessaud et al.,
2014). Thus, our findings highly encourage further investi-
gations of olesoxime for use as a therapeutic for
Huntington’s disease. Still, some questions arose from the
present study, which need to be addressed further.
Table 1 Expression levels of mitochondrial proteins
Cortex Striatum
WT BACHD WT BACHD
Placebo Olsx Placebo Olsx Placebo Olsx Placebo Olsx
MFN1 Mean 1.00 1.33## 0.77* 1.18++ 1.00 1.66 1.10 0.96
SD 0.18 0.11 0.16 0.14 0.32 0.36 0.57 0.71
n 4 4 4 4 3 4 4 3
MFN2 Mean 1.00 1.17 0.93 1.87++ 1.00 2.41 1.63 1.63
SD 0.16 0.29 0.38 0.39 0.11 0.37 0.90 1.63
n 4 4 4 4 3 4 4 3
OPA1 Mean 1.00 1.84## 0.96 2.33+++ 1.00 1.90 1.39 1.37
SD 0.40 0.30 0.29 0.52 0.49 0.55 0.60 0.88
n 4 4 4 4 3 4 4 3
DRP1 Mean 1.00 0.92 0.84 0.52++ 1.00 1.36 0.98 1.04
SD 0.06 0.14 0.14 0.05 0.04 0.52 0.15 0.27
n 4 4 4 4 3 4 4 4
FIS1 Mean 1.00 1.40# 1.23 1.17 1.00 2.16# 2.08 1.31
SD 0.13 0.33 0.15 0.31 0.29 0.70 0.93 0.34
n 4 4 4 4 3 4 4 3
CS Mean 1.00 1.95# 1.23 1.86 1.00 1.64# 1.11 0.94
SD 0.56 0.94 0.33 0.22 0.11 0.36 0.33 0.22
n 4 4 4 4 3 4 4 3
ATP5A Mean 1.00 1.85 0.78 3.20++ 1.00 1.51 1.68 1.68
SD 0.10 0.66 0.09 1.53 0.19 0.47 1.01 0.39
n 4 4 4 4 3 4 4 3
TOM20 Mean 1.00 2.05 1.36 3.19+ 1.00 1.36 1.34 8.24++
SD 0.30 0.99 0.51 1.42 0.78 1.26 0.88 4.68
n 4 4 4 4 4 4 4 4
The table contains group means, standard deviation (SD) and the number of animals analysed (n). Individual values were related to b-actin levels and normalized to the mean
expression of placebo-treated wild-type (WT) rats. Significant differences from two-way ANOVA and Fisher LSD post-test are indicated in bold for the comparisons.
*wild-type versus BACHD rats.
#untreated versus treated wild-type.
+untreated versus treated BACHD rats with */#/ +P5 0.05; **/##/++P4 0.01 and ***/###/+++P4 0.001. Fusion: MFN1, MFN2, OPA1; Fission: DRP1, FIS1; Matrix: citrate synthase (CS);
Inner membrane: ATP synthase (ATP 5A); Outer membrane: translocase of the outer mitochondrial membrane (TOM20 encoded by TOMM20).
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Are the beneﬁcial effects of olesoxime
restricted to speciﬁc brain regions?
The current results indicate that olesoxime reaches higher
concentrations in the frontal and prefrontal cortex com-
pared to other brain regions, when given orally. In line
with this, both in vivo and ex vivo analyses indicated a
predominant cortical effect of olesoxime treatment. MRI
results revealed increased frontal cortex thickness, while
atrophy of other brain areas such as the striatum was not
alleviated. Further, olesoxime-treated BACHD rats showed
a selective improvement of reversal learning and anxiety
deficits, while motor phenotypes remained. Important in
this regard is that lesion studies have tied attentional set
shifting difficulties and reduced anxiety in the elevated plus
maze to the prefrontal and frontal cortex (Birrell and Brown,
2000; Shah and Treit, 2003), while motor performance cru-
cially involves the striatum (Soll et al., 2013; Bergeron et al.,
2014). Thus, it is possible that the apparent selective effect on
behaviour was a result of the uneven distribution of olesox-
ime. However, it is important to note that olesoxime still
exerted strong effects on mutant HTT fragmentation and nu-
clear accumulation in striatum, despite its lower concentra-
tion. The reason for olesoxime not mitigating more
striatum-based phenotypes could thus be that neuronal
pathologies differ among brain regions. Most notably, the
overactivation of the calpain system seemed to be a cortex-
specific phenotype in the BACHD rat, and appeared to play a
major role in olesoxime’s beneficial effects. It is possible that
striatal neurons suffer more from other mutant HTT-
mediated deficits, and that neuronal dysfunction thus per-
sisted, despite sufficient olesoxime concentrations.
An alternative hypothesis on the selective effects of ole-
soxime might be that some deficits, such as the rotarod
phenotype, were already manifest prior to the start of ole-
soxime treatment in the current study. Similar results have
been obtained in a recent study on the effect of cholesterol
oximes on the pathological phenotypes of Parkinson’s dis-
ease mice. The compounds ameliorated non-motor pheno-
types and gene expression changes in mitochondrial genes,
but were not able to reverse motor dysfunction with onset
prior to the start of treatment (Richter et al., 2014). The
fact that olesoxime treatment did not generally ameliorate
brain atrophy in BACHD rats could have the same cause,
as we recently reported that smaller body and brain sizes
among BACHD rats derive from growth impairment rather
than progressive degeneration (Jansson et al., 2014).
What is the primary target of
olesoxime?
It has previously been proposed that the presence of mutant
HTT might initiate a vicious cycle, in which mitochondrial
Figure 6 Olesoxime affects the expression of proteins involved in Ca2 + homeostasis. (A and B) Expression levels of the endoplasmic
reticulum Ca2 + transporter IP3R1, and the outer mitochondrial membrane channels VDAC 1 and VDAC 2, which are also involved in Ca2 +
transport, were assayed in cortical and striatal lysates from 13-month-old rats. -tubulin = loading control; ns = not significant. */#/ +P5 0.05;
**/##/++P4 0.01 and ***/###/+++P4 0.001.
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dysfunction leads to reduced Ca2 + buffering, subsequent
protease activation and generation of mutant HTT frag-
ments that further enhance the cytotoxic events (Peterse´n
et al., 1999; Bizat et al., 2003). Accordingly, we observed a
respiratory chain deficit, along with increased calpain acti-
vation and mutant HTT fragmentation in BACHD rats,
pathologies which were all alleviated by olesoxime (Fig.
7). Thus, we suggest that olesoxime interfered with the vi-
cious cycle by stabilizing mitochondria.
It is conceivable that mitochondria were the primary
effectors of olesoxime treatment, as olesoxime
concentrates at this site (Bordet et al., 2010), and choles-
terol-oximes have been shown to affect the expression of
genes important for mitochondrial function (Richter et al.,
2014). Such gene expression changes include the upregula-
tion of MFN1 and downregulation of DRP1, consistent
with our findings on a protein level. Importantly, abnor-
mally increased fission activity has recently been shown to
contribute to the cellular pathology in Huntington’s disease
(Costa and Scorrano, 2012). Counteracting this by inhibit-
ing fission or enhancing fusion, further, has been found to
ameliorate Huntington’s disease-related phenotypes (Wang
et al., 2009; Costa et al., 2010; Song et al., 2011). This is
possibly due to improved mitochondrial Ca2 + handling, as
suppressing fission or enhancing fusion generally renders
neurons less susceptible to excitotoxic stress (Jahani-Asl
et al., 2011; Nguyen et al., 2011; Grohm et al., 2012;
Kushnareva et al., 2013).
Another interesting effect of olesoxime is a modulation of
mitochondrial membrane fluidity. We reported earlier that
olesoxime was able to reverse an increase in mitochondrial
membrane fluidity observed in the BACHD rat and two
other Huntington’s disease models (Eckmann et al.,
2014). We further showed that olesoxime-treated BACHD
rats had significantly higher mitochondrial membrane chol-
esterol levels than untreated BACHD rats, which might be
causal for the reduction in membrane fluidity (Eckmann
et al., 2014). Here, we demonstrate that olesoxime dramat-
ically increased the levels of the outer mitochondrial mem-
brane transporter VDAC, which is involved in
mitochondrial cholesterol import (Rone et al., 2009). The
additional increase in the levels of the outer mitochondrial
membrane import component TOMM20 suggests that ole-
soxime exerted a general beneficial effect on transport pro-
cesses across the mitochondrial membrane. It had been
argued before that energetic deficits and impaired Ca2 +
homeostasis might be the result of impaired communication
between mitochondria and cytoplasm due to the accumu-
lation of mutant HTT on the outer mitochondrial mem-
brane (Gellerich et al., 2008, 2010). A recent study
specifically demonstrated that mutant HTT impairs mito-
chondrial protein import by interaction with the inner
membrane transport complex TIMM23, and that overex-
pression of TIMM23 leads to restoration of protein import
and prevention of cell death (Yano et al., 2014). Thus,
there are several indications that the mitochondrial mem-
brane environment is modulated by olesoxime, which
might connect to its beneficial effects.
We hypothesized that the compound had exerted its
beneficial effects by improving mitochondrial function,
thereby stabilizing Ca2 + homeostasis, decreasing Ca2 + -
related calpain-1 activation and aborting the generation
Figure 7 Schematic of the hypothetical Huntington’s disease-related pathology and beneﬁcial effects of olesoxime, in a
BACHD rat cortical neuron. (A) The presence of mutant HTT (mHTT) provokes an increase in cytosolic Ca2+ , leading to the overactivation
of calpain, a major executer of mutant HTT cleavage in the BACHD rat. Enhanced calpain-mediated cleavage generates large amounts of mutant
HTT fragments, which accumulate in cytosol and nucleus, and are recruited to form cytosolic and neuropil aggregates. Mutant HTT fragments
impair mitochondrial function by transcriptional dysregulation and direct interaction, thereby reducing mitochondrial Ca2+ -buffering capacity,
further elevating cytosolic Ca2 + -levels and fuelling the vicious cycle. (B) Olesoxime interrupts this by improving mitochondrial function, reflected
in increased respiratory activity, fusion protein and outer membrane transporter expression. This can in turn improve Ca2 + buffering, explaining
the reduced calpain activation, mutant HTT cleavage and accumulation of mutant HTT fragments, as well as the decrease in cytosolic and neuropil
aggregates seen in the current study.
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of toxic HTT fragments as well as their exaggerated nega-
tive influence on mitochondria (Fig. 7). As Ca2 + levels,
Ca2 + handling or the effects of olesoxime on Ca2 + balance
could not be directly evaluated in this study, the proposed
mechanism remains hypothetical. However, the finding of
overactive calpain-1 itself and the increased protein levels
of IP3R1 in untreated BACHD rats, as well as the restora-
tive effects of olesoxime on these parameters, strongly sup-
port the idea of improved Ca2 + homeostasis, if not as
primary effect then at least as part of olesoxime’s mechan-
ism of action.
Nonetheless, lacking a clear mechanism of action, it will
be difficult to develop pharmacodynamic biomarkers,
which will be crucial for conducting successful clinical
efficacy trials. This has for instance been proven true for
well-tolerated antioxidant molecules such as cysteamine
(CYTE-I-HD study), creatine (CREST-E study), ethyl-EPA
(TREND-HD study), and coenzyme Q10 (2CARE study).
While these small molecules targeting mitochondrial func-
tion showed efficacy in some rodent models (Ferrante et al.,
2000; Yang et al., 2009; Hickey et al., 2012) (although
there is also conflicting data: Menalled et al., 2010), they
mainly yielded negative findings in the clinics, emphasizing
the urgent need for pharmacodynamic biomarkers.
However, olesoxime is the first small molecule to modulate
soluble levels of mutant HTT, which can be quantified in
CSF, plasma and other tissues from animal models and
patients with Huntington’s disease using a TR-FRET
(Baldo et al., 2012; Weiss et al., 2012) or mutant HTT
immunoassay (Wild et al., 2015), and could therefore po-
tentially serve as a biomarker.
Can it be beneﬁcial to reduce mutant
HTT aggregation?
We observed a reduction in mutant HTT aggregation in
olesoxime-treated BACHD rats. It is widely accepted that
aggregates are not the most toxic species of mutant HTT,
and reducing aggregation has even been found to enhance
Huntington’s disease-related pathologies (Arrasate and
Finkbeiner, 2012). However, it is likely that in these
cases, reduced aggregation was accompanied by an increase
in mutant HTT fragments, as truncated mutant HTT, not
its full-length form, is thought to mediate mutant HTT
toxicity (Arrasate et al., 2004). This is different from our
study, as olesoxime specifically reduced mutant HTT frag-
ments, but led to an increase in soluble full-length mutant
HTT and endogenous rat HTT. There is evidence that not
only mutant HTT but also wild-type HTT fragments have
cytotoxic properties (Nasir et al., 1995; Hackam et al.,
1998; Kim et al., 1999), while the full-length form of
wild-type HTT exerts protective effects (Leavitt et al.,
2001; Tanaka et al., 2006). Our results further support
the idea that soluble full-length mutant HTT is non-toxic,
as we did not detect any adverse effects of olesoxime treat-
ment in vivo. Suppression of mutant HTT cleavage and
aggregation might also exert secondary beneficial effects
by increasing wild-type HTT levels.
It should be noted that the reduction of mutant HTT
aggregates in olesoxime-treated BACHD rats might not
only derive from reduced cleavage, but could be an effect
of increased protein degradation. Calpain activation has
been shown to interfere with autophagic degradation pro-
cesses (Yousefi et al., 2006; Xia et al., 2010), and inhibiting
calpain activity enhances autophagy (Kuro et al., 2011;
Kim et al., 2013; Menzies et al., 2014). The increase in
soluble mutant HTT that paralleled the decline in aggrega-
tion in the BACHD rat might, however, argue against a
strong increase in mutant HTT degradation.
Is it relevant and safe to suppress
calpain activity in neurodegenerative
diseases?
The calpain proteolytic system has been recognized as an
important player in neurodegenerative diseases (Haacke
et al., 2007; Samantaray et al., 2008; Getz, 2012;
Stifanese et al., 2014), including Huntington’s disease
(Gafni and Ellerby, 2002). The pivotal role is underpinned
by current studies addressing the mechanistic link between
calpains and Ca2 + dysbalance (Gladding et al., 2012),
mitochondrial dysfunction (Wang et al., 2014), axonal de-
generation (Yang et al., 2013), inflammation (Zhang et al.,
2014), and apoptosis (Sobhan et al., 2013). A variety of
calpain inhibitors have been developed to counteract the
detrimental effects of calpain activation, but unspecific in-
hibitors and strong inhibition might exert off-target and
side effects (Donkor, 2014). Such effects are less likely to
arise from olesoxime treatment, as this probably affects
calpains indirectly, and only lowers their activation. In
this regard, we recently demonstrated that decreasing cal-
pain activity in a mouse model of Parkinson’s disease by
cross-breeding with calpastatin-overexpressing mice, ameli-
orates Parkinson’s disease-related pathologies (Diepenbroek
et al., 2014). These, as well as other data (Menzies et al.,
2014), suggest that long-term reduction of calpain activity
does not have deleterious effects in mice in vivo.
Conclusion
Our study reveals behavioural and neuropathological im-
provements in olesoxime-treated BACHD rats due to im-
proved mitochondrial function, which halts a vicious cycle
of mitochondrial defects and calpain-mediated cleavage of
mutant HTT. The current findings once more emphasize
the connection between mitochondrial dysfunction and
the generation of calpain-derived mutant HTT fragments,
which underlies the molecular pathogenesis of Huntington’s
disease, and constitutes a pivotal therapeutic target. As
safety, tolerance and neuroprotective properties of olesox-
ime have been demonstrated, both clinically and in several
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neurodegenerative disease models, the compound represents
a promising candidate for the treatment of Huntington’s
disease.
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